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This thesis provides an empirical investigation of the geneticisation thesis.  
Geneticisation is one of the most prominent critiques of the social and cultural 
implications of developments in genetics.  It incorporates a set of claims and 
expectations about the way genetic knowledge and technologies are 
transforming or will transform ideas about health and illness, and health care 
practices.  This research aims to explore the empirical basis of these claims, by 
looking at the place of genetic discourses and practices in one specific area.  
The thesis focuses on familial hypercholesterolaemia (FH), a treatable 
hereditary cholesterol condition associated with high rates of coronary heart 
disease (CHD).  It asks how much and in what ways patients with FH and 
professionals involved with the condition construct FH and CHD as genetic 
conditions. 
 
The thesis draws on three main areas of data & biomedical literature concerning 
CHD and FH; ethnographic work concerning the activities of HEART UK, the 
main UK health charity involved with inherited lipid disorders and cholesterol; 
and interviews with patients with FH and with staff and members of HEART 
UK.  The analysis suggests that FH is not understood or managed within a 
strong genetic frame, and that neither professionals involved in HEART UK, 
nor patients with FH, provided or contributed to radically new or geneticised 
accounts of CHD.  In short, the research suggests that geneticisation overstates 
the transformatory potential of genetics, and that factors such as the availability 
of effective therapeutics, the sites where care takes place, the disciplines 
involved, and existing lay and professional models of disease are important for 
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the construction of a particular field.Furthermore, in arguing that FH is not 
associated with a strong specific disease identity or community, the analysis 
questions the notion of biosociality, suggesting that is may be less relevant to 
some biological states or conditions than to others. 
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CVD  Cardiovascular disease 
FCH  Familial combined hyperlipidaemia 
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This thesis is about the place of genetic knowledge in understanding and 
managing common diseases.  It is also concerned with changing ideas about 
expertise.  It looks at one condition, familial hypercholesterolemia (FH), an 
hereditary cholesterol condition associated with high rates of coronary heart 
disease (CHD).  The research focuses on patients with FH and on HEART UK, 
a health charity formed to support people with hereditary cholesterol problems.  
The thesis asks how much and in what ways these groups construct FH and 
CHD as genetic conditions.  It also asks in what ways lay people have 
contributed to particular understandings of FH through their involvement with 
HEART UK.  The aim of the thesis is to consider the claims of the 
geneticisation thesis (Lippman, 1991, 1992) about the increasing prominence 
and implications of genetic ways of thinking about health and illness, and to 
contribute to discussions about the role of lay health groups in the production 
and dissemination of biomedical knowledge.  The study draws on ideas from 
the fields of medical sociology, science and technology studies (STS) and 
studies of the public understanding of science.   
 
This introductory chapter will set out the context of this thesis, explain the 
rationale for the thesis and how this developed, set out the research questions, 
provide a brief account of the methods and findings, and finish by outlining the 
structure of the rest of the thesis. 
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This section provides the context for the thesis by discussing the three main 
conceptual areas on which it draws: geneticisation, genetic models for common 
conditions, and expertise and patients’ associations. 



In the early 1990s, Abby Lippman (1991, 1992) coined the term 
‘geneticisation’ to describe a process by which both professional and popular 
discourses about health and illness were increasingly drawing on genetics and 
genetic differences.  Indeed, Lippman argued that genetics had become the 
dominant discourse about health and illness.  Lippman based this notion of 
geneticisation on observations about both prenatal diagnosis and about the 
rhetoric surrounding the Human Genome Project at this time, particularly a 
discourse of ‘prediction and prevention’ concerning common adult&onset 
conditions.  She argued that the process of geneticisation would influence how 
health problems are defined and managed; It would affect our health care 
practices and our values and attitudes, leading to the increasing use of genetic 
technologies, the stratification of society on genetic lines, changing concepts of 
normality and abnormality, and an increasing focus on the biological rather 
than the social conditions associated with health and illness.  In short, it would 
lead, in Lippman’s view, to negative social consequences that both reflect and 
reinforce social inequalities in health. In her view, this process was mainly 
being driven by geneticists and their allies.   
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The geneticisation thesis provides a thoroughgoing critique of the socio&
political context and consequences of genetic ways of thinking and doing.  
Lippman’s ideas have been widely cited, discussed and enrolled across a range 
of disciplines, including sociology, anthropology, STS, bioethics, philosophy, 
and medicine, and in relation to a number of phenomena, such as kinship, 
ethnicity and race, adult&onset physical diseases, psychiatric illness, and 
prenatal carrier matching.  A large number of analysts have endorsed the idea 
of geneticisation including some distinguished scholars (see for example 
Franklin, 2003; Rapp, 1999; Rose, H., 2001).  It has also been critiqued on a 
number of fronts (Condit, 1999; Condit et al., 1998; Hedgecoe, 1998, 1999; 
Kerr, 2004; Novas & Rose, 2000).  One of the main critiques has been that 
geneticisation allows no place for the agency of lay people to adopt, contribute 
to, transform or resist genetic discourses (see for example Novas & Rose, 
2000; Rose, N., 2001; Rose & Novas, 2004), and this point is reinforced by the 
few empirical studies of geneticisation that have focussed on patient discourses 
(Gibbon, 2002; Raz & Atar, 2004).   
 
It is notable that a large proportion of commentators, both critics and 
proponents of geneticisation, have tended to bracket empirical questions about 
whether and how genetic discourses and practices are spreading, assuming that 
this is happening or will happen.  They differ, rather, in their analyses of the 
meaning and implications of this expansion.  In neglecting these empirical 
issues, one can argue that social analysts have not only commented on, but 
have contributed to a set of expectations about the transformatory nature of 
genetic knowledge and technologies.  There has been little empirical work that 
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directly engages with the notion of geneticisation, that aims to address whether 
the changes anticipated about the way health and illness are conceived and 
managed, are actually materialising.  This thesis starts from a position of 
neither endorsing nor challenging geneticisation, but aims to examine precisely 
these empirical questions.  It contributes to a small and, so far, relatively 
neglected area of research.   
 


	

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
STS scholars argue that the development of molecular genetics has led to a 
shift in conceptions of genetic disease in biomedical discourses (Martin, 1999; 
Turney & Balmer, 2000).  Biomedical models of many common conditions 
now include the idea that certain genetic variations may increase a person’s 
susceptibility to or predispose them to particular common diseases.  Proponents 
of genetic research envisage a new era of ‘preventative medicine’, focussed on 
the prediction and prevention of disease based on genetic information (Turney 
& Turner, 2000).  Visions of a genetic future for managing common conditions 
are embodied in UK health policy documents such as the genetics White Paper 
(Cm 5791 & II, 2003: 14): 
‘Most of the more common diseases, such as heart disease and diabetes 
also have a genetic component.  An individual’s susceptibility to these 
diseases is determined by a combination of genetic factors and 
environmental factors…Over the next decade, however, it should be 
possible to identify more genetic factors that increase the likelihood of 
people developing a given disease.  There will then be the option to test 
people for a predisposition to that disease, or a higher&than&normal risk.  
Prevention and monitoring services could then be tailored to an 
individual’s needs’. 
 
As this quote suggests, CHD features as a central example in this vision, along 
with conditions such as diabetes, cancer, schizophrenia and Alzheimer’s 
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disease.  Analysts of the social and ethical implications of new genetic 
knowledge have reinforced this message that common diseases are being 
reframed in genetic terms (see for example Davison, 1996; Davison et al., 
1994; Duster, 2003; Gannett, 1999; Hallowell, 1999, 2000; Helén, 2004; 
Lemke, 2004; Lippman, 1998; Rose, N., 2001; Sherwin, 2004).  Again, it must 
be noted that there has been little empirical research concerned with the uptake 
of genetics within biomedical discourses and practices concerning these 
common conditions.  Furthermore, although there is a growing body of 
research concerning patients’ constructionsof genetic disease, this has largely 
been concerned with ‘classic’ genetic conditions such as Huntington’s disease, 
or with hereditary breast/ovarian cancer.  In sum, although there are some 
notable exceptions (Cox & Starzomski, 2003; Hall, 2004, 2005; Hedgecoe, 
2001a, 2002), there has been little research concerned with either professional 
or patient constructions of genetic susceptibility for common conditions which 
are managed outside of the genetics clinic, and for which preventative therapies 
and treatments may be available.  This paucity of research seems remarkable in 
view of the policy relevance of these common conditions and the amount of 
discussion the genetic models of these conditions have generated among social 
and ethical analysts.   

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=

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
The idea of lay knowledge or expertise, which is based on close experience of 
a particular phenomenon or disease, has become established within the social 
science literature, although discussions continue about how to define it and 
who can be said to have it (Collins & Evans, 2002; Kerr et al., 1998; Lambert 
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& Rose, 1996; Popay & Williams, 1996; Jasanoff, 2003; Prior, 2003; Rip, 
2003; Shaw, 2002; Williams & Popay, 1994; Wynne, 1996a, b, 2003).  There 
has been particular interest in patients’ associations and other lay health groups 
as sites where expertise is challenged and renegotiated.  Such groups may aim 
to influence health policy and research agendas.  Recent analyses have 
highlighted cases where they have influenced the very practice of research and 
medicine (Epstein, 1995; Heath et al., 2004; Rabeharisoa & Callon, 2002; 
Rabinow, 1999; Rose & Novas, 2004).   
 
Rabeharisoa & Callon (Rabeharisoa, 2003; Rabeharisoa & Callon, 2002) 
suggest that patients’ associations may be finding formal ways of collectivising 
experiential knowledge and that a new ‘partnership’ model of collaboration 
between patients’ associations and professionals has emerged.  This model is 
characterised by the patients’ organisation retaining control of their research 
policy and through the recognition of their unique role in collating and 
communicating patients’ experiential knowledge, which is seen as equal to 
professional expertise.  Other commentators are more sceptical of the potential 
for lay health groups to contribute to or challenge biomedical science 
(Petersen, 2002; Stockdale, 1999; Williams, 1989).  This suggests that, 
although contested, patients’ associations are a potentially interesting site of 
lay knowledge and practice, viewed at a collective rather than individual level.  
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The initial focus for this research was on lay constructions of CHD and FH.  As 
the ideas for the thesis were coming together it seemed from the STS literature 
that genetic models of common conditions were emerging in biomedical 
discourses.  Furthermore, Adam Hedgecoe (2001a, 2002) had just started to 
publish the findings of his study, showing the rhetorical strategies whereby 
biomedical models of schizophrenia and diabetes had become geneticised.  
Social commentaries on genetic developments seemed to leave little doubt that 
genetic models of CHD would also emerge (see for example Davison, 1996; 
Davison et al., 1994; Lippman, 1998; Robert & Smith, 2004; Rose, N., 2001).  
At the same time, as noted in the previous discussion, the geneticisation thesis 
said little about the agency of lay people.  However, there was growing interest 
in the contribution of lay people to the production and dissemination of 
biomedical knowledge, and particularly the role of patients’ associations.  The 
initial aims of the thesis were, therefore, to explore the geneticisation thesis by 
looking at lay constructions of FH and CHD, focussing on individual patients 
with FH and on a patients’ association.  This would allow me to examine the 
degree to which lay people contributed to or resisted the processes of 
geneticisation of CHD, which I, at that stage, assumed to be occurring in 
biomedical discourses. 
 
Two key developments changed the shape of the thesis.  First, it became 
apparent that there had been little recent analysis of biomedical constructions 
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of CHD.  It was not at all clear what impact genetics was having in this area.  
Second, during the course of the first year of this study, the patients’ 
organisation for people with hereditary cholesterol disorders merged with the 
association for health professionals and scientists working in the field of lipid 
disorders.  The status of this new organisation as a lay health organisation fell 
into question.  My research design shifted to include some analysis of 
biomedical constructions of CHD and FH, focussing particularly on the 
professionals involved in the new joint organisation, and to look at the kinds of 
relationships between biomedical and lay expertise that were embodied within 
this newly merged organisation.

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CHD is the single most common cause of death in the UK, accounting for 
about one in five deaths in men and one in six deaths in women in 2002 (The 
British Heart Foundation, 2005).  It is, therefore, a very important condition in 
terms of health policy and its financial implications.  Furthermore, the 
condition features as one of the central examples in the vision of preventative 
medicine based on genetic information outlined above.  It is one of the key 
conditions discussed by the genetics White Paper (Cm 5791 & II, 2003) and is 
cited as a focus for the nationally&sponsored UK Biobank (The UK Biobank, 
2004; The Wellcome Trust, 2003).  As noted above, commentators on the 
potential social and cultural implications of developments in the genetics of 
common conditions also cite CHD as a key example.  In short, CHD is an 
important common disease for which genetic models seem to be emerging in 
some quarters. 
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FH is an hereditary form of raised cholesterol.  The condition, itself, is 
symptomless, but leads to increased risk of early and severe CHD.  However, 
once the raised cholesterol has been identified, it can be successfully treated, 
substantially reducing the risk of CHD in this group of people (Scientific 
Steering Committee on Behalf of the Simon Broome Register Group, 1999).  
The condition is relatively common, thought to affect about one in five 
hundred people in the UK.  FH, therefore, provides an appropriate case through 
which to examine constructions of genetic susceptibility for a common 
condition because it provides an example of an established genetic condition 
that increases susceptibility to CHD, that is relatively common and is treatable.   
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FH is characterised as a dominant single gene condition that leads to high 
blood cholesterol levels.  There are two forms of FH, the relatively common 
heterozygous form and the much rarer and more severe homozygous form
1
.  
This thesis focuses on heterozygous FH, which will be referred to simply as 
FH.  Studies undertaken before the introduction of effective cholesterol 
lowering drugs suggest that, without intervention, at least fifty per cent of men 
and about thirty per cent of women with FH would experience fatal or non&
fatal CHD by the age of sixty (Scientific Steering Committee on Behalf of the 
Simon Broome Register Group, 1999). FH is treated predominantly using a 
                                                
1
 People with heterozygous FH have one normal and one defective gene.  Homozygous FH 
results from having two defective genes.  Homozygous FH is thought to affect about one in a 
million people and, untreated, is likely to result in the onset of CHD in the teens or early 
twenties.   
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class of cholesterol lowering drugs called statins, combined with dietary and 
other lifestyle modifications.  The condition is currently diagnosed in the UK 
mainly on the basis of a set of clinical indicators, although DNA&based 
diagnosis is feasible.  Specialist care for people with FH is provided through 
lipid clinics, which are specialist outpatient clinics.  There are currently 135 
clinics providing lipid services in the UK (Marks et al., 2003a).  Neil et al. 
(2000) suggest that people who have been diagnosed with FH are rarely cared 
for exclusively by their general practitioner.  
 
The main health charity involved with FH is HEART UK (the Hyperlipidaemia 
Education and Research Trust).  This organisation was formed in 2002 as a 
result of the merger of the Family Heart Association (FHA), the main patient&
focussed charity concerned with inherited high cholesterol, and the British 
Hyperlipidaemia Association (BHA), the professional association for scientists 
and health professionals involved with lipid disorders, whose interests included 
both inherited and acquired conditions.  HEART UK must be seen as a kind of 
hybrid organisation which aims to act as both patients’ association and as a 
professional body.  HEART UK is connected to a further group, the Simon 
Broome Register Group.  This is a semi&autonomous research group 
concerning FH, made up of clinicians and biomedical scientists.  It has 
provided important data on the epidemiology and management of FH. The 
Simon Broome Register Group is now administered through HEART UK.  
Furthermore, the group includes several of the leading professionals involved 
in HEART UK.   

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The aim of this thesis is to consider the claims of the geneticisation thesis by 
examining constructions of CHD and FH.  The overarching question asked by 
the thesis is: 

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This question is broken down into three specific areas: 
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Geneticisation must be seen as both 	
	

	
 
(Lippman, 1998: 64).  The research, therefore, explores how FH and CHD are 
constructed by looking at different sorts of data.  First, it considers 
	
	
 about CHD and FH, by looking at the way these conditions are 
explained in explicit accounts of their aetiology provided in the biomedical 
literature, by HEART UK and by patients with FH.  Second, it considers 
	
in relation to CHD and FH, by looking at the way these conditions are 
constructed through the activities and actions of HEART UK and patients.  
This means, for example, for HEART UK, looking at who the organisation 
aims to support, the sorts of groups it collaborates with, the sorts of issues on 
which it lobbies or advises and the types of research, technologies and health 
practices it supports or pursues.  For patients this means looking at the way 
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health risks and responsibilities are configured through their talk about their 
experiences of FH and actions as a result of diagnosis.

The thesis also aims to contribute to discussions about lay expertise and the 
role of patients’ associations in the production of knowledge.  The research 
therefore asks: 
3; 	


	


	#

@-"*$+

This question recognises the unusual hybrid form of HEART UK and is 
concerned with the degree to which the organisation’s activities and discourses 
can be thought of as being indicative of lay constructions of FH and CHD 
specifically.   

1;)-,!
This is a qualitative study that draws on three main areas of data (1) analysis of 
papers published in biomedical journals, including selected recent commentary 
articles about CHD, the publications of selected professional members of 
HEART UK and the publications of the Simon Broome Register Group (2) 
interviews with staff and members of HEART UK, observation of their 
activities and analysis of the organisation’s written materials (3) semi&
structured interviews with patients with FH, accessed at a large lipid clinic in 
the north of England. 

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The thesis challenges the idea of geneticisation in a number of important ways.  
It suggests that FH is neither understood nor managed within a strong genetic 
frame.  Furthermore, neither health professionals involved with HEART UK 
nor patients with experience of FH provided or contribute to radically new or 
geneticised accounts of CHD.  In short, the thesis suggests that geneticisation is 
not evident in this case, where there is a recognised and established hereditary 
link to CHD.  This raises questions about the impact of genetics in other 
domains of medicine.  The thesis also suggests that HEART UK is a highly 
professionalised organisation.  Although patients’ experiential knowledge was 
valued, biomedical matters were largely delegated to biomedical experts.  This 
suggests, in the case considered, a rather less radical role for patients’ 
organisations as an expression of patient expertise than has recently been 
proposed elsewhere.

1;7,0-*0.-,"-*!
This introduction is followed by seven chapters. 
Chapter 2, 		, discusses the notion of geneticisation and reviews 
the way it has been enrolled since its introduction.  It outlines existing 
sociological work concerning both biomedical and lay constructions of CHD, 
and the social implications of providing genetic risk information. It then looks 
at the role of patients’ associations in the production and dissemination of 
biomedical knowledge.  The chapter provides the key theoretical concepts 
drawn on in the thesis and sets out the scope for detailed empirical 
investigation concerning geneticisation and complex, common diseases.  
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Chapter 3, 
, provides an account of the methods 
adopted and why they were used, including details of how samples were 
selected and the data analysed.  It addresses ethical and practical issues that 
arose and how the research design and focus developed in response to these 
issues. 
 
Chapter 4, 		
	

 looks at biomedical or 
‘expert’ constructions of the aetiology of CHD and FH, focussing on published 
biomedical literature.  It establishes that there are a number of models of CHD 
and suggests that biomedical professionals involved with HEART UK largely 
do not focus on genetic models of CHD.  It also suggests that there is 
ambivalence about the clinical utility of genetic information concerning FH.  
The chapter argues that the different models of CHD can be related to different 
disciplinary perspectives of the biomedical scientists involved. 
 
Chapter 5,  !"#
	$focuses on the structure, 
aims and activities of HEART UK.  It argues that the organisation is now 
professionally dominated and embodies traditional roles concerning expertise.  
Building on the findings in Chapter 4, it suggests that the organisation does not 
focus on genetics in relation to CHD risks generally or in relation to FH and 
that it was characterised by a CHD culture rather than genetic disease culture.  
The data also reinforce the idea of different disciplinary perspectives and 
boundary disputes in relation to CHD and FH.      
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Chapter 6, 	
	

%&	
	
&' looks at the accounts of FH 
and CHD provided by lipid clinic patients who have FH.  Although patients’ 
explanations of FH always included some talk of heredity, the condition was 
framed in a number of, sometimes, contradictory ways.  Their accounts of 
CHD in general did not draw heavily on genetics and even their explanations 
of cases of CHD in people with FH were not fixed on the hereditary aspect, but 
drew on a range of factors.  In short, lay models of CHD, embodied by the idea 
of the ‘coronary candidate’, appear to be very tenacious, even where 
specifically hereditary explanations are available.      
 
Chapter 7, 		
	, looks at how the lipid clinic patients with FH frame 
the condition through their talk about their response to it in their everyday 
lives.  These patients situated FH as part of normal, acceptable, unavoidable, 
treatable and manageable illness and drew a firm boundary between it and 
‘serious’ genetic diseases.  Reproductive decision making was not seen as a 
relevant theme in relation to FH.      Patients’ talk revealed as strong sense of 
responsibility for their offsprings’ welfare, but a looser sense of obligation to 
wider kin.  This again suggests that patients did not construct FH through a 
strongly genetic frame.     
 
Chapter 8, 		


	
discusses the findings in relation to the 
key theoretical concerns of the thesis.  It concludes that the study provides a 
fundamental challenge to the geneticisation thesis.  The analysis proposes that 
factors such as the availability of effective therapeutics, the sites where care 
takes place, the disciplines and technologies involved and existing lay models 
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of disease have important implications for the construction of a particular 
disease, suggesting that geneticisation is unlikely to be evident in relation to 
other common complex conditions.  The thesis also concludes that the 
transformation of expertise reported in relation to other patients’ groups is not 
seen in the area of FH, and suggests that the influence of patients and patients’ 
associations must be related to the state of a particular field and the existing 
actors within it.   
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This literature review is divided into two main parts.  The first part discusses 
geneticisation, as this provides the main analytical focus of the thesis.  This 
part introduces the principal arguments of the geneticisation thesis and reviews 
the way it has been critiqued and enrolled within the academic literature.  The 
second part of the literature review concerns disease constructions, focussing 
on constructions of CHD and of genetic disease.  This provides the context and 
background for the specific case considered in this thesis.   

';1-&-..!".,&
The geneticisation thesis is one of a number of commentaries that started to 
emerge in the early 1990s about developments in genetics.  This part of the 
literature review first discusses the main arguments of the geneticisation thesis 
and their links to the analytical landscape of the time.  It then reviews 
discussions about the notion of geneticisation and how it might best be studied.  
This is followed by a review of studies that draw on geneticisation, focussing 
particularly on the recent enrolment of the concept.  The aim of this review is 
to illustrate the wide uptake of geneticisation, discuss the main critiques of the 
notion and to highlight the main areas that have been discussed or studied 
under the rubric of geneticisation.      

"##

The geneticisation thesis was introduced by Abby Lippman in two key papers:  
Lippman (1991) focused on prenatal diagnosis and Lippman (1992) provided a 
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critique of the Human Genome Project, focusing particularly on a discourse of 
‘prediction and prevention’ for common adult&onset conditions.  Lippman has 
reiterated and developed her arguments about geneticisation in several 
subsequent papers (see for example Lippman, 1993, 1998).  Together, these 
papers provide a wide&ranging critique of the role of genetics in healthcare and 
make a comprehensive set of claims about genetics and its uses.  The following 
paragraphs are intended to provide a summary of these claims, paraphrasing 
Lippman’s arguments.  These are simply enumerated at this point, without 
commentary.  The claims are discussed in detail in the sections following this.      
 
Geneticisation is defined as: 
‘an ongoing process by which differences between individuals are 
reduced to their DNA codes, with most disorders, behaviors and 
psychological variations defined, at least in part, as genetic in origin.  It 
refers as well to the process by which interventions employing genetic 
technologies are adopted to manage problems of health.  Through this 
process, human biology is incorrectly equated with human genetics, 
implying that the latter acts alone to make us each the organism she or 
he is’ 
 (Lippman, 1991: 19).   
 
The central tenets of Lippman’s thesis are:  
1. 

	 
Both professional and popular (mass media) discourses about health and 
disease are increasingly drawing on genetics.  Indeed, this is the 	


	 about health and disease (Lippman, 1991: 15).  Common 
conditions such as cancer, alcoholism and schizophrenia have been 
reconstructed as genetic diseases.   
2. 
			
	 
They suggest that models of health and disease can be reduced to a set of 
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(biological) components and that, in the end, genes determine health.  This 
model is inappropriate, even for single gene disorders, where genetic 
testing neither predicts the severity of the condition, nor shows how it 
might best be managed and treated.   
3. !
#
	
;
Geneticisation redefines what are to be understood as significant 
differences between people, establishing hierarchies among people on the 
basis of differences in their DNA: ‘Geneticization is the ever growing 
tendency to distinguish people one from another on the basis of genetics’ 
(Lippman, 1998: 64).  
4. 

			
	%
 
Geneticisation is both a discourse and a practice, conditioning how health 
problems are defined, viewed and managed. It directs the application of 
intellectual and financial resources and ‘profoundly influences our values 
and attitudes’ (Lippman, 1991: 18).  Specifically it  
a. 
&
	
'
	  
In the search for susceptibility to common conditions and traits, genetic 
variations become recast as genetic abnormalities.  Similarly, prenatal care 
practices are ‘restricting concepts of what is “normal”’ (Lippman, 1991: 
25). 
b. &		
	
				
&
	'		 
Prenatal screening and diagnosis individualises a woman’s feeling of 
personal responsibility for her child’s health, just as the idea of genetic 
susceptibility testing  for common adult&onset diseases such as CHD 
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individualises responsibility to avoid disease through making appropriate 
behavioural changes
2
.  
c. 
	

'		
	
		
 
The focus on individual susceptibility and responsibility may detract 
attention and resources from social programmes to reduce structural risks, 
thereby increasing social inequalities.  Furthermore, opportunities to access 
and respond to genetic information are likely to reflect and reinforce 
current social inequalities.  Ultimately geneticisation could lead to a 
‘coercive model of medicine’, in as much as individuals are positioned as 
responsible for their health, and so could lead to ‘victim blaming’ of those 
who do not follow health advice (Lippman, 1992: 1473). 
d(	

	
		
.  
Geneticisation means that genetic technologies are ‘applied to diagnose, 
treat, and categorize conditions previously identified in other ways’ 
(Lippman, 1998: 64).  This means the increasing use of prenatal diagnosis 
and of predictive or susceptibility testing.   
5. 
				%
	
		
%; 
These discourses suggest that ‘increased understanding of disease and 
improvement in health will – and can only – be produced by mapping and 
studying genes’ (Lippman, 1992: 1470).   
 
 
                                                
2
 It is notable that Lippman’s discussion of genetic prediction and prevention talks only of 
expected behavioural changes in response to genetic information.  The possibility of 
prophylactic therapies is not discussed.      
 32
6. 
	
@	


	
#; 
A genetic narrative reflects the cultural assumptions of those with the 
power to name and assign causes.  These are mainly the ‘clinical and 
research geneticists and their colleagues [who] are conditioning how we 
view, name and propose to manage a whole host of disorders and 
disabilities’ (Lippman, 1991: 18).  The geneticists and their supporters have 
‘tremendous power …for defining how we think of ourselves and others 
and for determining who will manage us as individuals and as a society 
(Lippman, 1992: 1474). 
 
In sum, the geneticisation thesis means more than simply an expansion of 
genetic discourses about disease.  It is also more than just a critique, on 
scientific grounds, of reductionist explanations of disease.  Abby Lippman’s 
geneticisation thesis involves a programmatic critique of the socio&political 
context and consequences of genetic ways of thinking.  It involves a large 
number of claims concerning the dominance of genetic discourses, changing 
values and attitudes towards disease and disability, the increasing use of 
genetic technologies in health care and the powerful role of geneticists in 
shaping definitions of and responses to disease.  These claims have been 
challenged on both theoretical and empirical grounds and these critiques are 
reviewed in the following sections.  My own research starts from a position of 
neither endorsing nor challenging geneticisation, but aims to examine the 
empirical grounds of the claims laid out in the preceding discussion.  This 
position will also be expanded on in the following 
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Lippman’s analysis is informed by a constructionist model of health and 
illness.  While acknowledging a material reality to disease, Lippman argues 
that the way health problems are categorised, and causes attributed and studied, 
is grounded in particular social and cultural assumptions at a particular 
historical time.  Further, her discussion of prenatal testing is informed by 
feminist arguments about the medicalisation of pregnancy and childbirth.  
While largely following the conventions of scholarly writing, there is an 
element of agenda setting and campaigning in these papers.  Her aim is not 
simply to illustrate the social construction of genetic disease categories and a 
genetic approach to healthcare, but to prioritise a different ‘story’ about health 
and illness, concerning the social and structural determinants of health, which 
are very broadly conceived:  
‘Why not seek to change employment, income support, housing and 
taxation policy that influence the probabilities for illness in a population 
instead of – or at least in addition to& lobbying for ‘lifestyle’ 
modifications?’  
(Lippman, 1992: 1473). 
   
This argument exemplifies the more general and radical critique of public 
health practices, labelled the ‘ecological perspective’ (Lupton, 1995), 
demonstrating that the geneticisation thesis is part of a much wider debate 
about the construction and management of health and illness.    
 
Lippman’s focus reflects her biography, combining academic interests in the 
areas of epidemiology, bioethics and social studies of medicine, with a long&
time commitment to health activism, particularly relating to women’s health.  It 
is also important to point out the context of Lippman’s original papers, 
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published in 1991 and 1992.  They were partly intended to counteract the 
hyperbole surrounding the Human Genome Project (HGP) and to provide a 
broadside attack on ‘mainstream’ bioethical analysis of the time, with its focus 
on individual choice and autonomy.  Lippman’s papers can be seen as a call for 
more fundamental analyses of the social and ethical implications of 
developments in genetics.  Regardless of one’s views about the specific claims 
of the geneticisation thesis, these aims were both timely and valuable.  The 
geneticisation thesis is one of a number of similar analyses that emerged in the 
first half of the 1990s of contemporary developments in genetics, including 
Duster (1990), Hubbard and Wald (1993), and Nelkin and Lindee (1995).  
While these books have different foci and employ different terms, they share 
many of the key elements of the geneticisation thesis.  They demonstrate that 
Lippman’s papers contributed to a wider critique or unease about the 
(purported) growing prominence of genetic discourses and practices around 
this time.    
 
More widely than this, geneticisation resonates with a number of themes that 
are seen as characteristic of late or reflexive modernity (Beck, 1992; Giddens, 
1991) or of neoliberal government (Rose, 1996), in which risk, choice and 
individual agency and responsibility are central organising ideas.  Beck (Beck, 
1992; Beck & Beck&Gernsheim, 2001) argues that contemporary society is 
characterised by ‘individualization’, where traditional social categories no 
longer determine biography; individuals become the agents of their own life&
plans and identity (Beck, 1992; Beck & Beck&Gernsheim, 2001; Giddens, 
1991).  Contemporary society is also a ‘risk culture’ (Giddens, 1991: 3), 
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preoccupied with the future consequences of actions in the present.  This finds 
expression through the prominence of risk assessment and risk management 
across a range of political programmes (Murphy, 2000).  Drawing these two 
themes together, Rose (1996: 58) argues that in advanced liberal society, 
collective forms of risk management, such as social insurance, have given way 
to the ‘privatization of risk management’, in which ‘the citizen is enjoined to 
bring the future into the present, and is educated in the ways of calculating the 
future consequences of actions’.  Indeed, a calculative and prudent relation to 
the future becomes an individual obligation.   
 
The field of health is exemplary of these rationales of risk and individual 
agency.  Contemporary health prevention discourses are premised on the 
notion that risk factors can be identified and illness avoided, mainly through 
the actions of individuals.  In the construction of risk factors, through the 
techniques of epidemiology, there is a tendency to see certain risk factors as 
more manageable than others, privileging those that focus at an individual 
level.  Although the evidence for these factors may be contingent and 
uncertain, this uncertainty is lost as the evidence is translated into solid guides 
for action concerning ‘lifestyle’ through the discourses of public health.  
(Petersen & Lupton, 1996).  Under the dominant discourse of ‘healthism’ 
(Crawford, 1980), health becomes the result of rational choice and individual 
responsibility (Greco, 1993; Lupton, 1995).  All of this suggests that the 
arguments put forward by Lippman about genetics are not specific to genetics.  
Claims that geneticisation is reductionist, privatises and individualises health 
risks and responsibilities, and may lead to victim blaming, must be set within 
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the context of wider rationales relating to the organisation of health care and 
society.  These arguments will be expanded on particularly in relation to CHD 
in the second part of this chapter. 
 
$A


In the decade and a half since Lippman’s original publications, geneticisation 
has been widely cited, enrolled and discussed across a range of disciplines, 
including sociology, anthropology, communication studies, STS, bioethics, 
philosophy and medicine, and in connection with a range of phenomena and 
conditions, including ethnicity/race, kinship, a number of adult&onset physical 
diseases, psychiatric illness, sexuality, smoking tobacco, genetic 
enhancements, pharmacogenetics, prenatal screening and prenatal carrier 
matching. Citation data give some indication of the wide dissemination, 
although not necessarily support, of Lippman’s ideas.  The ISI Web of Science 
(WOS) database lists some 130 references that cite either Lippman 1991 or 
1992.  Searching WOS and the CSA Applied Social Sciences Index and 
Abstracts (ASSIA) databases for ‘geneticization’ or ‘geneticisation’ resulted in 
a total of 41 references
3
.  These searches are obviously not exhaustive.  In 
particular, books and book chapters are likely to be missing.  In addition, the 
term geneticiz/sation is sometimes used as a generic term, without reference to 
Lippman.  Such references are difficult to capture systematically.  It should be 
noted that the review includes only those papers that focus on geneticisation or 
refer to Lippman.  There are other studies of the social construction of genetic 
diseases, some of which are discussed in the second part of this chapter.  The 
                                                
3
 Searches undertaken on 19.4.05. 
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following sections first discuss the main critiques and commentaries on the 
notion of geneticisation, then the main proponents of geneticisation up to the 
early 2000s.  This is followed by a systematic review of the recent enrolment 
of geneticisation, in order to explore how far this concept has travelled. 
 



	

			

A number of aspects of the thesis have been discussed.  Some analysts have 
critiqued the empirical basis of the thesis, contesting the increasing dominance 
of genetic discourses (Condit, 1999; Condit et al., 1998).  Others do not 
necessarily contest the idea of increasing focus on genetic discourses, but have 
discussed what sort of concept geneticisation is, how it is defined and how it 
might be studied (Cox & Starzomski, 2003; Hedgecoe, 1998, 1999, 2001b, 
2002, 2004a; Hoedemaekers, 2001; Hoedemaekers & ten Have, 1998; Kerr, 
2004; ten Have, 2000), or have contested the specific claims of the thesis, 
seeing the social, cultural or political implications of genetic knowledge in a 
different way (Novas & Rose, 2000; Rose, N., 2001; Rose & Novas, 2004).  
 
Condit’s analyses are unusual in so far as they actually challenge claims about 
the increasing significance of genetic discourses, based on her studies of 
popular media discourses and the audience reception of metaphors.  In fact, 
these are mainly a critique of Nelkin and Lindee’s (1995) analysis of popular 
writing and images associated with genetics (see Hedgecoe, 1998 for a more 
detailed review).   
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Hedgecoe (1998, 1999, 2001a, b, 2002, 2003a, 2004a) is probably the most 
prolific commentator on the notion of geneticisation as well as an important 
contributor to empirical work in this area.  His critique of geneticisation 
(Hedgecoe, 1998, 1999, 2001b) can be situated in his own background in 
bioethics and can be seen as a call for a move to empirical research rather than 
bioethical analysis concerning geneticisation.  In principle, he is critical of the 
use of geneticisation in bioethical analyses, focussing his attention on two 
particular studies by Hoedemaekers & ten Have (1998) and Sherwin & 
Simpson (1999).  He argues that geneticisation as formulated by Lippman and 
enrolled in these studies is an inherently critical concept, in other words that 
the implementation of genetic technologies can only be seen as negative; its 
use as an analytical tool for assessing the ethics of genetic technologies leads to 
‘moral circularity’:  
‘since geneticization is inherently negative towards genetic 
technologies, using it to assess the ethics of genetic technologies results 
in the rather predictable conclusion that such technologies have 
unwelcome, unethical effects’  
(Hedgecoe, 2002: 8).   
 
Hedgecoe (1998) argues that the failings of geneticisation as an analytical tool 
stem from its origins in medicalisation, and that it is open to the same 
criticisms levelled against the original formulation of medicalisation.  In 
parallel with these earlier discussions, he argues that the inherently negative 
framing of geneticisation prevents ‘a balanced discussion of the pros and cons 
and an accurate picture of how the process of geneticisation takes place’ and 
proposes that what is required is: ‘a more neutral attitude’ (Hedgecoe, 1999:17) 
and ‘convincing empirical evidence rather than theory&derived polemic’ 
(Hedgecoe, 1998: 235). On this basis, he makes two related suggestions for the 
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analysis of geneticisation: (1) he suggests a ‘stripped down’ definition, which 
is ‘geneticisation takes place when a condition is linked to a specific stretch of 
DNA’ (Hedgecoe, 2002: 8) and (2) he calls for ‘detailed empirical research on 
how geneticisation is taking place, carried out in as many different contexts as 
possible’ (ibid: 23).  
 
Hedgecoe (2001a, 2002, 2003a) employs his stripped down definition in his 
own studies of scientific texts concerning schizophrenia, diabetes and cystic 
fibrosis.  These studies analyse a small number of review papers written by 
influential scientists to show how the rhetorical features of their writing work 
to construct particular arguments and models, in this case a focus on genetics.  
Hedgecoe’s analyses are very interesting from an STS perspective, concerning 
the construction of scientific models and arguments within published papers.  
Yet the stripped&down definition and the method he uses suggests that is it 
enough that some scientists frame a condition in a genetic way in order for it to 
be considered geneticised.  Hedgecoe’s definition includes no explicit 
references to whether such genetic models are dominant or widely accepted, or 
the possible repercussions of such models.   
 
My discussion of Hedgecoe’s work illustrates the difficulty of deciding 
whether and when an area could be considered to be geneticised.  As Cox & 
Starzomski (2003) comment, how we research geneticisation is related to how 
we understand the concept.  While Hedgecoe’s work has been important in 
setting the agenda for empirical investigation of geneticisation and for 
illustrating one way of studying this area, I am not convinced of the need for 
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his stripped&down, ethically neutral definition of geneticisation.  One might 
agree that geneticisation is a bad thing if the empirical reality matched up to the 
expectations spelt out in Lippman’s thesis.  However, as indicated earlier in 
this chapter, my interest at this stage is less in the normative questions, and 
more concerned with the empirical questions about and genetic 
knowledge and technologies are changing disease concepts, health&related 
practices, social relations and values.  Lippman’s construction of geneticisation 
is useful for keeping these areas in view, and her wider claims can be 
supported or challenged through empirical studies.  In my view, Lippman’s 
work can be used to set an agenda for empirical work.  I intend to organise my 
own analysis around what I have interpreted to be the key tenets of Lippman’s 
thesis.  To recap, these are that: genetics is the dominant discourse; genetic 
discourses are reductionist and deterministic; society is becoming stratified 
along genetic lines; genetic discourses are affecting our values, attitudes and 
health care practices; genetic research is seen as imperative; and geneticists 
have great influence in how health problems are classified and managed.  My 
aim is to examine these statements through empirical investigation.   
 
Such empirical enquiry might take place at a number of levels
4
:   
1. popular culture e.g. books, films, images, media 
2. scientific discourse and practice e.g. written texts, conferences, scientific 
practices, development and uptake of particular technologies, institutional 
changes 
                                                
4
 ten Have and Hoedemaekers (Hoedemaekers, 2001; Hoedemaekers & ten Have, 1998; ten 
Have, 2000) also suggest a number of levels at which geneticisation could be studied including 
conceptual, institutional, doctor&patient, cultural and philosophical.  These should be seen as 
conceptual or analytical levels rather than practical or empirical levels for investigation. 
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3. social/health/science policy discourse and practice e.g. analysis of policy 
initiatives, documents and processes, funding patterns 
4. clinical discourse and practice e.g. technologies and practices adopted, 
doctor&patient interaction 
5. lay discourses and practices e.g. patients, prospective parents 
 
Research at these different levels could provide evidence about changing 
definitions, practices, values and attitudes concerning health and disease and 
about the relative influence of geneticists.   
 
It is notable that Hedgecoe talks of the need to elucidate  not  a 
process of geneticisation is taking place, demonstrating his commitment to the 
concept.  Kerr (2004) has questioned this analytical stance in her 
thoroughgoing critique of Hedgecoe’s (2003a) work on cystic fibrosis.  Kerr 
claims that Hedgecoe’s analytical focus on geneticisation means that genetic 
reductionism is foregrounded at the expense of ambiguity and uncertainty, 
criticises his methodological focus on a small number of papers, and argues 
that, overall, this provides an ahistorical and inflexible model.  She concludes 
that geneticisation is of limited value when applied to the social construction of 
genetic disease.  Since it can be argued that many diseases are being reframed 
as genetic, it is not clear what Kerr means by ‘genetic disease’, or whether she 
thinks geneticisation may have utility elsewhere.   Although Kerr concludes by 
enjoining us to ‘give up’ on geneticisation, her paper seems to be more a 
critique of Hedgecoe’s particular methods and analysis. 
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Hoedemaekers (2001) and ten Have (2000) have also taken issue with 
Hedgecoe.  They regard geneticisation, like medicalisation, as an heuristic tool 
that helps bring different moral perspectives into view.  Reflecting Lippman’s 
own arguments, they suggest that it draws attention away from the dominant 
ethical debate at the level of individual decision&making to the wider socio&
ethical issues.  Pointedly, and mainly in response to Hedgecoe’s critique of 
their work (see Hedgecoe, 1999; Hoedemaekers & ten Have, 1998), they claim 
that geneticisation should not be seen as a sociological explanation of the 
reality of scientific and everyday life, but rather as a ‘ philosophical 
interpretation of the self&understanding of today’s human life and culture’ (ten 
Have, 2000: 298), which is not necessarily demonstrable through empirical 
research.  Their exchange with Hedgecoe is part of a larger debate about the 
relationship between bioethics and social science (Hedgecoe, 2001b), which 
goes beyond the scope of this review.  Nevertheless, it would seem that both 
ethicists and social scientists can fruitfully engage with geneticisation, 
regardless of any boundary work between these disciplines (Gieryn, 1983; 
Hedgecoe, 2001b) 
 
Novas and Rose (Novas & Rose, 2000; Rose, N., 2001; Rose & Novas, 2004) 
make several important points, suggesting, overall, a more complex and 
nuanced picture of the role and implications of new genetic knowledge.  First, 
they argue that geneticisation ultimately implies the subjection and control of 
individuals and groups. They disagree with this construction of patients at 
genetic risk as passive, arguing that:  
‘they are increasingly demanding control over the practices linked to 
their own health, seeking multiple forms of expert and non&expert 
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advice in devising their life strategies, and asking of medics that they 
act as the servants and not the masters of this process’  
(Novas & Rose, 2000: 489).   
 
Second, they argue that genetic information is both individualising and 
collectivising.  It is individualising because of an expectation of ‘genetic 
prudence’, the responsibility to manage oneself in the light of knowledge about 
one’s future.  However, it is also collectivising in two ways, through locating 
individuals in a network of relations and through increasing ‘biosociality’ 
(Rabinow, 1992):  
‘Choices about marriage, procreation, financial planning, inheritance, 
career and much more are made in a web of entanglements involving 
actual and potential kin, employers, partners and children. And ‘at risk’ 
individuals are joining into groups and organizations, not merely 
demanding public provision and rights, but making their own claims on 
the deployment of biomedical technologies and the direction of 
biomedical research’  
(Rose, N., 2001: 19).  
 
Third, they argue that genetic identity must fit within a multitude of other 
identity claims and that it is rarely hegemonic; it will not necessarily be the 
dominant aspect of identity in administrative or regulatory systems such as 
insurance or legal cases.  In essence, this different vision is based on very 
different conceptions of power relations.  Rose draws on the notion of ‘pastoral 
power’, a form of relational power, which is diffuse and multi&directional.  It 
cannot be thought of as organised or administered by ‘the state’, however 
widely this is conceived.   
 
Several observations can be made about Novas and Rose’s analysis.  Franklin 
(2003: 74) also comments on the agency of lay people/patients in the face of 
genetic information, arguing that ethnographic accounts of the new genetics 
suggest:  
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‘There is a lot of picking and choosing going on at the level of which 
information is accepted as useful knowledge, what kinds of authority 
are relied upon, and how individual decisions are reached’.   
 
As is shown later, the agency of patients is one of the recurrent themes in 
discussions about geneticisation, echoing criticisms of the medicalisation thesis 
(Lupton, 1997).  The idea that genetic knowledge is collectivising is 
interesting, but seems to be based on a particular model of genetic disease as a 
classic single gene condition.  Indeed, Novas and Rose often use the example 
of Huntington’s Disease.  It is difficult to see whether this web of connections 
applies in the same way to other cases.  For example, some visions of genetic 
susceptibility testing, based on multiple or minor genetic variations, may imply 
genetic prudence for the conduct of one’s own life, but are unlikely to have 
implications for choice of partner or reproductive decisions.  Finally, it is 
notable that ideas about increasing biosociality and changing relations 
concerning expertise are integral to Novas and Rose’s critique of 
geneticisation.  These notions will be discussed in more detail in the second 
part of this chapter. 
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Key proponents of geneticisation provide an indication of the range of its 
uptake.  They include Hoedemaker and ten Have (1998), Hallowell (1999, 
2000), Sherwin and Simpson (1999) and Hedgecoe (2001a, 2002, 2003a), all of 
whom cite Lippman and use geneticisation as a frame for their studies or 
discussions concerning prenatal screening programmes for β thalassaemia, 
BRCA testing for breast cancer and biomedical constructions of diabetes, 
schizophrenia and cystic fibrosis.  Rapp (1999) endorses the idea of 
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geneticisation as an ideology or worldview in her detailed ethnography of 
prenatal screening.  Gannett (1999) takes geneticisation as a starting point for 
her philosophical analysis of the meaning of ‘cause’. 
  
Authors who employ geneticisation as a generic term, without reference to 
Lippman, include Franklin (n.d., 2003), H. Rose (2001) and Petersen (1998).  
Franklin (n.d.) refers to the ‘geneticisation of medicine, reproduction, kinship 
and identity’. Franklin (2003: 72) talks of the ‘geneticization of reproductive 
choice’ and discusses the implications of geneticisation for kinship, drawing on 
the ethnographic work of Finkler (2000) and Rapp (1999).  H. Rose’s (2001: 8) 
work on the Icelandic database, talks of the ‘geneticisation of clinical disease 
entities’ and the ‘cultural geneticisation of disease’ (ibid: 10), which seems to 
refer to the turn to genetic explanations in aetiological models and the 
widening uptake of genetic models in the lay population.  Petersen (1998: 68) 
refers to the ‘geneticization of society’ and ‘the ‘geneticization’ of health and 
illness’ (ibid: 69), and his paper implies increasing scientific and popular 
interest in the genetic basis of a range of diseases, behaviours and attributes 
and changing notions of normality and health as a result of developments in 
genetics.  
  
In sum, these discussions illustrate that a number of authors, including some 
highly distinguished scholars, have adopted the notion of geneticisation across 
a range of topics.  It is not always obvious what these authors mean when they 
enrol the concept of geneticisation and how much of Lippman’s original 
conception they are evoking.   
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This section provides a comprehensive review of recent papers that either cite 
Lippman (1991) or Lippman (1992) or were identified through a key word 
search on geneticisation/geneticization.  The details of the searches undertaken 
were outlined earlier in the chapter (see page 36).  This analysis was 
undertaken in order to explore systematically the ways in which geneticisation 
has recently been enrolled, what kinds of empirical work has been undertaken 
and the degree to which the concept is being endorsed or critiqued.  The 
searches found 14 papers that focused on geneticisation in the last three years, 
2002&2004.  These constitute more than one third of the total 41 papers 
identified.  Furthermore, this sample contains the majority of the empirical 
papers found.  Details of these sample papers are provided in appendix 1.  To 
typify their stance on geneticisation, six of these papers explore and critique 
the concept through their analyses (Gibbon, 2002; Hall, 2004; Kerr, 2004; Raz 
& Atar, 2004; Shaw, 2003; Wilcox, 2003), five papers explore and support the 
notion through their analyses (Cox & Starzomski, 2003; Hedgecoe, 2002, 
2003a, 2004a; Melendro&Oliver, 2004) and three of the papers enrol the idea of 
geneticisation without questioning it (de facto geneticisation) (Chadwick & 
Aindow, 2004; Ellison & Jones, 2002; ten Have, 2003).   
 
Nine of the papers report on empirical studies, providing data on a number of 
levels. Key features of these papers are summarised in Table 2.1 below. 
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Wilcox (2003) sexuality Media discourses 
Melendro&Oliver (2004) Complex diseases & traits Media & scientific 
discourses 
Hedgecoe (2002) Diabetes Scientific discourse 
Hedgecoe (2003a) Cystic fibrosis Scientific discourse 
Shaw (2003) Dysmorphology Clinical practice 
Gibbon (2002) Breast cancer Clinical & patient 
discourses 
Cox & Starzomski (2003) Polycystic kidney disease  Clinical & patient 
discourses 
Hall (2004) Heart disease Clinical & patient 
discourses 
Raz & Atar (2004) Spouse selection & 
prenatal screening 
Lay/patient discourses 
 
Wilcox (2003) questions whether 
%	 of biological research on 
sexuality should necessarily be interpreted as geneticised.  Hedgecoe and 
Melendro&Oliver are concerned with 
	
 of genetic 
disease.  As already discussed, Hedgecoe’s (2001a, 2002, 2003a) work, 
including a slightly earlier paper, shows how common conditions such as 
diabetes and schizophrenia can be constructed within biomedical literature in 
such a way as to prioritise genetic elements at the same time as downplaying 
other elements in aetiological models.  Melandro&Oliver (2004) provides a 
broad&brush analysis of the concept of genetic disease, drawing on biomedical 
and media texts.  She argues that common diseases such as diabetes, asthma 
and hypertension are being redefined in genetic terms, and indeed that genetic 
disease is being reframed from a disease category to a new explanatory model 
for all types of diseases.  She concludes that the last decades have not seen an 
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end of reductionism and genetic determinism in scientific discourses, despite 
the findings of the HGP, which might contradict these (for example the much 
lower than expected number of genes).  Although this paper makes a number of 
interesting points, the lack of discussion of the method and the selection of data 
severely detracts from the author’s claims about the dominance of this new 
genetic disease model. 
 
Cox & Starzomski (2003), Hall (2004), Hedgecoe (2002, 2003a) and Shaw 
(2003) all raise questions about the utility of genetic information and 
technologies in 	.  This is an area that Kerr (2000) has also 
commented on, in an earlier paper.  Hall (2004) provides the only research 
relating specifically to CHD, undertaken with health professionals and patients 
at a coronary unit.  He reports that the health professionals say they are likely 
to foreground lifestyle issues in consultation with their patients, because of a 
concern about fatalism, whereas patients would have liked genetics to be 
acknowledged.  Davison et al. (1989, 1992) made similar observations, at a 
time almost predating the HGP, about the lifestyle&centred focus of clinicians 
and health educators compared with a lay interest in heredity and heart trouble.  
The health professionals’ lack of focus on genetics reported by Hall may reflect 
the current paucity of genetic technologies and treatments in this area, but Hall 
provides no discussion on this.  Nevertheless, this work suggests that clinical 
discourses in the area of coronary care have not changed significantly in the 
last fifteen years.  It is not clear the extent to which the patients’ discourses 
reflect a geneticised model, or a more long&standing hereditarian discourse 
about CHD reframed in the language of genetics.  Cox & Starzomski’s (2003: 
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161) study of autosomal dominant polycystic kidney disease (PKD) found that 
‘recent advances in genetic knowledge and techniques [have] had a minimal 
impact on the clinical management and social construction of PKD’.  The 
authors propose a number of factors that might mitigate geneticisation such as 
the management of PKD along with all other kidney disease, the lack of a PKD 
culture, and the availability of non&genetic diagnostic techniques.  This 
discussion of mitigating factors seems to indicate that Cox & Starzomski 
(2003) are committed to the idea of geneticisation, although their findings 
could be interpreted as detracting from the notion.       
 
In addition to Hall’s work, discussed above, there were two other papers that 
focus on 
	.  Gibbon (2002) and Raz & Atar (2004) discuss 
the agency of patients in the two very different settings of breast cancer 
genetics and community genetic services for prenatal carrier screening and 
matching.  Both argue that patients were not passive recipients of service, and 
that analyses must take account of patients’ expectations and how they respond 
to and use such services. 
 
In sum these papers suggest that genetic models for common conditions are 
emerging at the level of scientific discourse, although it is not clear that they 
represent the dominant constructions.  However, there are questions about the 
current utility of genetic information and techniques in clinical practice and the 
uptake of genetic discourses by clinicians, as well as questions about the 
passive position attributed to patients within the geneticisation thesis.  There 
 50
have apparently not been any empirical analyses in this time period that focus 
on policy discourses and practices. 
 
The papers discussed so far have geneticisation as their analytical focus.  To 
indicate the wider uptake of Lippman’s ideas, there were a further 15 papers in 
the last year, 2004, that cited either Lippman 1991 or 1992 (see appendix 1 for 
details).    It is instructive to see which of Lippman’s ideas are being enrolled.  
The argument with which she was most frequently associated was that there 
was increasing uptake of reductionist and deterministic genetic models of 
health and illness.  Mostly this referred to popular culture, lay discourse or 
society in general, but occasionally scientific discourse or medical practice 
were specified.  There were a much smaller number of references to arguments 
about the individualisation of responsibility, ideas about normality, new 
genetic identities or the diversion of resources.  Crudely, these papers can be 
divided into nine that enrol Lippman’s ideas without questioning them (Baylis 
& Robert, 2004; Kirby, 2004; Robert & Smith, 2004; Santos & Maio, 2004; 
Schubert, 2004; Sherwin, 2004; Shields et al., 2004; Surbone, 2004; van 
Delden et al., 2004) and six papers that critique some aspects of her analysis 
(Ceccarelli, 2004; Condit, 2004; Greco, 2004; Helén, 2004; Koch, 2004; 
Lemke, 2004).  The critiques they make have largely been covered in the 
preceding discussions.  
 
Overall, this review suggests that geneticisation is often used to imply simply 
an increase in genetic discourses.  Furthermore there is frequently limited 
specificity as to the location of these discourses.  It also suggests that, more 
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often than not, Lippman’s arguments are enrolled without question, implying a 
de facto geneticisation.  In as much as references to Lippman continue to 
increase and her work is often enrolled uncritically, we do not appear to be 
‘giving up on geneticisation’ (Kerr, 2004). 
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There is one final observation to make about the papers reviewed in this part of 
the chapter.  Regardless of whether they endorse or critique Lippman’s work 
and geneticisation, a large proportion of the papers construct genetic 
developments as leading to the wide&scale transformation of knowledge and 
practice concerning health and illness.  Proponents of geneticisation including 
Duster (2003), Gannett (1999), Hallowell (1999, 2000) and Sherwin (2004) as 
well as critics including Helén, (2004), Lemke (2004) and Rose, N. (2001) 
reinforce the message that common diseases are being reframed in genetic 
terms.  Heart disease is almost always cited as a key exemplar, along with 
cancer, schizophrenia, Alzheimer’s, and diabetes.  For example, Rose, a key 
critic of geneticisation, asserts that it is now ‘routine for doctors as well as 
geneticists to consider that any individual’s vulnerability to any disease has a 
genetic component’ (Rose, N., 2001: 11&12) and that tests for genetic variations 
associated with Alzheimer’s, breast cancer and certain types of heart disease 
are increasingly in development.  Robert & Smith (2004), recent proponents of 
the idea of geneticisation, assert that governments and funding agencies are 
focussed on ‘genetic predisposition to cancer and heart disease’ rather than the 
broad determinants of health.  There is little doubt, then, for these 
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commentators that conditions such as heart disease are being reconstructed as 
genetic at a number of levels. 
 
Given the fairly widespread assertion that complex common conditions are 
being reconstructed as genetic, there appears to have been astonishingly little 
systematic empirical research into the recent scientific, policy and social 
constructions of such conditions, particularly those managed outside of clinical 
genetics.  Although a number of papers included in this review are concerned 
with prenatal screening or with hereditary breast/ovarian cancer, Hedgecoe 
(2001a, 2002), Cox & Starzomski (2003) and Hall (2004) provide the only 
research that focuses on the construction of common conditions outside of the 
genetics clinic.  
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This review has argued that the geneticisation thesis should be understood as a 
programmatic critique of the socio&political context and consequences of 
genetic discourses about health and illness.  It encompasses claims about the 
widening uptake of (reductionist) genetic models, changing definitions of 
normality and abnormality, shifting attributions of health risks and 
responsibilities, the increasing use of genetic technologies in health care, and 
the role of particular actors in bringing about these changes.  While 
geneticisation contributed to a growing unease in the early 1990s about 
developments in genetics and their dissemination, its foundations are found in a 
radical critique of public health practices, whose concerns extend beyond the 
domain of genetics.    Further than this, its themes resonate with the wider 
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characteristics of contemporary life, whether characterised as late modernity or 
neoliberal society. 
 
Critiques of geneticisation have challenged the thesis in a number of ways, 
questioning the uptake and dominance of genetics, challenging the model of 
power relations it embodies, and questioning its use as an analytical tool.  
Nevertheless, Abby Lippman’s arguments have been widely enrolled across a 
large number of disciplines and in connection with a wide range of disease 
conditions and phenomena.  It is not always clear what aspect of geneticisation 
is being enrolled, but it often seems to mean simply an expansion of genetic 
discourses or criticism of deterministic and reductionistic models, rather than 
the programmatic critique proposed by Lippman.  In view of the wide 
enrolment and discussion of Lippman’s ideas, there have been surprisingly few 
empirical studies of geneticisation, and even fewer that focus on common 
conditions outside of the genetics clinic.  With some notable exceptions, the 
papers reviewed in this chapter often bracketed empirical questions about 
 and genetic discourses and practices are spreading, tending to 
assume a de facto expansion of genetic ways of thinking and doing. 
 
This thesis is concerned with precisely these empirical questions about whether 
and how genetic knowledge and technologies are changing disease concepts, 
health practices, social relations and values.  The review has identified a 
paucity of empirical work concerning common conditions.  This study of FH, a 
genetic condition associated with susceptibility to CHD, contributes to this 
hitherto relatively neglected area.  I have suggested that empirical study of 
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geneticisation can take place at a number of different levels.  This study 
bridges several of these levels, looking at written scientific, health 
practitioners’ and lay peoples’ discourses about CHD and FH.  In contrast to 
much of the literature reviewed, I have explicitly defined geneticisation and 
detailed the set of claims that I think geneticisation incorporates.  These will be 
used to orient my analysis. 
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This part of the literature review is divided into three main sections concerning 
biomedical constructions of CHD and genetic disease, lay constructions of 
CHD and genetic disease, and the contribution of patients’ organisations to 
disease constructions.  It charts the rise of a ‘risk factor’ model for CHD within 
biomedical discourses and discusses the more recent emergence of a ‘genetic’ 
model for common conditions including CHD.  It then discusses lay 
constructions of CHD, showing the place of genetics in lay models of CHD, 
and the possible social implications of framing a condition as genetic.  This 
section includes discussion of the (limited) existing research concerning lay 
constructions of FH.  The final section reviews recent discussions that have 
problematised the distinction between lay and professional knowledge.  These 
arguments are then related to discussions about the rise of lay health groups 
and their role in knowledge production. 
 
Like Lippman’s notion of geneticisation, the discussion here, and in this thesis 
overall, is premised on a constructionist view of disease aetiology and 
categories.  There are a number of different versions of social constructionism 
(Bartley, 1990; Brown, 1995a), differing in the role attributed to particular 
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actors, structural factors and ‘non&human’ entities such as biology or 
technology, but they would all recognise that what are understood to be the 
medical ‘facts’ at any particular time are shaped by social and cultural factors.  
As Yoxen (1982: 144) argued in relation to the construction of genetic disease, 
the idea that biomedical knowledge is socially determined:  
‘does not demand, as some might suppose, that we regard medical 
conditions as mere artefacts of their social context without organic 
cause…One can claim…that many of the phenomena of genetic disease 
are grounded in material reality, whilst at the same time asking why we 
isolate or delineate certain phenomena for analysis, why we say that 
they constitute diseases and why we seek to explain their nature and 
cause in genetic terms’.  
 
My own position is similar to Lippman’s and Yoxen’s, in as much as it 
recognises that there is a material reality to disease, but asks why certain 
conditions come to be recognised at a particular time, or become categorised 
and understood in particular ways.  The thesis is concerned with the 
circumstances under which a condition might be understood as genetic.   
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Aronowitz’s (1998) account of the history of CHD suggests that during the 
twentieth century angina pectoris became redefined from a condition of chest 
pain, which was not linked to a specific and localised pathology, to a condition 
associated with coronary arteries which was linked to specific anatomical and 
physiological changes.  Aronowitz argues that in the first half of the century 
angina was understood to be related to individual predisposition, and a range of 
social influences, in particular the pace of modern life.  A holistic approach to 
treatment was advocated which might include drugs, but also aimed to help 
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patients adjust to or counteract the characteristics of modern life or a particular 
constitution.  Linking CHD to the conditions of modern life was congruent 
with claims in the mid century that the incidence of the disease had increased 
dramatically since the First World War.  However, observers then and more 
recently have questioned whether this was a new epidemic of CHD or reflected 
the emergence of new diagnostic categories such as coronary thrombosis 
(Aronowitz, 1998; Bartley, 1985).  By the early fifties, angina had become 
largely associated with coronary thrombosis, but was still seen as a chronic 
degenerative disease connected to ageing, that was not amenable to specific 
preventative measures.   
 
The second half of the century saw the emergence of the ‘risk factor’ approach 
to CHD.  Indeed, according to Aronowitz (1998), the very term ‘risk factor’ 
was first used in relation to CHD
5
.  By the early 1960s the accepted model of 
CHD linked specific behaviours such as smoking, measurable physiological 
characteristics such as high blood pressure, or a family history of CHD, with 
increased risk of CHD.  Aronowitz relates the ascendance of this model to a 
number of factors including the increasing focus of epidemiologists on chronic 
disease (the epidemiological transition) and a shift to seeing chronic disease as 
a result of specific mechanisms that may be preventable, the development of 
new laboratory tests and of new statistical methods.  As noted earlier in this 
chapter, risk has come to be a central cultural construct in western society 
(Beck, 1992; Giddens, 1991; Lupton, 1993).  The rise of the risk factor 
approach in CHD can be seen as part of a general increase in focus on risk 
                                                
5
 Aronowitz (1998: 119) suggests that the first us of the term ‘risk factor’ was in 1961 in a 
report on the Framingham Heart Study.      
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within medical discourse, which has been attributed to a similar set of factors 
(Skolbekken, 1995). 
 
The new model of CHD is multi&causal, yet as both Aronowitz (1998) and 
Petersen and Lupton (1996) argue, the risk factor approach tends to privilege 
individual level risk factors.  This can be in part attributed to nature of risk 
factor modelling:  
‘Putative risk factors need to meet certain conditions.  They need to be 
measurable and specific characteristics of the individuals in order to fit 
into the risk equations that express the results of epidemiological trials.  
While pack&years of smoking could be entered easily into risk factor 
formulas, the role of farm subsidies to tobacco growers or marketing of 
high&fat foods are not so readily modeled’.  
(Aronowitz, 1998: 133) 
 
Earlier ideas relating CHD to the features of modern life were reformulated in 
risk factor terms.  For example, the Type A hypothesis emerged in the 1950s, 
which linked individual proneness to CHD to a set of behaviours and 
characteristics particularly associated with white middle&class men, concerning 
ambition, competitiveness and a preoccupation with deadlines.  Riska (2000, 
2002) argues that ‘Type A behaviour’ and the ideas of ‘Type A personality’ 
and of ‘hardiness’ by which it was successively replaced provided the 
antecedents to the construction of ‘stress’ as a risk factor for a number of 
chronic diseases.  She argues that these psychosocial explanations of CHD 
provide individualistic frameworks for explaining disease, although they are 
derived from social categories, particularly class and gender.     
 
There has been continued discussion by epidemiologists and others concerning 
the limitations of risk factor models in explaining the distribution of disease 
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and their inability to include factors at levels above the individual.  Indeed, as 
the first part of this review argued, Lippman’s geneticisation thesis can be seen 
as belonging to this critique.  In the UK, alternatives to these individual&
focussed models can be found in the programmes of epidemiological research 
concerned with health inequalities (see for example Davey Smith, 2003; 
Marmot & Wilkinson, 2005). They are also present, to some degree, in the 
rhetoric of recent health policy concerning CHD in the UK (see Department of 
Health, 2000).   
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Aronowitz (1998) suggests that by the early 1960s both biomedical 
professionals and the lay public had accepted the idea that the risk of CHD was 
linked to eating high fat foods and hypercholesterolaemia (high blood 
cholesterol levels).  Yet the cholesterol hypothesis has been highly contested at 
various points in its history.  Garrety (1997) shows how ‘the facts’ about 
dietary fat and cholesterol and CHD became established despite ongoing 
controversy about the supporting evidence.  The process by which these facts 
emerged involved the work and interaction of a variety of actors.  Garrety 
argues, for example, that messages about dietary cholesterol were 
enthusiastically received by the lay public because this was in keeping with lay 
health movements’ focus on diet, and that the food industry also drew on the 
hypothesis to develop and market ‘healthy’ products such as polyunsaturated 
margarine.  Findings announced in 1984 as the first conclusive evidence that 
lowering cholesterol reduces heart attacks were, in fact, those of a clinical trial 
that targeted men with particularly high levels of cholesterol using a 
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cholesterol&lowering drug.  This nevertheless led to national recommendations 
about dietary fat and cholesterol intake for everyone, defining a large 
proportion of the population to be at risk.  Garrety (ibid: 753) concludes that by 
the time the results were announced:  
‘the cholesterol hypothesis had been inside the boundary of orthodox 
medical knowledge for a quarter of a century.  Most people were 
unaware, or did not care, that the ‘definitive proof’ was still lacking.  
The scientific ‘evidence’ had simply become irrelevant’  
 
Aronowitz (1998) argues that hypercholesterolaemia was transformed during 
the 1980s from being a lifestyle issue of marginal interest to clinicians, to 
become fully established as a CHD risk factor to be seen as a medical problem 
to be managed in the clinical setting.  He attributes this to the introduction of 
drug therapy and the creation of national recommendations on cut&off points 
for cholesterol levels.  Writing from his north American perspective, he argues 
that the incentive for doctors was the creation of a reimbursable medical 
diagnosis with a specific definition and treatment.  More recent controversy 
flared up in the late 1980s and early 1990s, when biomedical papers were 
published that again questioned the link between blood cholesterol levels and 
CHD and suggested that there was a link between low blood cholesterol and 
increased mortality from other causes (see Petersen & Lupton, 1996, pages 44&
45 for details).  
 
)'		
Health promotion discourses concerning CHD have been criticized for 
focussing on lifestyle to the exclusion of other possible risk&factors, and for 
oversimplifying epidemiological evidence, for example associating lifestyle 
modifications with avoiding disease rather than decreasing risk of illness 
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(Davison et al., 1992; Hunt & Emslie, 2001; Petersen & Lupton, 1996).  Brett 
(1991) argued that professional, media and food industry presentations of 
cholesterol foster false expectations about its management and is particularly 
critical of the message that ‘serum cholesterol is universally lowered by 
prudential dietary habits’ (ibid: 645).  Davison et al (1992: 677&8) argue that: 
‘health educators and product marketing professionals have waged an intense 
public campaign to place lifestyle at the centre of CHD causation’.  The 
implication within this discourse is that heart disease is largely attributed to 
either ignorance or lack of self&discipline, leaving little room for any 
uncertainty about the controllability of the disease (Davison et al., 1991, 1992).  
Davison et al (1989, 1991, 1992) argue that this construction of CHD is 
imbued with moral positioning.  Sachs (1996: 637) has similarly described 
hypercholesterolaemia as: ‘a condition redolent with blame for unhealthy 
living’. 

These observations about public health campaigns concerning CHD and 
cholesterol exemplify a wider critique of public health discourses, which 
emphasise personal responsibility, premised on the notion that illness can be 
avoided through identifying and acting on risk factors (Petersen & Lupton, 
1996).  Drawing on Greco (1993), Lupton (1995: 90) argues that: 
‘failure adequately to control risk through strength of will has become a 
form of irrationality, or evidence of the inability to master the self.  
Disease has become linked to the state of one’s moral qualities rather 
than individual constitution’.  
 
Death, therefore, becomes the ‘ultimate failure of self&control and rationality’ 
(Petersen & Lupton, 1996: 49).  These arguments reiterate points made in the 
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first part of this literature review concerning the expression of contemporary 
rationales of risk and individual agency within the field of health. 
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So far this section has argued that a risk factor model for CHD emerged in the 
second half of the twentieth century, bringing with it the idea that CHD was 
essentially predictable and preventable.  This model places great emphasis on 
individual behaviour, framed as ‘lifestyle’ factors such as diet and exercise, 
and on measurable physiological factors such as blood pressure and blood 
cholesterol levels.  Socio&historical accounts of CHD have, to date, made very 
little reference to specific genetic models, other than general references to 
family history.  Davison et al (1989) writing in an era that predates the 
completion of the Human Genome Project, argued that there were different 
levels of interest in heredity and CHD in different branches of medicine.  They 
suggest that there was some interest in epidemiological literature in genetic 
factors, which were thought to account for a moderate component of the 
variation in cholesterol levels, blood pressure and physical fitness.  They argue 
that within clinical medicine interest lay mostly in the familial 
hyperlipidaemias and that materials for primary health care and health 
education paid relatively little attention to familial risks.   
 
The first part of this review suggested that a large number of social analysts 
believe that common conditions are being reframed in genetic terms.  The 
following discussion is intended to show the origins of these ideas.  While 
there has been longstanding interest in the construction of genetic disease (see 
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for example Yoxen, 1982), in the field of the sociology of science and 
technology there has been growing interest in the development of molecular 
genetics and the re&construction of what counts as genetic disease.  Martin 
(1999: 518), for example, suggests that a more ubiquitous genetic model of 
disease is emerging in biomedical discourses:  
‘there has been a shift from an account of disease based on ‘classical’ 
genetics and the inheritance of deleterious genes, to one which explains 
many common acquired pathologies in terms of errors in the way gene 
(sic) are regulated’.   
 
This focus on errors in the expression and regulation of ‘normal’ genes forms 
part of a wider shift toward describing pathology at the molecular level.  
Martin and Kaye (1999) argue that this has resulted in a number of conditions 
being reclassified into subcategories on the basis of their molecular biology 
e.g. breast cancer, asthma and diabetes.  Further, many common diseases are 
now thought to incorporate a ‘genetic’ subset in which there is a clear 
association between certain variants or mutations and the occurrence of disease 
e.g. BRCA genes and breast/ovarian cancer.  Therefore, a new model of 
genetic disease has emerged that encompasses both explanations in terms of 
gene function at the molecular level for the underlying pathology, and the idea 
of genetic predispositions for common acquired conditions.  It is notable that 
describing pathology in terms of gene function can apply to all cases of disease 
and does not relate to inherited differences between people, whereas the idea of 
genetic susceptibility depends on the inheritance of specific genetic mutations 
or variants.
 
A vision of a genetic future for understanding, managing and treating common 
conditions emerged in the 1990s.  In this vision, common conditions are 
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constructed as polygenic (i.e. involving many genes), multifactorial conditions, 
in which susceptibility is conferred by the interaction of numerous 
susceptibility or complex disease genes; genetic research will lead to new 
classification systems, aiding diagnosis, and to the development of 
susceptibility/predictive testing, new treatments and targeted treatments  (see 
for example Bell, 1998; Cm 5791 & II, 2003; Department of Health, 1995; 
Mathew, 2001; McCarthy, 2000).  Matthew (2001: 1013) epitomises this view: 
‘If the promise of the genome sequence is even partially fulfilled, the 
next decade will see genetics spreading rapidly beyond the confines of 
specialist centres to impact on the diagnosis and management of 
common disorders in primary care’   
 
CHD features as a central example in this vision.  In the UK, for example, it is 
one of the conditions that form the focus of the genetics White Paper (Cm 5791 
& II, 2003).  This offers a vision of predictive genetic risk assessment for CHD, 
accompanied by personalised lifestyle advice and personalised therapeutic 
drugs.  CHD is certainly the focus of research activities for firms engaged in 
work with large biological sample collections (Martin & Kaye, 2000).  Indeed, 
it is one of the key conditions cited as a focus for the nationally&sponsored UK 
Biobank (The UK Biobank, 2004; The Wellcome Trust, 2003).  As has already 
been noted, commentaries on the potential social and cultural impact of 
developments in the genetics of common conditions also cite CHD as a key 
example (see for example Davison, 1996; Davison et al., 1994; Lippman, 
1998).  The idea of a genetic future for coronary heart disease is firmly 
embedded within (some) biomedical, social science and policy discourses.  
Nevertheless, there has not been a detailed analysis of the recent constructions 
of CHD that elucidates how this picture is emerging, or how widely these 
genetic models have currency.   
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This section has argued that a ‘risk factor’ model of CHD emerged in the 
second half of the twentieth century, which also saw the reframing of CHD 
from an intractable degenerative disease of ageing to a condition that is largely 
predictable and preventable.  This time period also saw the establishment of the 
cholesterol hypothesis, although controversies have continued to flare up 
around this.  The ‘risk factor’ approach to prevention of CHD has been 
criticised for privileging individual level factors, positioning individuals as 
responsible for avoiding illness through adherence to appropriate ‘lifestyles’.  
It has been argued that a genetic model for common conditions, including 
CHD, emerged in the 1990s, accompanied by a rhetoric concerning predictive 
or susceptibility testing and personalised preventative strategies for such 
conditions.  This has been noted and discussed widely in social analyses of 
genetic developments.  It is notable, however, that although socio&historical 
accounts of CHD make reference to family history of CHD as a risk factor, 
detailed studies exploring the emergence and wider acceptance of a genetic 
model of CHD are absent. 

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Studies within general populations about the causes of heart disease have found 
that family health histories and personal actions and attributes all figure large.  
Davison et al. (1991:5) have argued that the idea of the ‘coronary candidate’ or 
‘the kind of person who gets heart trouble’ is central to lay accounts of CHD.  
 65
They describe three main elements that contribute to coronary candidacy: 
physical appearance, social and personal information: Physical aspects include 
obesity, in particular, and evidence of lack of fitness.  Important aspects of 
social information are a family history of heart trouble, occupational factors 
(such as mental or physical stress, physical inactivity, and poor work 
environment), and geographical location (relating to ideas about local habits 
and economic and environmental influences).  Personal information relates to 
individual behaviour and disposition.  Smoking, eating large quantities, 
particularly of fatty foods, and high alcohol consumption were strongly 
associated with candidature, as was a tendency to be nervous, worry a lot, or 
anger easily.  The model clearly includes both ‘lifestyle’ factors and areas not 
perceived to be within the control of the individual, such as heredity, 
upbringing, relative wealth, occupational risks, climate or pollution.  Emslie et 
al. (2001) re&evaluate the role that gender plays in ideas about heart problems 
and coronary candidacy.  They note that when respondents in their study cited 
specific examples of the ‘coronary candidate’ or of ‘the last person you’d 
expect to have heart trouble’, these were both almost without exception male.  
In other words, men are perceived as both the most likely and the least likely to 
suffer heart disease in lay constructions, leading Emslie et al (ibid: 203) to 
suggest that women are ‘invisible’ in lay accounts.   
 
Davison et al. (1992: 683) argue that, because lay models of CHD recognise 
that health is related to heredity, social conditions and the environment, as well 
as personal behaviours, they may be ‘more in step with scientific epidemiology 
than the lifestyle&centred orientation of the health promotion world’. Davison 
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and colleagues (Davison et al., 1991: 14) argue that a striking feature of 
coronary candidacy is a recognition that it is a ‘fallible system’, in other words 
many people who do not fit the candidacy profile will become ill or die of 
CHD (‘anomalous deaths’) and not all identified candidates succumb to CHD 
(‘unwarranted survivals’) (ibid:16).  Thus the notion of candidacy is concerned 
with increased risk & a random element remains.   
 
Lupton and Chapman’s (1995) study of lay peoples’ responses to the 
cholesterol controversies of the early 1990s suggests that lay constructions of 
high cholesterol fit neatly within the notion of coronary candidate.  This 
suggests that raised cholesterol is associated with strongly moralistic overtones, 
linking the condition with bodyweight and diet.  Yet, complexity and 
uncertainty associated with cholesterol was also acknowledged.  This included, 
for example, references to a propensity for a particular metabolism, or for 
raised cholesterol.  This meant that raised blood cholesterol was not necessarily 
related to appearance and lifestyle, but was also down to luck or heredity:  
‘It was commonly noted that some individuals, regardless of their 
ingestion of dietary cholesterol or fats, simply manufacture high levels 
of cholesterol, while others may have low blood cholesterol despite 
their ‘unhealthy’ diet  
(ibid: 489). 
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Davison et al (1989) have argued that in lay constructions, an hereditary input 
to CHD operates in a number of ways.  One can inherit discrete physical 
attributes, such as high blood pressure or ‘heart attacks’, one’s constitution e.g. 
a weak heart, a tendency to be fat, or elements of personality and behaviour 
such as being a worrier or being laid&back. They argue that inheritance is a 
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subject ‘shot through with a strong flavour of chance’ (ibid: 335) and because 
of the complexity of heredity and the importance of other causes, it was used 
more to explain existent cases of heart trouble than to predict cases. 
 
Ideas about a hereditary element to CHD are widespread.  Hunt et al (2000a) 
found, for example, that a fifth of their respondents thought they had a family 
history of heart disease or heart trouble.  Perceptions of a family history of 
CHD are patterned by gender, class and age (Hunt et al., 2000b, 2001; Watt et 
al., 2000).  Overall, older people were less likely to perceive this family history 
of CHD.    Men seemed to need more affected relatives than women in order to 
assess themselves as having a family history of CHD.  Working class men and 
women tended to attribute deaths to old&age for relatives at younger ages than 
did middle class people.  Overall, working class men were particularly 
ambivalent about whether they had a family history of CHD.   

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The findings of studies concerning lay constructions of CHD fit with other 
studies of lay constructions of health and illness.  In summarising such studies, 
Blaxter (1997: 750) comments that lay models of the causes of illness cannot 
be simply described, arguing that lay respondents tend to ‘move back and 
forwards between concepts of cause which seem opposed’, such as 
responsibility for health&related behaviour, having the right mental attitude and 
ideas about chance, luck and inevitability.  Blaxter considers whether notions 
concerning health inequalities, present in the epidemiological literature 
discussed in the preceding section, are evident in lay accounts.  Observing that 
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that working class people, in particular, are likely to reject the idea of 
inequalities in health, she draws on Crawford (1980), to suggest that this is tied 
up with a ‘healthist’ culture that links illness to moral failings.  She argues that 
it is not surprising that the idea of ‘not giving in to illness’ is prominent in 
working class respondents accounts, suggesting that this ‘can be seen as a 
claim to moral equality even in the face of clear economic inequality’ (Blaxter, 
1997: 754).  Such studies show that health and illness are tied to personal 
responsibility as much in lay accounts as in professional constructions.    
 
Although some have suggested that providing information about genetic 
susceptibility to disease may lead to greater fatalism (see for example Senior et 
al., 1999, 2000), others, such as Hallowell (1999), Novas & Rose (2000) and 
Polzer et al. (2002) argue that, within a logic of risk management and 
individual responsibility, such information opens up new areas of 
responsibility.  The first part of this chapter discussed Novas & Rose (2000) 
notion of ‘genetic prudence’, which involves the duty to become informed of 
future health risks based on genetic information and to undertake risk 
management in relation to oneself and those to whom one is connected.  
Specific studies concerning genetic responsibility will be discussed shortly, but 
at this point the notion can be related to lay accounts of CHD.   
 
Davison et al. (1992) argued that in popular explanations of CHD, non&control 
areas, particularly the field of luck/fate, are subsidiary to lifestyle and have 
suggested that the scope to change individual behaviour was seen as ‘‘counter&
acting’ the effects of heredity’ (Davison et al., 1989: 338).  Hunt et al (2000a) 
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report that people who assess themselves to have a family history of CHD 
attribute even greater importance to lifestyle and were no more or less fatalistic 
than other respondents overall.  Ponder et al (1996) report that nearly half of 
participants with affected relatives did not think this was relevant to their own 
risk of CHD.  Personal risk was assessed through interpretations of family 
experiences and events which tended to lessen the impact of inherited risk in a 
number of ways: the illness could be seen as particular to that relative due to 
lifestyle, environment or chance; the inherited susceptibility could be 
counterbalanced by the participant’s own actions; or the risk was lessened 
because the participant ‘did not take after that side of the family’ (ibid: 489).   
 
These studies suggest that the notion of genetic prudence or responsibility is 
compatible with lay accounts of CHD and that a commitment to individual 
responsibility for CHD is not disrupted by its hereditary aspects.  The last 
reference to reduced risk through not ‘taking after that side of the family’ also 
suggests that the notion of genetic responsibility must take account of lay 
constructions of heredity, since the importance of genetic risk factors for self 
and others may depend to some extent on how these risks are understood.  
Although there have been a number of studies of lay models of heredity (see 
Emslie et al., 2003 and Richards, 1996a, b, 1997), the implications of these 
models have not been discussed in relation to genetic responsibility.   
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There has been relatively little research on patients’ experiences of FH, 
specifically, and existing work is mainly concerned with the psychological 
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aspects of the diagnosis (reviewed in Marks et al., 2000).  Lambert & Rose 
(1996) provide the only broadly sociological analysis of FH.  The study was 
based on interviews with people with a variety of familial hyperlipidaemias 
(FH in the main).  Lambert & Rose (1996) argue that FH is defined by abstract 
information unrelated to feelings of well&being and that its treatment involves 
action on the body although the results of these actions cannot be directly 
perceived by patients.  The central concern of this study was to explore how 
people make sense of the ‘disembodied knowledge’ concerning FH, in other 
words, the interplay between this knowledge and the patients’ embodied 
understandings.   

Although this is not the main focus of their study, they do provide some 
evidence about how patients construct the inherited aspects of the condition, 
finding that prior to diagnosis, most interviewees had not been aware that high 
cholesterol could be associated with inherited factors.  Indeed they generally 
became aware of the significance of FH in terms of their family history in 
retrospect i.e. only after their own diagnosis of high cholesterol or CHD.  
Lambert & Rose (1996) touch briefly on ideas about the significance of FH to 
patients’ life plans, finding that the condition is not deemed relevant because 
high cholesterol was seen as an ‘everyday thing’ (ibid: 79).  This suggests that 
the idea of genetic prudence may have less resonance in this case.  Lambert & 
Rose (1996: 79) conclude that:  
‘[participants’] comments about the implications of this hereditary 
disorder integrate it effectively into a view of human life that 
acknowledges individual variation, the multifactorial causation of ill 
health, and the normality of human imperfection’.   
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However, there is some evidence that patients may make a distinction between 
those with FH and people with raised cholesterol for other reasons, perceiving 
people with FH to be less culpable for their status (see Senior et al., 2002; van 
Maarle et al., 2003) 

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As has already been argued, the possibility of providing people with 
information about genetic susceptibility to disease has been associated with 
two different responses: fatalism or genetic responsibility.  Hallowell (1999) 
and Polzer et al. (2002) have explored lay constructions of genetic 
responsibility in the cases of hereditary breast/ovarian cancer (HBOC) and 
familial melanoma.  Hallowell found that women at risk of HBOC felt an 
obligation to determine and manage their risks, inform others and encourage 
them to do the same.  The study makes clear that pubic health discourses about 
genetic risk and responsibility also circulate among the lay people experiencing 
genetic technologies.  According to the women interviewed, the motivation for 
gaining risk information and acting on this was largely concerned with other 
people’s needs, including researchers’.  Further, the women’s responsibility 
was linked to current, past and future generations.  Hallowell (1999: 616) 
comments that it is not clear the degree to which the sense of obligation felt by 
these women was connected specifically to genetic risks rather than health 
risks more generally: ‘their accounts suggest that it was their acknowledgement 
of their social connections and associated obligations which led them to 
manage their own risk and inform others about their risks and encourage them 
to engage in risk management’.  Hallowell questions whether men in similar 
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positions to women in her study would account for their behaviour in the same 
way.  Richards (1996a: 258) has also commented on a possible gendered 
relationship to genetic risks and responsibilities, suggesting that ‘women 
usually act as genetic housekeepers for the kinship’.   

This idea, however, is not supported by Polzer et al.’s (2002) study of genetic 
testing for familial melanoma risk, which involved both men and women.  The 
study provides remarkably similar findings to Hallowell concerning people’s 
motivations for testing.  Polzer et al. (2002) argue that participants felt a duty 
to know and manage genetic risks and to inform family members.  As in 
Hallowell’s study, participants expressed a strong sense of obligation to raise 
the issues of genetic risk with family members not only to pass on genetic 
information, but also to encourage them to monitor themselves.  While Polzer 
et al. suggest that responsibilities extend to blood relatives, Hallowell frames 
responsibilities in terms of social connections.  Cox & McKellin’s (1999) work 
on how families with Huntington’s disease (HD) construct risk suggests that 
even among blood relatives, ideas about genetic closeness are shaped by social 
connections.  They comment:  
‘Factors such as geographic and social proximity to an affected family 
member are as important as biological ties in explaining test candidates 
and their families’ intersubjective constructions of hereditary risk’.   
(ibid, 1999: 641) 
 
This reinforces the argument that the notion of genetic responsibility must be 
considered alongside lay constructions of heredity. 
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These studies of genetic responsibility and other studies concerning the 
communication of genetic information within families, for example 
d'Agincourt&Canning (2001), Forrest et al. (2003), Green et al. (1997) and 
Kenen et al. (2004) have been undertaken with samples drawn from clinical 
genetics (and relate almost exclusively to HBOC).  Furthermore, the rationale 
for obtaining genetic information in these cases has related to making 
behavioural changes, and self and medical surveillance.  Novas & Rose’s 
(2000) discussion of genetic prudence draws on the example of Huntington’s 
Disease.  Cases such as FH and CHD which are managed outside of clinical 
genetics and for which prophylactic therapies are available have not been 
considered.     
 
+
This section has suggested that lay constructions of CHD, embodied by the 
notion of the ‘coronary candidate’ involve a range of factors including 
‘lifestyle’ and heredity.  Studies of lay constructions of CHD or a family 
history of CHD suggest that lifestyle is seen as having the potential to counter&
act hereditary susceptibility.  These constructions are congruent with wider 
studies concerning lay accounts of health and illness in which personal 
responsibility represents a dominant theme.  The review has suggested that 
there is a paucity of studies relating specifically to patients’ experiences of 
genetic susceptibility to CHD or other conditions for which prophylactic 
therapies are available.  Existing studies concerning the provision of predictive 
genetic information suggest that acquiring such information is associated with 
a sense of genetic responsibility relating to oneself and to others.
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The inclusion in this study of HEART UK, the health charity originally formed 
as a patients’ association to support people with hereditary lipid disorders, was 
based on recent sociological discussions about the role of such groups in the 
production of knowledge.  These discussions are linked to the increasing 
acceptance in sociological debates of the notion of lay knowledge, and the 
positioning of lay health groups as important sites where expertise is 
renegotiated and lay knowledge expressed.  This section briefly reviews the 
discussions about lay expertise and then turns to the literature on lay health 
groups and their role in the production of knowledge.   

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In the previous sections, the literature on disease constructions was presented 
under two distinct headings, biomedical constructions and lay constructions, 
reflecting the way research on these topics is often organised.  Nevertheless, 
these two categories create an artificial divide to some extent.  As Davison et 
al. (1989: 329) have argued, medical and popular concepts of health and illness 
‘merge almost imperceptibly’ in contemporary Britain, calling into question the 
idea that they form two distinct types of accounts:  
‘The non&professional majority are habitual users of the medical idiom 
when illness is under discussion, and the professional minority remain 
members of the wider society, sharing the common framework of 
cultural and moral norms.   
 
Shaw (2002: 287) similarly asks ‘how lay are lay beliefs?’, arguing that the 
expert or biomedical model is integral to contemporary ‘common sense’ 
understandings of health.  He argues that patients, particularly with chronic 
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illness, become expert in the biomedical knowledge associated with their 
condition:  
‘but also utilizing their experience of suffering as a way of negotiating 
or critiquing that knowledge…this expertise can challenge the doctors’, 
particularly the non&specialists, authority’  
(ibid: 295).   
 
These comments exemplify an increasing recognition of the notion of lay or 
experiential knowledge in sociological writing.    
 
Discussion of lay knowledge has been integral to critiques of the production of 
scientific/medical knowledge and of the development of science/health policy 
(see for example Kerr et al., 1998; Popay & Williams, 1996; Williams & 
Popay, 1994; Williams et al., 1995; Wynne, 1996a, b; Yearley, 2000).  These 
have contrasted expert claims, based on ‘universalistic knowledge’ (Yearley, 
2000) against lay people’s ‘situated understandings’ (Lambert & Rose, 1996: 
80) based on experience and knowledge of local conditions.  This critique has 
both epistemological and political elements and is enrolled in calling for the 
involvement of lay people in the production of scientific knowledge and in 
science/health policy.  The idea of lay knowledge or expertise is now relatively 
established in social science literature (although see Prior, 2003).  Recent 
debate has concerned its definition, extent and role (Collins & Evans, 2002; 
Jasanoff, 2003; Rip, 2003; Wynne, 2003).  The notion is also slowly gaining 
recognition in some policy circles in the UK.  It is recognised, for example, in 
the Department of Health’s %&)	
 initiative (Department of Health, 
2001a) and through the Department’s involvement agenda (see Baggott et al., 
2004, page 318 for details).   
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Lay health groups have been prominent in the analysis of lay knowledge and 
expertise and its relationship to biomedical science and policy.  Such groups 
offer a potentially important site of lay knowledge and a point of contact or 
negotiation between lay people/patients and clinicians and researchers, at a 
collective or institutional rather than individual level.  There seems to be 
agreement that there has been a growth in the numbers of lay health groups 
from the 1970s onwards (Allsop et al., 2004; Epstein, 1995; Kelleher, 1994; 
Rose & Novas, 2004; Wood, 2000).  While the literature on lay health groups 
is not new (see for example Robinson & Henry, 1977), there is also agreement 
that lay health groups have been relatively little studied within the social 
sciences (Epstein, 1995; Rabeharisoa & Callon, 2002; Wood, 2000).   
 
Lay health groups can mean a great many things including self&help groups, 
patient organisations, advocacy or activist groups and medical research 
charities.  Health professionals can be involved in these groups in various 
ways, e.g. as founders, members or staff.  This raises the question as to what 
counts as a lay health group (or perhaps to borrow from Shaw, 2002, how lay 
are lay health groups?).  Wood’s study of disease&related patients’ associations 
attests to the difficulty of delimiting these groups, with Wood admitting to 
having to apply pragmatic inclusion criteria as to whether an ‘association 
seem[ed] to be patient&led and independent’ (Wood, 2000:23).  These groups 
may engage in a variety of ‘inner&focused’ activities such as self&help or 
support groups and ‘outer focused’ activities such as educating professionals 
and lobbying for resources or recognition (Kelleher, 1994).  The extent to 
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which these different activities might be considered a challenge to medical 
authority has been a consistent theme within the literature on lay health groups.  
It could be argued that ‘outer focused’ activities present more potential for 
overt challenges to biomedical expertise or for renegotiating the status of lay 
knowledge.  Kelleher (1994: 111) argues that while activities such as support 
groups could be seen as complementary to medical work, they provide an 
implicit challenge to biomedical knowledge, displaying ‘a subversive readiness 
to question the knowledge of doctors and to assert that experiential knowledge 
has value’.  Rose & Novas (2004) similarly argue that such groups offer a 
space where biomedical science can be problematised.     
 
There are a small number of documented cases in which lay health 
organisations have attempted to influence knowledge production.  Brown 
(1995b: 93) suggests three sets of aims for lay health advocacy groups, which 
could be usefully extended for thinking about lay health groups more widely: 
1. To increase resources for the prevention and treatment of already 
recognised diseases 
2. To gain increased recognition of unrecognised or under&recognised 
diseases 
3. To establish knowledge about aetiological factors in recognised 
diseases. 
 
The aims of the AIDS activists in bringing about changes to access to clinical 
trials could be placed within the first category (Epstein, 1995) (this will be 
discussed in more detail shortly).  Within the second category, lay health 
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groups have been involved in successfully establishing, or trying to establish, a 
number of important diagnostic categories, including sudden infant death 
syndrome, post traumatic stress disorder, Alzheimer’s Disease and repetitive 
strain injury (see Arksey, 1994; Fox, 1989; Johnson & Hufbauer, 1982; Scott, 
1990).  Brown’s own work (Brown, 1992, 1995b) on toxic waste and popular 
epidemiology relating to a cluster of childhood leukaemia in Woburn 
Massachusetts provides an example of the third category.  McLean (1990) 
provides a further example concerning the influence of the National Alliance 
for the Mentally Ill, in shifting ideas about the aetiology of schizophrenia from 
family&based explanations to biological or organic models.  

In these studies, lay health groups successfully employed a range of methods 
including lobbying state funding bodies and politicians to gain research 
funding, involvement in official policy bodies, cooperating with and 
participating in professional organisations, disseminating information to health 
care professionals, organising conferences to bring interested parties together, 
public awareness campaigns, initiating and funding research, helping to 
provide research subjects or materials and even involvement in undertaking the 
research.   
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Recent discussions have highlighted cases where lay health organisations have 
influenced the very practice of research.  One of the most well known of these 
is Epstein’s work on the influence of AIDS activists.  Epstein (1995: 409) 
demonstrates how these activists became:  
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‘genuine participants in the construction of scientific 
knowledge…[effecting] changes both in the epistemic practices of 
biomedical research and in the therapeutic techniques of medical care’.  
  
A major issue was the design of randomised controlled clinical trials 
concerning therapies.  From the activists’ perspective, entry criteria aimed at 
providing ‘clean data’ failed to take account of the social realities of the time.  
Activists recognised that clinical trials provided a way to access potentially 
useful therapies that may otherwise have been unobtainable.  Clinical trials 
were seen, therefore, as both scientific experiment and contributing to health 
care, and equity of access was a major issue.  Activists were also aware of 
arguments within biomedical science about the design of clinical trials, 
concerning the degree to which trial populations should be homogeneous or 
reflect the heterogeneity of intended target populations.  Epstein argues that by 
bringing together methodological, epistemological, moral and political 
arguments the activists successfully:  
‘won support for a number of modifications in trial design including the 
use of broader entry criteria, more diverse subject populations, and 
concomitant medication’ (ibid: 424).   

The case of the Association Française Contre les Myopathies (AFM), the 
French muscular dystrophy association (Callon & Rabeharisoa, 2003; 
Rabeharisoa, 2003; Rabeharisoa & Callon, 2002; Rabinow, 1999) has received 
considerable recent attention.  Callon & Rabeharisoa (2003) discuss how the 
AFM set about gathering information about the condition in the form of 
photos, films, written accounts and conducting surveys.  These methods were 
used as a means of formalising and publicising members’ knowledge about the 
condition, which led to collaborative research with biomedical scientists and 
clinicians.  This resulted in, for example, the identification of different forms of 
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the disease and clarification of clinical profiles.  Rabinow (1999) argues that 
AFM’s collaboration with CEPH, Frances’s most prestigious genomics 
laboratory, not only managed to get the muscular dystrophies onto the research 
agenda, but also influenced research practice, particularly the wide and rapid 
public dissemination of findings.  It created a research model both more 
‘entrepreneurial’ and more ‘civic’ than state&funded laboratories could provide 
(ibid: 44).  Heath et al. (2004), Rapp et al. (2001), Rose & Novas (2004) and 
von Gizycki (1987) provide further examples of collaborative work and 
innovative research relationships in which patients’ organisations have 
influenced or controlled how knowledge is produced and used.   
 
On the basis of these examples, Rabeharisoa and Callon (Rabeharisoa, 2003; 
Rabeharisoa & Callon, 2002) propose that there are now three different models 
concerning the engagement of lay health organisations with research, the 
auxiliary, emancipatory and partnership models.  Rabeharisoa (2003) argues 
that the auxiliary association either delegates decisions about research priorities 
and knowledge dissemination to the biomedical specialists or acquires 
biomedical expertise in order to enter into the discussions.  In the emancipatory 
model, professional constructions may be challenged or rejected as groups 
strive to assert their own collective identity, as exemplified by some disability 
organisations.  It is suggested that cases like the AFM represent a third model, 
the partnership model.  This has two main characteristics, that the organisation 
retains control of their research policy, and that ‘patients are specialists’ 
partners in their own right’ (ibid: 2131).  Patients’ experiences are prioritised 
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and the role of the organisation is to collate this expertise and communicate it 
to the biomedical professionals in a way they can understand:  
‘if patients are to be regarded as “experts in experience”, their 
knowledge of the disease must be formalised in such a way as to 
demonstrate its value’  
(Rabeharisoa & Callon, 2002: 62).   
 
The organisation, therefore, has a unique role as custodian and translator of 
collective experiential knowledge.   
 
Both Rabeharisoa & Callon (Rabeharisoa, 2003; Rabeharisoa & Callon, 2002) 
and  von Gizycki (1987) point out that the potential for any patient organisation 
to influence knowledge production depends to an extent on the existing players 
and state of knowledge in their field, including the statutory authorities, 
research institutions, other voluntary organisations and industrial interests.  A 
collaborative or partnership model may be more likely to emerge where the 
research environment is unstructured and specialist scientific or medical 
groupings are absent.         
 
While the partnership model relates specifically to the contribution of collated 
and formalised experiential knowledge to research, it is likely that many 
patients’ associations would recognise a role in drawing together the views and 
experiences of patients in order to influence the direction of funding, research 
and medical practice.  This may involve analysing contacts with helplines, 
surveying members and drawing on the discussions of local meetings.(Allsop 
et al., 2004; Baggott et al., 2004).   
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So far this section has argued that studies of lay health groups have contributed 
to a wider reappraisal of expert knowledge.  They are seen by some analysts as 
part of a broader social movement in which people affected by biomedical 
science want to have a say in its making.  Epstein (1995: 428), for example 
argues:  
‘To varying extents, these groups challenge the hierarchical relations 
between laypeople and insist on the rights of those affected by 
biomedical science to participate in its production’.   
 
Rabeharisoa & Callon (2002) similarly argue that the involvement of patients’ 
associations in research is part of a broader trend which has seen the reshaping 
of relations between experts and the groups who are likely to benefit from their 
expert knowledge.  It has also been argued that these groups have the potential 
to change the way science is conducted.

	
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Stockdale’s (1999) study of the Cystic Fibrosis Foundation (CFF) in the US 
challenges these arguments about patient organisations as a new democratic 
form associated with new forms of collaboration in the production of 
knowledge.  He argues that the decision of the CFF to focus its considerable 
research funds to finding a ‘cure’ for cystic fibrosis, concentrating on gene 
therapies, was not necessarily widely supported by people with CF and led to 
other activities being marginalised.  Similar tensions about priorities were 
noted in a number of the case studies already discussed.  Stockdale also reports 
that, in the case of the CFF, there were poor relations between researchers and 
the researched, and that the CFF actively excluded patient participation in 
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discussions about clinical practice and research.  Stockdale (1999: 585) 
comments that  
‘the experience and relationships in the CF case are a striking example 
of the lack of consumer involvement in the research process’.   
 
Williams’ (1989) study of the National Ankylosing Spondylitis Society 
(NASS) provides a second example where lay knowledge did not seem to be 
prominent in the culture of the organisation.  At the national level, there was a 
greater focus on self&management rather than any kind of collective or 
interpersonal activities, which ‘seems to have been sustained by the dominance 
of middle&class professional values and interests’ (Williams, 1989: 152). 
However, this ideology was not necessarily reproduced by lay members at the 
local level.  The findings of these two studies suggest that research on patients’ 
organisations may need to pay attention to how widely patients’ knowledge is 
recognised and is contributing to knowledge production.   
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Rose and Novas (Novas & Rose, 2000; Rose, N., 2001; Rose & Novas, 2004) 
link ideas such as those discussed here concerning changing forms of expertise 
and the growth of patients’ associations to their critique of geneticisation, 
discussed in the first part of this literature review.  To recap, they argue that 
genetic information is collectivising as well as individualising, and it is 
collectivising partly through biosociality.  In other words, people are 
increasingly joining into groups based on shared biological identities and that 
such groups are:  
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‘not merely demanding public provision and rights, but making their 
own claims on the deployment of biomedical technologies and the 
direction of biomedical research’  
(Rose, N., 2001: 19).   
 
Indeed, they argue that, in some cases, active membership of a patient 
organisation is reconfigured as a duty.  Rose & Novas (2004: 451) argue that 
the biosocial communities represent a new kind of active biomedical 
citizenship and that:  
‘in a certain political, cultural and moral milieu, this idea of activism in 
relation to one’s biomedical condition becomes a norm.  Activism and 
responsibility have now become not desirable but virtually obligatory’.   
 
Taking the case of Huntington’s disease, Novas & Rose (2000: 506) argue that 
‘the responsible&genetic subject becomes active in the shaping of the enterprise 
of science’ through engaging in discussion, donating money, fundraising and 
participating in research.   
 
Biosociality should not necessarily be seen as a widespread practice.  As 
Callon & Rabeharisoa (2004) report in their work on the muscular dystrophies, 
there are people who resolutely refuse a genetic identity and a genetically&
identified collective.  In general, Rapp et al. (2001) argue that certain kinds of 
people are more likely to engage in biosociality than others.  Commenting here 
about genetic identity, they argue:  
‘the class&inflected etiquette of voluntary organizations may feel more 
comfortable for middle&class families who are used to assuming “new” 
professional identities and seeking help from specialized sources.  
Working&class, and especially racial&ethnically marked populations 
…may find alternative sources of support that do not focus on health 
problems or genetic identity categories’  
(ibid: 397).    
 
There may also be attributes of particular conditions that are linked to the 
likelihood of them becoming part of identity practices.  For example, Allsop et 
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al. (2004) suggest that in UK and in the US there are fewer high profile groups 
formed by patients or carers in the area of heart and circulatory disease 
compared with other disease areas studied.  They comment (ibid: 744) that: 
‘[it] does not appear to arouse feeling of anger or resentment, or pose a threat 
to identity’ in the same ways as other areas included in their study.  
 
+
This section has argued that the boundary between lay and expert has 
increasingly been problematised in sociological discussions and that studies of 
lay health groups have played a prominent role in this.  A number of analysts 
have argued that such groups have the potential to influence the production of 
biomedical knowledge through contributing to or taking charge of research 
processes, based on the experiential knowledge and priorities of its members.  
The extent of the emergence of such novel relationships regarding expertise 
within patients associations is not clear and the idea that lay health groups 
privilege lay knowledge through their discourses and activities has also been 
contested. 
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This review has suggested that both biomedical and lay models of CHD are 
dominated by a focus on ‘lifestyle’ which strongly links CHD prevention to 
personal responsibility.  While there is a clear role for heredity in lay models, 
this is seen as secondary to lifestyle.  This is consistent with a genetic model 
that recently emerged in biomedical discourses, which is premised on the 
identification of genetic susceptibility to CHD and provision of personalised 
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preventative regimes.  This review has argued that, although references to a 
genetic model for common conditions such as CHD can be widely found in the 
social analyses of genetic developments, the degree to which such models have 
actually become established in biomedical discourse has yet to be studied.  It 
has also been suggested that existing studies concerning lay constructions of 
genetic risks and responsibilities have been undertaken mainly within genetic 
clinics and relating to conditions for which prophylactic therapies are absent.  
These observations about the current state of scholarship in these areas 
reinforce those made earlier about the state of empirical work regarding 
geneticisation.  In short, with the exception of hereditary breast/ovarian cancer, 
there have been few studies that relate to the genetic construction of common 
conditions.  This thesis, which looks at both biomedical and lay constructions 
of CHD and FH, is therefore novel in as much as (1) it is a study of genetic 
susceptibility for a common condition for which prophylactic therapies are 
available and (2) it focuses on a common condition for which there are already 
strongly established biomedical and lay models.  Finally, the review suggests 
that lay health groups are seen by some analysts as sites where biomedical 
knowledge is produced, or at least where lay or experiential knowledge is 
collated.  This suggests that such groups might be important places to study 
disease constructions.  The thesis adds to the limited body of research 
concerning patients’ associations and the construction of knowledge.      
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This chapter explains the rationale for the research design and how this 
developed, and provides a detailed account of the research process.  This study 
employed a number of qualitative methods drawing upon several different 
types of data sources.  The main methods were: 
1. "
#
		including a small number of 
selected recent commentary papers on CHD, and publications of 
HEART UK professional members and of the Simon Broome Register 
Group. 
2. -
	@
	A@-"*$+involving observation of the 
organisation’s public activities and analysis of the documents it 
produces. 
3. .	%@with senior members of HEART UK, and with patients 
with FH recruited through a lipid clinic.     
 
Table 3.1 provides a summary of how these different data sources relate to 
each research question.  To recap, the main questions ask how FH and CHD 
are constructed in recent biomedical literature, and how HEART UK and 
patients with FH construct these conditions.  These questions are intended to 
incorporate exploration of both explicit accounts of the aetiology of CHD and 
FH and the constructions of these conditions that are embodied in HEART 
UK’s activities and in FH patients’ talk about their experiences and actions as a 
result of diagnosis.   
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1. How are FH and CHD 
constructed in the recent 
biomedical literature? 
Analysis of : 
 a small number of commentary papers on 
CHD 
 selected publications of HEART UK 
professional members 
 Simon Broome Register group publications 
2. How does HEART UK construct 
FH and CHD? 
 Analysis of written materials concerning 
the aetiology and treatment of FH and 
CHD 
 Analysis of written materials concerning 
the aims, objectives and activities of the 
organisation including collaborative work, 
and the research, technologies and policies 
supported.  
 Observation of public events and other 
activities. 
 Interviews with staff, trustees and senior 
members of the organisation. 
3. How do patients with FH 
construct FH and CHD? 
 Interviews with patients with FH  
4. What roles do patients play in 
the construction of discourses 
about FH and CHD within 
HEART UK? 
 Interviews with staff, trustees and senior 
members of the organisation. 
 Written information about the workings of 
the organisation and its history.  
 Observation of activities  
 
 
This chapter first discusses the rationale for selecting the case of FH and CHD.  
It then discusses the methods employed including discussion of how the 
research plan developed, sampling, access and recruitment, the conduct of the 
research and analysis.  The last part of the chapter reflects on the research 
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process, considering ethical issues that arose in the research and reflecting on 
the limitations of the study.   
 
2;'"!-!--.,&
The previous chapter suggested that the geneticisation thesis generated a great 
deal of discussion, but has been the direct subject of little detailed empirical 
research.  The chapter also suggested that most empirical work concerning lay 
constructions of genetic disease had focussed on ‘classic’ Mendelian 
conditions, which tend to be relatively rare and untreatable, such as 
Huntington’s disease and Duchenne Muscular Dystrophy, or on hereditary 
breast/ovarian cancer (HBOC).  While this provides an example of an 
hereditary risk of a common condition, it can be characterised as a condition 
that tends to involve radical and invasive treatments and a condition for which 
preventative therapies are absent.   
 
The starting point for the research was to provide an empirical test of the 
claims of the geneticisation thesis.  By focussing on common adult&onset 
diseases, moving away from a focus on conditions managed through obstetric 
and genetic services, the aim was to provide quite a stringent test of the limits 
of the thesis.  Furthermore, this would provide an opportunity to compare 
whether the existing analyses of lay constructions of genetic disease had 
resonance in other settings.  The task was therefore to identify a case where a 
genetic condition leads to risk of a common condition, where preventative 
therapies and treatments are available.  The search was in some respects for a 
more ‘mundane’ condition.  Bearing in mind suggestions in the literature that 
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lay constructions of genetic risks and responsibilities may be gendered 
(Hallowell, 1999; Richards, 1996) and the existing focus of work on HBOC, 
the aim was also to identify a condition that affects both men and women.    
The choice of FH/CHD was, therefore, a strategic decision, driven by the aim 
of testing theoretical concepts.  This strategy can be seen as a form of 
‘theoretical sampling’, understood as:  
‘a process by which the researcher sets critical tests for the general 
validity of hypotheses and seeks to establish the conditions under which 
they do or do not hold’  
(Murphy & Dingwall, 2003: 113).     
  
Drawing on the arguments outlined in the literature review about the lack of 
agency attributed to lay people within the geneticisation thesis, my original 
intention was to focus on lay constructions of FH and CHD, by studying 
patients with FH and the patients’ association for people with FH, the Family 
Heart Association.  However, early in the study the FHA merged with the 
British Hyperlipidaemia Association (BHA), which was the national 
association for scientists and health professionals involved with lipid disorders, 
to form HEART UK.  Since HEART UK aims to act as both a patients’ 
association and a professional body, this raises questions about the degree to 
which it can be thought to represent a site of lay discourses and actions.  This 
necessitated some rethinking of the research strategy and questions.  For this 
and other reasons which are fully explained in the following sections, by the 
end of the pre&fieldwork phase, the focus had broadened to include biomedical 
constructions of FH and CHD.   
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As discussed above and in the introductory chapter, it was not my original 
intention to undertake an analysis of biomedical constructions of CHD, but to 
draw on existing analyses against which my own work on patients’ 
constructions could be set.  My initial reading of the literature suggested that 
genetic models for CHD were emerging along with such models for other 
common conditions.  However, I could not find any detailed analyses that 
focused specifically on recent constructions of the aetiology of CHD.  In order 
to get a feel for the scope and nature of the field, I started to undertake searches 
of the biomedical literature concerning CHD and FH and accrued a large 
number of papers and chapters from biomedical journals and books concerning 
the causes and management of these conditions.  Although initially I viewed 
this as secondary literature to be discussed in my literature review, I realised 
that this was actually primary data that should be analysed as such.  At this 
point, I took the decision that the research should include some systematic 
analysis of the biomedical literature. 
 
A full exploration of biomedical literature concerning CHD and FH would be 
beyond the scope of the thesis.  Indeed, it could be the subject of one or more 
entire theses.  There is a vast literature on CHD.  For example, by January 2004 
there were some 13,000 papers indexed in Medline under the MeSH heading 
‘coronary disease/etiology’ and almost 2,200 under the heading ‘coronary 
disease/genetics’.  My initial plan was to analyse a small number of general 
accounts of CHD, and this analysis was undertaken early in the study.  The 
merge between the FHA and BHA suggested the focus for further work, which 
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was undertaken later in the study.  The thesis, therefore, came to focus on three 
specific areas of literature:  
1. a small number of recent general accounts of CHD 
2. papers by professional members of HEART UK 
3. the publications of the Simon Broome Register Group.   
 
The Simon Broome Register Group is a semi&autonomous research group 
concerning FH, which is loosely connected to HEART UK.  The following 
sections will discuss the use of biomedical texts for studying disease 
constructions and the rationale for focussing on these three areas of literature. 
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There are potentially many ways of studying biomedical constructions of 
diseases including analysis of biomedical publications and undertaking 
interviews and ethnographic studies with biomedical professionals.  This thesis 
mainly draws on biomedical publications, but also includes some interviews 
with clinicians and scientists, which are discussed in later sections of this 
chapter.  Journal accounts of an area of science are highly accessible.  They are 
the accounts most likely to be available to and seen by others (Hedgecoe, 
2001a) and provide ‘potent markers of the state of knowledge in a particular 
field’ (Kerr, 2000: 854).  The different methods for studying scientists’ 
accounts of a given field tend to elicit different sorts of discourses.  One feature 
of journal accounts is that they tend to minimise ambiguity and controversy 
(Gilbert & Mulkay, 1994; Kerr, 2000; Kerr et al., 1997).  Myers (1990a) argues 
that although arguments are not uncommon in science, they rarely surface in 
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the scientific literature.  He proposes that the usual way of dismissing research 
in scientific papers is to ignore rather than to criticise it.  Because differences 
and ambiguity are often hidden, it is useful to compare different texts as a way 
of highlighting the different ways of constructing particular ‘problems, ‘facts’ 
and artifacts’ (Kerr, 2000: 854).  This requires sensitivity to the types of 
arguments and data that are included and those which are absent, and the kinds 
of understandings that remain implicit (Gilbert & Mulkay, 1994; Kerr, 2000).  
These principles guided my analysis of the biomedical literature concerning 
CHD and FH. 
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My initial analysis concerned general accounts of CHD within the biomedical 
literature, in order to gain an overview of this field.  The aim of this analysis 
was to indicate what aetiological models of CHD are present in the literature, 
to show how a genetic model of CHD and alternative models of CHD are 
constructed, paying attention to the kinds of arguments and evidence that are 
enrolled and the aspects that are absent.  This analysis identifies a number of 
different strands to aetiological models of CHD and types of arguments to 
support them, and this provides a framework for the subsequent analysis of 
biomedical constructions. 
 
The analysis focused on commentary articles. This type of article includes 
reviews, editorials and discussion pieces.  These discuss or draw together 
published research.  They are distinguished from original researchpapers, 
which present new, previously unpublished research.  The method of analysing 
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a limited number of commentary articles draws particularly on the work of 
Hedgecoe (2001a, 2002, 2003a) on the construction of genetic discourses in 
scientific review papers;

Review articles and other commentary pieces play an important and particular 
role in shaping scientific knowledge.  Citing the work of Greg Myers (1990a, 
b, 1991), Hedgecoe (2001a: 878) suggests that:  
‘review articles provide a textual space within which knowledge is 
constructed, allowing certain experimental reports to be seen as key 
papers.  Even the idea of the discovery of a particular fact depends upon 
review articles to organize the claims and techniques in a particular 
direction’.   
 
In other words, reviews shape scientific knowledge by selecting from existing 
research papers and putting these together to synthesise a particular narrative. 
The review draws the reader:  
‘into the writer’s view of what has happened, and by ordering the recent 
past, suggests what can be done next’  
(Myers, 1991:46). 
 
They are, therefore, concerned not only with what has happened, but also with 
shaping the future.  Hedgecoe (2003b) illustrates that commentary articles may 
well outnumber original research papers in emerging scientific fields.  This 
volume of commentaries would not be warranted if they were only concerned 
with reporting on current knowledge, but can be understood in terms of their 
importance in constructing future visions.  Following this logic, one would 
expect to find genetic discourses about CHD at least in commentary pieces, 
even if they were absent elsewhere.  

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This thesis analyses four commentary articles, selected from the fields of 
genetics, epidemiology and cardiology.  The selection of these articles was 
pragmatic to an extent, in as much as they were chosen at the early stages of 
the study in order to help get to grips with the scope of arguments about CHD.  
An initial search of Medline was undertaken using the MeSH term ‘coronary 
disease’ and key word ‘causes’.  This was limited to review articles in English 
from 1999&2003 and resulted in 79 papers.  However, the majority were very 
specific, concerning interventions, therapies, specific risk factors, CHD in 
relation to particular syndromes or conditions, or specific demographic groups.  
The search yielded two general epidemiological articles concerning CHD risk 
factors and one general review concerning genetics and CHD.  A second search 
of Medline using the key words ‘coronary heart disease’ and ‘genetics’ found 
20 commentary articles in English published from 1999&2003, of which six 
provided general overviews, including the one mentioned above.  The other 
articles concerned specific areas such as familial disorders, genetics and diet or 
lipid regulation.  Further searches of Medline using other keywords and MeSH 
terms, eg ‘Etiology’, and the same limits as the searches above were abandoned 
because of the large datasets they produced.  A search of the Eureka History of 
Science Technology and Medicine database was undertaken and this lead to the 
identification of a further four biomedical overview papers published in 
English between 1999 and 2003.  Taken together, these initial searches 
identified a dozen possible articles, from which four articles were selected for 
analysis.  They were chosen because they offered relatively general and 
accessible accounts.  They were also authored by eminent scientists in their 
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respective fields and were published in relatively influential (i.e. high&ranking) 
journals. 

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=.  This review paper is 
specifically concerned with genetics and CHD.  Professor Steve Humphries is 
one of the UK’s leading scientists in the field of cardiovascular (CV) genetics, 
Director of a British Heart Foundation funded centre for CV genetics and Chief 
Executive Officer of London IDEAS (London’s genetic knowledge park).  
Jeffrey Stephens was working as a clinical research fellow at the centre for CV 
genetics headed by Steve Humphries at the time of publishing.  This article was 
published in the Journal of Internal Medicine, which is ranked 13/103 in the 
2004 ISI Journal Citation Reports category medicine, general and internal.  ';C
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5This is a review 
and discussion piece concerning CHD risk factors and public health strategy.  
Robert Beaglehole is a well&known public health physician, currently working 
as an adviser to the World Health Organisation.  Paul Magnus, perhaps less 
well known internationally, is the medical advisor to the Australian Institute of 
Health and Welfare.  The article was published in the International Journal of 
Epidemiology, which is ranked 7/93 in the public, environmental and 
occupational health category.  The analysis also looks at the ensuing responses 
and discussion this article prompted.  This was unusual in that disagreements 
are made explicit in the texts.  It thereby casts into sharp relief the ambiguities 
involved in the construction of medical knowledge.  2C;D1999C
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	.  These authors were respectively Director of 
the American National Heart, Lung and Blood Institute and President of the 
American College of Cardiology at the time of writing these pieces.  Lenfant’s 
editorial was written to mark the fiftieth anniversary of the Institute and 
Beller’s lecture to mark the turn of a new century.  Both these texts very clearly 
provide the authors a space to create an account of the current field and 
envision the future prospects.  Lenfant’s article was published in the Journal of 
the American Medical Association, ranked 2/103 in the category medicine, 
general and internal.  Beller’s article was published in Circulation, which is 
ranked 1/71 in the category cardiac & cardiovascular systems.  Compared with 
the first two papers, the section of the analysis concerned with Lenfant and 
Beller is relatively short, reflecting the relatively shorter discussion of the 
causes and prevention of CHD in these papers.  
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HEART UK is now the professional organisation for a significant group of 
biomedical professionals involved in research concerning CHD and lipid 
disorders in the UK.  Furthermore, it is firmly connected to the Simon Broome 
Register Group.  This semi&autonomous research group, which is now 
administered through HEART UK, was formed around a national register of 
patients with hereditary lipid disorders to which a large number of lipid clinics 
contribute.  Research concerning the register is undertaken by the Simon 
Broome Register Group Committee.  It has been influential in the diagnosis 
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and management of FH, providing one of the internationally recognised sets of 
diagnostic criteria for FH (Austin et al., 2004) and epidemiological evidence 
demonstrating the efficacy of lipid lowering therapy in reducing CHD in 
people with FH.  Biomedical professionals involved with HEART UK and/or 
with the Simon Broome Group are an important subset of professionals 
involved with CHD and lipid disorders. The aim of this part of the analysis was 
to look at what aspects of CHD and FH aetiology this body of professionals 
contribute to through their research activities, drawing on the framework 
identified in the initial analysis.  
 
HEART UK has several hundred professional members and some 26 
professionals are either trustees of the organisation or sit on one of its 
subcommittees.  The analysis focuses on the recent publications of the 
individual members of HEART UK’s Research Committee and of the Simon 
Broome Register Group Committee.  They include 14 people in total, 10 
clinicians and four scientists, with three of the clinicians sitting on both of the 
committees.  The full details of the professionals and their publications is 
provided in Table 4.1 in Chapter 4.  The rationale for choosing these particular 
professionals was because they are members of the two committees within 
HEART UK that have a clear research remit.  In their positions as members of 
these committees they influence the research undertaken by HEART UK and 
by the Simon Broome Register Group.  They are, therefore, likely to both have 
an interest in research matters and represent the different research interests of 
the professional members of the organisation.  Furthermore, judging by their 
publications, résumés and performances at the HEART UK conferences, these 
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groups appear to include some of the most influential biomedical professionals 
in the field of lipidology and/or CHD risk prediction in the UK.  
 
An author search was undertaken in September 2005 in Medline for each of 
these members, limited to publications from 2000 onwards.  The analysis 
considered titles and abstracts, where provided, of all publications, including 
research and commentary pieces
6
.  A total of 330 papers were included in the 
analysis.  Medline provided abstracts for 80 per cent of these papers, and titles 
only for the remaining 20 per cent.  The titles and abstracts of papers presented 
at the HEART UK Annual Medical and Scientific Meetings in 2003 and 2004 
were also considered in this analysis, a further 59 papers.  The analysis focuses 
on enumerating the main areas of interest of these researchers and how these 
relate to the aetiological models described in the analysis of commentary 
papers.  This is not a detailed analysis of arguments and strategies, but a broad 
brush approach that builds on the framework provided by the initial analysis.  It 
provides a quantitative element by showing the main aspects of CHD aetiology 
this particular group of researchers contribute to, and enumerating the number 
of papers they have written that focus on genetic aspects of CHD and the other 
aspects of CHD aetiology identified in the initial analysis.  
 
 


                                                
6
 Steve Humphries, a member of the Simon Broome Register Group, has a prolific output, with 
185 publications listed just in the years from 2000 onwards.  It was necessary to limit his 
papers to a manageable number.  Therefore the analysis includes his papers from two years, 
2000 and 2005, only, which includes 45 papers.   
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The third set of biomedical papers analysed are the publications of the Simon 
Broome Register Group (Humphries et al., 2005; Huxley et al., 2003; Neil et 
al., 2003, 2004, 2005; Scientific Steering Committee on Behalf of the Simon 
Broome Register Group, 1991, 1999).  As I have already argued, in the UK 
context, this is a very important group concerning the diagnosis and 
management of FH.  It has provided a set of widely recognised diagnostic 
criteria for FH and important epidemiological data concerning mortality rates 
and treatment of the condition.  The analysis focuses on how the aetiology and 
classification of FH are constructed within these publications and particularly 
on the place of DNA&based information in these constructions.  This is 
compared with the constructions within a small number of commentary papers 
written by individual members of the group.  Like the initial analysis of the 
four commentary papers on CHD, this analysis again involves a close reading 
of the arguments and evidence used in these papers to show where differences 
and ambiguities exist and how these are managed.  It again shows how these 
articles are used as spaces in which to corral evidence to support particular 
arguments and envision specific futures for the diagnosis and management of 
FH.    

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My original plan was for this part of the research to focus on the Family Heart 
Association (FHA).  This organisation, founded in 1982 by patients, was the 
main patient&focused charity concerned with inherited high cholesterol.  In 
addition, I intended to include some analysis of two further and contrasting 
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patients’ associations concerned with CHD.  During the preparatory phase of 
the research the FHA merged with the BHA. This necessitated a rethink 
concerning the questions to be addressed and the research design.  As a result 
of the merge and in combination with reflections about the lack of detailed 
analysis of CHD aetiology, a new area of research concerning constructions in 
the biomedical literature had been added to the research design, as discussed in 
the previous section.  Because of this additional research area and the 
additional questions that opened up in connection with the forming of HEART 
UK, it no longer seemed feasible to pursue the research on the two further 
patients’ associations.  This section of research therefore focuses entirely on 
HEART UK.   
 
HEART UK remains a relatively small health charity.  It currently has seven 
members of staff and a membership made up of both patients and 
professionals.  Responsibility for the activities of the charity is divided between 
the staff, the board of trustees and a series of subcommittees with 
responsibilities for overseeing areas such as patient services, medical and 
scientific matters, and the finance and general administration of the 
organisation.  The overall remit of the charity has altered due to the merge, 
now including greater emphasis on professional education, dissemination and 
research.  Nevertheless, a central concern remains supporting and representing 
patients with familial hypercholesterolaemia.   
 
The aim of this research with HEART UK was to see how the organisation 
constructs FH and CHD and the way these constructions are embodied in and 
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reinforced by its activities.  Previous research suggests that different sections of 
patients’ associations may have different priorities and ways of constructing 
health problems.  Williams (1989), for example, showed there may be 
differences between discourses at the local and national level and Stockdale 
(1999) highlighted the existence of tensions concerning priorities, between 
focussing on the immediate care of members and focussing on research.  These 
differences may or may not map onto differences between lay and professional 
priorities.  This research was, therefore, concerned with the possibility that 
different people or sections within HEART UK may construct FH and CHD 
differently.  Related to this, and in view of the merger, the analysis was also 
concerned with how expertise is conceived within the organisation and the 
kinds of relationships vis&à&vis expertise that it embodies.  The research 
involved three main areas of activity: observation of the public events of the 
organisation; analysis of documentary material produced by the organisation; 
and interviews with members of HEART UK.  The first two of these are 
discussed in this section and the interviews are discussed separately.   
 
"
I made contact with the FHA at the outset of the research, as part of putting 
together the research proposal for my studentship application.  At that stage, 
the organisation expressed support, in principle, for the research.  The 
organisation has acted as both a research site and a source of information in 
developing the research plan.  My main point of contact has been the principal 
nurse advisor.  She provided preliminary details of the structure and 
organisation of HEART UK and also filled in details about how services for 
 103
people with FH are organised.  I requested that the administration provide 
some written approval for the research involving HEART UK and this was 
again fielded by the principal nurse advisor.  I also made contact with the Chair 
of the patient services committee, who agreed to facilitate contact with 
patients/lay people who are active in the organisation.   
 
A couple of months after approval had been provided, I received an e&mail 
saying that one of the professional trustees had raised some concerns about the 
research when it was discussed at a trustees’ meeting.  In essence, he was 
concerned that I would judge HEART UK’s activities or put them in a bad 
light.  As Hammersley & Atkinson (1995) note, gatekeepers approach research 
with a set of expectations about the identity and intentions of the researcher 
and often adhere to a model of the researcher as either ‘expert’ or ‘critic’.  It is 
not unlikely for gatekeepers to associate research with evaluation, as in this 
case.  The matter was resolved by me e&mailing the trustee.  I provided details 
of the project and its main aims, and reassurances that the research was not 
controversial, and that it was not my intention, nor was I qualified, to judge 
HEART UK’s activities.  This exchange flags an important issue concerning 
the research on HEART UK.  Because this is a small and identifiable charity, 
which is to some degree reliant on the maintenance of a particular image for its 
funding and support, I had to think carefully about how to present data on the 
organisation and about the nature of my relationship to the organisation. This is 
discussed in greater detail in the section concerning ethics.   

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Observation is often considered the ‘gold&standard’ for qualitative research 
(Murphy & Dingwall, 2003).  Due to the limitations of the doctoral research 
and the number of other aspects of the research I planned to undertake, and 
also due to the nature of the work of HEART UK, which includes a diverse set 
of activities in a variety of locations, extensive or extended ethnographic work 
was not feasible.  Nevertheless, I planned to undertake a limited amount of 
observational work.  It was not clear at the outset what this might include, 
although I planned, as a minimum, to attend public events of the organisation.  
Initially, I thought it might also be possible to attend some local groups and 
talk with local members.  However, it transpired that there are currently no 
local support groups.  The observational part of the research, therefore, 
included attendance of the HEART UK Annual Medical and Scientific 
Meetings in 2003 and 2004 and the patients’ workshops that run along side this 
meeting, the AGMs of 2003 and 2004 and the Annual Members’ Day in 2004 
(there was no members’ day in 2003).  I also visited the offices of HEART UK. 
 
These activities were important both for the research process, in terms of 
becoming familiar with the activities of HEART UK, identifying key people 
within the organisation, negotiating access and maintaining good relations, and 
because of the interesting data gathered at these visits.  Attendance at the 
earlier of the medical and scientific meetings, for example, provided an 
opportunity to identify some of the important people within the field and get a 
feel for the work of HEART UK more generally and the visit to HEART UK’s 
offices provided an opportunity to gather materials such as information leaflets, 
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back copies of the organisations bimonthly magazine, the ‘Digest’, details of 
the committee structure and contact details of the committee members, and to 
meet and talk with the administrative and health staff.  This eased further 
contacts and requests for information later in the study.   
 
At the public meetings, I made notes on the arguments and evidence enrolled in 
presentations and discussions, the number and type of attendees, the questions 
that lay members and professional members asked and how these were 
answered.  I also reflected on the way the meetings were organised and run and 
the types of interactions this elicited.  I endeavoured to keep a clear distinction 
in my records between observations of what was happening and what was said, 
in concrete terms, and my reflections and comments about the possible 
meaning of this.  After each meeting or visit I compiled summary notes of my 
main observations and thoughts, which fed into my developing ideas for the 
analysis.  The field notes were analysed in terms of how CHD and FH are 
constructed, looking particularly at the types of priorities and issues dealt with 
at the meetings and the way they were discussed.  They were also analysed in 
terms of the role of lay people at the meetings and the relationship between lay 
and professional members demonstrated. 
 

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HEART UK produces a large amount of written materials that provide a source 
of data about its activities, priorities, history and administration.  Before 
providing details of the analysis undertaken, it is necessary to consider the 
status of such documentary material.  Murphy & Dingwall (2003: 54) argue 
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that organisational documents sit somewhere between observation and 
interviews in as much as they are a source of ‘given’ data, in other words the 
data is not specifically created for the research, but involve the ‘artful 
reconstruction’ of events, as well as being part of the events of the 
organisation.  Such documents are concerned with the self&presentation of the 
organisation to itself and to others, and should not be treated as providing 
unequivocal evidence of what they report (Atkinson & Coffey, 1997).  Rather, 
they provide evidence of what the organisation would like to be thought of as 
doing (Murphy & Dingwall, 2003).  The documents included in this analysis 
were treated as both providing evidence of the activities undertaken by 
HEART UK, although with caution, and as a site where particular versions of 
CHD and FH and particular versions of HEART UK are constructed.  This 
discussion of how to understand documentary material anticipates, to some 
extent, the discussion of the status of interview data provided in the next 
section. 
 
The following documents were collected: an almost complete set of AGM 
minutes for FHA/HEART UK from 1984 onwards, annual reports for 2003 and 
2004, a complete set of patient information leaflets, copies of the ‘Digest’ from 
October 2002 onwards and other documents, including pages from the website 
and articles from newspapers and journals.  All these materials provided useful 
contextualising information about the organisation and its activities.  Detailed 
analysis was undertaken of the patients’ information leaflets and of the annual 
reports/AGM minutes, mainly because they were two discrete and largely 
complete sets of data of manageable proportions.   
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The analysis of the patients’ information leaflets focussed on the elements of 
CHD and FH aetiology that are present and absent in these leaflets and the way 
these elements are constructed.  This analysis follows on from the analysis of 
biomedical constructions of FH and CHD, drawing on the framework of 
aetiological elements this identified.   
 
The AGM minutes and annual reports were analysed in terms of the focus of 
the stated aims, priorities, plans and activities.  The key aspect of the analysis 
was to look at the distribution of focus on FH, CHD and genetics, and to look 
for indications of the role of lay members.  These documents also provided a 
source of information about the people who have been involved and a way of 
tracking changes in personnel.  The analysis recognises that the AGM minutes 
and annual reports include an element of image management, and that they are 
likely to talk up the achievements of the year and set an aspirational vision for 
the coming year that may or may not be realised.  They provide the public face 
of the aims and activities of the organisation.  In terms of concrete activities 
and events, I tried as far as possible to draw on multiple sources such as press 
releases, the interviews, the ‘Digest’ and commentary in the biomedical 
literature.  There were, however, references to a number of planned activities in 
the minutes that I did not come across elsewhere.  These were read as 
indicative of the aspirations of the organisation rather than necessarily direct 
evidence of the activity.  
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Although observation is generally seen as the method of choice in qualitative 
studies, there are a number of arguments in favour of interviews, and 
qualitative interviews in particular.  The main reasons in this study were 
practical and pragmatic ones.  Some research topics may not be amenable to 
observation, for example where there is no specific physical location for the 
topic in question, or where relevant events occur sporadically or in a private 
domain such as family life, where access is likely to be problematic (Bryman, 
2001; Murphy & Dingwall, 2003).  There may also be a pragmatic angle.  For 
example, it may be easier to negotiate access for interviews than for more 
protracted observational work.  My decision to undertake interviews was based 
on just such practical and pragmatic reasons.  I have already suggested that 
HEART UK’s activities are relatively dispersed and, that due to the constraints 
of doctoral research, observation over a long period of time was not feasible.  
‘Ordinary’ FH patients are a diffuse set of people who cannot be thought of as 
a social group.  There is little opportunity to observe how individual patients 
construct their condition in an organised setting.  To observe the relevant 
actions and interactions in their everyday lives, such as in their home, at work, 
with family or in their social lives would be lengthy and intrusive.   
 
Other reasons in favour of qualitative interviews include the argument that 
certain phenomena such as thoughts, intentions and the meaning people attach 
to events cannot be directly observed (Murphy et al., 1998).  It is also argued 
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that in comparison with more standardised approaches, qualitative interviews 
are more flexible, so that one is able pursue interesting aspects that arise during 
the fieldwork period, rather than having to know in advance the important or 
interesting aspects of the area being researched.  These arguments could also 
be used to justify my choice of interviews. 
   
However, the status of interview data, i.e. the types of claims that can be made 
using this data, is highly contested.  The main point at issue is the degree to 
which interviews are thought to provide access to external reality, e.g. the 
actions people take as a result of a diagnosis of FH, or internal reality, e.g. their 
ideas about disease categories and their motivations for their actions.  
Silverman (1985: 15&16, in Murphy et al., 1998: 105) has argued that 
interviews:  
‘provide idealized accounts of attitudes and behaviours which, because 
they are rationalisations have an uncertain relation to actual situations’.   
 
Studies that combine observation and interviews have highlighted the potential 
disparity between observed interactions and people’s accounts of these 
interactions (see for example Allen, 1997; Stimson & Webb, 1975).  The 
argument that interviews allow access to interviewees’ thoughts and 
perspectives (i.e. an internal reality) is also problematic.  Murphy & Dingwall 
(2003) argue that there is a tendency to use such data as evidence to explain 
why people behave as they do, and associate this with two problematic 
assumptions.  First, they argue that such a strategy is based on:  
‘the assumption that inside informants’ heads, there are stable meanings 
attached to an event or experience that the interviewer must …uncover.  
This approach fails to recognize the ambivalence characteristic of much 
of our thinking’  
(ibid: 94).  
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This leads them to the second problematic assumption, that the meaning and 
motivations given by interviewees can be seen as a direct representation of the 
mental states underlying their actions.   
 
These issues concerning interpretation lead some analysts to favour an 
approach to analysing interview data that explicitly recognises the interview as 
an %& of social interaction.  It is then seen as an event that occasions 
‘impression management’ guided by ‘a dance of expectation’ (Dingwall, 1997: 
56).  To put it simply, what we say at interviews depends on who we think we 
are talking to and in what situation.  They should be seen as events in which 
shared cultural understandings of a particular phenomenon are reproduced and 
the focus of the analysis should be on what people are 	
 with their talk.  
They are: 
‘occasions on which informants are called upon to offer “accounts” for 
their actions, feelings, opinions and so on.  In providing these accounts 
informants seek to present themselves as competent and, indeed, moral 
members of their particular communities.  Interviews are occasions for 
informants to display themselves as adequate parents, good patients, 
well&informed citizens, responsible adults, and competent 
professionals&or to produce socially acceptable explanation of their 
failure’ 
(Murphy & Dingwall, 2003: 95&96).  
 
In this way, interview accounts could highlight the thoughts and actions 
deemed to be appropriate to the competent FH patient or HEART UK trustee.  
Not all authors, however, have abandoned the possibility that interview data 
can say anything about the interviewees’ external or internal reality.  
Hammersley and Atkinson (1995:126), for example, suggest that informants’ 
accounts can be analysed in terms of both ‘information’ and ‘perspective’, 
arguing that participants’ knowledge can be treated ‘as both resource and 
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topic’.  These arguments about the status of interview data continue.  This 
discussion has highlighted, in any case, the importance of taking into account 
the context of the interview in analysing such data. 
 
In my own study the interviews with HEART UK members were seen as 
fulfilling two functions.  First, they provided information about the activities 
and policies of HEART UK.  As discussed in the previous section, combining 
data from the interviews and documents helped to provide a more 
comprehensive picture of the organisation’s past and present activities.  
Second, the interviews were analysed in terms of ‘perspective’.  The analysis 
focuses on the types of constructions of FH and CHD that are embedded in the 
interviewees’ accounts of the causes of these conditions, the activities of the 
organisation and its priorities.  The focus here, for example, was not so much 
on what activities are undertaken, but which activities and topics are discussed 
by interviewees and which are not discussed, or the way certain activities are 
foregrounded.   
 
In analysing these interviews I tried to keep in mind the way the context of the 
interview may have shaped the accounts provided.  For example, I was aware 
that there may be some incentive to project a positive or successful image of 
the organisation and that the interviewees were used to representing their 
organisation and giving media interviews.  It was particularly interesting to see 
how they approached the research interview.  Only one of these interviewees 
seemed to provide an ‘official’ account.  The others were more personal 
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accounts, providing an individual perspective in some way, although, like 
every encounter, they were also shaped through ‘impression management’. 
 
In terms of the interviews with FH patients, I have tried to avoid making 
assumptions about the veracity or otherwise of interviewees’ reported actions 
or thoughts.  It is not that there are any particular reasons to believe or doubt 
these accounts, but the emphasis was more on what they indicate about the 
normative frames associated with CHD, raised cholesterol and genetic disease.  
So for example, the section of the analysis concerned with telling relatives 
about the diagnosis is not so much concerned with which relatives the 
interviewee talked to about the diagnosis, but with the way telling was or 
was not framed as an obligation through their interview talk.    

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My intention was to undertake between 10 –15 interviews with a mixture of 
staff, professional members and lay members of the organisation.  Interviewees 
were mainly drawn from the staff, trustees and members of the sub&committees 
of the organisation.  At this time, there were 7 members of staff, a total of 26 
professional members who were trustees and/or committee members and a total 
of 5 patient members who were trustees and committee members.  I had 
planned to include some lay members who were active at a national level and 
some at a local level.  As already noted, it transpired that there are currently no 
official local support groups affiliated to the organisation.  I, therefore, asked 
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the chair of the patients’ services committee if she could suggest any further 
patient members who were particularly involved in the organisation.   
 
Potential interviewees were invited to participate by letter or email and this was 
accompanied by an information sheet.  Copies of these documents are provided 
in appendix 2.  Everyone approached agreed to participate with the exception 
of one trustee who declined on the basis that he had actually just retired from 
the board.  A total of 10 interviews were undertaken.  This includes five 
interviews with lay/patient members and five with staff and professional 
members.  All of the interviewees had senior positions within the organisation 
or had taken a lead in some part of its activities.  In an effort to protect the 
anonymity of the interviewees, I will not provide any more specific details of 
their role or functions within the organisation, other than to note that the lay 
members interviewed included both trustees and other members.    
 
-
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Interviews were semi&structured, guided by a set of questions drawn up in 
advance.  These focussed on the interviewees’ own involvement in HEART 
UK and its aims, structure and activities, its history, and hopes for the future.  
The exact areas and questions used in each interview depended to some extent 
on the role of the interviewee within HEART UK and how long they had been 
involved with the organisation.  An interview guide containing the main areas 
and questions drawn on is provided in appendix 3.  A few specific areas of 
questioning have been omitted from this, where they provide large clues as to 
the identity of specific interviewees.   
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All the interviewees agreed to the interview being recorded, and all were 
recorded digitally.  Interviews lasted between 50 minutes and one hour and 50 
minutes.  The majority of the interviews were undertaken face&to&face.  These 
took place in a number of settings, including the head offices of HEART UK, 
at one of the Annual Scientific and Medical Meetings, at the interviewees’ 
places of work, and in a café.  One was undertaken by telephone.  This came 
about for a number of reasons.  It was not clear at the outset how much 
involvement the interviewee had currently or recently had in HEART UK.  
Added to this, she was located in a different and distant part of the country to 
me, is retired and no longer travels to the HEART UK meetings.  This meant 
that the most likely venue for a face&to&face meeting would be at her home.   
Such a meeting would have involved a long and potentially not particularly 
fruitful visit for me and an imposition for the interviewee.  I, therefore, 
arranged to talk to the interviewee on the phone.  Despite my initial 
uncertainty, it turned out to be a very important interview and worked very 
well over the phone.  The call lasted for more than 90 minutes and, in this case, 
it was not difficult to build up a rapport quite quickly.  It was not different in 
character or substance to the face&to&face interviews conducted.  
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Murphy et al. (1998) argue that there has been increasing concern with the 
issue of generalisability of qualitative research.  Drawing on Schofield (1993), 
they suggest that in the process of selection: ‘pragmatic decisions should be 
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integrated with a commitment to drawing samples in a systematic and 
principled way’ showing concern for the typicality of the setting (Murphy et 
al., 1998: 93).  Hammersley (1992: 88) also argues that:  
‘being unable to use probability methods does not rule out the 
possibility of making reasonable judgements about the 
representativeness of findings drawn from a particular setting in 
relation to some wider population’.   
 
This section will discuss how the site for the research was selected and how 
sampling within this site was undertaken. 

Site selection 
People with FH were recruited through a lipid clinic in a large city in the north 
of England.  Lipid clinics are specialist outpatient clinics concerned with the 
care of people with lipid disorders.  There are currently 135 clinics providing 
lipid services in the UK (Marks et al., 2003a) and it has been estimated that the 
majority of people diagnosed with FH are registered with a clinic (Neil et al., 
2000).  The decision to recruit through a lipid clinic was based on the premise 
that they are likely to provide access to relatively large numbers of FH patients 
and to have diagnosed patients precisely, i.e. there is less chance of people with 
other forms of high cholesterol being put forward into the study.  By contrast, 
most general practices could be expected to have only a very small number of 
identified patients with FH.  An alternative may have been to draw on the 
patient members of HEART UK.  However, they are likely to be 
predominantly middle&class (see Rapp et al., 2001) and to have engaged with 
biomedical perspectives about FH.  In comparison, lipid clinics offer a source 
of ‘ordinary’ patients (Lambert & Rose, 1996: 70).   
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The selection of the particular clinic was largely pragmatic, but has interesting 
theoretical implications.  The pragmatic aspects were concerned with location 
and access.  The clinic is one of a handful that were geographically convenient 
for me to reach, and it was suggested to me that the consultant physician who 
heads this clinic was both very approachable and research&orientated.  
Furthermore there turned out to be practical benefits to this selection.  The 
operational aspects of the clinic and its size meant that it was possible to reach 
a reasonable sample size within a workable timeframe at this one clinic, 
avoiding the costs of having to negotiate access to further clinics.   
 
It is not clear how typical the clinic is of all FH clinics, and what difference the 
typicality of the clinic might make to patients’ constructions of FH.  There are 
a number of issues that may characterise lipid clinics, such as whether they 
undertake cascade screening or DNA diagnostics, the division of responsibility 
with primary care, and the size and prestige of the clinic.  Marks et al.’s 
(2003a) census of lipid clinics suggests wide variations in the size and 
operation of these clinics, suggesting it may be difficult to define what 
constitutes a typical lipid clinic.  The clinic at which the research was 
undertaken is large and run by a research&active consultant who is a recognised 
expert in the field.  Furthermore, the clinic has undertaken cascade screening of 
first&degree relatives (parents, siblings, offspring) of FH patients for at least a 
decade.  It has not yet been established the extent to which other lipid clinics in 
the UK are undertaking systematic cascade screening, although it is certainly 
patchy (personal communication, Dalya Marks, 23 June 2003).  It is possible 
that the clinic is unusual in this respect and that such screening may encourage 
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patients to frame FH in a more genetic/hereditary way than other patients.  On 
the basis of the size, location and prestige of the clinic, it is likely that it 
employs the most progressive practices and cutting&edge clinical techniques 
available.  One can argue that, if geneticisation were likely to be seen 
anywhere, then it would be at such a clinic.   

Within case sampling 
Hammersley & Atkinson (1995: 50) suggest that sampling of people may be 
undertaken on ‘fairly standard ‘face&sheet’ demographic criteria’.  However,: 
‘these face&sheet categories are important only as they are relevant to 
the emerging analysis or to rival theories, or to ensuring representation 
in terms of some larger population, and they will usually be 
complemented by other categories of analytic relevance’  
(ibid: 50).   
 
Clarity is called for in identifying which demographic and other criteria are 
important. Murphy’s (2000) study of first&time mothers’ feeding practices, for 
example, employs a quota sample based on two variables, occupational class 
and age, that had been identified as key variables in previous research.   
 
Following Murphy’s example, this study employs a quota sample on the basis 
of three variables indicated as important in the literature.   Work by Hunt and 
colleagues (Hunt et al., 2000b, 2001; Watt et al., 2000) suggests that 
perceptions of a family history of CHD are patterned by gender, class and age.  
It is likely, therefore, that these may also be related to patients’ understandings 
of FH.  The possibility of a gendered approach to genetic responsibility has 
also been raised (Hallowell, 1999; Richards, 1996).  A quota sample was, 
therefore, adopted for the categories of gender, class and age, with the intention 
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of ensuring that the sample was heterogeneous with regard to these categories.  
The quota sample used the categories and groups shown in table 3.2:  

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Gender Age Occupational class* Planned 
Number 
Male 18&45 Managerial, professional & intermediate 4 
  Routine & manual 4 
 46 + Managerial, professional & intermediate 4 
  Routine & manual 4 
Female 18&45 Managerial, professional & intermediate 4 
  Routine & manual 4 
 46 + Managerial, professional & intermediate 4 
  Routine & manual 4 
*Categories are derived from the new National Statistics Socio&Economic 
Classification.  Intermediate occupations include clerical and technical 
occupations and non&professional small employers and self&employed. 

The sample for the study was limited to people aged 18 or over who had been 
diagnosed for at least six months prior to the interview.  These selection criteria 
were applied because the interviews are concerned with people’s everyday 
understandings and experiences of FH and these may take some time to 
become established.  Furthermore, diagnosis is an exceptional time and may 
elicit a particular set of short&term concerns and issues.  The research focussed 
on adults with FH for practical reasons.  Other people for whom participation 
would be inappropriate, for example those who have serious illness, were also 
excluded. 
 
 119

	

HEART UK provided details of several lipid clinics in my locality and the 
names and contact details of the clinicians who run them.  As indicated in the 
section above, the principal nurse&advisor at HEART UK indicated that she 
knew one of the clinicians through the work of the HEART UK and that he 
was an approachable person and research&active.  I made contact with this 
clinician at the HEART UK Annual Medical and Scientific Conference 2003, 
introducing myself and mentioning my proposed research.  The clinician 
invited me to send him some project details and my C.V. and to make an 
appointment to meet him.  He responded very quickly by post, agreeing to 
allow me access to his patients on the basis of the written information I had 
sent him, even before we met to discuss the research in detail.  He has been 
helpful throughout, providing stewardship of the LREC application and 
guidance on completing the forms, and volunteered the assistance of his 
research nurse to help and advise with recruitment.  Fortunately, she was also 
extremely helpful, despite her own demanding work commitments.  In short, 
access to the clinic proved to be amazingly straightforward. 
 
Application for approval by the relevant LREC was submitted in September 
2003 and considered in November.  It was granted conditional approval subject 
to a number of minor amendments and clarifications and full approval was 
granted on 15
th
 January 2004.  I attended the clinic to observe consultations 
during November 2003.  This helped me gain familiarity with the organisation 
and administrative procedures of the clinic, which was useful in developing the 
recruitment procedures and forming ideas about the practicalities of the 
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interviews.  I was also able to start to establish a relationship with the staff at 
the clinic.  This period of observation also allowed me to start to become 
familiar with the language associated with lipid disorders and sensitised me to 
some of the issues surrounding FH.  
 
The clinic runs on one half&day per week and currently has a register of more 
than 300 patients with a diagnosis of definite FH.  Patients are seen every three 
months to year, depending on the stability of their condition and treatment.
Patients were recruited from January to August 2004 and the first interview 
took place on 29 January 2004.  The hospital was able to provide a clinic list 
on a two monthly basis and this was used to compile a list of patients eligible 
for the study, which included information about age, gender, occupation and 
length of time since diagnosis.  A total of 117 people with definite FH aged 
over 18 were booked appointments between January and August 2004.  This 
included approximately equal numbers of men and women.  There were more 
older than younger people, with just over a quarter falling into the 18 to 45 age 
group.  Occupational information was sometimes sketchy or missing and it was 
therefore not always possible to categorise occupational class with certainty or 
at all.  Nineteen of the people could not be categorised on the basis of the 
available information.  About a quarter of those who were categorised had 
routine or manual occupations.   
 
Patients were selected randomly from the list to fulfil the quota sample based 
on age, gender and occupational background.  Selected patients were sent a 
letter inviting them to participate in the study, which was accompanied by a 
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participant information sheet (these are included in appendix 4).  They were 
asked to complete a return slip confirming whether or not they were willing to 
participate and whether they would prefer to be interviewed at the clinic or 
elsewhere.    Fifty&five people were invited to participate and 32 people, or 
about 60 per cent, accepted.  When broken down by age, gender and 
occupational group, it was noticeable that men were much more likely to agree 
to participate than women (18/24 men compared with 14/31 women agreed).  
The possible significance of this is discussed in the final section of this chapter 
concerning the limitations of the study.  
 
A total of 31 interviews were undertaken in the time period indicated above.  
One interview was conducted at the interviewee’s home and all the remaining 
interviews were undertaken at the hospital.  Most of these were undertaken in 
the lipid clinic either immediately before or after the patients’ scheduled 
appointment.  Three interviews were undertaken in a separate location in the 
hospital when the patients came in to participate in a clinical trial.  Four 
women brought relatives into the interview, on two occasions their husbands, 
once a daughter and another time a daughter&in&law.   

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The characteristics of the interviewees, in terms of the quota sample, are shown 
in Table 3.3, below: 
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Gender  Age Occupational 
Group* 
Interviews 
Actual (planned) 
Male 18&45 1 6 (4) 
  2 0      (4) 
 46+ 1 7      (4) 
  2 4      (4) 
Female 18&45 1 4      (4) 
  2 1      (4) 
 46+ 1 5      (4) 
  2 4      (4) 

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*Occupational groups are based on the new National Statistics Socio&
Economic Classification.  Group 1 = managerial, professional and intermediate 
occupations (intermediate occupations includes clerical and technical 
occupations and non&professional small employers and self&employed).  Group 
2 = routine and manual occupations. 
 
Table 3.3 shows that it was difficult to recruit to two cells i.e. younger men and 
women with manual or routine occupations.   This can mainly be attributed to 
the low numbers of these groups of people attending the clinic rather than a 
lower response rate.  There were only four men and one woman in these groups 
booked in for appointments during the seven&month fieldwork period.  Two of 
the men and the woman were invited to participate in the study.  Both the men 
declined and the woman agreed.   
 
Demographic details 
Interviewees ranged from 24 to 69 years old at the time of interview, although 
the majority (27/31) were aged 40 or over.  There were slightly more men than 
women (17&14).  Interviewees had a variety of occupational backgrounds.  
Based on the new NSEC three&class categorisation, almost half (15/31) had 
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managerial or professional occupations, just under a quarter (7/31) worked in 
intermediate occupations including self&employed manual workers, and the 
remaining (9/31) interviewees had routine or manual occupations.  The 
majority of the interviewees had children (25/31).  All the interviewees 
classified their ethnicity as white, and the majority (28/31) as white British.   

Clinical details 
According to the clinic’s records, the interviewees were entered onto the 
clinic’s register of FH patients between 1983 and 2002.  This means that 
everyone had been diagnosed with FH for at least a year if not substantially 
longer at the point of the interview.  Interviewees were between 10 and 63 
years old when their diagnosis was entered onto the clinic register.  
Interviewees identified the point at which their high cholesterol was 
established, which according to their accounts was often several years earlier 
than the year their FH was registered at the clinic.  According to these 
accounts, the majority of interviewees found out that they had raised 
cholesterol in their twenties, thirties or forties.  
 
According to their own accounts, approximately half of the interviewees had 
experienced some form of CHD, either heart attack or angina, and/or 
undergone some form of heart surgery such as by&pass surgery or the insertion 
of stents.  As would be expected from the biomedical literature on FH, a larger 
proportion of the men than the women had experienced CHD (10/17 men 
compared with 5/14 women).  There was also a marked difference in 
experience of CHD in the sample by occupational category, with the 
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managerial and professional group having less CHD than intermediate group 
who had less than the manual and routine group (4/15, 4/7 and 7/9 
respectively).  There does not appear to be any published data on rates of CHD 
in people with FH analysed by occupational class, but these differences follow 
the same pattern of CHD analysed by socio&economic class within the general 
population
7
.   
 
-
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Interviews were semi&structured.  An interview topic guide was drawn up, 
based on the research questions and the literature on genetic responsibility and 
lay constructions of genetic disease.  It focused on explanations of FH and 
CHD, and interviewees’ accounts of their experiences and actions in relation to 
FH.  The final version of this is provided in appendix 5.  Since the aim of these 
interviews was to consider in what ways patients construct FH as genetic, a 
major issue in designing the interview topic guide was trying to avoid pre&
framing FH in a genetic way.  For this reason the guide asks, for example,  
patients talked to about their diagnosis, prompting for whether this included 
any family members, rather than asking primary questions about 	 family 
members they told and did not tell.  A second issue was how to access 
interviewees’ explanations of FH and CHD.  Asking people directly to explain 
how they understand particular disease categories is problematic.  They might 
feel like they are being tested against some standard textbook answer and may 
be reticent to answer because they feel that their knowledge is inadequate.  
This issue is discussed by Lambert & Rose (1996), who approached this by 
                                                
7
 It would be unwise to make too much of these differences in view of the small sample size, 
but at first glance, this might suggest that the severity of CHD in FH varies with occupational 
class or that people enter the clinic at different stages of their FH career.   
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asking their interviewees how they would explain their condition to other 
people.  Following Lambert and Rose, I included questions about the situations 
interviewees find themselves talking about their condition, what they say about 
it in these situations and how they might explain it to someone who had not 
come across it before.    
 
The guide was amended on the basis of the first few interviews, with one 
question amended, one dropped and a new area added.  For example, I initially 
intended to start by asking how the interviewee came to be diagnosed with FH 
or familial high cholesterol. I very quickly realised that interviewees did not 
necessarily identify with these terms and using them immediately framed the 
condition in a particular way.  The question was therefore rephrased to ‘how 
did you come to be a patient at this clinic’.  This provided an opportunity to 
pick up on whatever phrase the interviewee used to describe their condition and 
then to use this throughout the interview.   
 
All interviews began by dealing with the consent procedure and consent form, 
required as part of the standard LREC process.  Participants were asked as a 
separate question whether they would consent to the recording of the interview 
(consent form is included in appendix 4).  The interview then covered 
demographic details to confirm the interviewee’s occupation and age, and to 
provide details of their domestic situation and ethnicity, before getting into the 
main part of the interview.  The topic guide was then used in a flexible way, 
and interviews covered some or all of the areas depending on the direction of 
discussion and the relevance of the questions, and on any time constraints 
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indicated by the interviewee.  Interviews lasted between 20 minutes and one 
and a half hours.  All the interviews were recorded on a digital recorder and I 
also took notes.  These were made to help me keep track of details, to indicate 
areas to return to for clarification or interest, or to record particular non&verbal 
information or interruptions.  They also allowed notes to be kept of discussions 
before the tape was turned on or after it was turned off.   
 
"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
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This section describes the process of analysis of the interview data in some 
detail.  In principle this was a thematic analysis.  In this kind of analysis, 
themes or categories are often said to emerge from the data, with little 
explication of the processes involved.  As Hammersley & Atkinson (1995: 
209) put it:  
‘the development of analytical categories and models has often been 
treated as a mysterious process about which little can be said and no 
guidance given.  One must simply wait on the theoretical muse’.   
 
They suggest that there is a tendency to overemphasise the role of the creative 
imagination in this process, and to neglect the role of existing knowledge, 
arguing that the process of analysis relies on the existing ideas of the researcher 
and those derived from the literature, which are used as a resource to make 
sense of the data.  There has been criticism of some researchers for failing to 
acknowledge the place of the researchers’ interests and prior knowledge in 
shaping analysis, as if categories occurred naturally in the data, waiting only to 
be discovered by an impartial analyst (see for example Bryant, 2003, January, 
and, for a review, see Silverman, 2001: pages 71&73). 
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Hammersley & Atkinson (1995) describe analysis as an iterative process which 
typically starts with careful reading of all the data and identification of 
‘sensitizing concepts’ by: looking for interesting patterns and aspects that are 
surprising or puzzling, seeing how data relate to expectations, and looking for 
inconsistencies and contradictions.  The data are then reanalysed to firm up 
categories and develop new ones, resulting in a range of categories which 
include both concrete and more analytical ones.  This general description fits 
the process of analysis undertaken in this research.   
 
A similar, although different approach was adopted in analysing the interview 
data with HEART UK members and lipid clinic patients.  All the interviews 
were recorded on digital recorder and the audio files were transferred to 
computer.  For the HEART UK interviews, I made detailed notes on each 
interview and transcribed in full sections that were particularly pertinent to my 
developing ideas.  All lipid clinic interviews were transcribed in full.  I 
transcribed most myself and a small number (5) of the later interviews were 
transcribed by someone else.  I also made listening notes from each of the lipid 
clinic interviews.  The making of these notes and undertaking the bulk of the 
transcription was an important starting point of the analysis process, giving me 
familiarity with the data.  These activities were undertaken throughout the 
fieldwork period.  I also kept a research diary in which I recorded any thoughts 
or questions about the research.  All the notes and the diary were reviewed at 
regular intervals through discussion with my supervisors.  This often provided 
an occasion to summarise my ideas about the analysis and the issues raised, 
creating a kind of ‘analytic memo’.  At the end of the fieldwork period these 
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notes and memos were drawn together and used to develop two coding 
schemas.   

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There were two elements to the analysis of these interviews.  First I dew up a 
list of the activities that interviewees mentioned or said they had been involved 
in.  Activities mentioned in the written materials were also added to this list.  
Second, a thematic analysis was undertaken along the lines described in the 
previous section.  Coding was undertaken on hard copies of the 
notes/transcripts.  Because of the relatively small number of interviews and 
fairly circumscribed number of themes, the coding was managed by copying 
and pasting the coded sections into a Word document.  This document was then 
printed off and reanalysed to look for patterns within each category.   
 
Coding was shaped to an extent by the focus of the research questions.  For 
example, it was clear that one of the themes of the thesis would concern the 
merge between the BHA and FHA, and all data pertaining to the merge was 
coded together.  This was then reanalysed to look for the different types of 
explanations offered for the merge, which were further categorised using labels 
including 	


, 	'		, and 	./
	
.  Some of the 
themes were informed by the analysis of constructions in the biomedical 
literature.  For example, the place of DNA analysis was an important aspect of 
constructions of FH in the literature, and appeared also to be a relevant theme 
in interviews.  Other ideas emerged from a more general reading of the data, 
looking for patterns or recurrent concepts, for example, ideas concerning a lack 
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of a cohesive illness identity.  Thirteen categories were developed in total and 
these were organised under two main headings: aetiological issues concerning 
FH and CHD; and organisational aspects of HEART UK.   
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In addition to compiling listening and analytic notes on these interviews, as 
already described, I appended each transcript with a top&sheet on which was 
recorded summary data about some of the characteristics of the interviewee 
that I thought might be pertinent to the analysis.  This included gender, age, 
occupation, ethnicity, children, how and when high cholesterol was discovered, 
when FH was diagnosed, onset of CHD, whether CHD reported in family and 
whether physical signs of FH reported.  These were entered onto a spreadsheet 
along with a note to help jog my memory about the key aspects of the 
interview, for example ‘prompted by mum’s high cholesterol and angina, focus 
on own ill health’.  The data in the spreadsheet were used to tabulate summary 
data about the characteristics of the sample.   
 
The main coding schema developed related to four core themes: 
1. defining and explaining the problem 
2. ideas about inherited disease. 
3. health status now and in the future 
4. health responsibilities 
 
These themes map more or less onto the data chapters concerned with lipid 
clinic interviews.  Themes 1 and 2 are discussed in chapter 6 & defining and 
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explaining the problem, and themes 3 and 4 are discussed in chapter 7 & living 
with FH.  However health responsibilities permeate much of the analysis and 
are relevant to both of these data chapters.   
 
An initial set of 54 codes was devised relating to these themes.  Some of these 
codes related to a knowledge of the literature.  For example, I was aware that 
the social and geographic proximity of relatives has been discussed in the 
literature concerning lay constructions of genetic risk.  This sensitised me to 
this topic and I was able to recognise it in my own data.  Other codes arose 
through the occurrence of a recurrent phrase in the interviews, for example, 
‘normal life’.  Other areas were unanticipated. Prior to the interviews, I 
understood FH as an adult&onset condition.  Therefore, the amount of talk 
concerned with the welfare of the interviewees’ offspring was unexpected.  
This was related to several codes, such as ‘caring for children’, ‘testing 
children’ and ‘passing it on’.     
 
Coding was undertaken by marking up hard copies of the transcripts using a 
highlighter pen and annotating in the margins.  Electronic copies of the 
transcripts were then coded in NVIVO.  Further analysis of the initial codes 
was undertaken by printing out the data categorised in each code, reading 
through this data, differentiating it into a number of ideas, and marking this up 
on the hard copies.  The use of computer&aided qualitative data analysis 
software (CAQDAS) has been subject to much discussion and it has been 
proposed that it has the potential to transform the analytic process (see Murphy 
& Dingwall, 2003: pages 125&127 for a brief synopsis of the arguments). My 
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own use of CAQDAS was intended solely as a convenient way to manage 
coding, data storage and retrieval.  All of the procedures carried out within 
NVIVO could equally have been achieved using manual methods of data 
management (cutting up hard copies of transcripts with a pair of scissors and 
storing in cardboard files) and using a word processing package for the 
occasional word search.  The choice of NVIVO was because it was available 
and because I was already familiar with the package from previous research.   
 
The full coding schema was initially tested on three transcripts to check that it 
could be applied and see whether anything was missing.  It was then applied to 
the full set of transcripts.  There were several areas that I attempted to tabulate 
in order to get some overall sense of the data or distribution of ideas, with 
different levels of success.  For example, I tried to categorise the main talk 
about FH into three categories – medication, diet and heredity.  This 
information was recorded on the transcript top&sheet.  It turned out that most 
people focussed on two or more of these at different points in the interview. 
This provides an indicator of the multiple ways of constructing FH, which, in 
fact, became a major theme of the analysis discussed in Chapter 6.  
Nevertheless, this categorisation was useful in identifying the small number of 
interviews where there was no or little talk concerning one of the categories.   
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There are two aspects of this research that warrant some consideration of the 
ethical issues raised.  These are the interviews with FH patients and the work 
with HEART UK, including the interviews with its members and staff.   
 
The interviews with FH patients required approval from the Local Research 
Ethics Committee, which, to an extent, provided a template for the 
management of the interviews.  Nevertheless, these interviews did not raise any 
particularly novel ethical issues.  The recruitment and data management 
processes were designed to address the issues of informed consent, 
confidentiality and anonymity of participants and their rights of care.  This 
meant, in practice, that potential participants were sent a participant 
information sheet in advance of the study, and were asked to sign a consent 
form, transcripts were identified using a numeric ID number, hard copies of the 
transcripts and identifying details were stored securely, and electronic versions 
of transcripts and audio&files were pass&word protected.  Although conforming 
to the institutional demands regarding LREC approval, I recognise that these 
measures do not automatically ensure the ethical treatment of participants.  The 
idea of ‘informed consent’, for example, is a thorny issue.  Information 
provided to potential participants must be accessible and comprehensible to 
this audience.  It would be difficult to provide a full explanation of the aims of 
sociological research of this nature ‘without sending informants and 
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cohabitants to graduate school’ (Brewster Smith, 1979: 14, cited in Murphy & 
Dingwall, 2001: 342). 
 
Ethical issues concerning the research with HEART UK are less clearly 
defined.  HEART UK is a small organisation with a unique remit within the 
UK.  The organisation would be instantly recognisable whether or not it was 
named in the research.  It also has a small number of staff.  If I had identified 
interviewees as staff members, readers would have been able to a make fairly 
educated guess as to their identity.  I, therefore, decided to group staff with 
professional members in reporting the data.  Lay members are denoted as 
LM1&5 and staff and professional members as S/PM1&5
8
.  It is highly likely, 
nevertheless, that the interviewees will be recognisable to people within the 
organisation.  It is notable that the professional members interviewed were 
drawn from the same population as the sample whose published literature is 
analysed.  Where data pertained to a written source that is already in the public 
domain, I have named the authors.    
  
Earlier in this chapter, I indicated that there was a small amount of concern 
within HEART UK about the research and how it will be used.  I suggested 
that these concerns were allayed through the provision of information and 
reassurances about my intentions.  My own view is that this thesis does not 
evaluate the organisation, nor is it critical of its activities.  The work of the 
organisation is analysed to consider the concepts of geneticisation, lay 
expertise, biosociality and so on.  However, the information I provided to the 
                                                
8
 The same procedures for ensuring secure data storage and protection were followed as those 
described for the FH patient interviews .   
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organisation, as part of negotiating access, was not framed in these terms.  This 
would have been equally incomprehensible and irrelevant to the HEART UK 
as to the FH patients (see discussion above on the difficulties of informed 
consent).  The research was explained as being concerned with the work of 
HEART UK in supporting patients and shaping developments, and with the 
way patients and professionals work together in the newly merged organisation 
(see appendix 2 for the letter of invitation and information sheet for HEART 
UK participants).  This thesis represents the entry of this part of the research 
into the public domain and I cannot anticipate how it will be understood by the 
organisation or other audiences.  The point of publication may be the time of 
greatest risk of harm to participants in social research (Murphy & Dingwall, 
2001).  I will have relatively little control over how this research is read by 
others.  Nevertheless, I believe I have a responsibility to HEART UK to think 
carefully about how I write about its activities in a way that decreases the 
chance of this research being seen or used as an evaluation.       

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0As I have argued earlier in this 
chapter, there are many ways of studying biomedical constructions of diseases 
and the method chosen was the most accessible under the circumstances.  The 
decision to start by analysing four commentary papers followed Hedgecoe’s 
analysis of the rhetorical strategies used in constructing diabetes and 
schizophrenia (Hedgecoe, 2001a, 2002).  This method has recently been 
criticised, in part, for the small number of articles analysed (Kerr, 2004) and 
my analysis could, perhaps, be open to the same criticism.  Nevertheless, my 
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initial analysis is supplemented with a summary of a large number of papers 
published in a particular field, which builds on the framework developed in the 
early analysis.   
 
The study provides a systematic analysis of one small area of CHD 
constructions, relating to the work of HEART UK and researchers connected to 
this organisation.  The analysis is indicative of the variety and kinds of 
arguments that are currently enrolled in constructions of CHD, and the recent 
focus of HEART UK researchers, but is not an exhaustive account.  The 
analysis does not provide a basis on which to discuss whether there is a 
dominant model of CHD, what this is, or how it developed.  The analysis of 
constructions of FH focused particularly on the publications and members of 
one group, the Simon Broome Group, which has been important in the UK.  
Again, this was just one slice of the biomedical literature about FH, not a 
definitive account.  As I have argued at the beginning of this chapter, there is 
almost unlimited scope for detailed qualitative and quantitative work in this 
area.
 
1	 !"#0One of the characteristics of qualitative research is 
that the research design is flexible and develops throughout the research 
process.  The merge between the FHA and the BHA to form HEART UK 
contributed to the shift in focus of the study onto professional constructions of 
FH and CHD.  Had the research started three years earlier, this would possibly 
have led to a very different study and if the fieldwork had bridged the period of 
the merge this could have provided a unique opportunity to observe, first hand, 
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the process of the merge and the events surrounding this.  HEART UK is 
clearly in a state of flux, and rapid changes have occurred and continue to 
occur in its structure and activities.  It must be recognised that organisations 
such as HEART UK are dynamic entities and that this research provides an 
account of one particular moment in its development.   
 
The work with HEART UK was particularly shaped by the exigencies of the 
research process, being circumscribed by the timetable associated with doctoral 
research and the nature of the work undertaken by HEART UK.  A longer 
ethnographic study might have provided more insights into the roles of 
different actors in the organisation and balance of activities between FH and 
CHD.  It might have been possible, for example, with more time and good 
relations, to have negotiated access to committee and trustees’ meetings.  This 
still leaves issues concerning the large number of activities that take place ‘off 
site’ and in collaboration with others and raises questions about whether the 
various actors would have tolerated the researcher’s presence and issues of the 
need to repeatedly negotiate access.   
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2 Patients with FH were recruited through one lipid 
clinic only, due to the practicalities of gaining access and the usual constraints 
on doctoral research.  Although the sampling method employed was designed 
to obtain a diverse sample of patients attending the clinic, like many qualitative 
studies, questions remain about the generalisability of the findings (Murphy & 
Dingwall, 2003).  It is possible that there are aspects of the clinic’s 
characteristics or practice that have a particular influence on patients’ 
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constructions of CHD and FH.  Aspects that may be relevant, in the case of 
lipid clinics, include the size and location of a clinic, and the degree to which 
DNA testing and systematic cascade screening are already undertaken.  
However, as this chapter suggested earlier, on the basis of the characteristics of 
the clinic involved in the research, i.e. a large and prestigious urban clinic that 
operates cascade screening, one can argue that it would be one of the most 
likely sites where geneticisation would be evident, if it were to be seen 
anywhere.  
 
One must also consider the nature of the sample that is provided by a clinic 
population.  This is a sample of clinic attendees and three groups of people 
with FH are not represented here: First, there are people whose FH is managed 
through primary care, although Neil et al. (2000) suggest that this constitutes a 
relatively small proportion of those who have been diagnosed with FH.  
Second, there are people who may be aware of a family history of CHD or FH 
or have been diagnosed with FH, but who have chosen not to be in contact with 
health professionals regarding this or have declined an invitation to be tested.  
The size of this population is uncertain and accessing such a population is 
fraught with both ethical and practical difficulties, such as whether it is ethical 
to contact people who have declined service, and how to establish that there is 
FH in the family or that the person has FH.  Third, there is a group of people 
who declined the invitation to participate in my research.  It is possible that 
those who participated have a more morally coherent story or perhaps were less 
upset by their FH.  It was noted earlier that a larger proportion of men than 
women accepted an invitation to participate.  These observations would 
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certainly fit with the suggestion in the literature that genetic and wider health 
responsibilities are gendered.  Nevertheless, there were some stories of regret 
or self&blame present in the accounts of the participants, in other words they are 
not excluded from the sample, and examples are discussed in chapters 6 and 7.  
Furthermore, the data do not support any obvious gendering of responsibilities 
vis&à&vis FH.       
 
2;7!$"*8
This chapter has laid out in some detail the rationale for the research design 
and provided an account of the methods of the study, paying attention to the 
sampling decisions, the conduct of the research, the nature of the data produced 
and the process of analysis.  It has also provided a discussion of the limits of 
the study, which is intended to indicate the sorts of claims that can legitimately 
be made on the basis of the research.  As Murphy et al. (1998) argue, the clear 
exposition of the methods of data collection is one of the main criteria by 
which the validity of qualitative research can be evaluated.   
 
The chapter has shown how the original focus on patient constructions of FH 
was modified due to two key developments.  First, this was based on my 
growing awareness that there was, in fact, a paucity of detailed analysis of 
recent biomedical models of CHD.  Second, it was connected to the merge of 
the FHA with BHA to form HEART UK at the earliest stages of the study.  
These two factors contributed to the broadening of the research to include 
questions about the construction of biomedical models of CHD and about the 
relationship between lay and professional members in HEART UK.  The 
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research involved three main areas of research: an analysis of biomedical 
literature, ethnographic work with HEART UK and interviews with HEART 
UK members and patients with FH.  The following chapter presents the 
analysis of the first of these areas, the construction of CHD and FH in the 
biomedical literature. 
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This chapter focuses on biomedical or ‘expert’ constructions of the aetiology of 
CHD and FH, and particularly on the models supported by biomedical 
professionals who are involved with HEART UK.  The first half of the chapter 
looks at recent constructions of CHD within biomedical literature, to provide 
an overview of this field.  The aim of this analysis is to indicate the range of 
ideas currently circulating about the causes of CHD and the place of genetic 
ideas in this field.  This section is based on an analysis of four published 
commentary papers by eminent scientists.   
 
The chapter then turns to research connected to HEART UK.  The second 
section of the chapter discusses the contribution of HEART UK members to 
models of CHD.  This focuses on the research profiles of individual 
professional committee members, based on an analysis of their recent 
publications.  The third section focuses on constructions of FH and is based 
predominantly on an analysis of the publications of the Simon Broome 
Register Group.  This is a semi&autonomous research group, formed around a 
national register of patients with hereditary lipid disorders, which has been 
influential in the diagnosis and management of FH in the UK.  The group is 
now administered through HEART UK.  These two areas of publications 
represent the contribution of a significant group of biomedical professionals, 
who are involved in some way with lipidology, to constructions of CHD and 
FH.   
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The chapter will argue that a geneticised model of CHD exists, but that there 
are a number of alternative and competing models of CHD, and that genetic 
models were not dominant in the literatures included in the analysis.  It will 
suggest that even in the area of FH there is some ambivalence about the utility 
of genetic testing and, in the case of the UK, diagnostic criteria remain largely 
clinical rather than genetic.  This analysis leads to a discussion of the influence 
of different disciplinary perspectives on constructions of CHD.  The chapter 
concludes that the data presented challenge the geneticisation thesis in a 
number of areas. 
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Before setting out the analysis of biomedical publications on CHD and FH, this 
section will provide my own very brief account of current thinking on the 
molecular and cellular processes that lead to CHD.  This is included to provide 
the context for and aid understanding of the following analysis.   
 
Molecular models of CHD are concerned with the development of 
atherosclerosis in the coronary arteries.  This means the hardening and 
narrowing of the blood vessels that supply oxygen and nutrients to the heart 
muscle.  The focus of the molecular model of atherosclerosis is the 
development and stability of fatty plaques, or atherosclerotic lesions, which 
form in the lining of the coronary arteries.  This is currently thought to involve 
three main processes:  
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1. 
	
#
: Part of the process of fatty plaque formation 
involves the accumulation of cholesterol within the arterial wall.  
Lipoproteins are the molecules in which cholesterol and other lipids are 
carried around the body via the blood stream.  Two molecules, low density 
lipoprotein (LDL) and high density lipoprotein (HDL) are thought to be 
particularly important.  LDL carries the cholesterol to the cells and tissues 
and HDL carries cholesterol from the tissues to the liver, where it is 
processed for excretion.  High levels of LDL and low levels of HDL are 
associated with the formation of atherosclerosis.   
2. 
		
: this is also involved in the formation of the 
fatty plaques.  Macrophages, cells involved with inflammation, are 
responsible for the uptake of cholesterol into the arterial wall.  The 
inflammatory process is also involved in the stability of the fatty plaque 
and influences whether a plaque will rupture. Plaque rupture can cause the 
arteries to become blocked and result in a heart attack 
3. 


	

	
: this can occur as a result of plaque 
rupture and can also lead to the arteries becoming totally blocked and to a 
heart attack 
 
3;2,-!,.&- .,-.".-*"$*-
This section provides an overview of current constructions of CHD by 
considering in detail four recent commentary papers about CHD from the fields 
of genetics, epidemiology and cardiology.  The rationale for selecting these 
papers and details of the authors were discussed in detail in the previous 
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chapter.  The papers all provide very general and broad accounts of their 
subject areas.  They are:  
1. Stephens, J.W. and Humphries, S.E. (2003), 'The molecular genetics of 
cardiovascular disease: clinical implications', 3
-


		
, 253, 120&7. 
2. Beaglehole, R. and Magnus, P. (2002), 'The search for new risk factors 
for coronary heart disease: occupational therapy for epidemiologists?' 
-

	
3
&		, 31, 1117&22. 
3. Lenfant, C. (1999), 'Conquering cardiovascular disease: progress and 
promise', !3
	
			
, 282, 21, 
2068&70. 
4. Beller, G.A. (2001), 'Coronary heart disease in the first 30 years of the 
21st century: challenges and opportunities.  The 33rd Annual James B. 
Herrick Lecture of the Council on Clinical Cardiology of the American 
Heart Association', 		
, 103, 20, 2428&35.  

"


Stephens & Humphries (2003) is a review paper concerning the effects of 
functional polymorphisms
9
 on CHD.  The paper focuses on three examples of 
                                                
9
 *
	&&	 means gene variations.  Some variations have no effect on the gene’s 
function and may be referred to as neutral variants.  Others lead to variations in the gene 
product and may be referred to as ‘functional gene polymorphisms’.  These may or may not be 
thought to be disease causing or pathogenic (human blood groups are probably the best known 
example of functional gene polymorphisms).  	
 also means variation in a gene.  It can 
mean merely a random change in the DNA, but in medical papers it usually denotes a 
pathogenic change, and often means an inherited pathogenic change.  There is no precise 
definition of polymorphism or precise distinction between the terms polymorphism and 
mutation.  Use of polymorphism is often associated with more prevalent changes.  It tends to 
be used only where a variant occurs with a frequency of at least 1 per cent.  More importantly, 
in biomedical papers, polymorphism tends to be used for benign variations and mutation for 
pathogenic changes.  
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these, two involved in lipid metabolism and one involved in inflammation.  It 
demonstrates a familiar narrative about a genetic future for understanding and 
managing cardiovascular disease.  CHD is presented as a polygenic, 
multifactorial condition in which genetic risk results from the cumulative effect 
of variations in several different genes.  The overall message is that 
understanding the role of genetic polymorphisms is key to understanding the 
molecular and cellular pathology of CHD, which in turn may be important for 
the development of new therapies, diagnostic tests and prevention strategies:  
Unravelling the role that functional gene polymorphisms play in 
determining risk…is crucial to our understanding of the key metabolic 
pathways and physiology not only in the diseased, but also in the 
disease free state.  The identification of new molecules…may 
subsequently lead to potential targets for therapeutic intervention.  
Improving our molecular understanding may also lead to the 
development of improved diagnostics’  
(ibid: 126).   
 
At the same time the authors acknowledge the importance of the more 
established risk factors and a large part of the paper is devoted to gene&
environment interactions, focussing particularly on smoking.  Interaction is 
used to describe the situation where the cumulative risk of two or more factors 
is greater than the individual risks of each factor added together.   
 
The introductory part of the paper sets out the importance of genetic factors in 
the aetiology of CHD.  The key argument is that:  
‘functional gene polymorphisms account for much of the biological 
diversity in homeostatic systems.  In their absence all humans would 
respond in an identical manner to an environmental challenge, and the 
risk of developing disease would be directly proportional to the 
environmental stimulus. We know that this is not the case.  For 
example, some individuals exposed to cigarette smoke with an 
		
		&	 will go on to develop CHD, 
whilst others will not.  Therefore, the well accepted view is that CHD is 
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a multifactorial disorder, with both environment and genetic factors 
contributing’  
(ibid: 120&121, emphasis added). 
  
This argument hinges on the idea that it is possible to identify people with 
‘otherwise identical risk factor profiles’, which implies that all the risk factors 
for CHD are already clearly established and that they can be controlled for.  
This argument could perhaps be re&written as – 		
	



'
%&	

	'	
	
	
		

	(  This model of CHD allows a major role 
for genetic variations.  The authors claim this is &view, which 
closes off any scope for discussion.  It is, however, not a view that is 
universally accepted by biomedical scientists, as the analysis later in this 
section demonstrates. 
 
It is particularly striking how the paper constructs genetic differences, 
environmental risk factors, and the relationship between environment and 
genes.  The authors appear to use the terms mutation and polymorphism 
interchangeably with the same variations referred to as both ‘minor mutations’ 
and as ‘functional gene polymorphisms’ (ibid: 120&121).  Variations in 
apolipoprotein&E (APOE) gene are discussed, a gene that codes for a protein 
involved in lipid transport.  There are three APOE variants, E2, E3 and E4, and 
their frequencies are given as 8, 77 and 15 per cent respectively in white 
populations.  Through the discussion E3, the most common variant, emerges as 
the normal gene.  The other variants are referred to as ‘single common 
mutations with modest impact’ (ibid: 121).  Since more than 40 per cent of the 
population have at least one copy of the E2 or E4 variants, it could be argued 
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that this effectively constructs a large proportion of the population as abnormal 
in some way.   
 
An interesting conception of environmental risks also emerges in the paper.  
Environmental challenges are said to include: ‘diet, male sex, diabetes, obesity 
and cigarette smoking’ (ibid: 121).  It is not clear what the authors have in 
mind in their reference to diabetes.  They may have meant it as a proxy for 
‘lifestyle’ factors such as inappropriate diet and lack of exercise associated 
with obesity and Type 2 Diabetes.  However, it could also be read as a 
physiological or bodily state concerning glucose metabolism.  Reference to 
male sex, i.e. being male, certainly suggests that the environment envisaged by 
the authors is the biological environment of the genes or of the organs rather 
than the physical or social environment of the person.  The authors also link 
environmental risks and lifestyle choices, seeming to conflate the two 
concepts:  
‘individuals adopt a different position on the environmental spectrum of 
risk by the lifestyle choices they make (e.g. smoking).  However, 
although environmental risk factors are modifiable the genetic factors 
are not’  
(ibid: 124).   
 
The excerpt shows that, in this paper, one of the defining attributes of the 
environment is that it can be changed.  It is ironic, then, that male sex is 
included as an environmental factor.  This obvious contradiction serves to 
highlight the rather limited conceptualisation of environment employed.   
 
It is not clear in the model outlined in this paper whether environment is 
envisaged as being able to play a role on its own, in the absence of genetic 
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predisposition.  CHD is referred to as a ‘polygenic’ disease.  The only 
exceptions discussed are cases where the disease is monogenic, involving a 
single rather multiple genes.  The implication is that genes are always involved 
in CHD in some way.  One of the opening statements of the paper is that:  
‘CHD is a complex condition resulting from numerous gene&gene and 
gene environment interactions’  
(ibid: 120).  
 
This suggests that genes are a necessary part of CHD aetiology.  On the other 
hand, the authors go on to comment that CHD may occur: 
‘as a result of failure at the genetic level (e.g. gene transcription) or due 
to an environmental exposure (e.g. smoking) or due to an imbalance 
between the two’ 
(ibid: 120).   
 
This implies that environment alone may cause CHD in some cases.  
 
The paper’s discussion of gene&environment interactions suggests that certain 
people may be exposed to a given environment that ‘amplifies the risk 
associated with that gene’ (ibid: 121).  In terms of the priority attributed to 
these factors, this seems to privilege genes.  One wonders why the environment 
is seen as amplifying the effect of genes rather than the gene amplifying the 
environment, particularly as genetic variations on their own tend to account for 
only very minor differences in rates of CHD.  This is a matter of subtle 
difference and, in isolation, one might not be inclined to read too much into 
this way of ordering things.  Nevertheless, taken as a whole, there appears to be 
a subtle privileging of genetic factors in this paper.  There are parallels here 
with Hedgecoe’s (2001a) analysis of biomedical discourses about 
schizophrenia.  Hedgecoe suggests that these discourses under&specify and 
downplay the environment and prioritise genetic factors to the extent that a 
 148
‘genetic baseline’ is seen as necessary for the causation of the disease.  The 
conclusions here regarding the notion of a ‘genetic baseline’ for CHD are more 
tentative.  The analysis suggests that genetic variations may be seen as having a 
necessary part in CHD causation.  
 
Overall, Stephens and Humphries’ account of the causes of CHD does seem to 
attribute a large role to genetic differences between people, creating new 
categories of biological difference.  The interchangeable use of the terms 
variations, polymorphisms and mutations tends to pathologise some of these 
new categories of people.  It also presents a rather incomplete view of 
environmental factors in which the social and physical context are absent.  
Further, their discussion suggests that new genetic knowledge is imperative for 
progress in understanding CHD and will be useful for treating the disease.  In 
other words, in terms of Lippman’s definition, this is a thoroughly geneticised 
view of CHD.  It is, however, not the only available model of CHD, as the 
following sections demonstrate. 
  
-
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This section considers the article by Beaglehole and Magnus (2002a), 
provocatively entitled ‘The search for new risk factors for coronary heart 
disease: occupational therapy for epidemiologists’?  The article was 
accompanied in the same issue by four commentaries (Greenland et al., 2002; 
Law, 2002; Marmot, 2002; Nieto, 2002) and a response by the authors 
(Beaglehole & Magnus, 2002b).  This dialogue provides an interesting window 
on current debates about CHD within epidemiology.  It provides an entirely 
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different perspective on risk factors for CHD and demonstrates that genetics is 
just one of a number of emerging and contested areas of interest in CHD.   
 
Beaglehole and Magnus’s (2002a) basic argument is that the major risk factors 
for CHD have already been established, i.e. high blood cholesterol, high blood 
pressure, cigarette smoking and physical inactivity, and that these can be 
attributed to economic, social and cultural factors: 
‘The underlying causes of the CHD epidemic are the society&wide 
economic and cultural factors that determine whether a diet with a high 
proportion of saturated fat and low in antioxidants becomes 
widespread…The prevailing social and economic conditions are also 
responsible for the emergence and widespread distribution of other 
important contributing causes: tobacco smoking, physical inactivity and 
other inappropriate aspects of diet, with the latter two interacting to 
produce excess weight and high levels of blood pressure.  These major 
causes have a close and precisely defined (proximal) relationship to the 
CHD epidemics and are well established scientifically’  
(ibid: 1118). 
 
It is notable that what is '		
		in other words, what 
every one knows about CHD in Beaglehole and Magnus’s world already 
differs from the &	 in Stephens and Humphries’ world.    
 
Beaglehole and Magnus argue that the search for new risk factors is partly 
based on researchers underplaying the role of the main factors outlined, as a 
way of justifying new research.  They argue that there is a widely accepted 
‘myth’ that the established CHD risk factors explain only half or less of the 
occurrence of CHD, whereas in their view these major risk factors explain at 
least 75 per cent of new cases (ibid: 1119).   
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They go on to discuss the new risk factors, which they divide into six main 
groups:  
 Thrombotic factors and the effect of biochemical markers 
 The role of inflammation and infectious agents 
 The influence of early life exposure 
 The contribution of multiple genes 
 Oestrogen deficiency 
 The role of the psychosocial environment 
(ibid: 1119).   
 
The authors evaluate these factors in terms of their potential contribution to 
prevention of CHD and the degree to which they contribute to explaining 
‘CHD epidemics’.  They are particularly critical of genetic research and better 
disposed towards some of the other factors.  In the end, however, all the factors 
are variously dismissed due to lack of conclusive evidence or because their 
potential contribution to improving population health is doubted.  The majority 
of funding, they argue, should be directed to prevention strategies at the 
primary and population levels, including structural issues such as the salt 
content of processed food, the environmental factors leading to lack of physical 
activity and tobacco policies.  In an argument echoing Lippman’s, they 
conclude that preoccupation with identifying high risk groups and individuals 
reflects the dominant health paradigm, which, they argue:   
‘supports an individualistic approach to health improvement and 
ignores the wider social and economic determinants of the health of 
populations’   
(ibid: 1121).
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It is notable that, in contrast with Stephens and Humphries, environmental 
factors are framed in terms of the cultural, economic and social factors that 
lead to CHD risk, rather than as 	2	(
 
Beaglehole and Magnus’s argument is essentially that there is a gap between 
current knowledge and practice regarding population levels of the established 
risk factors and there should be more focus on prevention strategies at this 
level.  None of the four commentaries that follow the article take issue with 
these main arguments, but contest Beaglehole and Magnus’s arguments 
concerning the new or emerging risk factors and their potential contribution.  
The commentaries make three main types of arguments: they propose 
alternative aims for epidemiological research, dispute the evidence proposed by 
Beaglehole and Magnus and provide counter evidence and arguments to 
support the ‘new’ risk factors.  
 
One of the main arguments they make concerning the aims of epidemiological 
research, in essence, reflects Rose’s (1985) discussion of the two ways of 
understanding the aetiology of disease.  These are seeking the causes of cases, 
which focuses on the individual, and seeking the causes of incidence, which 
focuses on the population.  While Beaglehole and Magnus are solely interested 
in population levels of CHD, the commentators propose that there are other 
legitimate aims for epidemiological researchers.  One of these is to explain 
why certain groups or individuals are more or less likely to get CHD.  Marmot 
(2002: 1124), for example, is particularly interested in why rates for different 
groups of people vary so greatly, asking why: 
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‘among people more or less equally exposed, there remain such marked 
differences in the rate of occurrence of CHD’.  
 
His own work is concerned with explaining the social gradient in CHD and has 
particularly focused on psychosocial factors.  It is notable that Stephens and 
Humphries employed the idea that only certain individuals with a given level 
of the known risk factors go on to get CHD as an unequivocal argument for 
genetic influences, implying that there was no other possible explanation. Yet, 
the same argument can and is employed to support research into other risk 
factors.   
 
Commentators are critical of the idea that 75 per cent of CHD is explained by 
the established risk factors.  They also question the evidence provided by 
Beaglehole and Magnus in their evaluation of the emerging risk factors, 
criticising both individual papers cited and the types of evidence drawn on in 
general.  Counter evidence and arguments are made in support of psychosocial 
factors (Marmot, 2002), infections or inflammatory processes (Nieto, 2002; 
Greenland et al., 2002), early life exposures and the lifecourse approach (Law, 
2002; Greenland et al., 2002) and thromotic processes (Greenland et al., 2002).  
What these discussions make clear are that there are a range of proposed risk 
factors for CHD and they bring to the surface the uncertainty and contingency 
of scientific claims.  What is notable is that no defence of multiple gene 
influences is made.  In these discussions, in any case, genetic explanations 
appear to be low on the agenda.   
 
These discussions also illustrate a point made in the literature review, that 
Lippman’s concerns form part of a wider critique concerning individualistic 
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approaches to health and a lack of attention to the wider determinants of health 
and illness, which can be found in biomedical discourses as well as in social 
science discourses (see Aronowitz, 1998).  It is interesting that while 
Lippman’s criticism is directed towards geneticists and their allies, both 
Beaglehole and Magnus, and Marmot make antagonistic comments about the 
role of cardiologists in individualising prevention strategies for CHD:  
‘without strong epidemiological input and leadership, cardiologists will 
continue to dominate the prevention debate and individual approaches 
will remain the priority’  
(Beaglehole & Magnus, 2002b: 1134).   
 
The next section suggests that clinicians may tend to focus more on individual&
level prevention.  This does not mean a wholesale adoption of genetic 
discourses. 
 
=%@
This section considers papers by two clinicians, Lenfant and Beller.  Lenfant’s 
(1999) editorial piece sets out to provide an overview of recent progress and 
issues in cardiovascular disease research.  He makes three main arguments in 
relation to coronary heart disease: (1) there is still work to be done concerning 
the established risk factors, for example, there is a lack of knowledge about 
how obesity acts as a risk factor and how it leads to diabetes, (2) molecular 
biology and molecular genetics may offer major improvements in the field of 
cardiovascular disease, and (3) there is a need for better application of the 
established interventions, in other words that there is a gap between knowledge 
and practice. 
 
Lenfant (1999: 2069) is optimistic about the role of genetics:  
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‘On the eve of the next millennium it is safe to predict that the 
importance and application of molecular genetics and functional 
genomics will play major roles in the further improvement of 
cardiovascular health’.   
 
Although he makes reference to genetic polymorphisms, equally he includes 
discussion of developments in molecular biology concerned with the role of 
various molecules and cellular processes in the development and stability of 
plaques and the function of the arterial lining.  It is important to note that such 
developments may be concerned with understanding the molecular processes 
that lead to CHD, in general, and with finding new ways of assessing the risk 
of and progress of disease, based on this knowledge.  Such research is not 
necessarily related to identifying genetic differences between people.   
A major part of Lenfant’s argument is that there is a problem translating 
research results into lifestyle changes, public health interventions and clinical 
practice, i.e. a gap between knowledge and practice, and highlights this by 
discussing evidence concerning poor use of drugs for blood pressure and poor 
‘compliance’ with blood&pressure treatments.  He concludes that although 
molecular biology and genetics offer exciting and useful prospects, doctors 
should not forget about the ‘more mundane’, but effective methods like 
lowering blood pressure, decreasing obesity and physical inactivity and the 
appropriate use of established therapies such as β&blockers and aspirin:  
‘The real challenge for the new millennium may indeed be to strike an 
appropriate balance between the pursuit of exciting new knowledge and 
the full application of strategies that already are known to be extremely 
effective, but considerably underused’  
(ibid: 2070).     
 
Beller’s (2001) review, entitled ‘Coronary Heart Disease in the First 30 Years 
of the 21
st
 Century: Challenges and Opportunities’, would seem to provide a 
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perfect opportunity to focus on predicted developments in, and applications of, 
cutting edge technologies such as genetics.  However, the major challenges for 
CHD prevention and treatment are framed in more prosaic terms.  Discussion 
focuses on three main factors (1) an increasing proportion of older people in 
the population, (2) an ‘epidemic of type 2 diabetes’ and linked to this (3) an 
‘obesity epidemic’.  Beller’s main response to these challenges is to draw on a 
discourse of a gap between knowledge and practice.  He suggests that older 
people are already under&treated, arguing that they are not benefiting enough 
from ‘&
 diagnostic and therapeutic strategies’ (ibid: 2429, emphasis 
added).  The paper relates diabetes and obesity in part to genetic factors.  
Nevertheless, the main thrust of the discussion about these conditions is 
concerned with physical inactivity and poor diet.  Beller calls for greater 
emphasis on prevention in these areas, stressing the responsibility of 
cardiologists, parents and educators.  In contrast to Beaglehole and Magnus, 
with the exception of commenting on education policy concerning physical 
education programmes, these are largely taken as individual problems requiring 
individual actions.   
 
For the future, an array of technological developments, both biological and 
mechanical, in all areas of prevention and treatment are predicted.  Beller 
mentions the prospect of genetic screening to identify people at risk of diabetes 
and CHD, but he appears to link this solely to prevention for people at high risk 
of early CHD.  In other words, this is a fairly limited role for genetic 
developments, rather than the more global role suggested by Stephens & 
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Humphries (2003).  In conclusion, he concurs with Lenfant and urges us not to 
forget the: 
‘less costly, low&tech interventions [that] have already proven effective 
in preventing CHD and its complications’  
(Beller, 2001: 2434).  
 
In sum, Lenfant and Beller display some enthusiasm for developments in 
genetics.  Again, however, this could certainly not be thought of as  
dominant theme in their accounts of the future.  Their message is that health 
improvements may result from developments in genetics, but more 
importantly, could be accrued through better implementation of a raft of 
established low&tech, or even no&tech, interventions i.e. through better 
application of what is already known.  
 
!	

The analysis of Stephens and Humphries (2003) demonstrates that there 
certainly is a genetic model of CHD that has many of the elements of the 
geneticised discourse proposed by Lippman.  The account of CHD provided by 
Stephens and Humphries privileges genetic causes while detracting from other 
causes and creates new categories of biological normality and abnormality.  It 
also suggests that new genetic knowledge is imperative for increased 
understanding and improved treatment of CHD.  However, the analysis of the 
four commentary papers taken together suggests that genetics is just one of a 
number of streams of discourses about CHD.  One stream continues to focus on 
the established risk factors and includes emphasis on population trends such as 
levels of obesity and diabetes, or an ageing population.  This was connected to 
a recurrent argument that there is scope for major improvements, whether at 
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the population or individual level, if only better use was made of current 
knowledge and interventions.  This is far from the argument that health 
improvements will and can only be achieved through genetic research 
anticipated by the geneticisation thesis.   
 
Attempts to explain variations which cannot be accounted for by the 
established risk factors (although how much is already explained is contested) 
involve a range of risk factors of which genetics is just one.  Some of these are 
concerned with the molecular biological processes involved in atherosclerosis.  
There is interest in establishing whether certain molecules involved in 
inflammation and thrombosis could be used as new markers of disease 
progression and whether they play a role in causation.  It must be noted that 
this interest in new disease markers is not necessarily related to a genetic 
account based on inherited differences between people.  In other words, 
interest in molecular biological processes should not be conflated with interest 
in genetic variations between people. 
  
Overall, the analysis suggests that there is significant heterogeneity in 
biomedical discourses about CHD and that there are currently a number of 
ways of understanding the role of genetics.  It can be seen as a unifying genetic 
model, an explanation for a subset of early (‘premature’) CHD, or a general 
recognition that CHD can run in families.  Genetics certainly did not represent 
dominant discourse.  The analysis also demonstrates that there are a 
number of disciplines with an interest in CHD and has hinted at boundary work 
(Gieryn, 1983), at least by epidemiologists.  This is evident in their claims for 
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control over prevention strategies for CHD and admonition of cardiologists for 
promoting individual&level approaches to prevention.  This suggests that 
Lippman’s claims about the power of geneticists to condition how a host of 
diseases are viewed is, at the least, overstated.  Furthermore, the analysis 
suggests that disciplines may differ in their orientation towards individual or 
population/strategic level interventions, reflecting different ways of 
constructing responsibility for health and illness.  Nevertheless, those with a 
more individualistic orientation do not necessarily prioritise genetic discourses 
about CHD. 
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This section discusses the research undertaken by biomedical professionals 
involved with HEART UK.  These are an important subset of professionals 
involved with CHD in the UK.  One can argue that their research activities 
both reflect the priorities of the organisation, or at least those of its professional 
members, and potentially contribute to particular aetiological models of CHD.  
It will suggest that researchers’ interest in genetics is mainly concerned with 
specific hereditary lipid disorders rather than in polygenic influences as a more 
general risk factor for CHD, and that their main focus was concerned with 
elucidating the molecular pathways associated with atherosclerosis.   
 
The analysis in this section focuses on recent publications, since 2000, of the 
individual members of HEART UK’s Research Committee and of the Simon 
Broome Register group.  The rationale for selecting these two groups was 
outlined in the previous chapter.  To recap, these are the two committees with a 
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clear research remit within HEART UK.  It, therefore, seemed likely that the 
committee members would have an interest in research matters, and would 
represent the different research interests within the organisation.  The analysis 
involved a total of 14 people, 10 clinicians and four scientists, and included 
330 publications.  It should be noted that there has been a fair amount of 
collaboration between the members of these committees and about 10 per cent 
of the papers considered were co&authored by two or more of them.  Their 
research interests are summarised in Table 4.1.  In the main, their research has 
focussed on:  
 Molecular biology of lipid pathways and the processes involved in 
atherosclerorsis 
 Treatment and management of lipid disorders, CHD and diabetes 
 Effect of dietary fats and modifications in diet on lipid pathways and 
cardiovascular (CV) risks 
 Molecular biology, genetics, epidemiology, treatments and management 
of specific hereditary lipid conditions, particularly FH and familial 
combined hyperlipidaemia (FCH). 
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John 
Betteridge 
(SB) 
Clinician, 
Endocrinology 
& Metabolism  
43 Molecular biology/ treatment studies concerning 
lipid pathways and CV function, particularly in 
diabetes. 
Nigel Capps 
(SB & R) 
Clinician, 
chemical 
pathologist 
9 Dietary fat & effect of modifications on CVD risk 
and prevention. 
Laboratory methods for analysing variety of 
substances. 
Muriel 
Caslake       
(R) 
Scientist,   
vascular 
biochemistry 
33 Molecular biology/biochemistry of lipid pathways, 
especially related to atherosclerosis, Type 2 
Diabetes, effects of statins, kidney disease 
Biomarkers of inflammation as predictors of CHD or 
of diabetes 
molecular biology of FCH and FH 
Paul 
Durrington 
(SB & R) 
Clinician, 
lipidologist 
55 Role and activity of paraoxonase (PON) in CHD and 
diabetes 
Treatment of hyperlipidaemia in type 2 diabetes 
Effect of dietary fats on lipid metabolism & CHD  
FH epidemiology, management and treatment 
Bruce 
Griffin (R) 
Scientist,  
nutritional 
metabolism 
17 Effect of different sorts of dietary fats (fish oils, 
linoleic acid, polyunsaturated fatty acids) on lipid 
profile, markers of CV risk and on CVD  
Steve 
Humphries 
(SB) 
Scientist, 
cardiovascular 
genetics
45
10
 gene variations of lipid, coagulation and 
inflammation pathways and relationship to clinical 
measures, atherosclerosis and CVD.   
gene&gene or gene&smoking interactions concerning 
insulin resistance, triglycerides levels or CHD risk 
Rossi 
Naoumova 
(SB) 
Clinician, 
cardiovascular 
& metabolic 
disorders 
22 Non&lipid effects of statins 
Genetic studies & management of hereditary lipid 
disorders, particularly FCH and FH.   
Andrew 
Neil        
(SB & R) 
Clinician,   
clinical 
epidemiology 
38 Epidemiology, management & treatment of FH 
Treatment & management of diabetes (Types 1 and 
2)  
Dietary interventions concerning fruit & vegetables 
and plant sterols  
John 
Reckless 
(R) 
Clinician, 
endocrinologist 
13 Effects of and tolerance to different treatments for 
hyperlipidaemia and type 2 diabetes 
Alan Rees   
(R) 
Clinician, 
endocrinology, 
diabetes & 
metabolism 
12 Effect of treatments on dyslipidaemia and vascular 
function, particularly in diabetes. 
 
                                                
10
 Papers for the years 2000 and 2005 only included, see footnote 6, page 99 for further details. 
 161
&
D
C
 	 		

Tim 
Reynolds 
(R) 
Clinician, 
chemical 
pathologist 
46 Discussion and evaluation of different ways of 
undertaking risk estimation for CHD  
Laboratory methods for detecting or monitoring a 
variety of conditions 
The organisation and activities of clinical pathology 
services  
Downs Syndrome screening – ethical concerns 
Evaluation of grading systems and equipment for 
pressure sores  
Mary Seed 
(SB) 
Clinician,         
CV medicine
11 HRT and lipid management in menopausal women 
Different treatments for lipid disorders including 
drugs and plant sterols/stanol esters. 
Anne Soutar  
(R) 
Scientist, 
molecular 
genetics 
16  Genetics and molecular biology of FH 
Molecular biology of lipid pathways 
Gil 
Thompson 
(R) 
Clinician, 
lipidology 
24 Lipid and non&lipid effects of statins 
Effect of dietary plant sterol and stanol esters in 
addition to statin therapy 
Treatment and management of FH, particularly 
homozygous FH 
Methods for detecting/visualising extent of 
atherosclerosis and utility in CHD risk assessment.  
 
In terms of research relating to genetic differences between people, Steve 
Humphries work is almost exclusively concerned with the influence of genetic 
variations in cardiovascular disease (CVD).  Apart from his work, however, 
there was only a smattering of research or review papers that included analysis 
or discussion of genetic polymorphisms related to CV risks or response to 
treatment.  These were mainly co&authored by Caslake (Caslake & Packard, 
2004; Freeman et al., 2003), Griffin (Minihane et al., 2000a,b; Paschos et al., 
2005) and Durrington (Durrington et al., 2001; Mackness et al., 2000, 2001, 
2002a, b, 2004).   
 
The several papers co&authored by Durrington should not give the impression 
that he particularly emphasises the influence of polymorphisms in his work on 
CHD.  These references include two research papers that include the analysis 
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of polymorphisms in paraoxonase (an anti&oxidant enzyme found on HDL) and 
four papers that review the role of paraoxinase in general.  These reviews and 
his own research, in fact, play down the relative influence of genetic variations 
in paraoxonase.  The point is, however, less that his results and his reviews do 
not support a major role for genetic variations in this enzyme and more that this 
genetic analysis is included and discussed.  That is to say, this illustrates that 
polymorphism analysis is seen as a research strategy worth undertaking.  It 
should be noted that, in total, these papers still only represent a very small 
proportion of Caslake, Griffin, Durrington and the other researchers’ outputs.  
Overall, the committee members’ main connection with genetics was through 
an interest in the aetiology and management of specific hereditary lipid 
disorders.   
 
Research presented at the HEART UK conferences in 2003 and 2004 
reinforces this picture.  Papers were overwhelming concerned with the 
molecular pathways and management of CHD and lipid disorders and 
associated conditions including type 2 diabetes, obesity and metabolic 
syndrome.  A small proportion of the papers were concerned with FH and other 
familial disorders and only one out of about 30 papers presented each year 
related to genetic polymorphisms.  Therefore, although there was a limited 
amount of interest in genetic variations in relation to CHD in general, this does 
not represent one of the main aspects of their research.   
 
In terms of the other emerging risk factors for CHD enumerated by Beaglehole 
and Magnus, the measurement of various biomarkers of the processes of 
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atherosclerosis was part and parcel of much of the molecular research 
undertaken by HEART UK members.  There was a certain amount of interest 
in identifying and evaluating new biomarkers of CV risk, including additional 
lipoproteins or lipoprotein components (Seed et al., 2001; Sweetnam et al., 
2000), markers of inflammation (Caslake et al., 2000; Packard et al., 2000) and 
oxidative stress/anti&oxidant activity (Mackness et al., 2004; Nourooz&Zadeh et 
al., 2005).  The committee members made a minimal contribution concerning 
other emerging risk factors.  Out of the 330 publications considered, just one 
paper related specifically to infection as a risk factor (Grahame&Clarke et al., 
2003), two related specifically to the influence of the early environment 
(Huxley & Neil, 2004; Rodie et al., 2004) and there was no research relating to 
the psychosocial environment.   
 
Overall, the contribution of these members of HEART UK to aetiological 
models of CHD relate mainly to the molecular processes involved in 
atherosclerosis, focussing on lipid pathways, inflammation and thrombosis.  
Research related to other emerging risk factors such as the influence of gene 
variations, infection and the early environment is not a major component of the 
work of the committee members.  However, the abstracts indicate a certain 
amount of awareness of, or interest in, these areas.  This suggests the different 
elements of CHD aetiology do not represent discrete, but overlapping domains 
of research.  Most importantly, this analysis of the research interests of these 
HEART UK members illustrates that here, genetic difference is not the 
dominant discourse concerning CHD.  
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This section discusses how FH is defined, based particularly on the 
publications of the Simon Broome register group (Humphries et al., 2005; 
Huxley et al., 2003; Neil et al., 2003, 2004, 2005; Scientific Steering 
Committee on Behalf of the Simon Broome Register Group, 1991, 1999).  This 
group is particularly significant in the UK because it introduced the standard 
criteria for diagnosing FH.  The key issue in defining FH seems to be how 
much this is seen as a clinical syndrome based on a dominant pattern of 
inheritance of raised cholesterol or of high risk of early CHD, and how much it 
is seen as a diagnostic category based on the presence of specific gene 
mutations.  This is basically a question about the relationship between FH 
genotypes
11
 and a phenotype
12
 of raised cholesterol and of CHD.  In the 
publications of the Simon Broome Register Group, this issue has been played 
out in two key and related themes: 
1. FH diagnostic categories and DNA&based testing. 
2. the differential susceptibility to and possible risk factors for CHD for 
people with FH 
These have been discussed against a background of increasing complexity in 
the genes involved with FH, which is discussed briefly first.   
 
The issues discussed in this section relate very clearly to the central tenets of 
the geneticisation thesis, in particular: 
 the degree to which genes are thought to determine health outcomes  
                                                
11
 Genotype is used to describe the specific genetic make&up of a person or of a particular gene 
variant. 
12
 Phenotype means the observable physical characteristics or measurable physiological or 
biochemical characteristics of a person or a disease, for example eye colour, CHD or 
hypercholesterolaemia.   
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 the degree to which people are stratified or distinguished on the basis of 
their genes 
 the adoption of DNA&based technologies to replace other diagnostic 
techniques 
 the degree to which geneticists are involved with or control the 
identification and classification of FH 
 
%
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In the earliest Simon Broome paper (Scientific Steering Committee on Behalf 
of the Simon Broome Register Group, 1991: 893), FH was characterised as a 
dominantly inherited condition of raised cholesterol caused by LDL receptor 
mutations.  A very large number of different LDL receptor mutations have 
been identified, currently standing at more than 800 (Neil et al., 2005).  In the 
meantime, it has also become apparent that FH can be associated with 
mutations in other genes.  The Simon Broome group first mention this in 2003 
(Huxley et al., 2003), discussing the category of familial defective 
apolipoprotein B&100 (FDAB).  This disorder had been diagnosed in the late 
1980s (Austin et al., 2004) and it is understood that a small proportion of 
people with FDAB have the clinical signs and symptoms of FH, accounting for 
about 4% of cases of FH (Durrington, 2003).  By 2005 a third gene, PCSK9, 
had been identified (Humphries et al., 2005).  Therefore, it is now understood 
that single&gene mutations in a number of different genes can lead to an 
identical clinical phenotype.  To complicate things further, an autosomal 
	% form of FH has been identified (Durrington, 2003; Soutar & 
Naoumova, 2004).  This rare condition is known as autosomal recessive 
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hypercholesterolaemia (ARH) and relates to mutations in a different gene.  It is 
clinically very similar to the rarer and more serious homozygous FH. 
 
This genetic heterogeneity necessitated the introduction of new terms to refer 
to FH.  Durrington (2003), for example, talks of the ‘FH syndrome’, ‘clinical 
FH’ and the ‘FH phenotype’.  FH is no longer defined as a specific single gene 
defect, but a phenotype resulting from one of a number of (four or possibly 
more) genes which affect the same molecular pathways.  This clearly loosens 
the link between a single gene and a particular disease, moving away from the 
one&gene&one&disease monogenic model, to the possibility of a different&genes&
same&disease model.  This is just one way in which understandings of the 
genetic aspects of FH have become more complex over the last 15 years.  This 
complexity has emerged through the increasing volume of research on the 
genetics, molecular biology and clinical outcomes of FH, some of which are 
addressed in the following sections.   
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By the early 1990s, the molecular mechanisms of LDL metabolism and the 
genetic basis of FH were well established (Brown & Goldstein, 1986).  These 
were, however, not very important for the diagnosis of FH, which was based on 
clinical and biochemical signs.  The Simon Broome Register Group was 
instrumental in the UK in establishing a set of clinical diagnostic criteria for 
FH, introducing the two categories of definite and possible FH.  Each was 
characterised by raised cholesterol, but the presence of tendon xanthomas was 
seen as decisive.  Xanthomas, also referred to as xanthomata, are deposits of 
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cholesterol on the tendons which occur almost exclusively in FH (Durrington, 
2003; Durrington & Sniderman, 2002).  Thus definite FH was defined through 
raised cholesterol and the presence of tendon xanthomas, and possible FH was 
defined through the presence of raised cholesterol and a family history of either 
raised cholesterol or early heart disease (see Figure 4.1)  
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a) total cholesterol concentration (in adults +16 years) > 7.5 mmol/l or LDL cholesterol 
concentration > 4.9 mmol/l  
   AND 
b) tendon xanthomas in the patient or first or second degree relative (parents, siblings, 
children, grandparents, uncle or aunt). 
 

#
a) High cholesterol as defined in (a) above 
   AND 
b) Family history of myocardial infarction before 50 yrs in a second degree relative 
or before 60 yrs in first degree relative  
  OR  
family history of raised cholesterol levels > 7.5 mmol/l in first or second degree 
relative. 
(Neil et al., 2003) 
 
In 2003, Simon Broome publications (Huxley et al., 2003; Neil et al., 2003) 
start to talk up the possibility of DNA diagnostics for FH.  Huxley et al. (2003: 
23) introduce the amended Simon Broome criteria, which now include DNA 
diagnostics.  Definite FH is now defined by cholesterol levels in conjunction 
with the presence of tendon xanthomas and/or ‘DNA&based evidence of an 
LDL receptor mutation or familial defective apolipoprotein B&100’.  It is 
notable that DNA analysis is an optional part of the diagnosis; the definition 
remains largely clinical.  Huxley et al. (2003) and Neil et al. (2003) introduce a 
new argument concerning dissatisfaction with the purely clinical diagnostic 
criteria, based partly on their dependence on the correct identification of tendon 
xanthomas for definite diagnosis and the ‘the less specific clinical diagnostic 
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criteria’ of possible FH in the absence of xanthomas (Neil et al., 2003: 77).  
The papers problematise the possibility of misclassification of FH based on 
clinical diagnosis alone.  DNA analysis is framed as the arbiter of diagnostic 
decisions:             
‘There are no entirely satisfactory diagnostic criteria for FH.  Clinical 
criteria…result in false negative diagnosis in 10&20% of relatives of 
TX+ [xanthoma present] FH cases.  By contrast, DNA testing offers a 
definitive, highly specific, diagnosis, although its sensitivity remains 
limited.  DNA&based criteria are likely to replace clinical criteria, but 
will not be adopted in routine clinical practice until technical advances 
have increased the speed and sensitivity of mutation testing, and 
decreased its cost.  In the interim, clinical diagnostic criteria will 
continue to be used in routine practice’   
(Neil et al., 2003: 77). 
 
The message here is that it is only a matter of time before DNA diagnostics are 
introduced into routine practice.  The current obstacles to its introduction are 
framed as entirely technical, and temporary.  However, one could imagine 
other possible barriers to DNA based testing concerning for example 
conceptual, practical, or professional issues.  The message of Huxley et al. 
(2003) is slightly more cautious, raising some questions about the relationship 
between an FH genotype and FH phenotype.  They argue:  
‘We used the diagnostic criteria of the Simon Broome Register, which 
place more emphasis on clinical than on DNA&based criteria.  The 
reason is that a small number of LDL receptor mutations appear not to 
be associated with elevated cholesterol concentrations, and conversely, 
receptor mutations cannot be identified in all patients with 
xanthomatous (i.e., definite) familial hypercholesterolaemia’  
(ibid: 24).  
 
In other words, some ‘mutations’ do not seem to be pathogenic and they cannot 
find mutations in all people with definite FH.  This issue does not appear to 
have lead to a reappraisal of the overall causal model.  The inability to find 
mutations in patients with definite FH is largely framed as a technical matter:  
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‘It is not clear whether differences in detection rates relate to genetic 
heterogeneity of the particular case series, the accuracy of the clinical 
examination for xanthomata, or differences in DNA methodology’ 
(ibid, 2003: 24). 
 
In other words it might be attributable to the large number of different 
mutations in the LDL receptor, or to the limitations of clinical or laboratory 
techniques.  Although caveats are discussed, in the end the paper conveys the 
same message as Neil et al. (2003), that DNA diagnostics are an inevitable 
development, contingent only upon technical issues.   
 
The most recent publications, (Neil et al., 2004, 2005), do not use the updated 
diagnostic categories, they do not discuss DNA diagnosis, nor do they 
problematise diagnostic categories. However, an abstract from the 2005 
HEART UK conference, (Humphries et al., 2005), provides a postscript to this 
account of the group’s discussion about diagnostic categories, illustrating their 
continued interest in the area of DNA&testing.  It demonstrates that the group is 
involved in research concerned with the utility of DNA&based testing in UK, 
based on mutation testing of patients on the Simon Broome register.   
 
Although in the UK, diagnosis remains largely a clinical matter, internationally 
there has been some move towards DNA&based testing.  Most notably, the 
Netherlands and Norway have introduced national cascade screening 
programmes that involve genetic tests (Hadfield & Humphries, 2005).  The 
publications of the Simon Broome Group give the impression that it is in 
favour of DNA&based diagnostic criteria and testing.  Yet opinions differ on 
this area, even amongst the members of the group.   
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Steve Humphries, member of the Simon Broome group, has been a long&time 
champion of DNA&based diagnosis for FH (see for example Hadfield & 
Humphries, 2005; Heath et al., 2001; Humphries et al., 1985, 1997; Marteau et 
al., 2004).  Indeed, Family Heart Association records show that he gave an 
annual guest lecture entitled ‘Early diagnosis of FH using DNA (gene) probes’ 
at their AGM in 1987.  He is, in fact, a UK expert on FH mutations and 
custodian of the world&wide LDL receptor mutation database 
(http://www.ucl.ac.uk/fh/), and set up the first DNA diagnostic laboratory for 
FH in the UK in 1998.  His papers have consistently focussed on the benefits of 
DNA&based diagnosis and the limitations of clinical diagnosis for FH.  The 
benefits discussed are that DNA testing can give an unequivocal diagnosis 
where cholesterol levels are not decisive, particularly since there is an overlap 
in cholesterol levels between those with and without FH, and especially useful 
in children where raised cholesterol levels may develop later: 
‘The identification of the FH&causing mutation in a family allows 
unequivocal diagnosis, and the diagnostic problem caused by the 
overlap in cholesterol levels between the general population and FH 
subjects could be eradiated, eliminating false negative diagnosis. A 
single test, once in the lifetime will be able to ascertain FH status, and 
early diagnosis in children would also be possible’  
(Marks et al., 2003b: 5). 
 
In this construction, FH status is defined as the presence of a mutation rather 
than necessarily the presence of raised cholesterol, or high risk of CHD; 
genotype is the paramount and defining factor, not phenotype.   
 
Humphries’ work acknowledges that there is uncertainty about the relationship 
between genotype, raised cholesterol and risk of CHD in some cases, talking of 
cases where people have known mutations, but normal cholesterol levels.  It 
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also acknowledges the difficulty of DNA&based testing in countries like the 
UK, where there is ‘mutational heterogeneity’.  His own work in the UK 
(Heath et al., 2001), for example, found relatively low mutation detection rates 
of 32% for adults with definite FH and 14% for adults with possible FH.  Like 
the Simon Broome papers, this is attributed to both technical problems of DNA 
testing and clinical diagnosis, and aetiological issues concerning the possibility 
of as yet unidentified further genes involved in FH.   
 
Nevertheless, Humphries and his co&authors still tend to present low mutation 
detection rates as a mainly technical rather than conceptual issue. Hadfield & 
Humphries (2005: 430), for example, argue:  
‘It is unclear to what extent the low detection rates are due to technical 
inadequacies of DNA testing (i.e. low sensitivity or ‘false negatives’) or 
to incorrect clinical diagnosis (i.e. low specificity of clinical diagnosis)’  
 
This implies that if a mutation cannot be found then there is either a problem 
with the DNA testing or the person does not really have FH, in effect 
prioritising DNA status over clinical status.  In the end they conclude that: 
‘It is likely…that for optimal results both genotypic and phenotypic 
diagnosis should be used’  
(ibid: 430).   
 
 
Paul Durrington (Durrington, 2001, 2003; Durrington & Sniderman, 2002), a 
member of the Simon Broome group and chair of the HEART UK research 
committee, is less positive about DNA&based diagnosis.  He again calls into 
question the relationship between genotype and phenotype, and frames the 
introduction of DNA diagnostics as controversial and as an issue of priorities: 
‘Whether the familial hypercholesterolaemia genotype can be present in 
people without the clinical syndrome and whether, therefore genetic 
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testing could be useful is debated…Although the controversy over 
genetic testing continues, many people with obvious clinical features of 
familial hypercholesterolaemia who are at risk of premature CHD go 
undetected or the importance of the diagnosis and the rigour with which 
this disorder must be treated is not appreciated’  
(Durrington, 2003: 720).  
  
Durrington prioritises the better recognition of the clinical features of FH.  To 
paraphrase, why bother with DNA testing when so many obvious cases of FH 
go undiagnosed?  This is another example of the ‘gap between knowledge and 
practice’ discourse discussed in relation to models of CHD.  This may reflect a 
more general view among lipidologists.  However, the subject of DNA&based 
diagnosis does not appear to have generated much debate among clinicians in 
the UK.  For example, Heath et al. (2001), on the UK molecular testing service, 
drew no response in the medical journals from UK clinicians.  One possibility 
is that this is just not a burning issue for many clinicians.  This argument is 
supported to a degree by the HEART UK interviews, which will be discussed 
in the next chapter. 

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Although the Simon Broome publications have discussed diagnostic categories 
and DNA&based techniques, this is not the focus of their own research.  This is 
the epidemiology and management of FH.  The group has produced some of 
the key research in establishing the mortality rates for CHD and other 
conditions in treated and untreated FH, demonstrating the efficacy of statin 
therapy.  From the earliest paper, the Simon Broome group was concerned with 
why some people with FH have very early CHD and others get CHD later or 
not at all.  Their first publication (Scientific Steering Committee on Behalf of 
the Simon Broome Register Group, 1991) commented that they could not 
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explain the mortality patterns they had reported, but observed that the age of 
onset of CHD seemed to run in families.   
 
Since the clinical utility of FH as a diagnostic category is only as a predictor of 
early CHD, it is not surprising that the Simon Broome group were concerned to 
work out other factors that might contribute to risk of CHD in patients with 
FH.  The Scientific Steering Committee on Behalf of the Simon Broome 
Register Group (1999) suggested a number of possible explanations that 
include both genetic and non&genetic factors. These were that the severity may 
relate to different mutations in the LDL receptor gene or that response to 
therapy may differ depending on the mutation, that other genetic 
polymorphisms may be involved, and the influence of conventional CV risk 
factors.  This shows that the model of CHD in FH is not fixed on the effect of 
mutations in a single gene, but allows for the influence of other genes and the 
environment.   
 
The Simon Broome Register Group’s own research, to date, has not focussed 
on differentiating between different LDL receptor mutations, but on other 
factors.  This is demonstrated in Neil et al. (2004: 1431), which argues that 
people with identical LDL receptor mutations can have different outcomes:  
‘Although there is a strong intra&family correlation with the age of 
coronary death in affected sibling pairs, relatives with identical LDL 
receptor mutations and similar LDL concentrations may have different 
outcomes.  This suggests that both environmental factors and other 
genetic polymorphisms influence susceptibility to coronary disease and 
explain the wide variability in phenotypic expression’.  
 
The paper sets out to test the influence of established and ‘emerging’ risk 
factors for CHD in people with FH.  It is notable that although the excerpt 
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above mentions the possible influence of other genetic polymorphisms, the 
research did not include analysis of polymorphisms in other genes and there is 
little further discussion about such polymorphisms.  The research itself 
included only clinical, that is, phenotypic measures.  The paper argues that 
there is an unequivocal association between the established CHD risk factors 
with CHD in patients being treated for FH, whereas there was little evidence of 
an association with the emerging risk factors for this group, concluding that:  
‘extensive investigation of risk factors in patients with familial 
hypercholesterolaemia is not warranted.  LDL cholesterol 
concentration, duration of exposure to raised LDL concentrations, 
hypertension, and cigarette smoking appear to be the most important 
modifiable determinants of coronary risk in these patients’   
(ibid: 1435&1436). 
 
This is a clear statement that foregrounds traditional risk factors in the 
aetiology of CHD in patients being treated for FH, and seems to detract from 
genetic models.  It implies that further work on delimiting particularly severe 
LDL receptor mutations or the influence of polymorphisms in other genes is 
unnecessary.  Clinical measures, such as LDL cholesterol concentration and 
how long someone has had raised cholesterol, are seen as more important.  
This reinforces the clinical rather than genetic orientation in the management 
of FH.   
 
The group’s focus on traditional ‘lifestyle’ factors is further reinforced in Neil 
et al. (2005), which reports a significantly lower relative mortality for non&
coronary causes  in patients on the register, suggesting that this is likely to be 
due to advice&giving concerning healthy diet, physical activity and smoking 
cessation.  Neil et al. (2004) and (2005) taken together suggest that lifestyle 
measures, in addition to treatment, contribute to a reduction in mortality from 
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CHD and other causes in people with FH.  The Simon Broome Group’s interest 
in factors contributing to CHD in FH, particularly ‘lifestyle’ factors, and their 
lack of focus on the influence of genetic differences suggests a model in which 
genes are not necessarily the ultimate determinants of ill&health.  This is the 
opposite of the genetic reductionism and determinism anticipated by the 
geneticisation thesis.  The focus on ‘lifestyle’ factors also reflects the clinical 
orientation of the Simon Broome Group.    
 
It is notable that none of the Simon Broome analyses include socio&economic 
class as a variable.  This suggests that the group do not consider class to have a 
bearing on mortality or risk of CHD in people with FH.  Furthermore, the 
‘emerging’ risk factors included in Neil et al. (2004) are all biochemical 
markers of lipid metabolism, inflammation and clotting.  In sum, these 
observations suggest that the Simon Broome Register Group construct the 
aetiology of CHD mainly in terms of the established risk factors and the 
processes of atherosclerosis, with a relative lack of interest in the other 
emerging risk factors or in socio&economic differences in risk.  This concurs 
with the earlier analysis of HEART UK member’s constructions of CHD.   
 
Overall, the work of the Simon Broome group has not focussed on the genetic 
aspects of the aetiology of FH.  Their rhetoric of supporting treatment and 
lifestyle measures is far from a reductionist message that privileges genes.  
Recommendations urging the continued provision of advice&giving concerning 
‘lifestyle’ measures could be interpreted as focussing on individual level 
interventions and individualising responsibility as predicted by Lippman.  
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Nevertheless, clinical indicators of CHD risk are prioritised over genetic 
indicators.  

!	
To sum up, this section has argued that the Simon Broome group have been 
influential in the categorisation of FH in the UK and base their diagnostic 
criteria mainly on clinical indicators.  It has suggested that in recent years they 
have started to problematise these clinical indicators, arguing for a possible 
role for DNA&based information, and suggested that professionals involved 
with the Simon Broome group have differing views about the advantages and 
disadvantages of genetic testing.  However, this topic does not seem to have 
elicited much discussion amongst clinicians more widely in the UK.  This 
section has also discussed the contribution of research undertaken by the 
Simon Broome group to aetiological models of FH.  It has argued that their 
research does not focus on genetic analysis, and it prioritises traditional risk 
factors over genetic differences concerning risk of CHD for people with FH 
 
How does this discussion of the aetiology and diagnosis of FH relate to the 
geneticisation thesis?  First, the focus on traditional risk factors and lack of 
interest in genetic analysis detracts from the genetic reductionism and 
determinism anticipated by the thesis.  Second, although there has been some 
discussion about DNA&diagnosis in the biomedical literature, FH diagnostic 
criteria remain largely clinical at the current time in the UK.  The increasing 
stratification along genetic lines suggested by Lippman has yet to materialise in 
this case.  Third, the current picture in the UK, at least, is that DNA 
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technologies have not replaced other diagnostic techniques.  Fourth, the 
analysis suggests that there may be disagreement about DNA&diagnosis and 
that this may form along disciplinary lines.  Certainly in the UK, the geneticist 
Steve Humphries has been one of the key proponents of DNA&diagnosis, while 
there appears to be a lack of enthusiasm or interest amongst clinicians.  This is 
still an evolving area, but at present, it is largely the clinicians not the 
geneticists who control the identification and classification of FH in the UK.  
In this case, geneticists do not appear to be the all&powerful group of 
Lippman’s thesis.   

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The first part of this chapter, based on the analysis of four commentary papers, 
suggested that there is a genetic vision for understanding, managing and 
treating CHD that has many of the elements of a geneticised model proposed 
by Lippman.  However, the analysis suggested that there are a number of 
alternative and competing models of CHD, which draw on a range of emerging 
risk factors as well as the established ones.  Genetic models do not emerge as 
the dominant idea.  The second section demonstrated that the contribution of 
biomedical professionals involved with HEART UK to models of CHD are 
largely concerned with the molecular processes involved in atherosclerosis.  
Little of their research is concerned with the contribution of genetic variations 
to these processes in general.  Their connection to genetics is largely limited to 
research on specific hereditary conditions, and this research is often concerned 
with their treatment and management rather than their genetic aspects.  
Research concerning other emerging risk factors, the early environment, 
 178
psychosocial factors and infectious agents, is largely absent.  The same model 
of CHD is supported by the research of the Simon Broome Register Group on 
variations in CHD in people with FH.  This included the traditional risk factors 
and new markers of atherosclerosis, but not the other emerging risk factors.  
The papers have largely prioritised traditional risk factors over genetic 
differences between people with FH.  
 
The chapter has also discussed the definition of FH and the role of genetic 
testing in its diagnosis.  Although diagnostic criteria in the UK remain largely 
clinical rather than DNA&based, the Simon Broome Register publications have 
constructed genetic testing as an inevitable development, contingent only upon 
technical advances.  However, research involving genetic testing has raised 
some questions about the relationship between FH genotypes and a clinical 
diagnosis of FH and this has lead to some ambivalence about the utility of 
genetic testing, even amongst members of the Simon Broome Register Group.  
The analysis suggests that different views on this subject may reflect different 
disciplinary perspectives of lipidologists and geneticists.  It is notable that 
Hedgecoe (2002, 2004b), Kerr (2000) and Shaw (2003) have also raised 
questions about the clinical utility of genetic tests and/or suggested that there 
are disciplinary differences between research scientists and clinicians 
concerning diagnostic categories in relation to several other conditions.   
 
The analysis highlights that there are a number of disciplines with an interest in 
CHD and it has suggested that constructions of the aetiology and management 
of this disease might be analysed in terms of boundary work and boundary 
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disputes (Gieryn, 1983).  Boundary work, here, can be thought of as the 
strategies particular disciplines draw on to demarcate their own discipline from 
others, and which establish their own expertise, authority and claims on 
resources in a particular field.  In this case, just as Lippman, as an 
epidemiologist and social scientist, is involved in boundary work concerning 
geneticists, warning against their colonisation of areas of health and illness 
which she argues would be better seen in other ways, so the public health 
physicians and epidemiologists discussed in this chapter were warning against 
allowing cardiologists jurisdiction over CHD prevention.  The discussion of 
DNA&testing for FH hints at further boundary work between lipidologists and 
geneticists.  
 
Overall, these data challenge the geneticisation thesis in a number of areas. 
First, genetics could not be described as the dominant discourse in any of the 
literatures analysed, apart from those written by geneticists.  Second, the Simon 
Broome Register Group’s own research does not focus on genetic analysis and 
prioritises traditional risk factors in explaining CHD in people with FH.  This 
suggests a model of FH in which genes do not ultimately determine disease.  
Third, neither the literature on CHD in general, nor the Simon Broome research 
on FH, focuses on distinguishing people on the basis of their DNA.  Fourth, the 
literature on CHD suggests that the application of genetic technologies in 
clinical practice remains largely promissory rather than actual.  This is also 
largely the case in the management of FH in the UK, although this differs in 
other countries.  Fifth, the analysis demonstrates that there is a range of 
biomedical actors involved in the construction of CHD and FH, challenging 
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Lippman’s assertions about the power of geneticists to determine how health 
problems are defined and managed. 
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This chapter focuses on the structure, aims and activities of HEART UK.  It 
first looks at what sort of an organisation HEART UK is in terms of its 
structure, membership and organisation, in order to consider whether and in 
what sense it represents a site of lay discourses.  It then considers how HEART 
UK constructs the areas of CHD, hypercholesterolaemia and FH by looking at 
(1) the aspects of these conditions the organisation prioritises in its activities 
and membership and (2) the account it provided of the causes of these 
conditions, paying particular attention to the way genetic elements are 
presented.  The analysis is particularly concerned with the degree to which the 
organisation’s activities and discourses relate specifically to FH and to the 
genetic elements of CHD, hypercholesterolaemia and FH, and the degree to 
which it distinguishes between different causes of hypercholesterolaemia.   
 
The chapter is divided into the four main sections: the organisation of HEART 
UK and the role of patients/lay people; the focus of activities; the aetiology of 
CHD and hypercholesterolaemia; and constructions of FH.  The main sources 
of data drawn on are the interview accounts provided by senior lay and 
professional committee members of HEART UK and written material 
produced by the organisation including information leaflets, the website and 
annual reports.   
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The chapter argues that although HEART UK was originally founded by 
patients, from the accounts provided it is difficult to establish what kind of 
influence and the degree of influence lay people/patients currently have over 
the discourses and activities of the organisation.  It can be said, however, that it 
is a highly professionalised organisation.  The chapter suggests that the 
organisation has become less not more focussed on hereditary lipid disorders 
and that, although an aetiological distinction is made between the hereditary 
lipid disorders and ‘lifestyle induced’ hypercholesterolaemia, HEART UK 
does not stratify patients according to this division in terms of the areas it has 
become involved in or the support it offers to patients.  Finally, it suggests that 
FH is predominantly framed as a form of heart disease rather than as a genetic 
disease.  These findings place into question a number of the tenets of the 
geneticisation thesis. 
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This section is concerned with how the data on HEART UK’s constructions of 
CHD and FH should be understood.  It is concerned with the ways in which the 
organisation’s activities and discourses are indicative, specifically, of lay 
constructions.  As discussed in Chapter 2, there has been increasing scholarly 
interest in patients’ associations as sites where expertise may be renegotiated 
and new forms of knowledge production are emerging (Epstein, 1995; Novas 
& Rose, 2000; Rabeharisoa, 2003; Rabeharisoa & Callon, 2002; Rapp et al., 
2001).  My original rationale for studying the Family Heart Association (FHA), 
the pre&runner to HEART UK, was that it offered a potentially interesting and 
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important site where disease categories are constructed.  Furthermore, it 
potentially offered a second site of lay constructions of FH and CHD, at a 
collective rather than individual level.  However, as Chapters 1 and 3 
discussed, in November 2002 my research plans were overtaken by events.  
The FHA merged with the British Hyperlipidaemia Association (BHA), the 
professional organisation for health care practitioners and scientists who 
specialise in lipid metabolism and lipid disorders, to form HEART UK.  This 
new organisation offered a particularly interesting site for research concerned 
with the relationship between lay and professional expertise.  It raised new 
research questions about the kinds of relationships that were embodied within 
this new organisation and the sorts of ideas about expertise upon which the 
development was founded.   
 
This section provides a brief overview of the history and workings of HEART 
UK in order to consider whether and in what sense it represents a site where 
patient discourses are formulated and articulated.  The analysis will suggest 
that although there was some recognition of experiential knowledge, HEART 
UK maintains a fairly traditional allocation of roles and attribution of expertise.  
Lay members clearly play an important role in the organisation, but at the 
present time the discourses and activities of the organisation could not be 
thought of as strongly influenced by a collective lay discourse in any obvious 
way.  The data on HEART UK should, therefore, be seen as being as much, if 
not more, about professional as about lay constructions of FH, lipid disorders 
and CHD.  
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The Family Heart Association (FHA) was founded in its original guise in the 
early 1980s by patients with hereditary lipid disorders.  Its history up to 2002 
follows a recognised trajectory (Rabeharisoa, 2003; Wood, 2000), from being 
run on a voluntary basis to becoming increasingly professionalised through the 
employment of a small number of professional charity administrators and 
health care practitioners.  By the early 2000s, the FHA had permanent office 
accommodation, a hand&full of staff, produced a bimonthly newsletter, 
provided a telephone help&line, and undertook numerous other activities which 
will be more fully discussed in subsequent sections of this chapter.  Although 
the management of the charity was the responsibility of the predominantly lay 
committee members, the day&to&day activities were undertaken by the 
employed staff.  Annual reports suggest that there had been some local support 
groups in the early years, but that these had proved difficult to maintain.  The 
minutes from 1989, for example, report: 
‘the groups with a few exceptions, were not working and efforts are 
being made to restructure these’  
 
and minutes from 1992 report:  
‘A number of regional meetings had been held over the year, but 
attendance did not come up to expectations’.   
 
By the early 2000s, the main gathering of ordinary members was at the annual 
AGM/members’ day.  Annual reports suggest attendance at the AGMs was 
about 20 people and that total membership was around 1000.   
 
Clinicians were involved with the organisation from the earliest stages.  The 
interview data suggest that they were, for example instrumental in the founding 
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of the FHA through recruiting some of the early committee members from 
amongst their patients.  There was also a significant amount of cross&over 
between the FHA and the BHA, with the prime movers in the BHA often also 
acting as medical advisors to the FHA.  Furthermore, AGM minutes report that 
the nurse&advisors employed by the FHA helped to instigate, and were 
members of, the BHA’s healthcare section, a subgroup specifically for health 
care practitioners in the field.  The AGM minutes also show that latterly, 
several health care professionals were involved as trustees of the FHA, and that 
two clinicians went on to become the last two chairs of the organisation before 
the merge.  It is, of course, possible for people to be both clinicians and to have 
FH, and interviewees talked of one such trustee.  The status of the other health 
care professionals who acted as trustees was not discussed, but it is likely that 
their involvement was through professional not personal interest.  In sum, the 
FHA, in its later history, could be typified as a health charity 
	 people with 
lipid disorders more than a grass&roots organisation 
people with lipid 
disorders. 
 
It is worth digressing briefly tooutline the origins and history of a second, 
connected group, the Simon Broome Heart Research Trust (SBHRT).  This 
was a small charity that was founded by Katherine Broome and Dr Jim Mann 
in 1977, in memory of Katherine’s husband, Simon, who had died of a familial 
lipid disorder.  This charity was important both in the founding of the FHA and 
in the development of the professional scene. It provided support and funding 
to initiate the FHA, and Katherine Broome and Jim Mann were involved with 
the FHA as a trustee and medical advisor, respectively. The charity also 
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financed meetings for lipidologists at the stage when this discipline was in its 
infancy, and this grouping of lipidologists went on to develop into the BHA.  
The charity’s main activity was to found the Simon Broome register, the 
national register of patients diagnosed with familial hyperlipidaemias.  The 
administration of the register was passed on to the BHA, when the SBHRT 
folded in the late 1990s.  As discussed in the previous chapter, the Simon 
Broome Register Group has played an influential role in the management of 
FH in the UK.  This discussion of the SBHRT has shown that (1) this 
influential research group was founded through the collaboration of a layperson 
and a clinician, (2) the charity has played an important part in building the field 
of lipidology, through helping to initiate the patients’ association and the 
professional’s association, and through the research of the register and (3) there 
have been longstanding links between the SBHRT, the FHA and the BHA.   
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Interviewees offered a number of reasons for the merge between the FHA and 
the BHA, but a recurrent theme concerned gaining increased legitimacy with 
government and other organisations.  In part, this was simply a matter of scale; 
one large organisation rather than two smaller ones could command more 
fundraising and lobbying clout.  As one interviewee commented:  
S/HP5: certainly government takes much more notice if you’ve got five 
thousand members rather than fifty or five hundred.  
 
It was also concerned with the legitimacy conferred by patient involvement, 
which must be seen particularly within the context of the current policy climate 
in the UK of patient and public involvement (see for example Department of 
Health, 2001b, 2004).  This was summed up neatly by one interviewee: 
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S/HP1: If we are actually to sort of play in the main arena then a lot of, 
certainly government and a lot of the pharmaceutical industry are much 
more impressed by the fact that we’ve actually got patients on the 
committees than if we didn’t have […] it’s more value for money to 
have a good mix.  
 
Another interviewee commented that professionals’ associations might be seen 
as self&interested, whereas an organisation that included patients would be seen 
as having more ‘altruistic objectives’ (S/HP4).  The importance of being seen 
as a group that represents patients is made very clear in HEART UK’s Annual 
Report in 2004, which states plainly that: 
‘The Charity expects to see greater emphasis upon Patient Membership 
recruitment and thus a greater voice in the public arena’  
(HEART UK, 2004: 5). 
 
From the patients’ perspective, the merge provided their organisation with 
greater authority, by being associated with some of the leading experts in the 
lipid field.  This was explained by a clinician who had been a member of the 
FHA:   
S/HP2: Well basically what was in it for the patients I think was the 
perception of some intellectual integrity.  You know they, patients’ 
organisations always see themselves as inferior to the doctors […] They 
saw it as a way of getting intellectual integrity […] you know we can 
say these are all our people, instead of having well these are our 
medical advisors, which you know were pretty hot&shot people, but 
actually these people are signed up to our organisation.  
 
This concern with being taken seriously was also evident in the minutes of the 
FHA’s AGMs.  In 1999, for example, these talk of the aims of building a 
strong public image ‘as a serious medically authentic organisation’ in order to 
attract funding.  
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What was notable about the main explanations offered for the merge, was that 
they were concerned with instrumental or practical reasons.  By and large they 
were not about conceptual ideas concerning collaborative working. 
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		
HEART UK retained the offices and staff of the FHA, who continued with 
largely the same functions as before.  At the point of the merge, there was a 
staff of seven full and part&time employees, consisting of the director, the 
editor of the newsletter, two administrators, two nurse advisors and a dietician.  
The overall management and direction of the organisation is overseen by the 
main board and several subcommittees.  These are the patient services, the 
health care, the research, the medical & scientific, and the finance & general 
committees.  HEART UK also took over the administration of the Simon 
Broome register.  

Figures provided to me on my visit to HEART UK in December 2003 were 
that the organisation had a membership of 1400, made up of approximately 630 
‘patient’ members (lay members) and 770 professional members.  Figures 
provided in the Annual Report in April 2004 differ somewhat, suggesting a 
membership of around 2500, broken down into about 40 per cent professional 
members to 60 per cent ‘patient’ members.  Nevertheless, the membership 
figures are of a similar order of magnitude (low thousands), with a roughly 
similar division between lay and professional members (similar numbers of 
each).  Within the committee structure of the new organisation, professional 
members considerably outnumber lay members on the main board of directors 
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and subcommittees.  There were five lay committee members in total, 
compared with a total of 27 professional committee members.  The five lay 
members all sat on the main board of directors along with ten professional 
members.  These same five lay members also represented lay interest on the 
subcommittees, with every committee having at least one lay member, with the 
exception of the Simon Broome committee.  They had more involvement in the 
patients’ services committee and in the general & finance committee.  There 
was just one lay member on each of the healthcare, scientific & medical, and 
research committees.  Involvement in these areas was a new role for the lay 
members and there was a sense that they were still finding their feet.  As one 
interviewee commented: ‘I’m still finding out my role in that’ (LM2). 
 
The relatively low numbers of lay members involved in the running of HEART 
UK compared with professional members and staff gives only a limited 
indication of the position of lay discourses within the organisation.  It would be 
entirely possible for these five lay members to be very influential figures or for 
the organisation to be highly responsive to the ordinary lay membership.  It is, 
therefore, necessary to provide some details of the relationship between lay and 
professional members and the perceived role of patients within the 
organisation. 

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Interviewees described two major roles for patient committee members.  First, 
they were said to provide valuable input on patient experiences and priorities.  
It was suggested that it was important to have a pragmatic or real life 
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perspective on the committees and also at public events.  This view suggests a 
role for experiential knowledge, a knowledge borne from 		
2 
with the condition, as the following extract suggests: 
LM2: we live in the real world, we live with the condition and they 
don’t […] They’re thinking in statistics, in the general population, in 
their patients, in their research and this is what they’re focused on, 
which is great, but every now and then you have to say hay, you know, 
it’s us you’re talking about and this is how we have to cope with it […] 
they don’t realise what it’s like day&to&day living with this.  
 
This was seen as an important part of providing appropriate services for 
patients and of agenda setting by the organisation, a view expressed succinctly 
by one of the professional members: 
S/PM4: I think it’s important to have insights into how the patients feel 
they are affected by decisions and also to recognise what they see as 
priorities.   
 
Second, interviewees’ talk suggested that patient committee members were 
valued for their own particular professional skills.  Indeed, it was reported that 
a number of them had been headhunted by the director of the organisation or 
clinicians in recognition of the useful skills they could contribute.  These were 
people who had business and financial skills, knowledge of charity law, 
organisational skills and experience of public speaking.  This was explained 
very clearly by one of the lay members:   
LM4: Medics are an important profession, but many of them are not 
brilliant accountants, or lawyers or business men […] Now patients 
have all those skills and if the lipid clinics can find them and bring 
some of them on the committees, you have a much more effective 
organisation.  
 
The interview schedule did not specifically ask about how the views or 
experiences of ordinary members, or of other patients, fed into the work of the 
organisation, and this was rarely discussed in the interviews.  As already noted, 
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there are currently a fairly limited number of occasions when ordinary lay 
members meet.  One interviewee reported that that the organisation keeps a 
record of the questions most frequently asked of the information and support 
services, and tries to answer these questions in the ‘Digest’.  This suggests that, 
in keeping with other patients’ associations (Allsop et al., 2004; Baggott et al., 
2004), there was at least some formalised way for lay views to feed into the 
work of the organisation, although the degree of influence is not clear.   
 
In sum, interviewees’ accounts suggest that although patient experience 
(expertise) was valued, to some degree a division of labour was accepted 
within the organisation, with lay members largely happy to leave scientific and 
technical matters to the biomedical experts.  In this sense, the organisation 
could be thought of as an ‘auxiliary association’ (Rabeharisoa, 2003; 
Rabeharisoa & Callon, 2002), in which responsibility for the production and 
dissemination of knowledge and practice is delegated to the scientists.  It is, 
however, unusual that these scientists sit in the same organisation.   
 
The current ratio of professional to lay trustees and committee members 
suggest that the organisation is professionally dominated.  The history of staff 
and clinicians headhunting particularly useful lay members is a further 
indication of the professionally&led nature of the organisation.  The sense that 
the organisation was and currently remains professionally dominated is 
reinforced by one interviewee’s talk about, and my own observations of, the 
patients’ day and patient workshops, which are the main opportunity for 
ordinary lay members to meet.  There seemed to be a disjunction between the 
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very technical topics covered and the very practical questions asked by the 
attendees.  The interviewee explained it like this: 
LM5: The presentations by medical professionals to the general public 
were very interesting in their own technical right, but they weren’t, 
dumbed down isn’t the right word, but simple English, simple analogies 
weren’t there.  
 
Within the organisation, itself, there was a feeling that they had rather low 
levels of patient involvement and there was talk of scope for greater patient 
input at the patients’ day, and of setting up a support group.  This rhetoric of 
greater involvement is reinforced in the Annual Report of 2004 which states 
that the directors intend that: 
‘the place of passive patient [sic] will be replaced with one that sees 
greater action and involvement in the plans of the Charity’  
(HEART UK, 2004: 6). 
 
It is likely that this rhetoric of greater involvement is being driven by the 
current policy climate rather than a particular commitment to the notion of lay 
expertise.  Nevertheless, it does demonstrate that HEART UK sees itself as an 
organisation currently lacking in patient involvement.   

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Although HEART UK’s future plans include the aim of significantly increasing 
its patient membership, many of the interviewees talked about the difficulty of 
retaining members and increasing membership numbers because of the nature 
of raised cholesterol and FH.  In essence, they attributed this to raised 
cholesterol having no symptoms and to its treatment being unobtrusive.  This 
points to the ‘abstract ‘disembodied’’ nature of the disorder (Lambert & Rose, 
1996: 65). They suggested that people tended to seek support or information 
only at the point of diagnosis and not on a long&term basis.  Several illustrated 
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this by contrasting raised cholesterol with diabetes, which can have symptoms 
when it is poorly controlled and where treatment may be difficult to manage: 
LM1: A feature of the organisation is that people join when they get a 
diagnosis.  After about a year, they don’t need you anymore.  They feel 
fine and stabilised.  Therefore there’s never been a big membership.  
People manage their ailments and then they don’t need help.  It’s not 
like diabetes; they’re not stabbing themselves.   
 
Another interviewee talked of the difficulty of trying to increase membership 
numbers because people do not identify raised cholesterol as a disease:  
S/HP4: It’s largely an asymptomatic disease, which they will see as a 
condition and possibly not even as a disease, let alone an illness, so it 
may be much more difficult to get them attuned to this.   
 
 
The current aims to increase patient numbers would, therefore, seem to involve 
the creation of a high cholesterol or FH identity that does not presently exist.  
While talk of getting more patient members on board can be interpreted as part 
of the image management of the organisation, reflecting the current 
involvement agenda of the national government, it was also tied up with 
normative ideas about what a cholesterol patient should be, in as much as such 
a person  want to be part of a group identified through cholesterol and 
 want to be more informed about cholesterol.  This was articulated by 
one of the interviewees: 
LM3: We want to have ten thousand patients on board.  Not necessarily 
on the committee, but subscribed to the magazine, writing to it, the 
whole background of patients.  If you’ve got bad cholesterol then you 
should be a member of the society, if only because you’ll get the latest 
thinking and thoughts and opportunities to meet the great and the good, 
and other patients. 
 
This suggests that HEART UK is not tapping into a ready made constituency, 
but is actually involved in the construction of such a constituency.  This talk 
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illustrates Rose & Novas' (2004) argument that biosociality can be configured 
as an obligation, and that this involves a certain kind of biological subjectivity.   
 
!	
This section has discussed the history and organisation of HEART UK in order 
to consider the significance of data about this organisation’s activities, in other 
words, what this data can tell us about constructions of FH and CHD.  I have 
argued that: 
1. This was already a professionalised organisation before the merge, 
enjoying the support of clinicians in the lipid field 
2. The merge was mainly explained in terms of gaining increased legitimacy 
and influence, rather than a commitment to collaboration or different forms 
of expertise 
3. There was a recognition of lay knowledge, framed as ‘patient experiences’, 
but biomedical matters were largely delegated to the biomedical experts.   
4. HEART UK remains professionally&led, with a low proportion of lay 
members compared with professional members and staff involved in the 
management of the organisation, and low levels of grass roots activities. 
5. The data suggest that there is not a strongly established sense of an FH or 
cholesterol identity among the patient population that would form the basis 
of an increase in lay involvement and influence. 
 
In sum, while patients have influenced and continue to influence the direction 
and activities of HEART UK, it cannot be thought to be influenced by a 
collective lay discourse in any obvious way.  Data about its current activities 
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and discourses should be seen as reflecting professional constructions of FH, 
lipids and CHD as much, if not more, than lay constructions.     
 
4;2-,$!,".0..-!
This section discusses the overall work of HEART UK and the priorities of the 
interviewees.  It considers the balance of activities between FH and 
hypercholesterolaemia and CHD in general, and the focus of activities in these 
areas.    The aim is to consider whether the organisation has become more 
focussed on hereditary conditions and whether it draws a distinction between 
the different forms of hypercholesterolaemia in terms of the services it offers 
and activities it undertakes.   It will argue that the organisation has increasingly 
refocused its remit to include cholesterol and CHD risk factors in general, and 
that interviewees had different views about this expanding role.    

-	%
The FHA was founded in 1982.  Its original title was, in fact, The Familial 
Hypercholesterolaemia Association.  This was amended to the Familial 
Hypercholesterolaemia and Familial Hyperlipidaemia Association (Family 
Heart Association) in 1986, and shortened to The Family Heart Association in 
1991.  The title of the Hyperlipidaemia Education and Research Trust UK 
(HEART UK) was adopted in 2002 as a result of the merge.  Since October 
2004 the logo of HEART UK has been appended with the words ‘The 
Cholesterol Charity’.  This progression, from the Familial 
Hypercholesterolaemia Association to the Family Heart Association to HEART 
UK to HEART UK & The Cholesterol Charity, suggests a decreasing focus on 
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genetic conditions rather than an increasing focus.  The reality is less 
straightforward. 
 
The minutes of the first AGM, in 1984, state the aims of the organisation as:  
1. to make the public and medical profession more aware of this important 
and fairly common condition [FH]. 
2. To inform and support those found to have FH.  
3. To encourage further research into the cause and treatment of the 
condition. 
 
These aims focus entirely on FH and are concerned with trying to make sure 
people with FH were identified and supported.  The activities interviewees 
remembered from these early years focussed on getting publicity for the 
hereditary disorders, for example by persuading the media to run stories on 
them.  Early activities included producing a diet sheet and a booklet about FH.  
Although the early aims focussed specifically on gaining awareness of the 
hereditary lipid disorders, the organisation’s activities must be placed within an 
historical context.  It was formed at a time when the cholesterol hypothesis was 
emerging and was still seen as controversial, and before the introduction of the 
statins.  In some senses, the issue for the FHA was not just to make people 
aware that raised cholesterol could be an hereditary condition, but that raised 
cholesterol could be a problem at all.  The early activities and comments of 
interviewees provide a telling reminder about the general milieu concerning 
eating habits and ideas about CHD at that time in the UK, as one interviewee 
explained: 
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LM1: the problem at the time was you couldn’t buy low fat products.  
Skimmed milk was a very rarefied thing.  Everyone ate butter, milk 
puddings, nobody knew about what they should and shouldn’t be eating 
and even if you did it was difficult to find low fat products.   
    
In the absence of really effective cholesterol&lowering medication, it is not 
surprising that the FHA placed much emphasis on diet.  The minutes of the 
first AGM talks of the organisation being partly responsible for the 
introduction of new low&fat products: 
‘The arrival of new products in the shops such as Tendale and Shape 
low fat cheeses, Bipro – an egg substitute & and tofu a most useful 
soybean curd must in part been [sic] influenced by our efforts’.   
 
Although one cannot infer the degree of influence the FHA actually had in the 
introduction of such products, these minutes are indicative of the kinds of 
issues that were seen as pertinent at this time.  The data illustrate a concern 
with low&fat diets and low fat products that would have been available not just 
to people with FH, but to the general public.  In this way, the early activities 
can be seen as contributing to a growing culture concerned with ‘healthy’ or 
low fat diets in the UK. 
 
Several interviewees talked about a lack of acceptance of lipid disorders.  One 
of the professionals talked about the antagonism of the medical establishment 
at this time, including the British Heart Foundation, the BMJ, and 
cardiologists, and the importance of having an organisation that actually 
recognised FH and cholesterol problems: 
S/HP2: British Heart Foundation didn’t believe in cholesterol so where 
were you to get the information and where were you to get support for 
somebody […] the BMJ, which we knew as the anti&cholesterol journal, 
was promulgating people like, very well known people like Michael 
Oliver, you know, cardiologist, was saying this is a very dangerous 
thing to lower cholesterol […] I mean we used to go to meetings and 
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people would say, God those are the people that run lipid clinics, you 
know, they’ve got pointed ears and a forked tail, and we’d say hello 
cardiologists, don’t you wonder how that stuff ever got there in the first 
place.  So you have to remember that [founders of FHA] were working 
in that environment […] So they were really up against it.  
 
The controversy surrounding cholesterol and statin therapies at this time has 
been documented (Lupton & Chapman, 1995; Petersen & Lupton, 1996).  This 
extract also hints at earlier boundary disputes between lipidologists or 
metabolic specialists and cardiologists, as the field of lipidology was becoming 
established.  A number of interviewees suggested that health practitioners 
could be ignorant of or dismissive about lipid conditions.  LM1 remarked that 
people would write in asking what they should eat because: 
LM1: my doctor says it’s rubbish.  Most GPs knew nothing about FH 
and didn’t want to know anything about FH […] people who were 
going to the GP and saying you know I think I might have this thing 
were treated more often than not with scepticism by the medical 
profession.   
 
Part of the work of the FHA, therefore, was to gain increased recognition and 
acceptance of FH as a diagnostic category, one of the classic aims of lay health 
advocacy groups outlined by Brown (1995b).  LM4 suggests that the 
organisation had been successful in this aim, contributing to the greater 
acceptance of hypercholesterolaemia as a disorder:   
LM4: there used to be quite a number of GPs who said, oh don’t worry 
about it dear, and don’t believe everything you read, and didn’t do 
anything about it.  I’m pleased to say that I think partly through the 
FHA and HEART UK there are a lot less of those about now. 
 
In order to gain increasing acceptance of FH as a diagnostic category it was 
necessary for such GPs to recognise that raised cholesterol can be problematic 
in some circumstances.  It is, therefore, difficult to separate the early aims and 
work of the FHA from wider moves to gain increased recognition of lipid 
disorders and the cholesterol hypothesis in general.  The FHA can be thought 
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of as contributing to establishing the field of lipidology and of establishing 
cholesterol as a risk factor in CHD, as well gaining wider recognition of the 
hereditary lipid disorders.    

Annual reports suggest that the activities of the organisation branched out from 
a fairly early stage to include some work on CHD prevention in general, 
mainly relating to diet and lifestyle.  The minutes from 1989, for example, 
mention the administration of funding for the Family Heart Study.  This was 
one of the main pieces of research that the FHA was involved in and was 
concerned with cardiovascular (CV) risk factor screening and lifestyle 
interventions in primary care (see Wood et al., 1994).  This broader remit was 
indicated on the FHA website, whose home page stated: 
‘We aim to make all aware that high levels of cholesterol are a serious 
heart disease risk 
We are committed to tracing over 100 000 people in the UK who have 
inherited high cholesterol 
We endeavour to support and advise anyone who wishes to reduce the 
risks of heart disease’ 
(http://www.familyheart.org/pages/topbar.html, accessed 19/4/2002)
  
 
The current aims of the organisation were reported in the first annual report of 
HEART UK in 2003.  This states that: 
‘The company was incorporated on 19 July 1991 with the following 
objectives:  
1. To relieve those facing the effects of heart disease and in particular 
lipid disorders, familial hyperlipidaemias and related conditions. 
2. to promote the relief of sickness and the preservation and protection 
of health by reducing the incidence of vascular disease in the 
general population of the United Kingdom 
3. to provide counselling and advice to relatives of those diagnosed 
with inherited heart disease 
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4. to promote the study of causes, diagnosis and treatment of lipid 
disorders and associated metabolic diseases’. 
 
This shows that the current aims still focus on hereditary lipid disorders, but 
there is a wider remit which includes the prevention of vascular disease ‘in the 
general population’ and the promotion of research on all forms of lipid 
disorders and associated conditions.  The wording of this extract also suggests 
that these extended aims had already been adopted in 1991, long before the 
merge with the BHA.   

		%
The main activities of the organisation at the present time can be summarised 
as: providing information and support to patients; educating and disseminating 
information to health professionals and scientists and providing their 
professional forum; lobbying; and representation and advisory work.  These 
activities relate both to hereditary lipid disorders, specifically, and to 
hypercholesterolaemia and CHD risk more widely, although it is difficult to 
comment on the balance of work between these areas.  The following examples 
are intended to provide some indication of the different areas of work, rather 
than an exhaustive account of the organisation’s activities. 
 
Patient information and support services include the telephone, postal and e&
mail help&line staffed by health care professionals, the provision of information 
leaflets and the publication of the Digest, the bimonthly magazine of HEART 
UK.  It was not clear the degree to which queries to the help&line related 
specifically to hereditary lipid disorders, but the service is publicised in such a 
way as to attract a variety of enquiries.  HEART UK publishes a large number 
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of information sheets which cover risk factors for CHD, treatments for lipid 
disorders and numerous leaflets concerned with nutrition and diet.  These are 
listed in figure 5.1.  The majority of these leaflets do not relate specifically to 
hereditary lipid disorders.  The Digest magazine carries a mixture of articles on 
recent research findings and conferences, medications and food products 
relating to hypercholesterolaemia and CHD in general, with sporadic articles 
specifically relating to FH.     
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 For your heart’s sake: advice for those keen to lower their cholesterol 
 Risk factors for CHD 
 Young at Heart – Heart Disease and the Over 50s  
 Familial Hypercholesterolaemia 
 Children 
 Cholesterol and Lipoproteins 
 Triglycerides 
 Stress 
 Exercise – an Investment in Health 
 Fibrates 
 Resins  
 Statins 
 Glossary 
 
	

 Cooking methods to reduce fat intake 
 Making changes: how to eat less fat, suitable for ‘South Asian Diets’ 
 What can I do to reduce my fat intake? suitable for South Asian Diets 
 Losing weight 
 Homocysteine & heart disease 
 Guidelines for a Cardioprotective diet 
 Guidelines for a Cardioprotective diet for vegetarians 
 HEART UK diet sheet 
 Nuts and Seeds  
 Oils & fats  
 Fruit and vegetables 
 Fish in the diet 
 Sugars & sweeteners  
 Vitamins  
 Salt  
 Low fat salad dressing 
 Healthy snacks 
 Healthy lunchbox 
 Eating out 
 Eating out best choice 
 
 
Professional activities include the HEART UK annual medical and scientific 
meeting and Simon Brome register research, discussed in the previous chapter, 
running study days and producing information and guidelines for health care 
practitioners.  Perhaps the most significant areas of advice concerning 
professional practice are the Simon Broome diagnostic criteria for FH and 
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HEART UK’s contribution to the Joint British Societies’ guidelines on the 
prevention of cardiovascular disease.  These provide guidelines on 
cardiovascular disease (CVD) risk in the general population and are intended 
for use in primary care.  The FHA and HEART UK have been directly 
responsible for a relatively small amount of research.  This has related to both 
FH and to lipids in general.  The Family Heart Study, mentioned earlier, 
concerned CHD risks in general practice.  More recent research has included 
projects on family tracking and children’s lipid clinics, both concerned 
specifically with hereditary lipid disorders, and a survey of laboratory lipid 
services, which related to lipid disorders in general.    
 
Lobbying work again includes a mixture of activities.  Certain committee 
members were instrumental in gaining government funding for a national pilot 
project on cascade screening for FH, by organising a meeting with the 
Department of Health.  This seems to have been undertaken at the individual 
initiative of three committee members, rather than through the auspices of 
HEART UK.  Nevertheless, they ensured that the director of HEART UK was 
present at the meeting.  At the same time, HEART UK launched a new joint 
project with the British Cardiac Patients Association, and some pharmaceutical 
and food companies, called ‘Cholesterol UK’, which is a lobbying group 
concerned with promoting dietary and lifestyle approaches to CV risks and 
raising awareness about high cholesterol levels in general.   
   
In terms of the representation and advisory work, HEART UK is represented 
on the steering group of the national cascade screening project for FH and has 
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submitted evidence to the National Institute of Clinical Excellence (NICE) 
appraisal on FH.  It has also submitted evidence to NICE and other regulatory 
bodies on issues concerned with CVD in general, including obesity, lipids and 
CVD, statins, the sale of over the counter statins, and on clopidagrel (an anti&
platelet drug used in heart disease).   
 
In sum, the organisation undertakes a range of activities which are concerned 
with both hereditary lipid disorders specifically and hypercholesterolaemia and 
CVD in general.  It is not possible to assess, from this list of activities, the 
balance of work between hereditary lipid disorders and CVD risks in general. 
 
.	%@=	
	
Interviewees’ accounts of the aims and activities of HEART UK tended to 
acknowledge the span of work discussed in the previous section.  However, the 
interviewees emphasised different aspects of this work.  S/HP5 talked almost 
exclusively about cholesterol, lipids and CHD in general, and about associated 
conditions such as obesity, diabetes and stroke, with little mention of familial 
disorders.  By contrast, S/HP2 focussed entirely on FH.  These interviews 
represent the two extreme cases. Overall, interviewees tended to place familial 
disorders at the centre of the organisation’s work, whilst acknowledging an 
extended role concerning the problem of high cholesterol in general.  In the 
following extract, for example, S/HP3 describes the aims of HEART UK, 
suggesting that the primary focus for the organisation is on 	&	
 of 
patients with hereditary lipid disorders, which constitutes '	
: 
S/HP3: To provide the fullest possible support service for patients with 
inherited FH and/or FCH [familial combined hyperlipidaemia].  That’s 
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the primary role.  The secondary role is to make the general public 
aware of the first in order to track more people who inherit the disorder.  
The support behind that comes in primary and secondary prevention.  It 
is therefore important that they [health care professionals] are also 
provided with that education and awareness.  In addition, it’s important 
to support research wherever possible into improving the lot for 
patients.  That’s basically the bottom line.  But as we have a problem 
with raised lipid levels anyway, we should also be engaging the public 
generally with virtually the same messages.  Understanding that 
between fifty and sixty per cent of the population have a total 
cholesterol level which is above that which is recommended.  
 
LM4 expressed a similar view, saying that FH is still at the 
 of the 
organisation’s concerns, but that the organisation should not distinguish 
between people with FH and other people with raised cholesterol in terms of 
the services offered to patients:  
LM4: We are the cholesterol charity, not necessarily familial 
KW: And is that a move that you’ve gladly seen from the family 
cholesterol charity to the cholesterol charity? 
LM4: Yes, it’s not entirely removed, the concentration, the centre of it 
is still familial hypercholesterolaemia, but there is the inevitable, if 
you’re doing that, the government says, well what about the others?  
There’s only a hundred thousand of these [people with FH].  The lipid 
clinics, some of them are not familial patients, no family history, no 
genetic involvement, but they have very high cholesterol, so we can’t 
say we don’t want you, you go off to someone else.  
 
The extension of work to include general issues of cholesterol and CHD was 
associated with a certain amount of ambivalence.  When LM4 talked of an 
inevitable overlap of interests between the familial conditions and CHD in 
general, he was cautious because this led to a cross over of remit between 
HEART UK and other heart charities: 
LM4: Originally it was concentrated on FH and FCH [familial 
combined hyperlipidaemia] and other inherited diseases, but there is an 
inevitable overlap about which we have to be a bit cautious.  I would 
say we are the cholesterol charity now, but we do have to be a little 
careful not to be setting ourselves up as the heart charity because there 
are other large heart charities who would be very put out by that. 
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S/HP4 was more direct about his views on the remit of HEART UK, arguing 
that it should remain primarily concerned with the familial lipid disorders, and 
was somewhat critical of the past activities and focus of the FHA: 
S/HP4: certainly the FHA under a number of its directors, I think 
sometimes mistakenly, went way beyond familial hyperlipidaemias and 
FH in particular and was involved for instance with MSD 
[pharmaceutical company]and the know your number campaign which 
was really dealing with issues around polygenic hypercholesterolaemia 
[general raised cholesterol] and population risk of heart disease […] 
I’ve no doubt that HEART UK, if invited, make a positive contribution 
to general issues around lifestyle advice and sorting diet and so on, but I 
don’t see that as being specific to HEART UK.  It’s done by British 
Hypertension Society, BHF [British Heart Foundation], British Cardiac 
Society.  What I’m saying is, what is it which is specific and different 
about HEART UK, and it is that not only is it concerned about 
hyperlipidaemias in general, but its major remit seems to be, to me, 
those individuals that have got inherited dislipidaemias, ‘cos there’s no 
other group which sees them as its raison d’etre.  
 
By contrast, LM3 talked of the hereditary lipid disorders as having become a 
' of the organisation’s work because of the general expansion of the 
construction of cholesterol as a problem:  
LM3: It’s growing very fast because cholesterol is becoming a big issue 
and while we started with [hereditary] hyperlipidaemia, I wouldn’t say 
it’s become a subsidiary, but it’s becoming part of the cholesterol issues 
and problems, almost a subset within the whole. 

!	
This section has shown that the original aims of the organisation were 
exclusively concerned with hereditary lipid disorders.  The analysis suggests 
that the remit of the organisation widened to include some work on cholesterol 
as a risk factor in the general population more than a decade before the merge 
with the BHA and that current aims and activities cover both hereditary lipid 
disorders and CVD more generally.  However, HEART UK interviewees had a 
variety of views about the main focus of the organisation and the degree to 
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which it had or should expand its role away from the hereditary lipid disorders.  
Overall, the analysis suggests that the organisation has become less focussed 
on genetics during its history, in as much as it has expanded its remit from 
being concerned exclusively with hereditary lipid disorders to a wider focus 
including population&wide CVD risks, prevention and treatment.  Furthermore, 
even the early concern with hereditary lipid disorders must be seen as 
contributing to establishing and raising the profile of the cholesterol hypothesis 
in general.  In terms of the geneticisation thesis, it appears that, in this example, 
genetic discourses have in some ways become 		
	

, and that HEART UK does not distinguish between the causes of 
hypercholesterolemia in fulfilling its remit to support and inform patients. 

4;3-"-.,,8,"&8-*,-!-*,"-."
This section discusses how HEART UK publications and the HEART UK 
interviewees present the causes of CHD and of hypercholesterolaemia.  It will 
suggest that, like the biomedical constructions discussed in the previous 
chapter, there is relatively little interest in polygenic influences in CHD, but a 
focus on ‘malleable’ or ‘lifestyle’ risk factors, framed as diet, exercise, stress 
and weight.  It will argue that HEART UK’s interest in genetics is mainly 
concerned with specific hereditary lipid disorders rather than polygenic 
influences as a more general risk factor for CHD, and that in aetiological terms, 
a divide is maintained between hereditary lipid disorders and other 
hypercholesterolaemia.  
 
 208
Information leaflets produced by HEART UK (see figure 5.1) present the cause 
of CHD as multifactorial and discuss it in terms of risk factors and their 
additive effects.  Risk factors are divided into two types: things that cannot be 
changed, i.e. age, sex, family history; and things that can be changed through 
‘leading a healthy lifestyle’ (see figure 5.2).  These ‘modifiable’ risk factors 
include all the established risk factors, i.e. cholesterol, blood pressure, diet, 
smoking, obesity, lack of exercise, and also ‘excessive stress’.  The inclusion 
of stress must be seen as a recognition of the role of the psychosocial 
environment, categorised by Beaglehole & Magnus (2002a) as a new risk 
factor.  HEART UK produce a specific leaflet on homocysteine and heart 
disease, again a recognition of one of the new biomarkers of CHD risk.   
 
	4;'5
CHD is more likely: 
 With increasing age 
 In men rather than women before menopause 
 If there is a strong family history of CHD 
 
These risk factors cannot be changed.  But there are others that  be 
modified by leading a healthy lifestyle.  These include: 
 Elevated blood cholesterol 
 High triglycerides with low HDL 
 Elevated blood pressure 
 Diabetes 
 Smoking 
 Obesity 
 Inactivity 
 Excessive alcohol 
 Excessive stress
Taken from: ‘For Your Heart’s Sake: Advice For Those Keen To Lower Their 
Cholesterol’ (HEART UK, n.d: 3, original emphasis) 
 
The leaflets make very little reference to genetics, apart from sections that 
relate specifically to FH.  They mention that high blood pressure ‘tends to run 
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in families’ but go on to say that it is also influenced by lifestyle.  The amount 
of homocysteine a person produces is also said to be ‘influenced by your diet 
and your genes’.  These two references constitute the total discussion of the 
influence of genes on CHD, in general, within the leaflets.  All further 
references are concerned with specific hereditary conditions.  Raised 
cholesterol is framed as being either due to lifestyle factors, mainly eating the 
wrong foods, or to an inherited disorder: 
‘Cholesterol levels may rise due to lifestyle factors, such as eating a 
diet rich in saturated fat.  High cholesterol may also be inherited, as in 
the disorders of familial hypercholesterolaemia (FH) and familial 
combined hyperlipidaemia (FCH)’  
(HEART UK, n.d: 3)  
 
In sum, the leaflets are strongly focused on ‘lifestyle’ or ‘modifiable’ factors, 
with most leaflets concerned with diet.  The influence of polygenic gene 
variations on cholesterol levels or other aspects of CHD risk was practically 
absent.  Two classes of hypercholesterolaemia are set up: (1) hereditary and (2) 
lifestyle induced.   
 
A very similar picture emerged in the interviews with members of HEART 
UK.  There were no unprompted references to the possibility of genetic 
susceptibility to CHD beyond the well&established hereditary lipid disorders in 
interviews with either professional or lay members.  The only occasion on 
which the influence of genetic variations on cholesterol levels was mentioned, 
the issue was introduced by me.  The interviewee was discussing why people 
with FH have variable susceptibility to CHD and was stressing the importance 
of the established CHD risk factors.  I posed a question about the possible 
influence of other genes:  
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KW: and there’s no suggestion of any multi&gene or polygenic 
influences or interactions at all? 
S/HP4: There certainly isn’t in the sense that if you have an LDL 
receptor mutation, it’s not associated with any other genetic 
abnormality which enhances risk […] It’s simply that anyone with 
heterozygous FH can be exposed to environmental risk factors the same 
as anyone else, and they may or may not have the good fortune or bad 
fortune to have inherited high or low rates of, levels of HDL cholesterol 
for instance.   
 
This single reference to a genetic influence on HDL levels illustrates that the 
interviewee recognised a wider role for the influence of genetic differences on 
cholesterol metabolism.  The reason this subject commanded so little of his 
attention is perhaps because these genetic differences are not seen as 
modifiable.  He went on to emphasise the need for lifestyle advice for FH 
patients.   
 
Apart from this, HEART UK interviewees framed the causes of 
hypercholesterolaemia mainly in terms of hereditary cholesterol conditions and 
lifestyle issues, with occasional references to the influence of aging or 
menopause.  Just as with the information leaflets, the overall effect of 
interviewees’ talk was to construct two classes of raised cholesterol, due either 
to the established heredity disorders or to lifestyle.  As the data on HEART 
UK’s activities have demonstrated, this aetiological distinction does not delimit 
the interests of HEART UK.   
 
Given the lack of discussion of the possible influence of genetic variations on 
cholesterol metabolism, it seems strange that both the biomedical literature and 
the professional members interviewed refer to the ordinary, not specifically 
hereditary raised cholesterol as ‘polygenic hypercholesterolaemia’.  This term 
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implies the involvement of many genes.  Durrington (2003:722) explains 
polygenic hypercholesterolaemia as follows: 
‘The main causes are high fat intake, particularly saturated fat, and 
obesity.  Genetic factors are also assumed to be important, because 
individuals vary in their cholesterol response to diet.  However, there is 
no clear pattern of inheritance; a combination of more than one genetic 
variant is generally required for this type of hypercholesterolaemia 
(polygenic inheritance)’.  
  
This definition suggests that people have a variable response to dietary changes 
and that this is attributed to variations in a number of genes.  The idea that 
cholesterol levels respond differently to dietary changes in different people was 
discussed by Brett (1991) more than a decade earlier in an effort to dissipate 
the moral undercurrents of both professional and lay constructions of 
hypercholesterolaemia.  Brett’s arguments contribute to the more general 
critique of public health discourses concerning CHD prevention (Davison et 
al., 1989, 1991, 1992; Sachs, 1996; Petersen & Lupton, 1996).  These 
arguments seem to have had little sway here, as they are hardly present in the 
discourses of HEART UK, and lifestyle remains central to constructions of 
hypercholesterolaemia.  Therefore, although the term polygenic 
hypercholesterolaemia embodies a genetic aetiology, there was little interest in 
genetic influences and the term seems to be employed to mean raised 
cholesterol caused by lifestyle.  This was nowhere more clear than in the 
interview with S/HP2 who referred to ‘polygenic, lifestyle&induced high 
cholesterol’ and in a paper co&authored by members of HEART UK which 
referred to ‘non&genetic polygenic hypercholesterolaemia’ (Marks et al., 
2003:2).  The idea that a condition can be ‘non&genetic’ and ‘polygenic’, in 
particular, seems contradictory and confusing.  The data suggest that, in the 
case of hypercholesterolaemia, the term polygenic is used in order to make a 
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clear distinction to monogenic or more clearly hereditary forms of the 
condition.  Polygenic seems to mean a generic form of hypercholesterolaemia, 
without implying any specific interest in genetic variations.   
 
The model of CHD and hypercholesterolaemia presented by HEART UK 
continues to imply a high degree of personal responsibility.  However, there 
was rarely an explicit blaming discourse.  Indeed, I only recorded one example 
of this, which occurred at the patients’ workshop at the HEART UK 
conference in 2003.  On this occasion, a clinician was answering questions 
about the use of LDL apheresis, a treatment reserved for people with 
homozygous FH or where statins are not effective or not tolerated.  The 
clinician commented: 
‘Millions of people have got high cholesterol due to their lifestyle.  
That’s your fault.  You brought it on yourself.  We’re not interested in 
them.  People with FH can’t help it’ 
 
One can only speculate that the use of this particular rhetoric relates to the 
context in which it occurred.  It was an off&the&cuff comment to a lay audience 
made up predominantly of people with hereditary lipid disorders and their 
partners.  It is likely that the clinician enrols more neutral language in her 
written accounts of LDL apheresis and in presentations to other professionals.  
Nevertheless, this illustrates that it is possible for clinicians to slip into an 
explicit blaming rhetoric. 
 
HEART UK’s focus on ‘lifestyle’ factors is indicative of its fairly traditional 
health promotional approach that focuses on encouraging individuals to make 
behavioural changes.  There is little, if any, reference to social inequalities in 
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the distribution of CHD that have long been a theme in epidemiology and in 
more recent government policy in the UK (see Davey Smith, 2003; Department 
of Health, 2000; Marmot & Wilkinson, 2005).  There was some recognition of 
ethnic differences in the distribution of CHD and diabetes, illustrated by the 
two leaflets that focus specifically on low fat diets suitable for South Asian 
people, and a small number of research papers by HEART UK members 
concerned with molecular mechanisms and ethnicity.  Direct reference to, or 
research concerning socio&economic class was absent and there were only a 
few rather veiled references to socio&economic issues.  LM1 talked of healthy 
eating as a middle&class attribute, which she associated with education:  
LM1: my children do eat what you would call more healthily 
nowadays, but then everybody, well most people with education do on 
the whole, the chattering classes I should say. 
 
LM4 also talked about getting people to eat a healthy diet, connecting this with 
both education and economic opportunity: 
LM4: it certainly is more expensive to buy only healthy foods still.  It’s 
as so often, it’s those who can afford it who are the healthiest and those 
who can’t, not only know less about it, but can less afford to be healthy.  
A shameful situation and I’d like to see something done about it.  
 
This subject was almost entirely absent in the interviews with professionals.     

!	
This section has argued that HEART UK’s leaflets and the interviewees 
construct two classes of hypercholesterolaemia, hereditary lipid disorders and 
lifestyle&induced raised cholesterol, and the organisation focuses particularly 
on encouraging individual&level behavioural changes.  There is practically no 
reference to the possible more minor influence of other genetic variations in 
lipid metabolism or to polygenic influences in CHD.  While this construction 
 214
of CHD aetiology may individualise responsibility for CHD and detract from 
wider socio&economic determinants of health, as Lippman has argued, this 
cannot be attributed to a geneticised discourse about aetiology.  This section 
has argued that polygenic influences are not dominant in HEART UK’s public 
discourses.  This is consistent with the biomedical constructions reported in the 
previous chapter.   
 
4;4,&!*$.,&!,
This section is concerned with how HEART UK constructs FH and the degree 
to which it is framed as a genetic disease.  Following on from the previous 
chapter, this section will first discuss interviewees’ views on DNA diagnosis.  
It will then discuss in broader terms whether FH was framed in a genetic way 
through the activities of HEART UK and through interviewees’ talk.  It will be 
argued that the interviewees had a variety of views on DNA diagnosis, but that 
it was largely not seen as a priority.  Furthermore, the organisation tended to 
frame FH as a form of CHD rather than framing it through a genetic lens. 
 
&"

The previous chapter suggested that although the Simon Broome Group 
publications appeared to support DNA&based testing for FH, its members are 
not universally enthusiastic about it, and that this area did not seem to have 
elicited much discussion among clinicians in the UK.  In the interviews with 
the staff, lay and professional members of HEART UK, only one interviewee, 
S/HP2, raised the issue of DNA&based diagnosis spontaneously, arguing that it 
was one of the main priorities concerning developments for people with FH.  In 
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the other interviews, the discussion of the topic was prompted by me asking a 
specific question, or was entirely absent from the interview.  This certainly 
suggests that it is largely not a topic at the forefront of people’s minds. When 
asked, people involved with HEART UK had a mix of views on this topic, 
which largely aligned with the arguments in the biomedical literature discussed 
in the previous chapter.   
 
For S/HP2, DNA&testing was a priority area; a genetic diagnosis was seen as 
giving an unambiguous indicator of high risk:  
S/HP2: What would help so much would be to have a decent really 
sensitive and specific genetic screening tool.  Because at the moment 
we pay nearly five hundred pounds to one of two centres and they tell 
us, well this person’s got this mutation or that mutation, but actually we 
can only ever pick up fifty per cent of FH patients, so you know, we’re 
still left in the dark as to exactly what the risk is to an individual 
patient.  
 
Rehearsing an argument found in the literature, she suggested that the 
particular advantage of DNA testing was to be able to give an unequivocal 
diagnosis to people whose cholesterol is in the ‘middle ground’.  Her argument 
was that it was important to be able to distinguish people with FH who have 
moderately raised cholesterol, because they have had it from birth and are 
therefore at greater risk than other people with the same moderately raised 
levels of cholesterol.  This means that getting the right diagnostic label was 
about disease management, as FH patients, even with only moderately raised 
cholesterol, warrant much more intensive monitoring and treatment.  The issue 
was to be able to 	
 based on genetic analysis:   
S/HP2: the biggest problem is around those patients that have a 
cholesterol of 7.5 and above, because the Simon Broome Register gives 
possible FH as over 7.5.  Now the problem is I have a patient before me 
who has a cholesterol of 8.2.  Now out there are stacks of people with 
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cholesterol of 8.2. […] If you were able to have a test, a genetic test, 
that said oh yeah this man’s got FH, you know immediately this person 
must be on treatment, family history must be given and we must screen 
him annually, perhaps exercise test or whatever, so that’s what it’s all 
about […] It’s not like the 14s, the 15s, the 12s, cos that’s obvious.  It’s 
that sort of middle ground where potentially patients are really really 
disadvantaged […] you really need to be able to draw a line and say this 
person with a cholesterol of 7.8 has got FH therefore they’ve had it 
from birth, therefore the damage has happened from birth. 
 
S/HP4, when asked, was also largely positive about DNA diagnostics, 
suggesting that it would be particularly useful in diagnosing children, and in 
adults where either the family history was not available or clinical signs were 
inconclusive.  Other interviewees were more equivocal about it, prioritising 
clinical features over genetic information.  S/HP5, for example, talked of the 
limitations of genetic testing in terms of the expense, the large number of 
mutations and the inability to find mutations for a large minority of FH 
patients.  His main point was that high risk of CHD was the important aspect, 
regardless of genetic status.  The category of FH was not the paramount 
concern, but the clinical aspects of high cholesterol and early CHD that runs in 
families, whether or not this was labelled FH.  This is illustrated in the excerpt 
below, which suggests that the interviewee is not antagonistic towards DNA 
testing, he is just not excited about it:  
S/HP5: In practice you do it on family history, age and using the criteria 
under the Simon Broome Trust.  That is probably clinically the best 
way of doing it.  Because at the end of the day what you want to know 
is what their risk is.  It may not be FH, but if it’s got a familial 
component and they get their coronaries early, they need treating 
anyway.  So on a purely pragmatic point of view that’s probably the 
way to go.  Yes, fine, by all means we’ve no objection to organising 
what’s been dubbed a DNA bank and that they’re tested and checked.  
That isn’t an essential part of the cascade screening system. And I 
would go with either.   
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The discussion of DNA testing in the previous chapter hinted that this could be 
seen as a boundary issue concerning the role of geneticists and clinicians.  The 
wide introduction of DNA testing in the UK would see a shift in professional 
practice.  It would move the management of FH from the current situation, in 
which FH is practically the sole domain of clinicians, to a situation in which 
geneticists and the genetic services might have increasing influence.  The fact 
that some health care practitioners were positive about DNA diagnosis and 
others were less enthusiastic suggests a more complex picture, with differences 
of opinion not aligning strictly on disciplinary lines.  Nevertheless, the idea of 
a boundary dispute between clinicians and geneticists is also hinted at by data 
from one of the interviews: 
KW: Do you have a view about whether we should be pursuing DNA&
based diagnostics or whether it should be on the clinical signs? 
S/HP1: I think that’s a little nugget that comes up at every conference 
that we run.  You know you have the geneticists on one side and 
clinicians on the other.  The clinicians are louder than the geneticists. 
 
The interviewee frames DNA research as a rather esoteric activity, and is hard&
pressed to understand the clinical relevance of DNA&testing, gently making fun 
of the scientists who are involved in mutation identification.  The jocular way 
the interviewee talks about this area and her focus on the ‘clinical significance’ 
reinforces the idea of a divide between scientists and health care practitioners 
on this issue.  Like the previous interviewee, her focus is on the clinical 
indication of high cholesterol, which is seen as more important:    
S/HP1: at the end of the day, you have high cholesterol, you treat it 
with a statin, but you don’t necessarily need to know what particular 
mutation they’ve got.  There are so many different mutations […] until 
somebody can actually perfect it [gene therapy] I really don’t know that 
we need to actually pursue the DNA.  It’s a bit like stamp collecting to 
be honest.  You sit in a room with all these people who’ve worked out 
these different mutations and you sort of say well big deal, you know, 
it’s x13457 instead of x13456 fantastic, and you sort of say, what is the 
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clinical significance of that? And they all go, but it’s x13&&&, it’s a blue 
stamp instead of a pink stamp, and you just think well, clinically that 
won’t mean a lot to a patient.  They will not care what sort of LDL 
mutation they have got.  What they are worried about is have they 
passed it onto their kids and can you treat it. 
 
Lay members were similarly disinterested in DNA&diagnosis.  LM2, like 
S/HP5 was less fixed on the specific diagnostic category of FH.  In fact she did 
not distinguish between inherited forms of raised cholesterol and other lipid 
disorders. In her view the important factor was raised cholesterol.  As a result 
DNA&based diagnosis was a low priority: 
KW: do you see any benefits to a DNA&based test? 
LM2: No because if you’ve got raised cholesterol, whether it’s 
inherited or not, you’ve got a problem that if it’s not treated you’re 
going to have a heart attack or a stroke, so to me it doesn’t matter, 
that’s my personal view […] Even today people don’t get genetic tests.  
I mean this is a genetic condition, but you don’t get a genetic test.  If 
your cholesterol’s raised and you’ve got a family history like mine then 
the likelihood is you’ve got FH.  You don’t need to do a genetic test to 
treat people and even if it’s not FH, if you’ve got raised cholesterol you 
know, you need help, so.  
 
Two other lay members were not aware of DNA&testing as a current debate.  It 
was not a subject that they had particularly engaged with.  As LM4 said ‘It’s 
not something I’ve given much thought’.  In sum, DNA testing was not at the 
forefront of HEART UK’s agenda.  There was mainly a lack of support or lack 
of interest in DNA diagnostics among these key figures in HEART UK.  This 
could not necessarily have been anticipated on the basis of the arguments 
presented in the Simon Broome publications, discussed in the previous chapter.   
 

	5
Although a large part of HEART UK’s work focuses on the familial lipid 
disorders, there was very little within the organisation’s structure or activities, 
or interviewees’ talk that framed these in a genetic way.  The organisation’s 
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professional trustees and committee members are mainly specialists in 
metabolism, lipids, cardiovascular disease or chemical pathology, and include 
just two molecular geneticists and no clinical geneticists.  HEART UK is 
represented on the steering committee of the London Genetics Knowledge Park 
and on the Genetics and Insurance Committee, a government advisory body.  
However, these were the only organisations mentioned that are specifically 
focussed on genetics.  It is notable that collaborative working concerned with 
education, lobbying, and patient representation is largely oriented towards 
CVD rather than genetic disease, and a large number of organisations were 
mentioned in this respect including Diabetes UK, the Primary Care 
Cardiovascular Society, the Joint Federation of Primary Care Societies, the 
British Cardiac Patients Association, The British Cardiac Society and the 
British Hypertension Society.  These are organisations, for example, with 
whom HEART UK organises conferences or study days for health care 
practitioners.  This orientation towards CVD was also illustrated very clearly in 
the interview with S/HP3.  When asked about the types of groups HEART UK 
collaborates with, his immediate response was to talk about the ‘problem’ of 
CHD in general.  When asked directly about membership of the Genetics 
Interest Group (GIG), the national umbrella group for patients’ organisations 
associated with genetic disorders, he explained that HEART UK is not a 
member '
,	
:   
KW: Who are the main sorts of groups that you collaborate with? 
S/HP3: You have to seek partnership.  What we are dealing with is a 
major problem.  Heart disease is right there at the very top of the list.  It 
kills more than anybody else’s  disease or disorders so we’ve gotta do 
something serious about it […] we actually have extremely good 
relationships with small organisations who are in the heart charity 
business.  We should be much stronger within the BHF [British Heart 
Foundation] and we constantly work on that.  We have good relations 
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with Diabetes UK, we have good relationships with important people 
working in the field cardiology and within the commercial sector […] 
KW:  What about the genetics umbrella group, GIG?  
S/HP3: I think by default we’re connected with them.  I sit on a sort of 
committee, which is called the Genetics Knowledge Park in London, 
Alistair Kent [Director of GIG] also sits on the same committee, but as 
I say you can’t do everything.   
 
In the UK context, GIG can be through of as a defining group concerning 
genetic conditions.  This interviewee’s comment provides a strong indication 
of where HEART UK positions itself conceptually and politically.  His talk had 
the effect of framing FH as a subset of CHD and suggests that specifically 
genetic related activities are not prioritised.  This reinforces the construction of 
the hereditary lipid disorders as being more to do with heart disease than with 
genetic disease.   
 
A comment by S/HP1 further reinforces the idea that FH is not predominantly 
constructed within a genetic frame.  This comment refers to the national 
cascade screening project for FH, which was introduced by the genetics White 
Paper (Cm 5791 & II, 2003).  To understand this comment, it is important to 
note that the screening project will be based on clinical diagnostic criteria, 
although there was some talk of seeking extra funding to attach some 
additional research on DNA&diagnosis to the main pilot:   
S/HP1:  Heart UK has been part of the battle to get money out of the 
genetics White Paper.  On genetic screening and cascade screening […] 
Money’s come through the genetics people, that isn’t for genetics.  
They’ve got to get their money for the genetics bit separately.   
 
This talk of money for cascade screening coming through the genetics White 
Paper, but not being  
	 and of having to get the money  
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
	 '	 & frames genetics as something specifically to do with 
genetic testing, rather than genetic disease or hereditary disease. 
 
One area where there was explicit reference to genetics was talk about 
possibilities for the future.  Lay members talked of their hopes that one day 
there would be direct treatment of the genetic causes or of gene replacement 
therapy for FH.  This was discussed in quite a speculative way, perhaps 
because it was an area that they did not feel very competent to comment on:   
LM4: I think in the medium to long term future the fundamental causes, 
the genetic causes of the familial conditions are very important, in our 
core concern with them.  Genes have been identified, and again it’s no 
good asking me the details, and maybe in the future direct treatment of 
the genetic cause will be possible.  

Nevertheless, the topic was not a large part of any interview or portrayed as a 
major priority;This subject wasabsent from the research and interests of 
professional members.   
 
There was one notable exception, where an interviewee did frame FH in a 
genetic way.  S/HP2 talked about the possibility of genetic counselling and 
reproductive decision&making in relation to FH, drawing on arguments about 
	
			and people having &	
. She argued that these options 
were contingent upon the availability of DNA&testing:  
S/HP2: You would definitely advise about family screening, you’d be 
able to give genetic counselling to people thinking about having 
children you know.  You’ve got a one in two chance of it having, of a 
baby having the condition.  So all of that comes down from knowing 
that […] Then I think in discussion you have to be able to offer patients 
that option, like you know it’s not like Huntington’s Chorea but I mean 
[…] patients may choose not to know but I think we have to have the 
option to offer them that because it’s their life and they need to have 
that option.  
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These arguments about the provision of genetic counselling and the possibility 
of reproductive decision&making for people with heterozygous FH were unique 
to S/HP2.  They were not present in any other situation, neither in interviews 
with HEART UK members, nor in the biomedical literature nor at the 
conferences. 

!	
To sum up, HEART UK interviewees have different views on DNA&testing, 
but they tend not to see this as a priority.  Following on from the discussion in 
the first chapter, the data support the idea of a boundary dispute between 
clinicians and geneticists on this subject, at the same time as complicating this 
argument.  The analysis raises questions about how much use clinicians would 
make of genetic testing for FH in practice.  FH was predominantly framed as a 
subset of CHD, rather than as a genetic disease. Cox and Starzomski (2003: 
162) have described a similar lack of focus on genetics in the construction of 
polycystic kidney disease (PKD) arguing that it is defined through ‘a kidney 
disease rather than a PKD culture’.  In a similar way, HEART UK’s structure 
and activities in relation to FH could perhaps be described as being infused 
with a CHD culture rather than a genetic culture.  There was, however, one 
notable exception, which illustrates that is possible to see FH through a genetic 
lens, linked with talk of life plans and choices.  In terms of Lippman’s thesis, 
this analysis again suggests that (1) genetic discourses are not dominant.  
Indeed, they are barely evident at all. (2) Heart UK interviewees were not, in 
the main, interested in distinguishing people on the basis of DNA.  They 
tended to privilege clinical status instead. (3) HEART UK was largely 
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uninterested in the potential application of genetic technologies in the diagnosis 
and management of FH.   
 
4;)"-*!$"*8"&.!$!!.,&
This chapter has focused on the aims and activities of HEART UK.  It has 
suggested that lay people were instrumental in founding the FHA and the 
Simon Broome Register and continued to influence the direction and activities 
of the FHA/HEART UK.  However, the organisation became increasingly 
professionalised and currently appears to have low levels of lay influence.  Its 
current discourses and activities must, therefore, be seen as an expression of 
professional constructions as much as, if not more than, lay constructions of 
CHD and FH.  The analysis shows that the original focus of the FHA was 
solely on hereditary lipid disorders, but broadened out from an early stage to 
include CVD risks in general.  Nevertheless, even from the earliest times, the 
organisation contributed to establishing the cholesterol hypothesis and the field 
of lipidology.  While HEART UK may distinguish in aetiological terms 
between hereditary lipid disorders and ‘lifestyle induced’ 
hypercholesterolaemia, the organisation does not make such distinctions in 
terms of the support it provides to patients.  Overall, there was very little 
discussion of genetics in relation to either CHD risks in general or in relation to 
FH, and FH was predominantly framed as a form of heart disease rather than as 
a genetic disease.  Relating these findings to the geneticisation thesis, the 
analysis suggests that: 
1. Genetic discourses are certainly not dominant within HEART UK.  In 
fact, there has been a move away from genetic discourses, to some 
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degree, as the remit broadened to include cholesterol and CHD risks in 
general.  Genetic constructions of CHD in general were barely evident, 
and there was very little specifically genetic talk concerning FH. 
2. Heart UK does not distinguish between patients on the basis of their 
DNA, largely privileging clinical status. 
3. Heart UK’s activities may focus on individual level activities, 
individualising responsibility for CHD and detracting from the wider 
socio&economic conditions.  This, however, cannot be attributed to an 
increasingly geneticised discourse about heart disease, but is a 
continuation of a more long&standing approach to health promotion and 
disease prevention. 
4. HEART UK shows little interest in genetic technologies 
 
Cox and Starzomski (2003: 162) argue that one of the reasons for the absence 
of geneticisation in the area of PKD is the ‘lack of disease&specific support 
groups’.  The findings presented in this chapter suggest that even where such 
groups exist, as in the case of FH and HEART UK, this is no guarantee of 
geneticisation.  This highlights the value of studying patients’ associations as 
sites that contribute to the construction of particular disease identities or 
cultures.   
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The following two chapters present the analysis of the interviews undertaken 
with lipid clinic patients who have FH.  This chapter looks at interviewees’ 
general accounts of the areas of FH and CHD.  It focuses on how FH, 
hypercholesterolaemia and CHD are explained, and the underlying causal 
models implied by interviewees’ accounts of these areas.  In particular, it draws 
out the elements of these accounts where distinctions are and are not made 
between people with FH and others with raised cholesterol; and it draws 
attention to the degree to which genetics and genetic elements feature in these 
accounts of raised cholesterol and CHD.  The following chapter considers the 
implications of this condition for the lives of these interviewees and their kin.  
Following Murphy (2000: 303) the interviews were seen as occasions in which 
the interviewees were engaged in ‘constructing themselves, for themselves and 
for the interviewer, as normal, moral [and] responsible’ in relation to their 
condition.  The analysis, therefore, focuses on the 
	
of what people say 
in the interviews.    
 
The first two&thirds of the chapter discusses how interviewees explain FH and 
their accounts of hypercholesterolaemia and of CHD.  The last part of the 
chapter focuses specifically on interviewees’ constructions of the hereditary 
aspects of their condition.  The chapter argues that the interviewees drew a firm 
boundary between their own 	 raised cholesterol, which was only 
 226
controllable by medication, and other people’s 	2 high 
cholesterol.  It is suggested that, within the prevailing culture of personal 
responsibility for maintaining health, and particularly for avoiding CHD and 
high cholesterol, that this boundary allowed interviewees to establish their own 
lack of culpability for having raised cholesterol.  Nevertheless, interviewees’ 
talk about their condition was characterised by a great deal of reference to their 
own lifestyle, which was sometimes in direct contradiction with their 
characterisation of their raised cholesterol as being largely unaffected by 
lifestyle.  It is suggested that the ethos of personal responsibility concerning 
cholesterol and CHD is so strong in Western culture that interviewees do not 
necessarily relinquish it.  Instead, they tended to oscillate between these 
different discourses.  Lifestyle talk contributed to a wider theme, that FH could 
be controlled and CHD avoided by taking care of oneself.  Although genetics 
was seen as a contributing factor, interviewees’ accounts of their own and other 
people’s CHD did not foreground the genetic elements, but conformed to 
established lay models of CHD encapsulated by the idea of the coronary 
candidate (Davison et al., 1989, 1991, 1992).  The second part of the chapter 
suggests that FH was not associated with a strong disease identity and that 
interviewees may understand their condition as being a general category of 
hereditary hypercholesterolaemia, or high cholesterol that runs in families, 
rather than a specific genetic condition with quantifiable and predictable 
transmission patterns.  The implications of such an understanding are 
considered in terms of the construction of risks and responsibilities.     


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Interviewees had a number of different ways of referring to their condition.  
Some talked of familial hypercholesterolaemia or FH, and some expressed the 
meaning of FH in more manageable language, for example saying familial high 
cholesterol, family cholesterol or hereditary cholesterol.  Others indicated that 
they recognised the diagnosis, at the same time as demonstrating the 
complexity of the name, for example: ‘familial whatever’, ‘high 
cholesterodaemia blah, blah blah, the inherited type’ or ‘hyper fam, no i can’t 
get my tongue round it at all’.  Occasionally the idea of a specific diagnosis 
was absent, or the diagnosis was unmemorable.  This is demonstrated in the 
following extract with a patient and her daughter&in&law (denoted as DIL):  
KW: Right, and has anybody ever given it, sort of official name the 
high cholesterol problem? 
ID87: Oh no, no 
DIL: There is a name 
ID87: ay? 
DIL: There is a name 
ID87: Yeah there is a name, um I don’t know what it’s called 
DIL a long name 
KW: a long name? 
DIL: yes 
ID87: er whatsit’ll tell you um, the lady I’ve just been to see now. 
 
These data suggest that the specific diagnosis of familial 
hypercholesterolaemia is not necessarily particularly meaningful or 
memorable.  This is not to say that the familial aspect of the high cholesterol 
was not a theme, but rather that FH, as a particular diagnostic category, does 
not have a high profile.  This point is important in as a much as it explains the 
relatively few references in the data presented to FH, and the more frequent 
talk of a cholesterol problem or condition.  It also contributes to a suggestion 
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made later in this chapter concerning the lack of a specific disease identity for 
FH.   
 
);2-/".&.&
Every interviewee recognised an hereditary or familial aspect to their condition 
at some point during the interview, although the amount of focus and degree of 
significance placed on this element varied greatly.  Interviewees’ explicit 
accounts of FH, or their condition as they saw it, can be divided into three main 
elements: 
1. :		 e.g. ‘something that’s passed on in the family’, ‘an 
inherited problem’, ‘a faulty gene’. 
2. 

:
	
#

: e.g. ‘furring up of the arteries’, 
‘fats in the arteries that builds up’, ‘fats in the blood stream’. 
3. 	
#
	

	
: e.g. ‘body produces too much 
cholesterol’, ‘a missing enzyme to break down fats’, ‘liver doesn’t get rid 
of cholesterol properly’, ‘cells don’t excrete fats as they should’. 
 
Interviewees often drew on a combination of these elements in their accounts 
of the condition.  In some cases there was a very strong focus on the genetic 
elements.  This is exemplified in the following extract, in which the 
interviewee draws on two elements to explain his condition, heredity and 
cholesterol processing, although the main emphasis is on the hereditary 
aspects:  
KW: If you had to explain FH to somebody who had never heard of it 
before, what might you say? 
ID77: I’d just say it’s a genetic defect. I’ve in’erited from me father.  
Basically your liver doesn’t scrub out the cholesterol as it should do and 
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you’ve got a fifty per cent chance of in’eriting it.  I’ve inherited it and 
one in five hundred people suffer from it.  And that’s it, basically, that’s 
all I’d say. 
 
In others cases the genetic element was mentioned, but was less prominent.  
Significantly, the genetic element could be entirely absent in accounts of the 
condition.  The following explanation, for example, refers only to a problem of 
processing cholesterol that results in too much cholesterol in the blood:   
KW: Let me ask you now, if you had to explain your problem to 
somebody who didn’t know anything about it, what would you say to 
them? 
ID87: Well I usually say, whadit is, it’s um your body makes too much 
cholesterol and when you’ve got too much cholesterol, it clogs the 
arteries and if you smoke and you’ve got high cholesterol you could 
have your legs off, could turn to gangrene, um heart attack, could be 
fatal heart attack, could have a stroke. 
 
In some cases the account of FH given depended on who the interviewee 
imagined they were talking with.  For example, ID24 constructs FH as a liver 
condition, without mention of genetics, in his account of how he might explain 
the condition to someone who had never heard of it.  His account of what he 
told his children about the condition was similar in his focus on a liver 
problem, yet on this occasion the hereditary aspect was mentioned.  The two 
accounts are provided below for comparison: 
KW: If you have to explain FH to somebody who’s never heard of it, 
what would you say? 
ID24:  I would say I’ve got a condition that’s affecting my liver and, I 
mean we produce natural cholesterol fats in our bodies and we have 
them in our bodies through our diet.  I would say that my liver should 
be able to remove them naturally and my liver does it probably at a 
much lower efficiency than everybody else’s.  So I would say it’s 
probably a condition of the liver, that it’s not removing cholesterol or 
breaking down cholesterol as it should.   
 
KW: So what did you say to your kids? 
ID24: Well I told them what the problem was as far as I was concerned, 
I just simply said, well I’ve got this genetic problem connected with m’ 
liver really, m’ liver’s not removing cholesterol as it should do and 
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there’s a chance that you’ve got it, I said, and the earlier you get 
diagnosed for it the more chance you have of sorting it out. 
 
One possible interpretation is that the genetic element of FH is seen as 
stigmatising, and therefore this element might be left out of accounts of FH for 
a general audience.  However, stigma was not a major theme in these 
interviews (this will be discussed in more detail in later sections).  An 
alternative interpretation is that the hereditary aspect of FH is of variable 
relevance and in some situations is less important.  In any case, these data 
demonstrate that the genetic element of FH is not always at the forefront of 
accounts of the condition.  It can also be constructed predominantly as a liver 
or metabolic problem or as problem of high cholesterol.  

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Interviewees talked about different types of cholesterol.  There was ‘my type of 
cholesterol’ or ‘the inherited type of cholesterol’, and there was ‘ordinary 
cholesterol'.  These types of cholesterol can be related to the causes of high 
cholesterol, which were, in the main, divided into two categories: either 
genetic/hereditary, meaning FH or 
		
; or dietary, meaning 

.  FH or 
		
 can be typified as being a condition that 
#

	
# and 	B	
, in contrast to other high 
cholesterol, which may be controlled entirely by diet or other lifestyle 
modifications.  This seems to be the same distinction between hereditary 
hypercholesterolaemia and lifestyle&induced hypercholesterolaemia that is 
evident in HEART UK’s literature and in the biomedical literature, discussed 
in the previous chapters.   
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The construction of these two contrasting classes of high cholesterol, here 
framed as FH or my condition versus dietary or everyone else’s, reflects a very 
strong discourse of culpability and personal responsibility concerning raised 
cholesterol and CHD in both lay and professional discourses (Davison et al., 
1989, 1991, 1992; Lupton, 1995; Lupton & Chapman, 1995; Petersen & 
Lupton, 1996; Sachs, 1996).  This distinction between myhigh cholesterol and 
dietary high cholesterol allows the interviewees to distance themselves from 
potential reproach for unhealthy living.  This was also evident in the recurrent 
use of a phrase concerning FH that ‘there is nothing you can do about it’.  This 
was mostly used in the sense that one cannot avoid having FH, but was also 
used to mean that if one has raised cholesterol due to FH, there is not much one 
can do through altering behavioural regimes, to lower this cholesterol.  These 
points are illustrated in the following extract.  Here the interviewee was talking 
about how she explains her heart disease and cholesterol problem to her friends 
and workmates:  
ID18: I just say all I know that it’s to do with the fats.  There’s good 
fats, there’s bad fats or whatever and some people, cholesterol is in 
your body anyway, I mean it’s one of them things and it’s ordinary 
cholesterol, you can get it down by diet, but for some unknown reason 
this type of cholesterol I’ve been told is hereditary and there’s not really 
a lot I can do about it and it has to be done by tablets. 
 
The interviewee clearly distinguishes between 	
cholesterol, which one 
can 
'	and hereditary cholesterol, which ,



', so it has to be managed through medication.  In drawing a 
distinction between ordinary cholesterol and her own type of cholesterol the 
interviewee establishes that, in her case, she is not responsible or to blame for 
her raised cholesterol.   
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The censure of ‘ordinary’ hypercholesterolaemia is implicit in the 
interviewees’ accounts of the causes of their high cholesterol.  This is 
illustrated particularly well in the following extract, which was a response to a 
question about why the interviewee thought she had raised cholesterol: 
ID104: It’s genetic basically, I hope.  I know a little bit you can help it 
along by eating the right things and regular exercise, but apart from that 
it’s genetic. 
 
The use of the phrase -& in this context implies that it is better that raised 
cholesterol is due to genetic causes rather than due to behaviours that are 
ostensibly within one’s own control, like 	
		
and%	(  
The role attributed to diet and other lifestyle factors in FH or 
		
 
varied, but, as the extract above suggests, was mostly constructed as minor or 
adjunctive and certainly not sufficient to treat the condition.  The idea that FH 
or the interviewee’s condition cannot be controlled by diet and requires 
medication was sometimes substantiated by reference to their own experiences 
of the management of their high cholesterol.  In the following extract, when 
asked to explain her cholesterol problem, the interviewee’s immediate response 
was to provide an account of her initial attempts to reduce her cholesterol 
levels through dietary changes:  
KW: Um what sort of ideas do you have about why you’ve got the 
cholesterol problem? 
ID97: First of all, definitely ‘cos of the genetic factor because with diet 
it went down from 9.2 to 7.9 and that was me pulling out all stops with 
diet.  You know really sort of, I had a food diary.  I wrote everything 
down that I ate and I was good.  So I knew I couldn’t get it lower than 
7.9 and live happily, with just diet so I knew it must be a faulty gene. 
 
This account allows the interviewee to demonstrate the effort and diligence 
with which she attempted to control her cholesterol level through dietary 
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changes, firmly establishing that, in her case, the limited reduction was not 
through any lack of trying.  It is notable that the interviewee’s conviction that 
cholesterol is controllable by diet is not shaken by her own reported experience 
of diet making only a marginal difference to her own cholesterol levels.  This 
serves, rather, to reinforce the genetic causes in her own case.  There is little 
space for other possible causal elements or for the possibility that dietary 
modifications may be of variable efficacy for other people.   
 
There were occasional exceptions to this heredity versus lifestyle model of 
hypercholesterolaemia.  For example, four of the interviewees attributed a 
larger role to dietary causes in their own raised cholesterol.  It was notable that 
these were all somewhat older interviewees and that, in all cases, discussion 
concerned past rather than present behaviour, which allowed the interviewees 
to distance themselves from their earlier ‘errant’ dietary patterns.  The 
following excerpt provides the most explicit example of these:   
KW:  So um what sort of ideas do you have about why you’ve got the 
cholesterol problem and why you’ve had the heart attack now? 
ID102:  I think it’s eating fatty things.  You see before I got married I 
used eat a lot of butter you know, used to cook in lard didn’t they.  
They didn’t have these cooking oils like they have then, and I think it’s 
a lot to do with that really.  Same with bacon.  You’d eat all a round of 
bacon, you know so, I think it’s not watching me diet years ago in’t it 
that. 
 
At other points in these interviews, genetic causes were drawn on to explain the 
raised cholesterol.  This illustrates a more general theme of these interviews; 
interviewees expressed multiple and sometimes contradictory discourses about 
FH.  This theme will be discussed in more detail later.   
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There was very little discussion of the possibility that other factors might be 
involved in raised cholesterol.  Two areas that were mentioned were age and 
gender (these same areas were also mentioned by HEART UK interviewees, as 
discussed in the previous chapter).  The idea that raised cholesterol is 
something that people develop as they get older emerged in a small number of 
interviews.  Firstly this happened by comparison, which can be typified as 

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	'	,

&
,
		
, and secondly by reference to interviewees’ own parents 
developing raised cholesterol later in life:  
ID79: my mother, she’s 85, she’s incredibly fit and amazing, but she’s 
got a little bit of cholesterol, but I think it’s just age possibly. 
 
The relationship, or perhaps dissonance between the diet/lifestyle discourses 
and this age discourse was not discussed or problematised in any of the 
interviews. 
 
The second area concerns gender differences.  This is not so much that men 
and women have different levels of cholesterol, rather that raised cholesterol 
has a differential impact.  It was suggested that men with FH are likely to get 
heart disease earlier than women or that women are less susceptible to the 
disease.  The mechanism for this was related to women’s hormones, and the 
menopause was mentioned as an important life point after which cholesterol 
management might become more of a concern for women.  
 
So far, this section has argued that interviewees largely divided the causes of 
hypercholesterolaemia into two categories, hereditary/my type of cholesterol 
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and ordinary/lifestyle&induced cholesterol.  It is notable that the interviewees’ 
own experiences of an hereditary basis to hypercholesterolaemia do not appear 
to lead them to question the link between diet and raised cholesterol for other 
people.  Indeed, the distinction between dietary and hereditary 
hypercholesterolemia perhaps becomes more entrenched in interviewees’ 
accounts, as part of the process by which they establish their own lack of 
culpability.  This contrasts with Lupton & Chapman’s (1995) study of lay 
constructions of hypercholesterolemia, which drew on a sample from a general 
population.  Although this sample strongly linked hypercholesterolaemia to 
diet and body size, Lupton & Chapman (1995) reported considerable 
uncertainty and complexity in their accounts.  The difference between these 
studies is perhaps that Lupton & Chapman’s (1995) interviewees were talking 
of hypercholesterolaemia in general, whereas in this study the interviewees 
were obliged to account for their own hypercholesterolaemia, a situation which 
required them to demonstrate their sound moral standing. 
 
Since high cholesterol may be thought of as stigmatising
13
 in the sense that it is 
associated with lack of self&discipline and failure to behave appropriately, one 
might expect this to be a theme in interviewees’ discussions of their own 
experiences.  Yet, this was almost absent from their accounts of anticipating 
people’s responses to their high cholesterol.  According to interviewees, in the 
main they were happy to tell people about their raised cholesterol, with little 
indication that they expected to be judged for it.  My question about whether 
the interviewee had ever been in a situation where they wanted to avoid talking 
                                                
13
 The issue of whether the genetic aspect of FH is seen as stigmatising, as opposed to the 
raised cholesterol aspect, will be discussed in the next chapter. 
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about their condition mostly elicited a short answer such as ‘no, not at all’.  
This is a typical response: 
KW: And are there any situations where you’d avoid talking about 
having high cholesterol? 
ID29: No if somebody asks me a question I’ll tell’em all I know, like 
about diets and foods, best I can you know what to do. 
KW: So there’s nothing embarrassing about having high cholesterol? 
ID29: No I wouldn’t think so, why should there be? 
 
However, lack of stigma concerning their condition was also related 
specifically to the interviewee’s lack of agency for their raised cholesterol.  In 
the following extract the condition is framed as not embarrassing because there 
was 
	
-'	.  This implies that raised cholesterol may be 
stigmatising where it is seen as due to a person’s individual volition: 
KW: Alright, are there any situations where you would prefer not to 
talk about it or you would prefer to avoid talking about it. 
ID79: no, it doesn’t embarrass me or anything like that as I say because 
I took it straight away it was something I could do nothing about, that I 
was born with it and that’s it.   
 
Nevertheless, only one interviewee explicitly acknowledged that one might be 
judged for having raised cholesterol.  This young man reported that he was 
now more careful about telling people than in the early days because he was 
wary that everyone assumed he ‘doused everything in lard kind of thing’ or 
that ‘my mum didn’t feed me healthy food’.   
 
While accounts of FH and raised cholesterol are based on a model that involves 
a high degree of personal responsibility, interviewees rarely blamed other 
people with raised cholesterol outright for this condition, although, 
occasionally, explicit blaming language came to the fore.  For example, one 
woman distinguished her family high cholesterol from something ‘you do to 
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yourself through bad&eating’ and another man contrasted his own heart disease 
caused by FH with a colleague’s, which he attributed to ‘fatty dinners and 
smoking and sitting in the car all day’. 
  
Overall, there was clearly a discourse within these interviews of responsibility 
and culpability associated with raised cholesterol.  This was evident, for 
example, in the construction of two distinct classes of raised cholesterol and 
the use of the phrase ‘there’s nothing you can do about it’.  This distinction 
emphasised the idea that ‘ordinary’ cholesterol can be controlled through 
lifestyle measures, whereas FH or my condition cannot.  The ambiguity and 
uncertainty reported in other studies such as Davison et al., (1989, 1991, 1992) 
and Lupton & Chapman (1995) are absent here.  This may be because the 
distinction is necessary to allow interviewees to defend themselves against 
imagined accusations of inappropriate behaviour.  Nevertheless the language of 
culpability seemed to dissipate when interviewees talked about accounting for 
their condition to other people.  Given the strength of discourses of 
responsibility, it is surprising that this area of accounting for one’s high 
cholesterol to others, of avoiding blame or being required to refute it, gained 
such little attention during the interviews.   

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Despite the distinction interviewees made between their own hereditary 
hypercholesterolaemia and other people’s lifestyle&induced 
hypercholesterolaemia, all but two interviewees discussed or made mention of 
their own diet or dietary and lifestyle modifications they had made, and a 
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number of interviewees spoke at length about these.  This section will suggest 
that interviewees tended to emphasis lifestyle issues in their talk about their 
experiences of having FH and that this can be situated in the framing of CHD 
and hypercholesterolaemia as moral issues, strongly linked to personal 
responsibility and culpability concerning ‘lifestyle’.  The section proposes that 
the power of moral discourses about diet and lifestyle in Western society are 
such that, in spite of the availability of genetic explanations in the case of FH, 
and the discourse of the limited impact of lifestyle compared with medication, 
interviewees still found it necessary to demonstrate their moral probity vis&à&
vis lifestyle factors.   
 
The strength and significance of lifestyle talk for constructions of FH is 
illustrated particularly well through interviewees’ discussions about the impact 
of the condition.  Prior to the interviews, I anticipated that this might be framed 
in any number of ways, for example, in terms of the family, life plans, illness 
experienced or possible future disease, future uncertainly and so on.  Yet, in a 
number of cases, the impact of FH was immediately related to diet and 
lifestyle, either in terms of changes made, or the lack of necessity for making 
changes because the interviewee already had an appropriate lifestyle:  
KW: So what sort of impact would you say kind of getting this 
diagnosis has had on your life? 
ID90: Well dietary, my diet’s had to change, I mean it’s partly been a 
good thing, but once, I think once I was used to changing the sort of 
way that I ate to be honest, you sort of go up a level, and then it just 
becomes normal after a while.  So not having butter, not having full&fat 
milk and not having eggs, and not having a boiled egg for breakfast, 
which I did everyday, after a while it just, I don’t even notice. 
 
KW: um okay what sort of impact would you say having this familial 
hypercholesterolaemia has on your life? 
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ID100: I had quite a healthy lifestyle and I’d been brought up with a 
mother who years ago when you had high cholesterol you went on a 
low fat diet, so I’ve been brought up on it.  We never had butter, do you 
know what I mean, so it really didn’t change the way I lived like that, 
because that’s how I was brought up and that’s how I lived. 
 
The connection between lifestyle and raised cholesterol was so strong that 
some interviewees even said that having to make dietary changes had been the 
worst aspect of their condition, and this included people who already had 
CHD:  
KW:  What would you say are the worst aspects of having it? 
ID24:  Well the worst aspects I suppose are, it’s things like, it’s, I love 
cheese for example, I really do like cheese and I have to limit what I 
take.  You know I do, when I eat cheese, a small bit of cheese, I enjoy 
it, but I could have twice as much. 
 
While interviewees’ explicit accounts of the causes of their raised cholesterol 
attributed medication priority over lifestyle, their talk about their own 
behaviours and responses to the diagnosis could give equal or even greater 
focus to diet than to medication.  In the following extract medication is 
mentioned, yet diet and lifestyle seem to be constructed as the critical factors 
that could mean the difference between health and ill health: 
KW: What sort of impact would you say that it’s had on your life? 
ID21: Well I wouldn’t say that it’s had a big impact.  The only impact 
it’s had is like diet, have to watch what I eat you know, fat&wise and 
stick to low fat diet, just having to take medication’s the only impact I 
can see, yeah. 
KW: And do you think of it as a serious condition?  
ID21: I suppose it can be if you didn’t watch yourself.  You know, I 
mean if I was to go mad and not follow, like the diet sheet that I’ve 
been given to watch what I eat and all that, I suppose I could be a lot 
less healthier than I am, because I really look after myself, knowing 
I’ve got this condition, and knowing it could be serious if I didn’t take 
care of myself and what I eat and drink and all that. 
 
This extract suggests that the interviewee is engaged in showing herself to be a 
responsible person, who .  This is entirely congruent with 
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an ethos of individual responsibility for health and illness.  The interviewee’s 
sound moral status is demonstrated through reference to adhering to an 
appropriate diet.  Medication commands relatively little attention, yet 
responsibility for self&care could equally have been framed in terms of 
responsibility for taking medication appropriately.  This suggests that lifestyle 
remains an over&riding moral concern.   
 
On occasions interviewees’ discourses appeared to be plainly contradictory 
regarding the importance of lifestyle factors compared with medication.  For 
example, when I asked ID80 how he might explain his condition to other 
people, he provided the type of account discussed in the previous section, 
focussing on the need for medication and the relatively negligible impact of 
diet and exercise:  
ID80: The only understanding I’ve got is your body just produces all 
this cholesterol and it doesn’t matter really ‘ow much you diet or ‘ow 
much y’ exercise, your body’ll just carry on producing it.  So even 
though diet and exercise can ‘elp a little bit, it’s just basically like, it’s 
just barely touching it.  You could never drop it down from, say my 
14.3, I could never ever get that down no matter ‘ow much dieting or 
exercise I do, you can never ever gerrit down, ‘cos your body just 
carries on producing it.  So it can only be reduced through medication. 
 
Nevertheless, this interviewee devoted a great amount of time in the rest of the 
interview to talking about his lifestyle, including a lengthy account of the 
dietary changes he had made as a result of diagnosis, a discussion of his 
changed drinking habits and the exercise he takes.  Here is an example of this 
recurrent lifestyle talk in this interview:    
KW: And um when you think about your own future health now, how 
d’you see it?   
ID80: Er I need to get fitter and loose some weight (laughs), so I’ve 
joined a gym so I just try and keep me fitness levels [discussion of 
activities at gym] but I just wanna try and lose weight.  If I can lose a 
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stone I’d be ‘appy […] I’m determined I want to get fitter and if I can 
lose about a stone in weight er it’s not gonna be easy but I’ll do it.  I 
look after meself better now. 
KW: And do you think by doing that, that’ll help you to not have more 
heart problems? 
ID80: Yeah definitely and also, me diet’s a lot better as well now than it 
used to be, you know, ‘cos a lot of the times it used to be, er well not a 
lot of the time, but on a fairly regular basis used to be easy option for 
your tea, you know, lets go to the chippy, or whatever […] So we eat 
we eat better food, more healthy food than we used to do, so continue 
doing that. 
 
Here again, questions about future health are used as an occasion on which to 
demonstrate that the interviewee is taking care of himself  by adhering to 
particular fitness and dietary regimes.  Again lifestyle is constructed as the 
critical factor in maintaining health, even though this man asserts elsewhere in 
the interview that medication is the critical factor.   
 
These data suggest that interviewees had multiple and sometimes contradictory 
ways of framing FH, which emerged at different points in the interview, and 
that these were tied up with interviewees being able to present themselves as 
morally sound in relation to their condition.  This involved, on the one hand, 
refuting responsibility for having hypercholesterolaemia through reference to 
an hereditary basis which decoupled raised cholesterol from lifestyle in their 
own case, but, on the other hand, also taking responsibility for looking after 
themselves, which was framed more in terms of adherence to appropriate 
lifestyle rather than to taking medication.  Issues of lifestyle and diet retain a 
high position for FH patients, despite claims that these factors had relatively 
little impact.  This reflects the strong, seemingly incontrovertible link between 
diet/behaviour and personal responsibility for raised cholesterol in health 
discourses in contemporary Western culture.  This discourse is so dominant 
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that interviewees do not necessarily relinquish it, even when faced with 
knowledge of a genetic aetiology that might allow them to do so.  Instead they 
tend to hold multiple discourses, weaving back and forth between them.   
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The previous section demonstrated the strength of lifestyle discourses in 
constructions of FH.  These contribute to a wider discourse concerned with 
taking care of oneself.  A strong theme in interviewees’ talk about FH was the 
controllability of this condition and the avoidance of disease through taking 
care of oneself by adopting an appropriate lifestyle, taking medication and 
attending appointments with health care practitioners: 
ID16: It could be a serious condition if I did nothing about it or if I 
disrespected everything that people tried to do to make my life last 
longer and be better. But provided I stick to the guidelines then I hope I, 
respecting everything that people are doing for me, I’m able to extend 
my life to be healthy. 
 
One could argue that these discourses of avoiding CHD through taking care of 
oneself conform to Novas & Rose’s (2000) notion of genetic prudence i.e. the 
responsibility to manage oneself in the light of genetic risk information.  
However, in this case it is difficult to tease apart the degree to which this 
imperative to take care of oneself is related specifically to genetic risks or to 
more general personal responsibilities that might apply to any person deemed 
to be at any kind of risk of any condition.  The idea of genetic prudence is 
based on the provision of genetic risk information in the absence of 
physiological measures.  In the case of FH, however, risk of future CHD is 
based on measuring cholesterol levels.  In this respect it would be illuminating 
to compare these constructions with how people with ‘ordinary’ or ‘polygenic’ 
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hypercholesterolaemia, or perhaps with high blood pressure, construct their 
condition and the attendant risks and responsibilities.   
 
Taking care of oneself was constructed as an area of &
	'				


.  This was concerned with avoiding disease whilst managing the 
practicalities of every day life or maintaining a reasonable quality of life.  This 
idea was sometimes expressed in a confessional language such as ‘pinching a 
biscuit’, or not being ‘a monk’, ‘a virgin’ or ‘perfect’.  It was important not to 
be too ‘anal about things’ or to ‘take things too seriously’.  In the discourse of 
‘responsibility within reason’ a balance is required between avoiding disease 
though taking care of oneself properly, and maintaining a reasonably normal 
life.  It is possible to take FH both too seriously and not seriously enough.  This 
was demonstrated neatly by one woman’s discussions about herself and her 
siblings.  On the one hand, her sister died at the age of fifty of a ‘massive heart 
attack’, because she would not take it seriously enough; she was ‘overweight 
and everything that she shouldn’t do, she still continued to do’.  There was also 
a question mark about whether she actually took her medication: 
ID33: Whether she took it or not, she was a bit dizzy (laughs), lovely, 
but wouldn’t take anything seriously, would she? 
 
On the other hand, her brother ‘takes his medication too seriously’ and is ‘a bit 
obsessive’ about his cholesterol level.  The interviewee’s own view was that 
you have to get ‘a happy medium’:  
ID33: alright you’ve got a problem, you can’t override your life.  You 
know you deal with what you have to deal with it and then you forget 
about it. 
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This echoes Backett’s (1992) work on lay health moralities, cited in Lupton 
(1995), which found that ‘being obsessive about one’s health [was] just as 
much a taboo as being overly cavalier’ (Lupton, 1995: 140), and others who 
have suggested that lay people are cognisant of public health messages, but 
weigh these up in terms of the practicalities of everyday life (Lambert & Rose, 
1996; Williams et al., 1995). 
 
There was only one exception to this discourse of controllability and avoidance 
of disease, where an interviewee expressed explicitly fatalistic ideas about her 
condition:     
KW: the idea of getting heart disease, is it something that worries you? 
ID04: It does in one way, I just kinda think, oh well it runs in the 
family, it’s gonna ‘appen to me anyway, so if it ‘appens, it ‘appens kind 
o’ thing.  But it just, if I really think about it, it does scare me a little bit, 
but I just kinda think, oh well I’m one of them that are gonna go early, 
if the rest of the family ‘ave, so. 
 
This section has suggested that FH was constructed as controllable and CHD 
modifiable by 	

and that actual cases of CHD were 
explained within this discourse.  The following section discusses interviewees’ 
accounts of CHD more widely.  
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Interviewees’ accounts of CHD confirm a role for genetics in the case of FH.  
However, the degree to which CHD was attributed to genetics for people with 
FH varied between interviews.  In some cases this was offered as the main 
cause.  In the following example a woman who does not have CHD accounts 
for her sister’s CHD.  We have already established that her sister has FH:  
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KW: So why d’you think she’s got the heart problems? 
ID19: She must have more of the genetic makeup, I may have more of 
my mother’s genes than she has.  Or I could have more my dad’s 
father’s family’s genes.  She’s obviously got more of the maternal 
makeup, my grandmother’s family’s make up in her
14
.  
 
In other interviews, CHD was attributed to a combination of factors, which 
were all recognisable aspects of general lay constructions of CHD, 
encapsulated by the idea of the coronary candidate (Davison et al., 1989, 1991, 
1992).  This included factors such as temperament, stress, appearance and 
behaviour.  In the following example a man discussed his father’s CHD:  
(Para 15) 
ID77: My father died when he was forty&seven. He wasn’t particularly 
overweight, even though he was overweight, but not particularly obese.  
He wasn’t particularly fit, but even so, forty&seven was too young. 
(Para 43) 
ID77: Got married when he was thirty&two, was slim up to that point.  I 
don’t know what kind of exercise he did at that point.  But he’s 
obviously, by the time he’s forty&seven he is overweight, did he say 
fifteen, sixteen stone.  I think he was six foot, five foot eleven I think he 
was, overweight, but not excessively, drank too much beer.  He had a 
good life, enjoyed himself completely, no doubt about that, had a kind 
of fiery temperament, did have a bad temper. 
 
In this interview, although the father’s early death requires some additional 
explanation, the account of his CHD still draws on ideas about weight, fitness, 
alcohol consumption and temperament.  Even where interviewees explained 
their own CHD, they might still draw on a wide set of factors.  One woman, for 
example, suggested that her own CHD was due to: raised cholesterol; the stress 
of bringing up her children more or less on her own, working and ‘rushing 
about’; and being ‘very highly strung’.  Interviewees sometimes included 
admissions of inappropriate lifestyle in their accounts of their own CHD.  In 
                                                
14
 This excerpt indicates another theme concerning how inheritance patterns for FH were 
constructed, which will be discussed later in this chapter.   
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the following example, although the interviewee makes clear that he was aware 
that heart problems ran in his family, this is not his main focus: 
(Para 42) 
ID88: Prior to that I did live a good life […] at my heart attack point I 
was maybe two stone overweight.  So you know, I knew the family 
history, that I was sat on a time bomb, but at the end of the day, you 
know I was smoking as well, so as I said to you I had all the 
qualification, I was a highly qualified candidate. 
(Paras 60&62) 
KW: If you had to say why you had the heart problems and why you 
think you got it in ‘96, what would you say to that? 
ID88: Er not taking head of things and not stopping smoking, eating the 
wrong things, not taking much exercise, um and generally being blasé 
towards life. 
 
The role attributed to genetics varied not only between interviews, but also 
within them.  This further illustrates the observation that interviewees wove 
between multiple discourses.  One woman, for example, accounted for her 
CHD entirely in terms of her raised cholesterol and, by implication, genetics: 
KW: D’you think there was anything specific that brought on the 
angina at the time that it came on? 
ID33: No, I think it was the cholesterol deposits that would’ve, what 
ever would’ve gone on in my life, wouldn’t it? It would’ve come along. 
 
Elsewhere in the interview, however, she talks of lifestyle and stress, 
suggesting a more multifaceted aetiological model: 
ID33: We read up on both our conditions and er got to grips with it and 
tried to cut, you know, a lot of stress out of our lives, didn’t we? 
Changed our diets completely and , well we both feel that if we 
hadnt’ve done, we’d both be in um, you know, a pretty poorer state than 
we are now. 
 
These data reinforce the construction of CHD as avoidable through taking care 
of oneself.  They also reinforce the suggestion that interviewees were obliged 
to oscillate between distancing themselves from responsibility for having high 
cholesterol, and showing that they, nevertheless, maintain a healthy lifestyle.  
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So far this section has discussed interviewees’ accounts of CHD for people 
where a diagnosis of FH was established or suspected.  In the following 
example, an interviewee provided an account of early CHD that was not related 
to FH.  This woman understands that her FH comes through her mother’s side.  
Coincidentally, according to her account, her father had heart disease, which 
started with a heart attack at the age of thirty&six.  She explains this as follows:  
ID60: The fact was my dad’s mum left him when he was about nine and 
that’s when the dad […] came back and started looking after my dad 
and he would have had fish and chips and really extremely bad 
nutrition, right from the word go.  And then my dad went into a trade 
and became a brick layer.  So it would be fish and chips everyday and it 
was only when my dad was first thirty&six, when he had his heart attack 
and my cholesterol was discovered, um that our diet changed […] So I 
would say that, bad luck and whatever genetics that are in him 
contributed to it.  But I would say a really bad diet contributed to my 
dad.  
 
This account mainly draws on the ideas of the manual trade and poor diet, 
leaving some space for luck and genetics in general.  Given this interviewee’s 
own diagnosis of FH, I find it surprising that she does not draw more strongly 
on genetics or heredity to explain her father’s early CHD.  In an earlier section, 
it was similarly suggested that interviewees do not seem to draw on genetic 
factors in explaining raised cholesterol, other than in the case of FH, or ‘my 
condition’. 
 
In summary, interviewees’ accounts of CHD in the case of FH are not 
necessarily fixed on the genetic elements.  Furthermore, experience of FH does 
not appear to mean that interviewees adopt more genetic models in accounting 
for raised cholesterol or CHD in general.  Indeed, the coronary candidate 
appears to be extremely tenacious.  Davison et al. (1989) argued that in this 
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model, areas of non&control are seen as subsidiary to lifestyle.  This does not 
appear to be radically changed through knowledge and experience of FH. 
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This thesis set out to explore the extent to which FH is constructed as a genetic 
condition and one part of this must be to look at the ways in which or sense in 
which interviewees constructed the hereditary element of their condition.  This 
section will focus on the ways in which people identified their condition as a 
family or hereditary condition and on their understandings of the transmission 
of the condition between generations.   
 
.
The previous chapter concerning HEART UK suggested that there was not a 
strong FH identity and this is supported by the data from the interviews with 
lipid clinic patients.  This contrasts with findings from other studies of genetic 
conditions, such as Richards (1996a) and Cox & McKellin (1999), which 
suggest that, particularly for dominantly inherited conditions, an awareness that 
the kinship may be ‘prone’ to the condition may become part of ‘family 
culture’; it becomes ‘this thing in our family’ (Cox & McKellin, 1999: 629).  In 
the case of FH, also a dominantly inherited condition, the minority (about a 
third) of the interviewees talked about a family narrative of a family history of 
CHD or raised cholesterol.  One very clear example was provided by ID100, 
who explained that she came to be a patient at the clinic because she noticed 
that she had ‘deposits’ above her eyes and that she recognised them because 
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her mother, aunt and grandmother, who all have angina, also had them.  She 
explained that she was not surprised by her own diagnosis of FH: 
ID100: Because I knew my mother had it.  It was a thing I’d grown up, 
d’you know what I mean, although there was no label to it.   
 
In the remainder of the interviews either family history was simply not 
discussed or interviewees talked of piecing family health histories together 
after their own diagnosis was established.  ID11, for example, said that she 
found out that she had raised cholesterol when she was thirty through having a 
‘lump’ removed from her ankle, and was diagnosed with FH at the age of 
forty&four.  She suggests that it was only at this point that she started to 
recognise the significance of her mother’s own health history.  Here she 
describes how she came to realise that her mother almost certainly had FH:  
ID11: my mother wasn’t one for talking a lot about things and she had 
big lumps on her hands which she wasn’t bothered about because they 
never hurt her.  She never actually said she had high cholesterol, she 
just took these tablets that they gave her at the hospital.  It was only 
when I started taking them that I realised that they were the same ones 
that she’d been on, but because by then she’d passed away. 
   
These data support the suggestion by Lambert & Rose (1996) that the 
hereditary aspect of FH often only becomes significant retrospectively, once 
the diagnosis of FH has been established.   
 
The idea of a lack of FH identity or family narrative of FH is further supported 
by interviewees’ accounts of how they came to be tested for cholesterol.  These 
can be grouped into four categories, which are outlined in Table 6.1 
 


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Death, CHD, raised cholesterol or FH in relative 12 40 
Outward signs of cholesterol 9 30 
Opportunistic testing 7 25 
Own CHD 3 10 
* per cent rounded to nearest 5. 
 
The largest group (40%) decided, or were advised, to take a cholesterol test as 
the result of the onset of CHD or death in a relative, or the diagnosis of raised 
cholesterol or FH in a family member.  The second largest group (30%) were 
referred for cholesterol testing as a result of consulting about lumps that were 
bothering them, on the ankles, knees, knuckles and around the eyes.  These 
lumps turned out to be cholesterol deposits, although to the interviewees this 
connection between lumps and raised cholesterol was unexpected.  One  
quarter of the interviewees reported that they found out they had raised 
cholesterol through opportunistic testing, for example through a workplace 
testing scheme or primary care ‘MOT’.  A small number found out about their 
raised cholesterol only as a result of being treated for CHD.  Overall, the 
diagnosis of raised cholesterol often came about by chance and was 
unanticipated for a large proportion of these interviewees.  As exemplified by 
ID11, prior to diagnosis of raised cholesterol, and even after, interviewees did 
not necessarily have a strong sense of a family history of CHD.   

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This section focuses specifically on how interviewees understood the 
hereditary aspects of their condition.  This did not constitute a particularly 
large part of patients’ talk and the interview schedule did not contain any 
specific questions in this area.  While it was a relatively minor aspect of the 
 251
interviews, it is nevertheless important to draw out this data in order to get a 
sense of the ways in which interviewees constructed their condition as 
hereditary.  It has already been suggested that, for the interviewees, FH does 
not have a high profile as a particular diagnostic category.  Even where 
interviewees use the terms familial hypercholesterolaemia or FH, it is not self&
evident what they understand by this.  This section will consider in more detail 
how the hereditary aspects of the condition are discussed, whether and in what 
sense this is understood as a particular single gene disorder and the 
interviewees’ understandings of the transmission patterns of the condition.    
 
The aim here is not to ‘test’ interviewees’ models of heredity against the 
‘correct’ biomedical models.  Indeed, as Emslie et al. (2003) comment, and 
chapter four of this thesis illustrates, biomedical knowledge about inheritance 
is not fixed, but can be contested.  The aim is rather to consider the way genetic 
risks and responsibilities may be configured in relation to interviewees’ 
understandings.  The notion of genetic responsibility involves not only an ethos 
of responsibility for taking care of oneself, but also involves people 
constructing linkages between themselves and other people such as potential or 
actual partners, offspring and wider kinship.  How these linkages are 
constructed, therefore has implications for the degree or sense in which genetic 
responsibility is assumed.  The section suggests that in contrast with 
biomedical accounts, and possibly the expectations of analysts such as Novas 
& Rose (2000), a large proportion of interviewees may see the transmission of 
their condition as somewhat sporadic or unpredictable.   
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Richards (1996a, b, 1997) has made a number of observations about lay 
understandings of heredity, drawing together several central recurring concepts 
and these have been more recently reinforced by Emslie et al. (2003).  These 
observations are based on studies of general populations and clinic populations 
for genetic counselling services, particularly relating to Huntington’s disease 
and hereditary breast/ovarian cancer.  The present study, therefore, offers an 
opportunity to consider these ideas in a new type of population.  Important lay 
concepts about heredity include the idea that a condition can ‘skip a 
generation’, that characteristics are linked together, so that children who inherit 
a condition are likely to resemble or ‘take after’ their affected parent either 
physically or in character, and that certain characteristics are gendered, passing 
from mother to daughter or father to son.   Richards (1997) and Emslie et al. 
(2003) observe that lay people often use genetic terminology such as gene and 
DNA, but that this is not linked to particular technical understandings of these 
terms.  Rather, this language stands for the whole area of heredity:  
‘in this context, ‘gene’ seems to be a term for the general concept of the 
biological transmission of characteristics between generations’ 
 (Richards, 1997:190)  
 
Many of these observations about lay people’s talk about heredity are 
reproduced in the present study.  Interviewees had a number of ways of 
referring to the hereditary aspect of their condition, ranging from very general 
notions of heredity, such as ‘a condition that runs in families’ or ‘a hereditary 
thing’ to more specific references to a gene, such as ‘a genetic defect in your 
body’ or ‘a defective gene’.  About half of the interviewees talked of 
, in 
the singular, and in perhaps seven or eight of these cases, the discussions 
included elements of a Mendelian account of FH, such as (1) it is a single gene 
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defect (2) the prevalence of the condition is one in five hundred people (3) 
offspring have a fifty&fifty chance of inheriting the condition (4) there are two 
forms of the condition, heterozygous and homozygous, and the homozygous 
form is much more serious (although these specific terms were not necessarily 
used). 
 
ID19, for example, indicated that this condition involves a particular gene 
when talking about her daughters coming for testing, saying that ‘two of them 
have the gene and one hasn’t’.  Later on she demonstrated several elements 
consistent with a biomedical account of FH, particularly that this is an 
autosomal condition, in other words it affects both sexes, and that each child 
has a chance of inheriting the condition.  Her talk implies a technical 
understanding of chance, as a random event for each child, through her 
suggestion that this is independent of how the child looks and of the status of 
any other children: 
ID19: I’ve obviously inherited some genetic factor that runs in our 
family on my father’s mother’s side and it’s passed on to either sex, but 
you’ve a fifty&fifty chance of getting it […] because two of mine have 
and one hasn’t, and yet they’re all exactly the same […] They don’t 
look the same, I mean they’re very different to look at the children, but 
it’s just this gene that’s floating your way or not.   
 
It is not clear exactly what this group understood the term ‘gene’ to mean and I 
did not ask this, and there was no mention of any specific genes, such as the 
LDL receptor gene. Nevertheless, this small group of interviewees 
demonstrated that they understood FH as a Mendelian condition on some level.  
They had some notion of a specific single gene condition, connected to some 
model of the processes and substances of hereditary transmission.   
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In other cases it was much less clear what an interviewee meant when they 
talked of a gene, genes, genetic factors or an inherited condition, although 
sometimes it was obvious that that they did not have Mendelian understandings 
of FH.  ID78 stands out as extreme example.  She explains her condition using 
the language of genetics, which at first glance implies some technical 
understanding of the condition.  The following excerpt suggests three things (1) 
it provides a process that connects a ‘rogue’ gene in the liver to raised 
cholesterol (2) it makes a connection between genes and DNA (3) It establishes 
that ID78 is the only one of five siblings who has inherited the ‘rogue’ gene:  
ID78: Well it’s a rogue gene in the liver, they say it’s like you’re in a 
chocolate factory and it’s pumping out coffee creams.  When you’ve 
got too much cholesterol, it’s just working overtime on the coffee 
creams are pumping out.  ‘Cos in about fifty years time they’ll be able 
to do gene transplants.  I’ve got some blood sent off for DNA in 
London […] So what happened was out of the five children, I’m the 
one who inherited the rogue gene. 
 
However, she went on to draw on a number of ideas about inheritance that are 
clearly incompatible with a Mendelian account.  For example, although she 
repeated several times that none of her siblings had inherited the ‘rogue gene’ 
she reported that two of her siblings and several of their children had received 
treatment for raised cholesterol and her talk suggests that this is hereditary in 
some way.  The implication in the following excerpt, for example, is that 
although the brother does not have the rogue gene, raised cholesterol has 
somehow been passed onto his daughter:  
ID78: My son’s been tested.  He hasn’t got any high cholesterol and me 
brother’s children’ve been tested.  He’s got two boys, clear, and a girl, 
she took statin drugs.  So it seems it’s all gone onto the women.    
 
My own immediate assumption, based on the account provided by the 
interviewee, was that it is very likely that this brother and one of her sisters had 
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FH and I find the interviewee’s ideas both surprising and confusing.  One 
interpretation is that she sees heredity and genes as different things, belonging 
to separate domains.  This means that the idea of a rogue gene can stand along 
side more everyday ideas about heredity without causing tensions.  This idea 
will be discussed again.  The interviewee’s talk, in any case, illustrates that 
some interviewees talked of genes and genetics without this being connected to 
a Mendelian model of FH.   
 
A number of lay notions about heredity emerged in relation to the transmission 
of FH.  These ideas fit better with understandings of FH as a more general 
hereditary or familial condition than as a specific and knowable Mendelian 
condition.  These included: 

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The idea that FH might affect a particular 
gender was suggested in four interviews, implicating both men and women.  In 
these cases the suggestion was related closely to recent family experience.  For 
example, one woman with six siblings reported that it was the girls who had 
got the condition, commenting that: 
ID21: it’s something that’s hereditary and passed onto, sounds like the 
female side of my family.    
 
In this case, the link to gender is purely observational.  In other cases the link 
was taken to be a recognised and predictable fact, for example, one man 
commented: 
ID90:  Well, I understand from [consultant] it tends to run down the 
male line.   
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In contrast to Lambert & Rose (1996), it is notable that this gendered 
construction of FH was applied to both men and women.   

!A	
Richards (1997) notes that the idea that a disease may 
‘skip a generation’ is very common and provides one way to explain the 
intermittent appearance of diseases within families, particularly in conditions 
with incomplete penetrance
15
.  FH is generally understood to have high or near 
complete penetrance
16
.  This means that it is very unlikely for the high 
cholesterol to skip a generation and this is reflected in the interviews.  Nearly 
everyone identified a parent who had raised cholesterol, who had ‘passed on’ 
the condition, and no one suggested that FH had actually skipped a generation 
in their own case.  Nevertheless, the possibility that FH might skip generations 
was present in four interviews.  In the following example the interviewee has 
indicated that the condition comes from his father’s family, that his father and 
grandmother had raised cholesterol and that a number of his father’s siblings 
died of CHD.  Yet his talk suggests a much looser lineage:  
ID85: You may not be aware that your parents have had cholesterol.  
Maybe they didn’t, maybe someone further along the line had high 
cholesterol […] I couldn’t explain it, other than the fact that it’s in your 
genes and it’s from somewhere of the genetic line. 
 
It seems that ‘skipping a generation’ is such a central idea in everyday 
understandings about heredity that it filters through in the case of FH, even 
though it rarely ties in with personal experiences in this case.  The fact that 
ID85 and others draw on the idea of ‘skipping a generation’ suggests a 
                                                
15
 Penetrance is the relationship between having the mutation and having the condition or 
disease.  Penetrance is said to be complete or 100 per cent in cases where everyone who carries 
the mutation develops the condition.   
16
 Although there has been some discussion of the relationship between genotype and 
phenotype in the biomedical literature, as discussed in chapter four.   
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construction of FH as a condition that belongs to the general category of 
hereditary conditions or conditions that run in the family rather than as a 
specific Mendelian condition. 
  
<
	#	Although most people identified a lineage on 
one ‘side’ of their family for the FH, in three cases interviewees mentioned 
both parents.  This implies a model of raised cholesterol as a result of the 
mixing or blending of their parents’ genes, traits or pronesses, rather than the 
passing on of a gene from one parent.  In the following extract, the interviewee 
talked about inheriting a deformed gene, at the same time as discussing the 
heart disease of both her parents:   
KW: What sort of ideas do you have about why you’ve got the 
cholesterol problem? 
ID04: Because I’ve got a deformed gene that doubles the cholesterol.  
It’s hereditary, that’s all I know (laughs) 
KW: okay, no that’s a really good answer (laughs), was that a surprise 
to you when you were told about it or were there things in your family 
background that’d made you think you might have a  
ID04: Well no, because of me family background.  Me mum died, that 
was heart problems that me mum died, she was only fifty&one.  Me dad 
died of heart attack.  So I wasn’t really surprised when you know they 
turned around and said, well, you’ve got this hereditary thing. 
 
Later on in the interview I asked again about the family history and she talked 
again about both her parents.  This suggests that she understands her own 
raised cholesterol to be the result of an additive effect of both her parents.  The 
excerpt also supports Richards’ observation that talk of genes can stand for the 
whole area of heredity.   
 
	AWhile several people proposed that the chance of getting 
FH was fifty per cent for each child, on two occasions interviewees seemed to 
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suggest much higher risk in their particular situation.  In one case this was 
based on the high prevalence of the condition within the family.  The 
interviewee suggested that his son was very likely to have inherited the 
condition, since everyone else in the family seems to have got the condition.  In 
the second case, the suggestion is that the higher the parent’s cholesterol level, 
the greater the risk of the child having raised cholesterol.  Again this was 
substantiated through experience.  In the excerpt, the interviewee is 
commenting on how she felt about taking her young daughter to be tested:  
KW: But I think, I mean I suppose it might’ve been traumatic the idea 
of having to take her, to find out one way or the other? 
ID11: Er no, well I suppose yes because there was always that fifty&
fifty chance, but I think in my head I thought, well with me having such 
a high one to start with, she probably would, and she did.  She had a 
high count.   
 
The extract shows how Mendelian knowledge (the fifty&fifty chance) and other 
ideas, in this case perhaps a more blended model of heredity, coexist.   

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	Both Richards (1996a, b, 1997, 2003) 
and Davison (1996, 1997) have commented on the grouping or linking of 
characteristics in lay talk about heredity, suggesting that who someone is 
thought to look like or take after may be used as a basis for predicting future 
health trajectories or making risk assessments concerning specific genetic 
conditions.  It was notable that there were only two examples of talk of ‘taking 
after’ in these interviews, both by people who had demonstrated a relatively 
biomedical understanding of FH.  Taking the case of ID06, a man who works 
as a health professional, he observed that his young son ‘is said to be more like 
me, I wonder if he might also have it’.  There was no further talk about this in 
the interview and he gave no impression that he might treat his son and 
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daughter differently on this basis, or that he viewed his daughter to be less at 
risk.   

<
	The data presented support Richards’ observation that 
many people talk about genes as a kind of short&hand for the whole area of 
heredity, rather than having technical understandings.  This talk appears to sit 
alongside existing lay notions about heredity.  Even those with relatively strong 
biomedical understandings of FH and genetics in general still also drew on 
other ideas about heredity, as in the case of ID06 discussed above.  These data 
support the ideas proposed by both Richards (1997) and Emslie et al. (2003) 
that everyday ideas about inheritance and abstract biomedical knowledge about 
genetics may co&exist in separate domains.   
 
In sum, this section has suggested that a number of recognised lay concepts 
about heredity were present in these interviews.  While there were only a few 
references to any one of these, overall the data suggest that a large proportion 
of interviewees had some ideas that were at odds with a Mendelian model of 
FH.  Perhaps half or more of the interviewees do not necessarily see their 
condition as one for which the mode of transmission is quantifiable and 
predictable.  Rather, the condition belongs to a more general category of 
hereditary conditions or conditions that run in families that appear in a more 
sporadic or less predictable manner, or in the case of gendered constructions 
may be seen as only partially transmitted.  This may have implications in terms 
of the way risks and responsibilities are constructed.  These constructions of 
hereditary linkages must be coupled with other aspects of constructions of FH 
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which foreground individual actions and responsibilities.  One might, therefore, 
speculate that for these interviewees, responsibilities based on genetic 
connections may assume less significance than might be anticipated through 
following analysts such as Novas & Rose (2000).  This is borne out to some 
degree in the data concerning how interviewees construct responsibilities to 
others, which is presented in the next chapter. 
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This chapter has argued that interviewees had multiple and sometimes 
contradictory strands in their constructions of their condition and that they 
tended to weave between these different strands.  Interviewees explained FH 
drawing on three elements, heredity, a problem to do with high blood 
cholesterol, and a cholesterol processing problem.  The genetic elements were 
not necessarily at the forefront of these accounts.  However, they tended to 
frame the aetiology of raised cholesterol as a dichotomy, hereditary and only 
amenable to medication in my case, lifestyle&related for other people.  At the 
same time, there was a strong degree of lifestyle talk in interviewees’ 
discussion of their responses to their own cholesterol condition, which 
contributed to an overall ethos concerning FH that CHD is avoidable through 
taking care of oneself.  The construction of the two distinct categories of raised 
cholesterol, and the fact that lifestyle talk remains prominent despite these 
constructions, reflects the seemingly immutable link between lifestyle and 
personal responsibility for hypercholesterolaemia in contemporary Western 
culture.  In oscillating between different discourses at different points in the 
interview, interviewees managed to establish their sound moral status.  
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Interviewees presented multifactorial models of CHD that conformed to 
established lay constructions embodied by the notion of the coronary candidate 
(Davison et al., 1989, 1991, 1992).  Genetics was attributed variable 
importance in these accounts, but was rarely seen as decisive in either their 
own or other people’s CHD.  
 
The chapter also suggested that FH is not associated with a strong disease 
identity.  The terms familial hypercholesterolemia or FH did not have a high 
profile in interviewees’ talk.  Furthermore, the idea of a family history of CHD 
or cholesterol problems did not appear to have been an established part of 
family culture in the majority of cases.  Interviewees’ constructions of the 
specifically hereditary aspects of their condition suggest that many saw its 
transmission in less specific or predictable ways than suggested by a 
Mendelian model and it is argued that this may be significant concerning the 
way genetic responsibilities are constructed. 
 
What can these findings contribute to the discussion of geneticisation?  First 
genetics was not the dominant discourse in these interviewees’ accounts of 
CHD.  It is notable that even in this case, where people have specific 
knowledge concerning a genetic contribution to their own 
hypercholesterolemia, this did not lead them to foreground genetics in their 
accounts of their own CHD or other people’s hypercholesterolaemia or CHD.  
Their constructions conformed to established lay models of CHD.  Second, 
geneticisation suggests that society will become stratified along genetic lines.  
This was true in these interviews, in as much as interviewees distinguished 
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between their own hereditary hypercholesterolaemia and other people’s 
lifestyle&induced hypercholesterolaemia.  In this case, this enabled them to 
construct themselves as less, rather than more accountable for their condition.  
However, as already noted, in their general accounts of CHD, genetics was 
only one contributory factor, not a defining factor.  Third, the great emphasis 
that interviewees placed on lifestyle and taking care of themselves could be 
interpreted as an expression of the individualisation of responsibility for 
preventing disease.  However, as already argued, this is an established 
discourse concerning CHD and hypercholesterolaemia.  Interviewees drew on 
constructions that already circulate in the lay population. This cannot be seen 
as a novel set of responsibilities imposed by an elite group of geneticists or 
other experts.  These findings reinforce the argument that lay accounts as much 
as professional constructions tie health and illness to personal responsibility.  
In this sense, the findings support the critique of geneticisation that it 
underestimates the agency of lay people. 
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This chapter is the second of the two chapters that draw upon the interviews 
with people with FH, undertaken at a lipid clinic.  The chapter is concerned 
with what it means to have FH, how interviewees view their condition and their 
response in their everyday lives.  The analysis focuses particularly on the ways 
in which FH is framed as a genetic condition through interviewees’ talk about 
their actions in relation to FH.  Rose and Novas (Novas & Rose, 2000; Rose, 
N., 2001; Rose & Novas, 2004) have argued that genetic knowledge creates 
obligations to consider decisions about the whole scope of life plans, which 
link individuals into a web of relations:  
‘Choices about marriage, procreation, financial planning, inheritance, 
career and much more are made in a web of entanglements involving 
actual and potential kin, employers, partners and children’  
(Rose, N., 2001: 19). 
 
One can argue that the degree to which people frame responsibilities in relation 
to genetic connections provides an indicator of the degree to which a condition 
is constructed as genetic.  In other words, ‘genetic responsibility’ can be seen 
as an indicator of the genetic framing of a condition.  If genetic or hereditary 
connections are at the forefront of people’s concerns about FH, then one would 
expect to see much talk in these interviews about people’s actions in relation to 
their kin, and other people to whom they are connected.  The analysis is 
therefore concerned with interviewees’ talk about their actions in relation to 
others and the sense in which obligations are derived through genetic 
knowledge or connection.   
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The chapter first briefly reviews the notion of genetic responsibility and then 
presents data concerning the construction of responsibilities in relation to 
others.  The main areas considered are reproductive decision making, taking 
care of one’s offspring and talking with kin.  The chapter argues that the 
construction of FH as highly treatable and manageable is used to distinguish it 
from other, more serious genetic conditions.  This construction is central to 
interviewees’ almost universal rejection of reproductive decision&making in the 
case of FH.  However, there was a strong sense of responsibility for ensuring 
the appropriate testing, treatment and care of one’s offspring.  This can be seen 
as one aspect of genetic responsibility.  There was a much less clear message 
about responsibilities to other kin, with only a small proportion of interviewees 
claiming responsibility for communicating information to their kin or for 
encouraging them to manage their cholesterol;Furthermore, interviewees also 
talked of informing other people in general about FH and cholesterol, and 
encouraging them to get tested or manage their cholesterol.  These data suggest 
that responsibilities in relation to others are not solely or even predominantly 
derived through genetic risks and genetic connections.     
 
6;'-&-.*-!,&!. ..8
Genetic responsibility or prudence (Hallowell, 1999; Kenen, 1994; Novas & 
Rose, 2000; Rose & Novas, 2004) can be defined as the obligation to know and 
to manage the implications of one’s own genome.  It implies two areas of 
action.  First, there is an obligation to become informed about one’s genetic 
constitution and to undertake risk management to monitor and try to modulate 
one’s own genetic risks.  This is a continuation of discourses of personal 
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responsibilities to avoid illness though identifying health risks and adopting 
appropriate health&related behaviours (Petersen & Lupton, 1996).  The 
previous chapter has shown that interviewees amply demonstrate these 
discourses, through constructing CHD as avoidable by 	

(  
Second, genetic responsibilities are extended towards other people, particularly 
family members.  Hallowell (1999) and Polzer et al. (2002) have discussed the 
responsibility to disseminate information to relatives and encourage others to 
get tested, as well as to know and manage one’s own risks for the sake of 
others.  Novas and Rose’s (Novas & Rose, 2000; Rose & Novas, 2004) notion 
of genetic prudence relates to a range of life plans, including forming 
partnerships, procreation, working life and financial arrangements.  One can 
argue that recourse to reproductive decision making, in particular, has become 
integral to genetic ways of constructing conditions.  In the UK, prenatal genetic 
testing and pre&implantation genetic diagnosis (PGD) are available for a range 
of Mendelian conditions such as Huntington’s disease and cystic fibrosis, and 
consultation is underway concerning the extension of PGD for inherited 
susceptibility to cancers such as hereditary breast/ovarian cancer and an 
inherited form of susceptibility to bowel cancer (Human Fertilisation and 
Embryology Authority, 2005).  This area could perhaps be thought of as 
emblematic of genetic ways of constructing disease. 
 
6;2*-*,$.0--.!.,&"+.&
In Chapter 5, it was noted that the idea of reproductive decision making in 
relation to FH was almost absent from HEART UK interviews and entirely 
absent from the biomedical literature analysed.  This theme was similarly 
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unimportant to the FH patients interviewed at the lipid clinic.  Discussions 
about reproductive decisions were mostly prompted by me and were almost 
universally framed by interviewees as a non&topic, i.e. they had been 
contemplated, but quickly dismissed, or were out with the bounds of what is 
thinkable about FH.  This came through in discussions about interviewees’ own 
children and in discussions about the potential of DNA&based technologies to 
lead to prenatal screening.  The rejection of reproductive decision&making 
hinged on the construction of FH as treatable, manageable and not serious 
enough to warrant such a course of action.  In the following extract, for 
example, FH was framed as something that is not necessary to consider when 
planning to have children, because it is a 
'
		
:
KW: I was going to ask you when you were thinking of having your 
own kids whether it was something you thought about at all? 
ID90: well we wanted to have children and the fact that you know I had 
this condition [… ] and the fact that it was a manageable condition 
meant it was, to be honest, not really, it was a no&brainer.  We wanted 
to have children, as long as we could.  

The treatability and relative lack of impact of FH were underscored through 
comparisons with other diseases.  The following extract again illustrates that 
reproductive decision making is outside the realm of considerations for FH, 
that this is because it is treatable and not that serious, and that this distinguishes 
it from other genetic diseases:   
KW: do you think it would ever be a consideration for your children 
whether to have children or not, is it something that you’d have to think 
about? 
ID15: No I don’t think so.  My son is not married but he’s got a child 
from a relationship, he’s now split up from the girl and I don’t think it’s 
ever been considered, no. 
KW: No, I mean, not that it should be, but why is it not a consideration? 
ID15: Er, well it’s treatable isn’t it by diet and drugs.  It’s not 
something that is incurable, if you know what I mean, it’s a gradual 
thing.  It’s not just, as an example, Huntington’s chorea or something 
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like that.  It’s not, you know, where you definitely don’t want to have 
children because of that particular disease. 
KW: Yes sure. 
ID15: No I don’t think it’s that serious because it’s reasonably treatable. 
 
Again, in the following extract, the interviewee was at pains to distinguish FH 
from other genetic conditions for which reproductive decision&making would 
be conceivable.  It is noticeable that she was unable to specify examples of 
what kind of conditions or abnormalities would merit this. This does not 
however, detract from the strength of her assertions that FH does not fit into 
this (unspecific) category:   
KW: I suppose I was wondering whether it was something you might 
think about in terms of, well should I have children or should I not have 
children? That was never a question? 
ID60: Oh no, no, no.  It’s a serious condition, but it’s not that serious 
[…] it’s not that kind of genetics where you’re thinking, if I was tested 
would it sway me one way or another, because you know it isn’t that 
much of a problem, in so much as it can be managed.  So that 
absolutely would not be on the table, it wouldn’t even be thought about. 
Whereas people that inherit diseases, they know they’ve got a gene and 
it could be passed on, I can’t think of anything at the moment, that 
would cause some other kind of abnormality, then that’s different, but 
it’s not even on the continuum I would say.   
 
This distinguishing between FH and other more serious genetic conditions fits 
with the construction of FH as being part of the normal spectrum of life and 
illness.  Indeed, four of the interviewees drew on ideas concerning normality to 
show that having FH does not set one apart from one’s contemporaries. As one 
young man put it: 
ID112: Other families have different illnesses and different complaints 
or what have you, so it’s just another one on the list. 
 
The previous chapter suggested that FH was not seen as stigmatising and this 
can be linked to the construction of FH as treatable and, perhaps, as part of the 
ordinary spectrum of disease.  Two younger men discussed this quite frankly, 
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making a clear link between their (normal) social status and the treatability of 
their FH, as the following extract illustrates: 
ID77: Bear in mind I am on the statins.  I’m a normal person now.  You 
know, I’m not, it’s a genetic defect, but I’ve been brought into society, 
you know what I mean? I’m being brought back to being a normal 
person. 
 
These ideas about normality were explicitly linked to reproductive decision 
making in the following example.  Here the interviewee explains his rejection 
of such decision&making in terms of the ability to lead a 
	:  
ID54: we took ‘em to see a consultant paediatrician and funnily enough 
that was the only negative reaction I’ve ever had from any medical staff 
to the condition and he actually said were we, had we ever considered 
not having children and I was a bit annoyed with him and I said I 
couldn’t understand why we’d take that point of view […] I mean I was 
forty&ish then and thought well you know I’d had forty years of normal 
life with no side effects, even taking the tablets and, you know, why 
should we not have children, you know.   
 
These data illustrate that rejection of reproductive decision making was tied up 
with the construction of FH as treatable, manageable and not that serious, and 
perhaps part of what can be considered normal illness.  On the other hand, they 
also support the suggestion that it is possible to consider FH in terms of 
reproductive decisions.  Two cases have now been noted i.e. one of the 
clinicians involved with HEART UK and, according to ID54’s account, this 
paediatrician.  The patients with FH universally rejected the idea of 
reproductive decision&making concerning FH, with one exception.  In contrast 
to other interviews, in this case the discussion was generated by the 
interviewees, a woman and her husband (annotated as H).  I had not anticipated 
that my initial question, about why the interviewee thought she had high 
cholesterol, would lead onto this talk about reproductive decisions: 
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KW: So can I ask you what sort of ideas you’ve got yourselves about 
why you’ve got this high cholesterol and why you’ve had the heart 
problems? What would you say? 
ID101: Oh I think it’s just one of those things that happens through 
family like anything else really.  You know families can get things that 
they pass on, you know, illness. 
H101: I suspect she, I’d probably say that if she’d’ve known when she 
was younger, before she had children that she had this problem she says 
she would never of had the 
ID101: I don’t think I’d’ve had them, you know 
KW: really 
ID101: No because me son’s ill with it you know and he complains you 
see 
H101: And the eldest girl has got a ???  
ID101:Yes, me eldest girl, she’s having problems you know with it, so  
H101: She’s being treated for cholesterol related problems.  She’s had a 
minor stroke, it hasn’t left her sort of  
ID101: deformed in anyway, but she has had a minor stroke, yes. 
 
Compared with the other interviews, the forthrightness of this discussion about 
choosing not to have children was very striking.  Perhaps what was exceptional 
about this woman’s circumstances was the severity of the effect of the 
condition in her family.  Like many interviewees, she reported that a number of 
people in her father’s and her own generation, including herself, had CHD or 
had died early.  More exceptionally, she observed that two of her own children 
had experienced symptoms related to FH.  Witnessing her children’s illnesses 
was pivotal to these discussions, as she put it:  
ID101: ‘Cos I don’t like to think of them being ill, obviously, or, you 
know, anything wrong with them. 
  
In sum, this section has suggested that, almost without exception, interviewees 
constructed FH as not like other genetic diseases because it is treatable and 
manageable. In this way, a boundary was drawn between it and the ‘serious’ 
genetic conditions.  The data demonstrate that the archetypal genetic condition 
is serious, untreatable and can legitimately be the subject of reproductive 
decisions.  There was resistance for FH, a treatable, and therefore less serious 
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condition, to be placed within this category.  In one sense, this could be seen as 
resisting the genetic construction of FH, or at least resisting any challenge to 
the status of FH as situated within the realm of everyday normal illness.  These 
data support Lambert & Rose's (1996: 79) findings that people with hereditary 
lipid disorders see their conditions within ‘the normality of human 
imperfection’.   
 
6;3"!!.&.,&
Although the idea of reproductive decision making was almost universally 
rejected, around a quarter of interviewees talked of feelings of regret at the 
possibility of passing on FH to their children.  Just one interviewee expressed 
feelings of guilt:   
KW: So can you remember what you thought at the time, when the kids 
were being tested? 
ID19: I felt guilty when it, well at the time I was worried, I was hoping 
they didn’t have it and I felt guilty that it was through me that they had 
to come […] there’s no bad feelings [from daughters] you know, that 
you’ve passed this onto me now, but you do feel a bit guilty for passing, 
for having been the person to cause them to have to, because it’s not 
pleasant to have to think about what they’re eating all the time. 
 
While this interviewee talked about her own feelings of guilt about passing on 
FH, she did not blame her own father for passing on the condition.  Indeed, 
there was not a single case where blame was attributed to a parent.  In this case, 
her father passing on FH was constructed as just one of those (unavoidable) 
things that happen:   
ID19: But it’s never been any, I mean I don’t think about me father you 
know, oh what’s he done passing this, it’s nothing, it’s just something 
that happens.   
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There were a few further cases in which there was an out and out rejection of 
blame for passing on FH.  In the following excerpt, for example, the 
interviewee rejected blame of his parents or himself because of the limited 
impact of FH and, again, because passing it on was an (unavoidable) chance 
thing: 
KW: I’m wondering what ideas do you have about why you got FH?  
ID67: It’s just the cards I was dealt.  That’s it.  You know, that’s the 
way it is.  It’s like, I’m about to have a child.  The FH hasn’t affected 
that, you know, it’s a gamble.  The baby may or may not have it and, I 
mean it’s not a debilitating condition.  You know I’m perfectly healthy 
as I am now, and there’s treatment for it, so I don’t apportion any kind 
of blame or any guilt or anything like that.  It’s just one of those things.   
 
Again, FH is constructed as 4
	
as well as a manageable 
condition, which is treatable, 
 '			
 and compatible with being 
&.  The combination of these discourses of FH as just one of 
those things, that one can not do anything about it, and as a manageable 
condition, reinforce the construction of FH as part of normal, acceptable, 
unavoidable illness.  It is possible that this construction of FH as highly 
treatable, unavoidable and unproblematic, function to lay off responsibility for 
passing on the condition to one’s offspring.   
 
The construction of the hereditary aspect as uncertain or contested could also 
function to lay off responsibility in a similar way.  This came to the fore in one 
very tangible example, in which a man talked in a mixed way about the origins 
of his son’s raised cholesterol.  At various points in the interview this was 
attributed to genetics, but the genetic origin was also contested.  The following 
passages seem to illustrate that the interviewee was struggling to come to terms 
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with the hereditary aspects of FH precisely because this implies responsibility 
or blame for his son’s raised cholesterol: 
(Paras 220&224). 
ID13 my son has just gone on medication, he’s twenty&one, but he’s 
super fit […] and we find that hard to take that he’s got high cholesterol 
and has probably never eaten as much as a bag of chips in his life […] 
and that sometimes makes me think how important the diet is when 
you’ve got this high cholesterol, this genetic type one […] So that 
concerns me a bit that he’s got the, looks as though he’s got the genetic 
side of it.       
 
(From Para 254) 
ID13: nobody is a hundred per cent, even [consultant] and people like 
that. My son thinks […] he’s convinced that he’s inherited it now off 
me and even we don’t know whether it is inherited fully quite yet do we 
from my experience with the research I’ve seen, but going back to my 
point, if they did a gene test and they could say “Oh you’ve got half a 
gene or a gene too many,” we could actually say we know probably.  
It’s just that you’d worry about whether you’ve given it to your children 
or passed it on.   
KW: Yes but I mean what do you think, what’s your gut feeling, do you 
think your son has inherited it off you or not? 
ID13: No I’m not convinced, I’m not convinced it’s inherited yet.  
KW: No, but if I put you on the spot and said well okay why do you 
think your son has got slightly high cholesterol, how would you explain 
that? 
ID13: Well that’s a funny one that with [son] because with him being 
super fit you see he’s probably inherited it off me yes (laughs). 
 
It should be noted that these discussions about passing on FH were a relatively 
minor part of interviewees’ talk about having FH.  For example, just five 
people mentioned this topic as the worst aspect of FH.  This compared with 
larger numbers of references to aspects of treatment/medication, the possibility 
of illness or early death, and changes to diet.  In sum, although there was some 
discussion of regret concerning passing on problems to children, and 
interviewees’ talk appeared to be structured so as to provide a defence against 
potential accusations of blame, the data suggest that this aspect of FH is not at 
the forefront of patients’ constructions of the condition.  
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Interviewees’ almost overwhelming rejection of reproductive decision making 
has already been discussed.  Novas and Rose (Novas & Rose, 2000; Rose, N., 
2001; Rose & Novas, 2004) notion of genetic prudence suggests that having 
knowledge of genetic risk information is associated with obligations regarding 
other areas of life planning such as financial and occupational planning.  There 
was very little talk concerning the influence of FH on life plans in these 
interviews.  Just three interviewees made any kind of reference to knowledge 
of being 	 of CHD having influenced their life plans, as distinct from talk 
of changes made as a result of actually having CHD, and in only one case was 
this linked directly to responsibilities to other people.  Here the interviewee 
said that one of the impacts of having FH was that he had chosen a job with a 
stable ‘blue chip’ company with ‘a good pension’ to make sure that his wife 
and family would be financially secure should he experience health problems.  
In the other two cases the interviewees talked of making sure they did things 
they wanted to do, or that the diagnosis had made them think more about what 
they wanted to do.  In short, although ideas about life planning were present, 
this was hardly a major theme in the interviews.       
 
The previous chapter and the first section of this chapter suggest that FH is 
constructed as treatable, manageable, unavoidable and relatively 
unproblematic, and that CHD is seen as largely avoidable by taking care of 
oneself by maintaining appropriate lifestyle, taking medication and following 
medical advice.  So far the analysis has suggested that these ways of framing 
FH and CHD underlie interviewees’ constructions of responsibilities to self and 
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discussions concerning having children.  While talk of the treatability and 
manageability was very prominent, FH was not constructed as entirely 
unproblematic.   At least a third of the interviewees said that they thought of 
FH as a serious condition, relating this to early deaths of family members or 
talking of its potential to cause CHD, and several others said it would be 
serious if it was not controlled or treated.   
 
The idea that predictive health risk information might result in a new health 
status between health and illness has been prominent in scholarly discussion 
(inter alia Armstrong, 1995; Crawford, 1980; Davison, 1996; Finkler, 2001; 
Scott et al., 2005).  Four of the interviewees talked about being or having been 
alert to particular bodily feelings.  These were sensations in the chest which 
were associated with anticipating heart problems:  
ID67: it’s always in the back of your mind, if you ever have a twinge in 
your chest you sort of, at my age, you start thinking of well what’s that? 
Is that anything to do with that? 
 
In one other case, a woman talked about FH as being frightening and 
something that was ‘in your head all the time’.  These expressions of bodily 
awareness or constant consciousness are perhaps manifestations of the liminal 
status (Scott et al., 2005) of people living ‘at risk’ of CHD.  This was, however, 
a relatively minor theme in interviewees’ talk about their experiences of FH.   
 
A second theme concerned the resistance of younger people, in particular, to 
engaging with predictive health information of this nature.  Around a third of 
interviewees made some reference to the relevance of age and life course.  Ill&
health was described as something that young people do not, or do not want to, 
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think about.  Interviewees talked about the difficulty of persuading their adult 
children to be tested or attend the clinic, and of their own lack of engagement 
in earlier years, because ‘when you’re young you think you’ll live for ever’.  A 
handful of the interviewees was diagnosed with raised cholesterol in their teens 
and early twenties, and three of these suggested that this information had been 
actively rejected or ignored in earlier periods of their lives.  Two of these, both 
women and diagnosed at the ages of sixteen and twenty&four, framed their 
diagnoses almost as 

information; that an awareness of their own 
mortality had been prematurely imposed upon them: 
ID60: You see most people don’t think about heart problems I should 
imagine until they get older.  Whereas I was thinking about it from the 
age of seventeen, eighteen, and really as a woman and the menopause 
[…] you really can get to forty odd and it’s not a problem.  Whereas I 
was thinking it was, because it was told to me.  People don’t think 
about when they’re going to die.  Whereas I started thinking about it 
literally from the age of, I would say, seventeen. 
 
ID97:  At the time I didn’t want to know about it.  At the time I wanted 
to know about it after menopause when things became more important 
to get things sorted out.  I thought nothing can go wrong with me; I’m 
only twenty four.   
 
The notion that there are certain periods of life that are, or should be, free of 
thoughts of death and illness and other periods associated with increasing 
health&consciousness were present in several other interviews.  In the main, 
however, talk of worry or of resistance to knowledge of one’s at&risk status 
were not prominent aspects of patients’ discussions about FH.  The framing of 
this predictive health risk information as largely unproblematic is particularly 
significant in the interviewees’ talk about their own children, which is 
discussed in the next section. 
 
 276
6;)"+.&"*-,.*-&.
In a previous section it was noted that, although interviewees sometimes 
expressed regret for ‘passing on’ FH to their offspring, this constituted only a 
minor theme in their talk about having the condition.  By contrast, interviewees 
talked much more about their role in the care and treatment of their existing 
children.  This was evident in discussion about taking children, or 
persuading/encouraging adult offspring to attend for cholesterol testing in order 
to establish a diagnosis of FH, and encouraging appropriate behaviours and 
compliance with medication.   
 
Because I initially understood FH to be an adult&onset condition, it took me 
quite a while to recognise this area as an important theme for the interviewees.  
In order to understand this section, it is worth outlining recommendations 
concerning the diagnosis and management of FH in children.  Clinical 
guidelines produced by the BHA (Wray et al., 1996) recommend that children 
should be screened for FH between the ages of two and ten, with dietary 
modifications encouraged from the age of two.  Recommendations concerning 
the type of medication to prescribe and the age at which it is appropriate to 
start prescribing seem to be more equivocal (Durrington, 2003; Greene & 
Durrington, 2004; Marks et al., 2000; Wray et al., 1996).  It is, therefore, likely 
that parents may be encouraged to have their children tested from an early age, 
although advice on treatment and management may vary
17
.   
                                                
17
 Recommendations about FH are consistent with national guidance concerning genetic 
testing of children for adult onset conditions (Advisory Committee on Genetic Testing, 1998).  
This precludes only testing of young children where therapies are not available.  Although 
there is no discussion of any examples such as FH, in which treatments/behavioural regimes in 
childhood may help to prevent disease in later life, the guidance provides no obstacle to the 
early screening of FH.   
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More than half of the interviewees talked at some point about taking children 
or having been taken as children for testing.  This was, by and large, 
constructed as wholly obvious, straightforward and unproblematic; it was not 
framed as an action that would reveal something about one’s inner&self or 
identity, that might cause anxiety, or that might bring children prematurely into 
the medical sphere, but rather as a very practical act.  ID11, for example, 
discussed taking her young daughter for testing.  Her talk indicated that this 
was not something that was a matter for choice, but an obligation (,
	), and that it was a practical and immediate matter that needed to be 
:   
ID11: I was advised to have her tested when she was two, so she’s had 
tests since two. 
KW: Right, and I don’t know if this is a relevant question, but I just 
wondered what kind of decision that was whether to get her tested or 
not.  Was it obvious or was it difficult? 
ID11: Oh yes, no, it wasn’t difficult because obviously mine was very 
high when I first and no, it wasn’t difficult.  It was just something that 
you know, I thought, well, she’s got to have it, if she’s got it, it’s best to 
get it sorted out. 
 
In the following extract a woman and her husband (denoted as H) discussed 
asking their teenage children to go for testing: 
KW: You said we asked for our boys to be done and they got tested as 
well.  Can you just talk me through how that worked?  
H33: Well, it just, I mean, we didn’t insist on them, but we told them 
the situation with [wife] and that they should be tested, simple as that, 
and they did, didn’t they?   
 
The use of the phrase 	& is particularly striking here.  It again 
suggests that the diagnosis of children is uncomplicated for both parents and 
children.  In the previous section it was suggested that interviewees who had 
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been diagnosed at a young age occasionally talked of their anxiety or 
resistance.  This was particularly so in the case of ID60, who was diagnosed at 
the age of sixteen.  She talked of being in ‘complete denial’ about the diagnosis 
in her earlier years, that she ‘completely ignored it, but at the same time had 
real psychological problems in terms of thinking I was going to die early’.  Yet, 
even this woman constructed the testing of her own children as obvious and 
unproblematic, akin to taking them for childhood vaccination.  She said that 
her two children were tested at the age of six months and in the following 
extract she explained how that came about:  
ID60: I think it may have been my dad, because I went back to work 
straight away with [daughter] […] My dad tended to do most of the 
running around for me.  So I think he did the mumps and measles and 
all the other stuff […] I can’t recall actually taking her myself, so it 
must have been my dad.  Which I know that she was tested. 
KW:  I’m just wondering whether that was an obvious decision or 
whether that was something you had to kick around with your husband? 
ID60: No that was, it wouldn’t have been anything that would’ve been 
discussed in depth, because there might be two outcomes.  It was just 
anything like that, I just make the decisions on anyway.  So, no, that 
was just an obvious choice. 
 
She manages the disparity between her own experience and her actions toward 
her children by drawing a distinction between them, describing the situation 
with her children as ‘a different scenario altogether’.  This is achieved by 
drawing on parental familiarity with the issues and parental responsibility.  The 
diagnosis is constructed as problematic only under certain circumstances, 
where there is no ‘parental backup and knowledge’, a situation that would 
require additional thought and support.  In this way she demonstrated how she 
has acted responsibly towards her children, firstly by making sure that they 
were tested and secondly by showing how this decision took into consideration 
their psychological welfare:   
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ID60: Had either of them got raised cholesterol levels I would have 
been able to have dealt with it and therefore they would have dealt with 
it.  So that’s a different scenario altogether.  Children that are diagnosed 
early, I think, as long as they have the backup from parents, maybe with 
a large percentage of cases, it’s probably because parents have got 
cholesterol anyway.  So I think that if the parents do, that would be 
fine. If they hadn’t, I think there is a case for actually doing quite a lot 
with children if they haven’t got parental backup and knowledge, just to 
deal with it, because you don’t know what people are thinking in their 
internal life and, actually, it can be a big problem, I think.  
 
This extract indicates that parents have a duty to provide ‘backup’ to their 
children.  Only one other woman hinted at any psychological aspects to her 
parenting role, of ‘trying to train them to look after themselves’ without 
causing them anxiety, ‘without making them feel that they’ve not got a full 
lifespan ahead of them’.  For the other interviewees, talk of their actions 
relating to their children focussed on being mindful of their children’s diets, 
and of encouraging or training their children to take their medication.  In the 
following extracts, for example, the interviewee talks of getting his children 
into the '	 of taking their medication and of having to 	

		
 his children’s diet:  
(From para 85) 
 ID54: I wanted to make sure that all the family, the kids, if they needed 
the treatment they got it straight away and we make sure that they take 
their medication and I would think that they’re probably alright and live 
a normal life. 
KW:  How do you make sure that they take their medication? 
ID54: Er well, have you taken your medicine yet? Before you go to 
bed. Yeah 
KW: okay 
ID54: It’s because we’ve started them at a young age, it’s a habit.   
 
(Para 153)  
ID54: I mean my children have gorrit and I don’t see how it will affect 
their lives at all.  Dietary, I mean you’ve got to give some consideration 
to not taking the children to MacDonald’s everyday for their meals and 
you know we tend to eat lots of white meat, chicken, turkey, tuna, very 
little red meat at all.  We’re not great cheese eaters so. 
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It is also noticeable in these extracts that the interviewee connects his care of 
his children with the idea that they will probably have a 
life.  This 
suggests that demonstrating responsibility for managing one’s children’s 
cholesterol, as well as constructing this as a largely pragmatic and 
unproblematic area, may be connected to warding off reproach for ‘passing on’ 
the condition in the first place.   
 
There was only one case in which an interviewee talked of declining to have 
her child tested.  ID100 drew on a discourse of protecting her son from early 
diagnosis because she wanted him to be able to be a child with ‘no labels’ 
attached.  Her talk makes very clear that the fact her son has not been tested is 
not a matter of ignorance or fecklessness; this was a measured decision based 
on his psychological welfare and contingent upon his maintenance of 
appropriate behavioural regimes: 
ID100: They did ask me, I’ve been asked by several people.  I feel he’s 
ten years old, he’s a fit child.  I know he’s male, so his risks are higher 
if he’s got it.  He’s very active.  He eats the diet that I eat and I just feel 
now he’s a child and I want him to be that with no label attached.  I 
don’t want him to have a label.  And if he follows that regime for now, 
okay. 
 
She also drew on the notion of ‘choice’ concerning testing, an idea more 
familiar from the predominant discourses about the application of genetic 
technologies.  This reinforced the construction of her decision as measured and 
ethical: 
ID100: For adults, yes, I think once you have the right to make your 
own choice if you go for that test, if you ‘ave a symptom or if you’re 
worried, that’s your choice.  But you shouldn’t inflict, I feel on your 
child.  It’s got to be his choice when he’s old enough to make the 
choice. 
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The effect of this account was to present the interviewee as a considered and 
responsible parent; parental duties were demonstrably discharged through the 
provision of appropriate behavioural regimes, consideration of the children’s 
psychological welfare and appeals to autonomy in testing decisions.   
 
These data on testing and diagnosing children illustrate that this can be 
constructed as troubling information or an unnecessary intervention.  It was, 
however, mostly constructed as untroubling and the analysis suggests that, in 
these cases, moral probity was demonstrated through talk about having one’s 
children tested and their continued care.  In other words, whether children have 
been tested or not, these accounts position parents as responsible in one way or 
another.   
 
Parental responsibilities, evidently, continued into adulthood.  A number of 
interviewees talked of trying to persuade or encourage their adult offspring to 
get tested, to maintain healthy behavioural regimes and to take their 
medication, or of their parents doing this to them.  ID101 and her husband 
framed themselves as responsible not just for their own children, but also their 
grandchildren.  For example in the following extract they talk about trying to 
persuade their twenty&one year old grandson to have his cholesterol tested and 
to change his behaviours:  
ID101: He doesn’t really want to know, but we keep at him 
KW: What do you say? 
ID101: You must go, you must go, you know, eventually he will. 
H101: Well, we badger him about cut down on your smoking and what 
have you. 
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The welfare of one’s offspring is an unavoidably moral area (see Murphy, 
2003; Ribbens McCarthy et al., 2000).  The data presented suggest that 
interviewees may take different approaches to discharging their duties to their 
offspring, but however this is achieved it is difficult to remain silent on this 
topic.  Indeed all but three interviewees contributed to these discourses 
concerning the diagnosis of children or the care of adult offspring and two of 
these did not have children.  There was only one case where an interviewee 
was silent on the testing or welfare of his children.  In the following extract it is 
notable that the interviewee is silent about his two older children.  There is no 
attempt to confirm that he has told them about FH, or, alternatively, to justify 
why he has not told them. This could be framed as a rejection of obligation or, 
perhaps, an absence of obligation based on genetic connections: 
KW: And can you remember when you got the diagnosis, who did you 
tell about it?  Did you talk about it within your family? 
ID35: Yeah, my wife came with me 
KW: And what about your kids?  Have you got kids? Sorry. 
ID35: Yeah 
KW: How many kids have you got? 
ID35: Two that I don’t see at all from a previous marriage and one that 
I see regularly, but she was only three at the time 
KW: And have you talked to them about it now? 
ID35: No, she’s not mine actually, she’s me step&daughter, so it’s not 
familial, I’m not passing anything onto her. 
KW: And have you talked about it in your wider family? 
ID35: No we’re not very close 
 
What do these data, in sum, say about the genetic construction of FH?  The 
prevalence of talk in these interviews about actions in relation to one’s 
offspring may be an acknowledgement of the familial aspect of the condition 
and of genetic responsibilities that flow from this.  It is, in some ways, hard to 
separate this from the responsibilities that any parent feels for the continued 
well&being of an offspring with any health&related issue.  One woman explicitly 
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connected her duties to her children with her responsibility for passing the 
condition on.  In the extract she is talking about her reaction to being asked to 
have her children tested:  
ID18: I thought, that she was telling me like that whatever I’d got 
passed on to me kids and I didn’t like that idea obviously and that’s 
why I made them go.  I said I don’t want you going through what I’ve 
been through and if you listen now at this age and take what you’ve got 
to take, perhaps you know you’ll avoid having a heart attack or 
whatever. 
 
This comment helps to support the suggestion that interviewees’ talk about 
their offspring was not just concerned with parental responsibilities, but with 
genetic responsibilities.  In sum this section has suggested that interviewees 
largely framed the testing and management of their offsprings’ cholesterol as 
an unproblematic and practical issue.   Nevertheless, care of offspring was 
almost without exception constructed as an area of responsibility.  It is 
suggested that these responsibilities flow not just from parental responsibility 
in general, but also through more specific hereditary linkages.   
 
6;6"+.&.+.&
In their studies concerning hereditary breast/ovarian cancer and familial 
melanoma, Hallowell (1999) and  Polzer et al. (2002) have suggested that 
participants expressed a strong sense of obligation to communicate genetic risk 
information with their kin and to encourage them to manage these risks.  These 
studies suggest that this applies particularly to children, but also to siblings and 
wider kin.  These findings are consistent with other studies concerning the 
communication of genetic risk information within families by people attending 
for genetic counselling and testing (d'Agincourt&Canning, 2001; Forrest et al., 
2003; Green et al., 1997).  In the present study, as the previous section has 
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argued, there was an explicit discourse of responsibility regarding the welfare 
of one’s offspring.  By contrast, talk concerned with informing and educating 
other kin assumed much less prominence.  Indeed discussions concerning 
wider kin proved quite difficult to elicit in some cases.  This suggests that 
family connections are not at the forefront of thoughts about FH.   
 
In terms of the interview process, the interview topic guide included the 
question ‘who did you tell/talk to about the diagnosis’?  I had anticipated that 
this question would prompt a discussion about the communication of 
information with kin and possibly other people.  However, a number of 
interviewees did not understand the question, or did not understand it in this 
way.  The question, therefore, did not have an obvious logic for the 
interviewees and details about communicating with kin then emerged at other 
points in the interview, sometimes after considerable probing by me.  It is 
important to note that, in contrast with the studies cited above, the analysis is 
not so much concerned with whether interviewees had or had not 
communicated with their kin and their reasons for this, but with the way this 
area was presented or not at the interview.  This is a concern with the 
construction of moral meanings; the analysis is concerned with whether 
interviewees need to demonstrate they have communicated with their kin in 
order to be seen by themselves and others as proper and responsible people 
with FH (see Murphy, 2000).   
 
According to the interviewees’ accounts of how they came to be diagnosed, 
there must have been a certain amount of information sharing, since three 
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interviewees talked of attending for testing at the instigation of a sibling.  Talk 
of communicating with kin mostly involved siblings, but sometimes included 
wider kin.  As with other studies of the communication of genetic information 
(d'Agincourt&Canning, 2001; Forrest et al., 2003; Green et al., 1997), 
interviewees talked of informing those with whom they had social or 
geographically proximity.  While other studies have reported that a genetic 
diagnosis may lead to some tracing of family members where contact has been 
lost, there was just one example of this suggested in these interviews; a 
diagnosis of FH is not a reason to contact kin one has fallen out with or does 
not know.   
 
Interviewees’ discussions about communicating with their kin can be typified 
in four main ways: 
1. 	
#: those who readily credited themselves as having 
talked with kin or as being instrumental in others attending for testing. 
2. &
	
#:  those who talked of telling kin, but did not 
obviously present this as a purposive action out of concern for their 
welfare.  These interviewees’ talk of communicating with kin sometimes 
emerged only through persistent questioning on my part.  
3. &
: those who did not appear to have talked with their kin.  
4. *	
#: those who actively refuted responsibility for 
talking with kin.   
 
Only four interviewees clearly framed themselves as having a role in telling 
their kin about the condition and persuading them to be tested.  ID24 can be 
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seen to claim responsibility for, or attribute himself a central role in, the 
welfare of his kin, including his siblings and cousins.  This is established 
particularly though using the first person to describe events, --

-
,
	
-
: 
KW:  After you saw [clinician] what did you do then, I mean who did 
you talk to about the diagnosis? 
ID24: Well I talked to m’ family initially, cos I wanted all of them, I 
wanted them all to come down, I wanted them all to get involved, but I 
couldn’t convince them all at the time.  I mean I’ve got three children 
[talks about children].  I’ve got a twin sister, who actually did go, she’s 
the only one who went, she was OK […] My older sister has been, has 
found she’s got a high cholesterol problem and I said to her well, ask 
your doctor for a referral and she’s not been […] I mean I said, well I 
wish you get onto the clinic here, I’m sure you could if you asked for it.  
But she’s not pushed for it yet […] But I said, well you should be on 
these books here I think, but anyway. 
[more conversation about children and family history] 
KW:  But not the wider family, you’ve chatted within your own 
immediate family? 
ID24: Well me own immediate family, yeah, I mean I’ve got cousins as 
well.  I’ve got a cousin who also I think might have the same problem 
and again you know I’ve told her about it […] I made sure they all 
know, because I want them to be aware of it, cos it could affect them. 
 
The majority of interviewees who mentioned talking with their kin could be 
described as not claiming responsibility.  This tended to involve less directive 
language.  In the following example, the interviewee answered my question 
about who she told by talking about which of her siblings have raised 
cholesterol.  This demonstrates that she had taken an interest in their 
cholesterol status i.e. it was a relevant subject.  However, her use of the passive 
voice in talking about their testing, 	
-	
, suggests that she was reluctant to claim the 
credit for this; the responsibility for getting kin to come for testing was 
mediated by the clinic: 
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KW: When they told you it was this, some kind of family thing, can 
you remember whether you told anybody?  I mean, I’m not sure if 
you’ve got siblings or anything? 
ID11: Yes my brother has suffered with high cholesterol.  I have two 
sisters.  They don’t.  
KW: Yes and do you know how your brother and sisters came to find 
out about it? Who found out first say? You did? 
ID11: Yes and then they were advised to have a cholesterol check and 
as I say my brother has high cholesterol.  But he’s also had a by&pass 30 
odd years ago so  
KW: Okay, I was just wondering whether, you said they were advised 
to have tests.  I’m wondering how, whether you were the conduit, you 
were the one that said go? 
ID11: Yes, yes I was told to tell, you know, any relations, well brothers 
and sisters, to have a blood test. 
    
In another example, the interviewee’s talk suggests that he had a certain 
amount of discussion with his siblings about the raised cholesterol condition, 
but this was not framed as particularly urgent or significant.  The extract 
illustrates the relevance of social proximity to discourses about communicating 
with kin, through the reference to 
	
	


.  The 
interviewee’s discussions with his siblings were framed as more to do with 
accounting for his own CHD than concern for their welfare.  It is through my 
persistent and rather single&minded questioning that he reiterates that he did 
speak to his siblings about the hereditary aspect of the condition.  It is notable 
that it is my construction, not his, that his sister attended for tests 
		
: 
KW: And so did you ever talk to them [brothers and sister] about it? 
ID13: We did do, yeah, a long while ago but with marriage and children 
and things like that we only meet at weddings and funerals 
KW: Right, right. 
ID13: Yeah so I don’t know how they’re going on.  I think my sister 
attended, not here but I think she had a slight problem with cholesterol 
at one point. 
KW: But were you the first person to be told that it was this family 
thing? 
ID13: Yes, within the family I was the first one. 
KW: So were you the one that had to tell the others or had they found 
out through another way?  
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ID13: I don’t think it was really, it wasn’t really mentioned too much 
until I went in hospital and had an operation, had one of the operations 
and they said what’s up with him, oh it’s all to do with his high 
cholesterol stuff and basically like that really.  But I did speak to them 
[…] I’m almost sure my sister had some tests done at her local GP 
where she lived. 
KW: as a result of you talking to her about it, yeah? 
ID13: Yeah, just word of mouth really you know saying it could be 
inherited and stuff like that. 
 
This was not the only interview where talk of discussing the condition with kin 
was related first to the welfare of the interviewee rather than the welfare of the 
kin.  Interviewees also sometimes said they did not know how their siblings 
had come to be tested or whether they had been tested.  These data suggest that 
communicating with kin about FH out of concern for the welfare of these kin is 
not always seen as an imperative.  Although many said they had talked with 
their kin, there was not an explicit discourse of obligation. 
 
In a small number of cases, people did not appear to have talked with their kin.  
ID04 provides an example of someone who did not understand my question 
and who had, apparently, not talked with her kin.  Immediately preceding this 
extract we had discussed the clinic appointment at which the interviewee was 
diagnosed.  She described this as involving a discussion of her family 
background, including ‘me mum and me dad and me brothers and sisters’.  
This establishes that the interviewee has siblings and they are somehow 
relevant to her own diagnosis, but her talk is silent on whether she 
communicated information with them, suggesting a lack of obligation about the 
condition: 
KW:  So when you first were told you’ve got this high cholesterol 
problem can you remember who you told about it?  
ID04: What d’you mean, who I told? 
KW: Um like in your family or at work maybe? 
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ID04: Um me partner, when I went home, me husband.  
KW: Right, right, and was there anybody else you told at all? 
ID04: No 
 
In two cases the responsibility for telling kin implied by my questioning was 
plainly refuted.  In both of these cases not telling was attributed to social and 
geographical distance.  This, in itself, was not unusual, as other people also 
talked of relatives they had not communicated with because they were not 
close to or in touch with them.  It was the provision of explicit or further 
justification that made these cases distinctive.  These justifications suggest that 
the interviewees recognise that communicating with kin could be constructed 
as an obligation and that their actions are possibly being called into question.  
It is this recognition of obligation implied within these accounts that sets them 
apart from the other interviews.    
 
In the first of these, the interviewee described his family as ‘very loosely knit’ 
and explained that his brothers lived abroad and that he had sporadic contact 
with them, through ‘Christmas cards’ and ‘a ding on m’ mobile’ a few times a 
year.  In the following extract he talks about whether he has been in touch with 
his brothers about the condition.  It is notable that he immediately recognises 
the issue that I am trying to address with my questioning (-

,	
) and his response is quite defensive.  This suggests that he 
recognises the implied responsibility.  It is also notable that he does not 
confirm or disconfirm whether he has tried to talk with his brothers in the past, 
although his talk implies that he may have tried (		
&

).  Finally, his justification for not telling his brothers is in terms of their 
attitude, advice about getting tested would be rejected (	


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'	
), and he makes plain that getting tested is a matter of individual 
responsibility (	
	):  
KW: So you never really talk to them about it, or told them about it. 
ID35: Oh no I wouldn’t anyway, no 
KW: And you wouldn’t know if they’ve got any heart problems or 
cholesterol problems? 
ID35: I can see where you’re leading 
KW: Where am I, tell me where I’m leading (laughs)? 
ID35: To see if it’s familial, see if we’ve discussed it, and see if they’ve 
got it.  It’s on the maternal side.  My mother died of heart problems, 
had an uncle, he died at thirty nine, when they knew nothing about this, 
with a heart attack.  So I’m not sure if they’ve been checked or not, me 
brothers, because it’s something they clam up on.  If I phoned [brother] 
and said, have you been checked for cholesterol levels, he’d probably 
say, ‘it’s red hot here’, you know mind your own business, don’t 
bother, we know each other.  If he wants to get checked for ‘em he’ll 
get checked for ‘em without me as, so we don’t discuss it, no. 
 
In the second case, the interviewee reported that he had not discussed the 
condition with his brother because of both social and geographical distance 
(they 
,
and they live in different parts of the country).  This talk is 
then connected to a discussion about the health status of his father and uncles.  
The significance of this talk is not immediately clear, but implies that the raised 
cholesterol is sporadic and has unknown outcomes.  After all, one of his uncles 
has lived successfully with angina for fifty years and is now a ripe old age.  
The function of this talk may be to individualise the condition, detracting from 
its familial aspects and therefore mitigating his lack of contact with his own 
brother.  Earlier in this chapter, it was suggested that the construction of the 
hereditary aspect as uncertain or contested may function to lay off 
responsibility for passing on the condition to one’s children.  It is possible that 
this man’s talk functions in a similar way to lay off responsibility concerning 
his brother: 
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KW: I was just wondering whether there’d been any kind of discussion 
with your brother? 
ID88: no, we don’t particularly speak, you know, we don’t get on 
terribly well.  He lives in London so, and I live in [town].  But you see 
if you want you know, just as a note, my father died of a heart attack in 
1969, so did his brother, okay.  Now here’s the twist in this.  His other 
brother is ninety four next month and has had angina for fifty years and 
never had an operation, and he’s still playing the accordion, the 
keyboard and a successful artist, now put that in your pipe and smoke 
it, init really?  And his other brother is about eighty nine, so I dunno.  
There’s no answer is there. 

To sum up, this section has suggested that only a small proportion of 
interviewees actively constructed talking with kin and encouraging them to 
manage their cholesterol as an obligation.  Although many of them may have 
talked with their siblings or other family members about FH or raised 
cholesterol and know the status of these kin, family connections were not a 
prominent part of their construction of FH.  Occasionally, obligations based on 
such connections were actively rejected.  

6;7"+.&.,-*-,-
The previous sections have focussed on obligations regarding kin.  This section 
is concerned with wider obligations to other people.  More than a third of 
interviewees talked of discussing cholesterol or FH with their friends, 
colleagues or other people in order to draw attention to these conditions and 
encourage these people to get tested or change their lifestyles.  These 
interviewees could, perhaps, be described as constructing themselves a role as 
cholesterol ambassador or champion.  In the minority of these cases (4), this 
educational role linked directly with the possibility that others may have FH or 
an hereditary form of raised cholesterol.  One woman, for example, reported 
that she had encouraged a colleague to get his cholesterol checked, because 
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both his parents had died of heart problems at a young age.  In the main, 
however, this educational role seemed to be less specifically concerned with 
FH or hereditary forms of raised cholesterol, and more about recognising and 
managing raised cholesterol in general.  This suggests that interviewees have a 
responsibility to others based on their more general knowledge and expertise 
concerning cholesterol problems and management.  A few people (3) talked of 
being prompted to talk with others because they recognised that these people 
had some visual signs of a cholesterol problem, such as deposits around the 
eyes, as in the following example:  
ID19: I have told people, that I’ve met that have had these things.  
Three people up to now, that I’ve seen with these things and spoken to 
them about it and explained, that I had those and I’d got rid of them 
with medication because I have high blood fats, which can be quite 
dangerous. 
 
There were other occasions where interviewees reported undertaking more 
general awareness raising, seemingly unprompted by indications of any 
specific problems.  The following excerpt stands out as being a very clear 
example of cholesterol championing:  
KW: Do you think anything good’s come out of it [the high cholesterol 
problem]? 
ID85: Well I spread the word more than what I would’ve done before. I 
think I might have influenced half a dozen people to have their blood 
checked for cholesterol and with my job [joiner] I don’t work sites, I 
work customers, and most of the time we get on the friendly path and I 
would say fifty per cent of the time cholesterol may come into it, you 
know, I would suggest to them to go and have your blood tested, ‘cos it 
doesn’t matter how old you are, it is important. 
 
These data suggest that responsibilities to others are not solely derived through 
genetic connections, but a more general duty to spread the knowledge one has 
and help others where possible. Hallowell's (1999) study concerning genetic 
responsibility also considers the expression of wider obligations and suggests 
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that responsibilities to kin and to others may be derived as much through social 
as through genetic connections.  Hallowell’s suggestion is supported by the 
data presented in this and the previous sections.  These data also suggest that 
even though interviewees may distinguish between their own 
hypercholesterolaemia and other people’s on aetiological grounds, as 
illustrated in the previous chapter, they do not necessarily maintain this 
distinction in terms of their responsibilities to raise awareness and encourage 
action.  This contributes to the sense that FH is constructed as a cholesterol 
problem as much, if not more than, as a hereditary problem.   

6;9"-*!$"*8"&.!$!!.,&
This chapter has argued that one marker of the genetic construction of a 
condition is the degree to which obligations to others are derived through 
genetic connections.  The analysis suggests that the idea of reproductive 
decision making in relation to FH was almost universally rejected, setting it 
apart from other genetic conditions which were seen as more serious.  
Discussion of other areas of life planning in relation to FH were largely absent.  
The rejection or absence of discussion of life planning can be attributed to the 
construction of FH as unavoidable, manageable and largely unproblematic.  
Interviewees expressed a strong sense of obligation concerning the welfare of 
their offspring, to make sure they are tested and encourage them to manage 
their cholesterol.  While it is difficult to distinguish the extent to which these 
obligations to offspring flow from parental responsibilities in general or from 
genetic linkages more specifically, it is suggested that they can at least be 
partly attributed to genetic responsibility.  Obligations concerning other kin 
were much less clearly defined.  Only a small proportion actively claimed 
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responsibility for communicating information to their siblings and other family 
members, and for encouraging them to get tested and manage their cholesterol.  
Furthermore, more than a third of the interviewees constructed an area of 
responsibility for communicating information about cholesterol and FH and 
encouraging other people in general to get tested.  This confirms that 
responsibilities to others are not solely derived through genetic connections, 
but also through social connections.  In sum interviewees’ constructions of 
their responsibilities are not strongly framed through genetic connections, 
which suggests that FH is not predominantly seen through a genetic lens.  
   
In relation to the geneticisation thesis, these data reinforce the findings of the 
previous chapter; genetics does not appear to be the dominant discourse in 
interviewees’ accounts of their actions in relation to FH.  Interviewees framed 
FH as part of normal acceptable illness.  In other words, the contribution of an 
hereditary aetiology to FH does not set it apart from other kinds of illnesses.  
Interviewees resisted any challenges to their ideas about normality and 
abnormality.  In the previous chapter it was suggested that interviewees’ 
accounts of the causes of hypercholesterolaemia distinguished people along 
genetic lines.  The data here suggest, nevertheless, that a proportion of 
interviewees do not maintain this distinction when it comes to talking with 
other people to raise awareness and encourage action in relation to cholesterol, 
blurring the boundary set up in their talk about aetiology. 
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This thesis set out to examine the geneticisation thesis by exploring lay and 
professional constructions of CHD and FH, focussing particularly on the work 
and talk of HEART UK and publications of its professional members, and on 
the views of ‘ordinary’ patients with FH.  Chapter 3 argued that the 
geneticisation thesis makes a set of claims about the changing place of genetic 
knowledge in concepts of health and illness and the impact of this knowledge 
on health care practices, and values and attitudes.  It went on to suggest that 
each of these claims might be explored empirically.  The aim of this thesis was 
to focus on these empirical questions about whether and how genetic 
knowledge are changing disease concepts, health care practices and values and 
attitudes in the case of CHD and FH.  It is one of very few empirical studies of 
geneticisation and even fewer studies concerned with genetic constructions of 
complex common conditions that are managed outside of clinical genetic 
services.  Chapter 3 also suggested that empirical enquiry concerning 
geneticisation may consider data on a number of different levels and this study 
has looked at constructions of CHD and FH across several domains, including 
biomedical literature, clinical discourses and patient discourses.  The thesis 
also aimed to contribute to discussions about the influence of lay health groups, 
particularly those associated with genetics, on the production and 
dissemination of biomedical knowledge.  In sum, the data challenge the 
geneticisation thesis in a number of important ways.  They also suggest that 
HEART UK has not adopted the radical practices with regard to lay and expert 
relations reported by other studies.   
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This final chapter will summarise the main findings of the thesis and will then 
discuss these in relation to ideas about expertise, the notion of genetic 
responsibility, and the geneticisation thesis.  It then considers the implications 
of the findings for policy and practice and concludes by discussing further 
questions that are raised by the findings. 
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The thesis explores geneticisation by asking  
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This question was divided into three further questions  
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The thesis also aimed to explore how HEART UK’s activities and discourses 
should be understood, meaning the sense in which these can be thought of as 
indicative of lay constructions of FH and CHD.  The thesis therefore asked a 
fourth research question  
(4) 1&	
&	
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This section summarises the main findings concerning these four questions.      
 


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The analysis suggests that there are a variety of discourses about CHD within 
the biomedical literature.  The analysis of the four recent commentary papers in 
CHD presented in Chapter 4 suggested that there is a model of CHD that 
prioritises the influence of genetic variations on disease susceptibility as 
illustrated by Stephens & Humphries (2003).  However, this represents just one 
strand of research in the field of CHD.  The analysis suggests that there are a 
number of alternative and competing model, which draw on a range of 
emerging and established risk factors.  Beaglehole & Magnus (2002a), for 
example, classify multiple gene influences as just one of six emerging risk 
factor areas for CHD, in addition to the established risk factors.  They name the 
other emerging areas as thrombotic factors & other biochemical markers, 
inflammation & infectious agents, early life exposures, oestrogen deficiency, 
and psychosocial influences.  It is possible that other researchers in the field of 
CHD might characterise the emerging risk factors differently and these six 
areas should not be seen as an exhaustive list.  The analysis, nevertheless, 
highlighted the heterogeneity of current research and models concerning CHD 
aetiology. 
 
The HEART UK professionals studied had little involvement with genetic 
models of CHD in general and their interest in genetics was limited mainly to 
specific hereditary lipid disorders.  The research that they undertook in 
connection with aetiological rather treatment and management issues was 
mainly focussed on the molecular processes involved in atherosclerosis i.e. 
lipid, inflammation and clotting pathways.  This rarely included analysis of 
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genetic variations linked to these pathways.  In relation to Beaglehole & 
Magnus’s (2002a) analysis, this is an interest in two of the emerging factors i.e. 
thrombotic factors & the effect of biochemical markers, and the role of 
inflammation & infectious agents, although here the emphasis was on 
inflammation not infections.  It is notable that this interest in molecular models 
is not the same as an interest in genetic models that draw on inherited 
differences.     
 
Even in the case of FH there seemed to be some lack of certainty in biomedical 
constructions about the role of genes.  Analysis of the Simon Broome group 
publications demonstrated that the current diagnostic criteria for FH draw on a 
set of clinical indicators concerning blood cholesterol levels, the presence of 
tendon xanthomata, and a family history of hypercholesterolaemia or early 
CHD.  The group has recently started to discuss the possible benefits of 
including DNA&based testing into the diagnostic process.  Their discussion 
suggests that models of the genetic basis of FH have become more complex 
during the last decade or so, due to research involving genetic analysis that has 
raised questions about the relationship between the presence of an FH mutation 
and a clinical diagnosis of FH.  Although the Simon Broome group 
publications have constructed genetic testing as an inevitable development 
contingent largely upon technical advances, one of the group’s members, Paul 
Durrington, has displayed considerable ambivalence in his individual 
publications about the utility of genetic testing.  This suggests that FH cannot 
simply be defined as a monogenic hereditary disorder caused by a mutation in 
the LDL receptor or other specified genes.  Some clinicians may privilege a 
 299
clinical definition based on the presence of hypercholesterolaemia, tendon 
xanthomata and family history, regardless of the precise genetic aetiology.   
 
Chapter 4 argued that constructions of FH and CHD might fruitfully be 
analysed along disciplinary lines.  The geneticists, epidemiologists, 
cardiologist, lipidologists and other biomedical professionals discussed in the 
chapter may have different aims, priorities and ways of working which are 
reflected in the different models of FH and CHD that they tend to privilege.   
This idea will be expanded on in following sections of this chapter.   
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This research question was intended to capture both explicit accounts of FH 
and CHD in HEART UK’s written texts and in the interviews with HEART 
UK members, and the constructions of CHD and FH embedded in the aims and 
activities of the organisation.  HEART UK’s texts present the causes of CHD 
mainly in terms of the established risk factors, dividing these into non&
modifiable, i.e. age, sex and family history, and modifiable, i.e. ‘lifestyle’ 
related, categories.  Interviewees similarly constructed two main categories of 
hypercholesterolaemia, hereditary and lifestyle&induced.  The hereditary 
category was limited to the recognised familial lipid disorders.  There was 
practically no discussion of multiple gene influences on susceptibility to CHD 
or hypercholesterolaemia.  The models of these conditions continue to attribute 
a high degree of personal responsibility to causation and prevention, 
conforming to established public health discourses in these areas (Davison et 
al., 1989, 1991, 1992; Petersen & Lupton, 1996).   
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Following on from the findings concerning constructions of FH in the 
biomedical literature, there was ambivalence amongst both the professional and 
lay members of HEART UK about the clinical utility of genetic testing for FH.  
This again suggests a definition of FH that prioritises clinical attributes such as 
hypercholesterolemia and family history, over genetic attributes.  The data 
provided further evidence that different views on DNA&based testing may 
reflect disciplinary differences. The fact that two of the professional members, 
both clinicians, were largely positive about DNA&testing complicated this 
issue, suggesting that opinions do not align strictly down disciplinary lines.  
Nevertheless, the introduction of DNA&based diagnosis for FH did not appear 
to be prioritised within the organisation. 
 
Chapter 5 showed that HEART UK’s aims have broadened from their original 
focus on the hereditary lipid disorders to include CVD risks in general.  This is 
symbolised in the progression of the organisation from being 	
		
 to becoming 	.  The organisation is now 
involved in a range of activities concerned with FH specifically and CVD risk 
more generally, although interviewees differed in their views concerning how 
much the organisation had expanded or should expand its role.  It is notable 
that little in the organisation’s work is orientated specifically to the genetic 
aspects of FH.  Its collaborative and advisory activities mainly involved groups 
involved with CVD, or matters concerning CVD.  This orientation was also 
embedded in the professional membership of the organisation.  It could perhaps 
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be described as being infused with a CVD culture rather than a genetics 
culture. 
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The patients with FH interviewed at the lipid clinic had multiple and 
sometimes contradictory ways of constructing the condition.  It was not 
necessarily characterised solely as an hereditary problem, but also as a problem 
of the liver or as a cholesterol problem.  Interviewees constructed the same two 
categories of hypercholesterolemia found in HEART UK’s constructions.  
These were either hereditary cholesterol or lifestyle&related cholesterol.  The 
interviewees largely constructed hereditary cholesterol as only being amenable 
to medication.  Nevertheless, there was a high degree of lifestyle talk in their 
discussions concerning their own responses to having high cholesterol.  
Chapter 6 suggested that the prominence of this lifestyle talk, despite the 
construction of the two distinct categories of cholesterol, reflects the strength 
of the link between lifestyle and personal responsibility for 
hypercholesterolaemia in Western culture (Davison et al., 1989, 1991, 1992; 
Lupton, 1995; Lupton & Chapman, 1995; Petersen & Lupton, 1996; Sachs, 
1996).  The chapter argued that interviewees were able to establish their own 
moral probity by oscillating between these different discourses.    
 
Explanations of cases of CHD in people with FH were not necessarily fixed on 
the hereditary aspect, but drew on factors such as behaviour, physique, stress 
and temperament.  Furthermore, their explanations of other people’s CHD did 
not draw heavily on genetics, suggesting that knowledge of an hereditary basis 
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to one aspect of CHD does lead people to become more genetic in their outlook 
in general.  These data suggested that the model of the coronary candidate 
(Davison et al., 1989, 1991, 1992) is very tenacious, even in the face of 
specific knowledge about hereditary explanations.   
 
FH was situated within the realm of normal, acceptable, unavoidable and 
treatable illness and on this basis interviewees drew a firm boundary between 
their condition and other genetic diseases.  Reproductive decision&making was 
not seen as a relevant theme in relation to FH.  There was however, much talk 
about interviewees’ actions concerned with taking care of their offspring, both 
as children and as adults.  There was a much looser sense of obligation to 
inform and encourage action in their wider kin and some interviewees reported 
adopting the role of cholesterol or FH information&giver with friends, 
acquaintances and even strangers.  As Hallowell (1999) also observed in her 
study, it is difficult to separate the degree to which responsibilities to others 
were based specifically on genetic connections or more general obligations 
based on social connections.  Overall, responsibilities concerning 	


 were a more prominent feature of  the interviewees’ talk about FH, 
than responsibilities in relation to others.  This suggests that FH was not 
predominantly constructed through a genetic lens.    
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Coming back to the overarching question this thesis asks, the research suggests 
that biomedical constructions of CHD are heterogeneous and that genetic 
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models represent just one of a number of strands of research in this field.  
Biomedical professionals involved in HEART UK and patients with experience 
of FH do not produce genetically&focussed accounts of CHD.  Lifestyle 
continues to provide the dominant discourse.  Furthermore, FH is neither 
understood nor managed within a strong genetic frame.   

	
#
	


	#

@-"*$+
The thesis started out by viewing the FHA, the pre&runner to HEART UK, as a 
potential site of lay knowledge and action and it was selected as a research site 
on this basis.  However, as Chapters 1 and 3 have discussed, the research was 
reshaped due to the founding of HEART UK, the newly established hybrid 
organisation that aims to fulfil both the role of patients’ association and 
professional body.  One aim of this thesis was, therefore, to establish how the 
data about HEART UK should be understood, in other words, the degree to 
which its discourses and activities are indicative of specifically lay 
constructions.  The analysis suggests that lay people were instrumental in 
founding both the FHA and the Simon Broome Heart Research Trust, and 
continue to influence the direction and activities of HEART UK.  However, 
Chapter 5 observed that the FHA followed a recognised trajectory from being 
founded and run by lay people on a voluntary basis, to becoming increasingly 
professionalised (Rabeharisoa, 2003; Wood, 2000).  The data suggest that 
HEART UK currently has low levels of grass&roots activities, and professional 
members involved in the management of the organisation far outnumber the 
lay members.  In short, the organisation is somewhat professionally dominated.  
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The data suggested that lay views may feed into the organisation in quite a 
loose way, through the collation of queries to the support and information 
services.  However, the organisation could not be said to be influenced by a 
collective lay discourse in any obvious way.   
 
Interviewees recognised an important role for lay/patient trustees in both 
contributing their experiential knowledge and their own professional skills, and 
they contributed particularly to overseeing the work of the patient information 
and support services and the legal, financial and business aspects of the charity.  
The data suggest that a division of labour was maintained within the 
organisation, with the expectation, in the main, that scientific and technical 
matters would be left to the biomedical professionals.  In sum, the data about 
HEART UK’s current activities and discourses should be seen as reflecting 
professional constructions of FH and CHD as much, if not more than, lay 
constructions.   

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This section discusses what the findings contribute to discussions about 
expertise and the emergence of novel forms of knowledge production and 
dissemination through the work of lay health groups.  The analysis suggests 
that in the early years, the FHA was strongly patient&driven and one of its 
major aims was to gain recognition of an under&recognised and contested 
disease category, providing a challenge to contemporaneous medical 
knowledge and practice.  This is not a particularly novel finding in relation to 
lay health groups.  It illustrates one of the main aims of lay health advocacy 
 305
groups described by Brown (1995b) and has been discussed in relation to 
several other conditions (see for example Arksey, 1994; Fox, 1989; Johnson & 
Hufbauer, 1982; Scott, 1990) 
 
The merge between a patient and professional association at first sight seems 
like an innovative development with potential to lead to novel forms of 
knowledge production and collaboration.  Drawing on Rabeharisoa & Callon’s 
(Rabeharisoa, 2003; Rabeharisoa & Callon, 2002) model of the partnership 
organisation, the merge between the patient and professional associations to 
form HEART UK seemed to provide a potential structure in which collective 
lay knowledge, collated from patient members’ experiences, might interface 
with biomedical knowledge and in which patients might have some control 
concerning research policies.  The research asked how HEART UK 
interviewees constructed the role of patients, and how the patients’ knowledge 
is incorporated into the work of the new organisation.  The analysis suggests 
that the organisation recognises a role for patients’ experiential knowledge, but 
at the present time a division of labour is maintained, with lay committee 
members contributing to decisions about the work of patient services and 
providing financial and business expertise.  Matters concerning biomedical 
practice and research are delegated to biomedical professionals.  The reasons 
given for the merge were largely instrumental, driven by the potential for 
increased funds and influence, rather than any specific benefits of collaboration 
between patients and professionals.  The merge can be seen as a political move 
concerned with gaining increased credibility.  Despite the merge, current 
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relations fit with the idea of the ‘auxilliary’ association described by 
Rabeharisoa & Callon (Rabeharisoa, 2003; Rabeharisoa & Callon, 2002).   
 
These data suggest that the transformation of expertise that may be emerging in 
relation to other conditions such as HIV/AIDs, Muscular Dystrophy and PXE 
(Epstein, 1995; Heath et al., 2004; Rabeharisoa, 2003; Rabeharisoa & Callon, 
2002; Rose & Novas, 2004) are not seen in the area of FH.  It can be argued 
that the recognition of patients’ experiential knowledge within the organisation 
is indicative of the ascendancy of this notion more generally within health 
policy.  This does not appear to challenge the authority of biomedical experts.  
Matters concerning biomedical research and practice were largely seen as a 
separate domain.  One can argue that the ascendance of the idea of experiential 
knowledge and the UK government’s involvement agenda, in fact, provided the 
environment in which such a merge became thinkable.  Indeed, interviewees 
reported that a similar development had occurred in the field of diabetes 
resulting in the formation of Diabetes UK.  It would be instructive to explore 
the background to this merge and the relationships embedded within Diabetes 
UK, to compare with the findings of this present study.     
 
Furthermore, the analysis suggests that although HEART UK provides support 
and information to patients and is seen as representing patients in consultative 
work, there is currently limited patient input into the running of the 
organisation.  Data suggest that even before the merge, the FHA was highly 
professionalised, with relatively low levels of grass&roots activities.  It was 
further suggested that in the latter years of the FHA, several of the trustees and 
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the last two Chairs were biomedical professionals.  The current rhetoric within 
HEART UK of a need for increased patient involvement was not, by their own 
accounts, being driven by the demands of FH patients.  Indeed, interviewees 
commented on the difficulty of recruiting and retaining patient members.  It 
also did not seem to be driven by any particular commitment to patient 
expertise, but seemed to be largely driven by the demands of government for 
patient involvement.  Wood’s (2000) study of patients’ associations highlighted 
the difficulty of defining such organisations.  He talks of basing his inclusion 
criteria partly on whether organisations appeared to be patient&led and 
independent.  It is, perhaps, time for a reappraisal concerning the meaning of 
patients’ associations.  One of the key questions concerns whether they should 
be defined through their aims and activities or through their membership and 
management.   
 
Many analysts have noted a rise in the number of lay health groups over the 
last three decades (see for example Allsop et al., 2004; Epstein, 1995; Kelleher, 
1994; Rose & Novas, 2004; Wood, 2000), and this may be interpreted as an 
indication of changing relationships concerning expertise.  The present study 
contributes to a more detailed analysis concerning the exact nature of the 
relationships embedded within such organisations.  In sum, it can be argued 
that in the case of the FHA and HEART UK, the organisation was only patient&
led under particular conditions at a particular historical moment.  The early 
years were characterised by lack of recognition of the cholesterol hypothesis or 
conditions, insufficient medical support, lack of treatments and lack of a 
professional field.  By the time of the merge, the cholesterol hypothesis and 
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biomedical expertise about lipid disorders were largely established, and 
successful treatments were available.  The analysis reinforce the argument that 
the influence of patients and patients’ associations depend on the state of a 
particular field and on the existing players within it (Rabeharisoa & Callon, 
2002; von Gizycki, 1987).   
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The thesis has drawn on the notion of genetic responsibility as one of the ways 
of analysing whether FH is constructed through a genetic frame.  This section 
turns this analysis around to discuss what this study can say about the notion of 
genetic responsibility.  Although Novas and Rose (2000) reject the idea of 
geneticisation, they are still committed to the idea that genetic knowledge 
transforms individuals’ subjectivities in some way.  They have argued that 
genetic information places individuals in a web of relations to other people, 
and discuss this particularly in terms of life plans such as decisions about 
getting married, having children, careers and finances.  They also link the idea 
of genetic responsibility to wider notions of biological citizenship and 
biosociality, arguing that people are increasingly joining into groups based on 
shared biological identities and that activism in relation to such identities can 
be constructed as an obligation.  The case of FH did not seem to fit neatly 
within Novas and Rose’s (Novas & Rose, 2000; Rose, N., 2001; Rose & 
Novas, 2004) notion of genetic prudence, or active biomedical citizenship.   
 
It is notable that Novas and Rose’s (Novas & Rose, 2000; Rose & Novas, 
2004) discussions of genetic prudence often enrol the example of Huntington’s 
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disease.  This can be characterised by the possible identification of genetic risk 
in the absence of discernable markers of disease processes or preventative and 
therapeutic options.  Under these circumstances one can imagine that taking a 
genetic test is concerned almost entirely with the social consequences of being 
at risk of the condition.  In this situation, issues concerning ‘marriage, 
procreation, financial planning, inheritance and career’ (Rose, N., 2001: 19) 
may be relevant.  FH is different in two major respects.  First, in the UK it is 
largely diagnosed through cholesterol testing.  Patients know they are not just 
potentially at risk; cholesterol testing provides an indication of bodily status 
that is given on an on&going basis, although this still only signifies a risk of 
CHD.  Second this cholesterol test can lead to immediate therapeutic 
consequences that significantly decrease the risk of CHD, and cholesterol 
treatments are not particularly intrusive.  It is should perhaps not be surprising 
that FH patients talked a great deal about lifestyle, medication and management 
of their FH and very little about their ideas about their life plans in the light of 
the diagnosis or of informing their kin.  This suggests that the notion of genetic 
prudence as defined by Novas and Rose may only be relevant to a small subset 
of serious genetic diseases where a genetic test is available, but biological 
markers of risk are absent and preventative or treatment options are lacking.  
Drawing on the findings of the present study, this notion may be of little 
relevance when talking of genetic risk of a common and treatable disorders 
such as CHD, diabetes or asthma.    
 
Rose and Novas (2004) have suggested that biosociality may be specific to 
certain times and places and Rapp (2001) has commented on the influence of 
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class and ethnicity/race.  Only Allsop et al. (2004) provide any suggestion that 
biosociality might also be specific to certain biological states or conditions.  In 
the case of FH, trustees of HEART UK may construct membership of this 
charity as an obligation, but they also reported difficulties in recruiting and 
retaining patient members.  There were also apparently no grassroots activities 
such as local support groups or web forums in which ‘ordinary’ patients might 
talk with each other.  These data, and the talk of HEART UK members and 
‘ordinary’ FH patients all suggest that FH is not associated with a strong, 
specific disease identity, and patients also aligned themselves loosely to a 
wider ‘community’ of people with hypercholesterolemia or people with CHD.  
In short, while interviewees expressed a strong sense of obligation to take care 
of themselves by adhering to appropriate ‘lifestyle’ regimes, taking medication 
and attending medical appointments, the condition did not appear to draw 
individuals into a ‘responsible community of biological citizens’ (Rose & 
Novas, 2004: 451). 
 
It seems that an expectation of active biological citizenship and biosociality are 
embedded within UK health policy relating to patient involvement and was 
also rehearsed by members of HEART UK.  It was not, however, a dominant 
part of ‘ordinary’ patients’ constructions of their condition.  This can again be 
seen as related to the characteristics of FH i.e. it is treatable and relatively 
unobtrusive, and perhaps also to the ‘ordinariness’ of hypercholesterolemia and 
CHD.  This is just one case study and it is possible that FH is atypical, but the 
findings here suggest that Rose and Novas may overstate the significance of 
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biosociality.  Future analysis might help to characterise the kinds of conditions 
where it is most and least evident.    
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The findings of this study challenge the geneticisation thesis in a number of 
important respects.  Chapter 3 laid out a set of key claims incorporated within 
the idea of geneticisation.  These were drawn on in each chapter in order to 
help to structure the analysis.  This section will draw together the arguments 
relating to each of these claims:  
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 The analysis suggests that there is a 
range of models of CHD in the biomedical literature and that genetic models 
are not dominant in the research of HEART UK members, in the talk or official 
texts of HEART UK, or in the talk of FH patients.  Indeed, the influence of 
genetic variations on CHD risks in general was practically absent from all these 
discourses.  HEART UK continued to emphasise the established risk factors for 
CHD, framed mainly as ‘lifestyle’ factors, while FH patients continued to draw 
on established lay models of CHD embodied by the idea of the coronary 
candidate.  Furthermore, neither the Simon Broome publications, HEART UK, 
nor FH patients constructed FH through a strongly genetic frame and there did 
not seem to be a specific FH identity.  The activities of the FHA and HEART 
UK could be said to have become less rather more focussed on genetics over 
the last two decades, as the organisation broadened its remit to include 
cholesterol and CVD risks in general.  This is the opposite of geneticisation.

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nor lay constructions framed genes as necessarily the determining factor in 
cases of CHD for people with FH.  This was demonstrated in the Simon 
Broome Group’s interest in explaining differential rates of CHD in FH as well 
as patients’ accounts of their own and their relatives’ CHD.   
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Both HEART UK and 
‘ordinary’ patients with FH constructed an aetiological distinction between 
hereditary and ‘lifestyle&induced’ hypercholesterolaemia.  This conceptual 
distinction enabled people with FH to construct themselves as less accountable 
for their condition than other people.  However, distinctions on genetic grounds 
were not necessarily constructed as useful in practical terms.  While the Simon 
Broome publications have discussed the possibility of incorporating DNA&
based information into the diagnostic criteria for FH, current diagnostic criteria 
in the UK remain largely based on clinical indicators.  HEART UK 
interviewees were divided about the benefits of distinguishing between patients 
with raised cholesterol on the basis of their DNA and often privileged clinical 
status.  Divisions on the basis of genetics were not seen in the activities of 
HEART UK, which provides information and support to all people with raised 
cholesterol regardless of the aetiology. Patients with FH also did not 
necessarily draw a sharp line between their own raised cholesterol and other 
people’s.  Some described talking with other people to raise awareness and 
encourage action in relation to cholesterol in general. 

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Patients with 
FH largely rejected the genetic framing of the condition in terms of 
reproductive decisions, drawing a line between it and ‘serious’ genetic disease.  
They constructed FH as part of normal, acceptable and unavoidable illness and 
this was strongly related to the treatability and manageability of the condition.  
This supports Lambert and Rose’s (1996: 79) observation that the hereditary 
lipid disorders are seen as part of the normal spectrum of human health and 
illness; they are part of ‘the normality of human imperfection’.  Furthermore, 
the idea of reproductive decision making in regard of FH was almost entirely 
absent from the biomedical literature and the talk of HEART UK interviewees.
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It is true that models of CHD constructed through the research of 
HEART UK members, the Simon Broome publications and HEART UK’s 
texts and activities tended to individualise responsibility for CHD risks, paying 
little attention to the structural, social and cultural context of these risks.  In 
this case, however, this has little to do with a rise of genetic discourses about 
CHD, as such discourses were not evident in the sites researched.  The findings 
reinforce the argument made in Chapter 3 that the geneticisation thesis is part 
of a wider critique concerning the appropriate way to define and manage health 
problems.  Abby Lippman, like other social scientists, public health physicians 
and epidemiologists, is trying to draw attention to the social and structural 
factors that contribute to disease and is critical of preventative strategies that 
focus on individual action and responsibility.  The data show that the same 
 314
criticism Lippman makes of geneticists concerning the locus of responsibility 
for preventative action, is also levelled by epidemiologists and public health 
physicians (Beaglehole & Magnus, 2002b; Marmot, 2002) at cardiologists.   
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	As already discussed, in the UK, FH is diagnosed largely on the basis of 
clinical indicators, i.e. raised cholesterol, family history, and physical signs.  
DNA&testing has not been widely introduced in the UK.  The discussions of the 
Simon Brome register Group and HEART UK interviewees suggest that even 
if the use of DNA diagnostics were to widen, they would be unlikely to replace 
clinical methods of diagnosing FH.  Furthermore, genetic technologies have, so 
far, had little impact on the diagnosis and treatment of CHD more widely. 

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%The review of the biomedical literature suggests that 
there is a range of research interests concerning CHD.  The idea that genetic 
research is imperative was found in the review paper written by geneticists, as 
might be expected, but was absent elsewhere.  Research by HEART UK 
members was rarely concerned with genetic variations in CHD, but was much 
more concerned with the molecular pathways involved in atherosclerosis and 
the management and treatment of lipid disorders.  One recurrent theme in 
relation to both CHD and FH was that health improvements could accrue 
through better application of current knowledge and practice.  This was also 
manifest in HEART UK’s focus on ‘lifestyle’ aspects of CHD and the better 
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identification and management of FH based on current recommendations.  In 
the sites studied there was no drive for genetic research. 
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# This analysis has argued that there are a number of 
disciplines with an interest in CHD including geneticists, epidemiologists, 
public health physicians, cardiologists and metabolic specialists.  This is 
probably not an exhaustive list.  It has suggested that it may be fruitful to 
consider the notion of geneticisation as part of a boundary dispute between 
epidemiologists and other disciplines, and also that there may be a number of 
boundary disputes concerned with constructions of CHD and FH.  The data 
have shown that epidemiologists and public health physicians including 
Lippman, Beaglehole, Magnus and Marmot privilege socio&structural 
understandings of CHD risk and are critical of both geneticists and clinicians 
for individualising CHD prevention.  It has also suggested that there may be 
disputes between metabolic specialists and geneticists over the definition and 
diagnosis of FH as well as historical disputes between metabolic specialists and 
cardiologists over the acceptance of the cholesterol hypothesis.  These disputes 
are all concerned with who has the jurisdiction to decide what kinds of 
conditions CHD and FH are, and the best ways of managing them. While the 
analysis has suggested that biomedical discourses about the aetiology and 
management of CHD and FH are heterogeneous, it has also recognised that 
these discourses do not necessarily divide strictly along disciplinary lines.  The 
data illustrated, for example, that some clinicians are in favour of DNA 
diagnosis for FH.  It must, in any case, be recognised that geneticists are just 
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one of a number of important players in the field of CHD. 
 
Differences in disciplinary perspectives concerning CHD should, in some 
senses, come as no surprise.  These reflect the different concerns, objectives 
and professional practices of the different disciplines.  While molecular 
geneticists are concerned with processes at the molecular level, epidemiologists 
are largely concerned with disease prevention at the population level and 
clinicians are concerned with practical interventions at the individual level.  
Arguments in this thesis are premised on the idea that geneticisation is not just 
represented through discourse, but it is embodied through medical practices 
and technologies.  Kerr (2000) and Shaw (2003) have demonstrated that even 
for so called established genetic conditions such as cystic fibrosis and the 
dysmorphologies, genetic information is not necessarily of utility to clinicians.  
Hedgecoe (2002, 2004b) has illustrated that there were disciplinary differences 
between scientists and clinicians concerning diagnostic categories for diabetes 
and has shown that clinicians were resistant to the inclusion of genetic testing 
in the diagnosis of Alzheimer’s disease.  The current research has demonstrated 
that in the case of FH, as well, clinicians were ambivalent about the utility of 
genetic information in the diagnosis of the condition.  In more general terms, 
Cox & Starzomski (2003) and Hall (2004) have suggested that clinicians may 
be reluctant to focus on genetic elements when discussing common diseases 
with their patients.  This may be, in part, because it currently makes little 
difference to the therapeutic treatments they can offer.  The same seems to be 
true in the area of FH, where the focus was on treatments and risk factors seen 
as ‘modifiable’.   
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Drawing these different areas together, the analysis suggests that the 
expectations embodied by the geneticisation thesis do not so far appear to have 
been realised in the area of CHD and FH.  There may be a number of factors 
that contribute to explaining why genetic constructions of FH are not 
prominent in this study and why there was not a strong sense of an FH identity.  
These relate to the particular characteristics of the condition, the setting where 
health care is provided and the way FH and CHD are understood.  First FH is 
treatable and, of itself, has no symptoms.  It was perceived by patients to be 
highly manageable and not serious enough to be classified in the same category 
as other genetic conditions. Second, the clinical aspects of FH are not distinct.  
It is monitored, treated and managed in much the same way as ‘polygenic’ 
hypercholesterolaemia.  Third, the condition is treated by metabolic specialists 
rather than through the genetic services, drawing on the techniques and 
practices of metabolic medicine rather than of clinical genetics.  Fourth, there 
are already well&established biomedical and lay models of CHD that focus on 
‘lifestyle’ or ‘modifiable’ factors.  Lay models already included a general sense 
that CHD can run in families, and the diagnosis of FH seemed often to be 
understood in this general way, rather than as a specific Mendelian condition 
with predictable transmission patterns.  Fifth, prior to diagnosis, patients with 
FH had not necessarily picked up on a family history of early CHD.  This was 
perhaps due to the commonness of CHD in general and the availability of other 
explanations.   
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Cox and Starzomski (2003) enumerate a similar list of factors to explain the 
lack of geneticisation in the case of PKD, suggesting additionally that the lack 
of a specific disease support group may contribute to the lack of a genetic 
construction.  The analysis of HEART UK showed that one cannot assume that 
diseases will be constructed in a genetic way, even where there is a specific 
patients’ association.  These associations must be seen as sites where disease 
constructions are negotiated, subject to the same influences as other sites.  
Hedgecoe, (2002: 9) talks of ‘geneticisation by stealth’ in the case of diabetes, 
suggests that diabetes is constructed in some quarters as a paradigmatic 
multifactorial genetic disease, and demonstrates how its classification came to 
have a genetic basis. Nevertheless, there is a strong thread of emphasis on 
‘lifestyle’ factors in explaining Type 2 diabetes and links to the rhetoric of an 
‘obesity epidemic’.  There are many parallels between constructions of 
diabetes and CHD and it seems likely that the same heterogeneity of discourses 
and practices will be evident.   
 
In sum, this thesis has argued that geneticisation is not evident in the case of 
FH and that factors such as the availability of effective therapeutics, the sites 
where care takes place, the disciplines and technologies involved and the 
existing lay models of disease may have important implications for the 
construction of a particular field.  If geneticisation is evident in neither the case 
of FH nor PKD, where there are established hereditary links to CHD and 
kidney disease, this raises questions about the impact of genetics in relation to 
other common complex conditions, the utility of the concept and the kinds of 
phenomena to which it can be applied.   
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This section relates the findings of the study, in the broadest terms, to health 
policy concerning genetics, making some fairly general observations.  It then 
discusses the findings in relation to two very specific aspects of practice 
concerning FH. 
 
Policy and initiatives in the UK relating to the development and use of genetic 
knowledge and technologies within healthcare embody high hopes and 
expectations for this knowledge.  In the forward to the genetics White Paper 
(Cm 5791 & II, 2003: 5), John Reid, the former Secretary of State for Health, 
talks of both ‘the promise of more personalised healthcare with prevention and 
treatment tailored according to a person’s individual genetic profile’ and of the 
likelihood that genetic based healthcare will ‘expand and permeate every area 
of medicine as new genetic tests and therapies come on stream’.  These 
expectations embody a set of assumptions about the way biomedical 
professionals and lay people will be likely to view this knowledge.  They 
assume both that biomedical professionals in ‘every area of medicine’ will 
welcome genetic knowledge and technologies and that lay people will seek 
personalised preventative strategies.  The thesis provides a number of insights 
on these areas that may be useful to policy makers involved with genetics and 
healthcare.   
 
First, as the previous discussion has highlighted, professional constructions of 
disease are complex and heterogeneous.  They relate to specific practices and 
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cultures of particular biomedical fields.  Different professionals are likely to 
have different priorities.  The analysis has suggested that, for example, DNA&
based testing will not be universally welcomed by clinicians.  In the case of 
FH, although DNA&based testing was seen as helpful by some of the clinicians, 
it was certainly not seen as definitive and would be unlikely to replace clinical 
criteria.  In some cases clinicians prioritise clinical criteria, partly because of 
the uncertainties concerning the relationship between identifying a mutation 
and the clinical expression of the condition.  Other studies have also 
demonstrated that clinicians may question the utility of genetic testing, even for 
so called classic genetic conditions (Hedgecoe, 2004b; Kerr, 2000; Shaw, 
2003).  Policy makers should be aware of this complexity.  Lack of clinical 
demand would not necessarily be indicative of lack of knowledge about 
genetics, but would be likely to reflect different priorities and aims of the 
clinicians involved
18
.  Findings of this and other studies, therefore, suggest that 
policy makers may need to develop more realistic expectations about the utility 
of genetic information and technologies in clinical practice. 
 
Second, the vision of a personalised preventative strategy rests on the 
expectation that lay people will want and choose to engage with such 
information and adhere to recommended strategies.  Marteau & Lerman (2001) 
suggested that there was a paucity of data concerning people’s actual rather 
than intended behaviours following the provision of genetic risk information.  
This thesis suggests that in the case of FH, the patients who are lipid clinic 
                                                
18
 It should be recognised that even among geneticists, doubts have been raised about the 
predictive value and clinical utility of genetic testing for common complex diseases, 
particularly where multiple genes are involved.  See, for example, Holtzman & Marteau, 
(2000), Janssens et al. (2004), Wilkie (2001).   
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attendees had been largely unfazed by their diagnosis and that they had adopted 
the preventative stance embodied within policy expectations.  The analysis has 
suggested that interviewees’ construction of FH as largely unproblematic was 
tied up with the availability of effective medications; they saw FH has highly 
treatable.  This research cannot predict the uptake of genetic or other health 
related risk information where prevention is based entirely on the adoption of 
‘lifestyle’ interventions in the absence of specific medications or other medical 
interventions.  
 
Furthermore, although interviewees presented having FH as largely 
unproblematic, their talk about their relatives and their own younger lives 
sometimes suggested that people may resist genetic or other health risk 
information.  This was often related to age and lifecourse.  Interviewees 
suggested that young people, in particular, may be less willing to engage with 
such information, because ‘when you’re young you think you’ll live for ever’.  
Lawton (2002) has suggested that the degree to which people are conscious of 
health and the possibility of ill&health is related to age and, more importantly 
the embodied experience of ill&health.  This may relate to people’s 
receptiveness to predictive health information.  Policy makers should be aware 
that people are unlikely to be universally receptive to the idea of genetic 
susceptibility testing and that this may depend on the availability of 
therapeutics or to demographic or other characteristics of the patient. 
 
This section will now turn to two very specific points concerning FH arising 
out of the data.  As has already been argued, this research suggested people 
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who attend lipid clinics do not find the management of their condition 
problematic.  Nevertheless, a small number of people who reported that they 
were diagnosed in childhood or early adulthood reflected that they had 
perceived this as an unwanted intervention at the time, and their discussion 
suggested perhaps a need for a certain amount of support for children.  
Diagnosis and care of children was certainly one of the more prominent areas 
of interviewees’ discussions about living with FH.  Although there is guidance 
concerning the diagnosis and management of FH in children, it appears to 
make little reference to any psychological aspects of this.  The Department of 
Health’s Cascade Screening Project does not discuss whether children will be 
included or any special issues that may arise from this (Hadfield & Humphries, 
2004).  National guidance concerning genetic testing of children for adult onset 
conditions (Advisory Committee on Genetic Testing, 1998) does not 
specifically discuss FH, but provides no obstacle to its early screening, 
precluding only the testing of young children for conditions where therapies 
are not available.  Policy makers and practitioners may wish to reflect on 
services and guidelines concerning the diagnosis and treatment of children.  
There may be an argument for providing support to families, particularly in 
cases where the parents have been previously unaware of a family history of 
CHD or hypercholesterolemia.  It is notable that HEART UK has already 
recognised this area and has been involved with running two children’s lipid 
clinic projects. 
 
The second point arising from the study relates to a fairly minor observation in 
the methods chapter.  This noted that within the sample of 31 lipid clinic 
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patients, there was a marked difference in experience of CHD by occupational 
category, with those with managerial, professional and intermediate 
occupations having less CHD than those with manual and routine occupations. 
Comments on this observation are necessarily very speculative because of the 
small sample size.  If these patterns were replicated within the whole lipid 
clinic population this might suggest that people with FH who work in manual 
and routine occupations have higher rates of CHD or perhaps that they enter 
the clinic at later stages of their FH career.  Chapter 3 noted that there does not 
appear to have been any analyses by occupation of rates of CHD in people with 
FH.  Should this pattern be seen across the whole clinic population, this would 
be an argument for further analysis to explore whether this was related to 
access to service and/or differences in morbidity and mortality.  In either case, 
the issue of occupational class and FH would seem to warrant some further 
analysis.  
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The analysis raises a number of additional questions that point to potential 
areas of research that would build on the thesis.   
 
 
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	

The thesis provided an analysis of the rhetoric of a small number of 
commentary papers about CHD and an overview of the research of one very 
specific group of CHD researchers.  There is scope for a wider analysis of 
research and research funding in the area of CHD.  It would be fruitful to adopt 
both quantitative and qualitative methods in this area. 
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The analysis of biomedical constructions of CHD undertaken in this thesis 
focussed on a limited, recent time period and it is not clear, for example, when 
or how the notion of ‘polygenic’ hypercholesterolaemia or a polygenic model 
of CHD emerged.  There is scope for a more detailed socio&historical work in 
this area to show how and why a genetic model of CHD came about and how 
this relates to the emergence of the cholesterol hypothesis and other bodies of 
research in CHD. 
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The thesis focussed mainly on the biomedical literature and FH patients’ 
accounts of living with FH, and included the talk of a small number of 
clinicians about their clinical practice.  It has not looked at how clinicians and 
patients construct FH through clinical consultations.  It would be possible to 
extend this research to undertake an observational study, with the aims of 
analysing how FH is constructed during these consultations and how this 
relates to patients’ accounts of FH provided in this thesis.    
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The thesis has drawn on the work of Davison and his colleagues (Davison et 
al., 1989, 1991, 1992) on lay constructions of CHD to provide comparison 
data.  Their analysis was based on a study of the general population.  It could 
be argued that more direct comparison data would be provided through a study 
of how patients with ‘polygenic’ hypercholesterolaemia account for their 
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condition.  This might also help to clarify whether responsibility to others, such 
as encouraging kin and other people to be tested, relates directly to a genetic 
connection or to a social connection.    
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It has already been noted that practice concerning FH may vary trans&
nationally.  The Netherlands stands in particular contrast to the UK because it 
has implemented a national policy of cascade screening, based on genetic 
diagnosis which is undertaken through the genetic services.  It would be 
instructive to analyse the context and circumstances through which this policy 
came about and the similarities and difference to the UK situation.  Interviews 
with FH patients in the Netherlands would provide comparison data that could 
provide evidence about the possible influence of screening and DNA testing to 
patients’ constructions of FH and responsibility.  
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Since its introduction by Lippman in the early 1990s, the concept of 
geneticisation has been widely adopted across a number of disciplines.  It has 
come to hold a range of meanings from the increasing prominence of genetic 
explanations in the media, professional or public discourses, to a full&scale 
critique of the implications of genetic ways of thinking and doing.  Chapter 3 
argued that many of the social analysts who have enrolled or discussed 
geneticisation, both its supporters and detractors, have assumed, without 
questioning, that genetic discourses and practices are spreading.  In doing so, 
they have contributed to a set of expectations about the great influence that 
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genetics and geneticists have or will have in health care and beyond.  While 
some of these analysts see this influence as negative and others less so, they 
have all reinforced the image of strong ‘genetic agency’ (Webster, 2005).  This 
image is not supported by this study of patient and professional constructions 
of FH and CHD.  The thesis contributes to a more nuanced understanding of 
the place of genetics in healthcare and in society. 
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Press, 144&161. 
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Ellison & Jones 
(2002) 
Social 
identities 
Discussion 
piece 
 classification of 
social identity 
(race/ethnicity) in 
genetic research and 
testing.   
‘a 	geneticization of social identities shifts 
responsibility for social inequalities in health on shared values, 
beliefs and behaviours’ (p.267 original emphasis) 
Gibbon (2002)20 Breast cancer  Patient & 
clinical 
discourse  
Clinical 
genetics 
use of family trees 
in clinical practice  
Critique of the ‘impact’ approach of social studies about 
genetics.  Patients had an active role and investment in the 
process.  There is a need to ‘rethink normative notions of 
geneticization and medicalization’ (p. 454 ) 
Hedgecoe (2002) Diabetes Scientific 
discourse 
review 
papers 
Classification of 
diabetes 
Genetic information was pivotal to the reclassification of 
diabetes on aetiological rather than clinical grounds.  
Demonstrates ‘geneticization by stealth’ where genetic 
explanations enter into classification at early stage, only 
becoming apparent later. 
Hedgecoe (2003a). Cystic fibrosis Scientific 
discourse  
review 
papers 
Classification of CF CBAVD, a form of male infertility, has been redefined as part 
of a CF&continuum, leading to tensions between this new 
categorisation and clinical diagnostic practices. 
                                                
19
 Identified through search of ‘geneticisation’ or ‘geneticization’ of WOS and ASSIA, undertaken on 19/4/05 
20
 Identified through Google web search on 1/3/05, not through WOS/ASSIA search 
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Shaw (2003). dysmorphology Clinical 
practice    
Clinical 
genetics. 
Diagnostic process 
in clinical genetics 
Clinical geneticists do not prioritise genotypic information over 
phenotypic in diagnosis.  As in other diagnostic settings, genetic 
diagnosis is a clinical process, not a form of genetic 
reductionism.   
ten Have (2003)  Discussion 
piece 
 Bioethical 
discussion of 
geneticisation 
Geneticisation is useful as a tool to refocus bioethical analysis 
and can be analysed on a number of levels.  
Wilcox (2003) sexuality Media 
discourses 
TV & print 
media   
Media coverage of 
biological research 
on sexuality 
There are multiple meanings attached to biology, genetics and 
being ‘born with’ a characteristic.  These should not necessarily 
be read as an indication of geneticization.   
Chadwick & 
Aindow (2004) 
Psychiatric 
illness 
Discussion 
piece 
 treatment and 
research ethics in 
psychiatric illness 
Discusses geneticization because it has ‘far&reaching 
implications because of the potential for predictive testing and 
gene therapy’ p293.   
Cox & Starzomski 
(2003) 
Polycystic 
Kidney Disease 
Patient & 
clinical 
discourses  
nephrology 
& clinical 
genetics   
the social 
construction and 
clinical 
management of 
PKD  
 ‘recent advances in genetic knowledge and techniques [have] 
had a minimal impact on the clinical management and social 
construction of PKD’ (p161).  Discusses factors that may 
mitigate geneticization. 
Hall (2004) Heart disease Patient & 
clinical 
discourses  
coronary care 
unit  
 
the ‘seeming 
geneticization’ of 
heart disease 
The process of geneticization is not straightforward as imagined 
by Lippman.  In the clinical setting, professionals foreground 
lifestyle, because of concern about patient fatalism, whereas 
patients would have liked an acknowledgement of a genetic 
contribution.  
Hedgecoe (2004a)  Discussion 
piece 
 Reply to Kerr 
(2004) 
Contests methodological questions and substance of argument. 
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Kerr (2004)  Discussion 
piece 
 Critique of 
Hedgecoe (2003) 
Hedgecoe’s analysis overstates the impact of molecular 
knowledge on the definition and diagnosis of CF and he 
produces an ahistorical and inflexible model.  
Melendro&Oliver 
(2004) 
Common 
acquired & 
complex 
behavioural 
traits 
Media & 
scientific 
discourse 
journalistic & 
scientific 
texts. 
The redefinition of 
genetic disease  
The Human Genome Project challenges reductionist and 
deterministic models of disease and behaviours, the shift to 
genomics has not seen an end of determinism.   
Raz & Atar 
(2004). 
Spouse 
selection & 
prenatal 
screening 
Lay 
/patient 
discourses 
Community 
genetic 
services 
Introduction of 
community genetics 
to Bedouin Arabs in 
Israel.  
This community were not passive, but actively participated in 
response to this new service, with some accepting it, some 
rejecting it and some using it with a different rationale (for their 
own ends) 
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Baylis & Robert 
(2004) 
Ethical analysis of genetic enhancements  Diversion of resources 
 Individualisation of responsibility 
No No 
Ceccarelli (2004) Analysis of metaphors used in speeches at 
completion of HGP 
 metaphors & 
reductionism/determinism  
Yes No 
Condit (2004) Review of research on media and lay discourses 
about genetics  
 metaphors & 
reductionism/determinism 
Yes No 
Greco (2004) Analysis of the indeterminacy of health as a 
political issue.  
 Scientific discourse concerning 
genetics 
 Normality/abnormality 
Yes No 
Helén (2004) Analysis of new reproductive technologies, 
diagnosis and abortion from a governmentality 
perspective 
 Focus of high&tech medicine on 
prediction and prevention 
 Agency of pregnant women 
Yes Yes 
Kirby (2004) Analysis of the film ‘GATTACA’ and its 
implications for race and genetics 
 Societal trend toward genetic 
reductionism.  
No Yes 
Koch (2004) The different meanings of eugenics and its use 
by both critic and supporters of new genetic 
technologies 
 genetics as reductionist and 
undesirable 
Yes No 
Lemke (2004) Analysis of genetic risks from a 
governmentality perspective. 
 ‘Geneticization of society’ (p550) 
 Genetic reductionism in scientific 
discourses 
Yes Yes 
                                                
21
 Identified using WOS on 19/04/05 
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Robert & Smith (2004) Ethical analysis of the Environmental Genome 
Project 
 Analysis of complex diseases, not 
just classic genetic diseases 
 Individualisation of risk and victim 
blaming 
No No 
Santos & Maio, (2004) Analysis of arguments about national identity 
ensuing after report on a study into the ‘genetic 
origins of Brazilians’  
 Geneticization as an ‘array of 
transformations and generation of 
new meanings’ resulting from new 
genetics (p348) 
No Yes 
Schubert (2004) Ethical analysis of pharmacogenetics  reductionism and determinism in 
other areas of testing 
 (pharmaco) genetic identities – new 
stratification 
No Yes 
Sherwin (2004) Ethical issues associated with BRCA testing and 
the implications of susceptibility testing. 
 Growing ‘public sentiment’ that all 
health risks reside in genes. 
 Reductionism and determinism 
 Public belief that health 
improvements will follow directly 
from genetic knowledge 
 Diversion of support from other 
factors 
No Yes 
Shields et al. (2004) Ethical and social implications of research into 
the genetics of smoking 
 Role of media in constructing 
promise of genetics 
 ‘overly geneticized view of human 
identity, behaviour and health’ 
(p684) 
 geneticization as a problem of 
public understanding of science 
No Yes 
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Surbone (2004) Moral implications of BRCA testing  the privileging of the role of genes 
in disease causation, in both medical 
practice and social attitudes. 
No Yes 
van Delden et al. 
(2004) 
Ethical implications of pharmacogenetics  uptake of genetic determinism by 
both patients and healthcare 
professionals 
 both increasing and decreasing 
individual responsibility 
No Yes 
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Dear [name]
 
*

-"*$+

I am writing to you at the suggestion of Julie Foxton to see if you might be able 
to help me with my research.  This is concerned with the work of patients’ 
associations in supporting patients with familial hypercholesterolaemia.  I am 
particularly interested in the work of HEART UK.  The research is funded by 
the Economic and Social Research Council and has been approved by the 
administration at HEART UK.  I have enclosed an information sheet which 
provides further details.  
 
I am hoping to undertake a limited number of interviews with professionals and 
patients who are involved in the activities of HEART UK, with the aim of 
finding out more about the work undertaken by the Trust, the policies 
supported and roles of the different groups within the Trust. 
 
If possible, I would like to meet with you to talk about your work with HEART 
UK and your involvement in the [name of committee/s].  I estimate that an 
interview would take an hour at the very most and anything discussed would be 
in confidence.   
 
I hope you might have time for a brief meeting of this sort.  I intend to ring you 
in the near future to see if this will be possible.  Please do not hesitate to 
contact me if you would like to discuss the research further or you have any 
queries 
 
Many thanks 
Yours sincerely 
 
 
 
 
 
Kate Weiner 
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 What is your role within HEART UK and what does this involve? 
 How did you become involved? 
 

	
 What do you see as the main aims of the organisation? 
 What arethe main activities of the organisation? 
 What research has HEART UK been involvedin? 


		
 Have you done any advisory or collaborative work on behalf of HEART 
UK? (With which other organisations, member of any umbrella groups, 
types of consultations) 
 What public campaigns has HEART UK instigated or been involved in? 
 

	
 Before the merge, were you involved with the FHA or BHA? (in what 
ways?) 
 Can you tell me anything about the history of HEART 
UK/FHA/BHA/Simon Broome Heart Research Trust? (origins, aims and 
activities, people and organisation, links between the organisations, 
developments)  
 




 In your view, how did the merge between FHA and BHA come about?  
 What do you think have been the main changes since the merge? (Benefits 
and disadvantages?) 
 In your view, what role do patients play in the organisation? [FOR STAFF 
AND PROFESSIONALS]  How do you see your role in relation to the 
clinicians and staff? [FOR LAY MEMBERS]  
(Is it important to have patients on the committees? Why? What do patients 
bring to the organisation?)  




 What do you see as the main priorities for people with FH? 
 What developments would you like to see take place in HEART UK in 
coming years?  
 What research or policies would you like to see HEART UK support or 
undertake? 
 What do you think about DNA diagnostics for FH? – do you see any 
advantages? 
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Dear 
 
I am writing to invite you to participate in a study that will be taking place in 
the clinic between January and June 2004.  This is concerned with patients’ 
views about and experiences of familial hypercholesterolaemia.  Participation 
will involve being interviewed on a single occasion and will not involve any 
change to your current care or medication.  Please read the enclosed participant 
information sheet for details of the study and how you were selected. 
 
The study will be undertaken by a PhD student, Kate Weiner.  The research has 
been approved by the [research ethics committee].  
 
I would be grateful if you could complete and return the reply slip in the 
envelope provided, indicating whether you are willing to participate.  Two 
options are provided for people who are willing to participate.  You are asked 
to choose whether you would prefer to be interviewed at the clinic on the day 
of your next appointment, or somewhere else, like your workplace or home.  If 
you indicate you are interested in participating, your contact details will be 
passed on to Ms Weiner.  She will contact you regarding the arrangements for 
the interview.  If you do not wish to participate, no further contact regarding 
this matter will be made. 
 
Thank you in advance 
 
Yours sincerely  
 
 
[clinician] 
 
 
*-8!.
 
Participant identification number: 
         Please tick as 
appropriate 
        
Yes, I am interested in participating.  I would like to be 
interviewed at the clinic when I come for my next appointment 
 
Yes, I am interested in participating.  I would like to be 
interviewed at a time and place convenient to myself 
 
 
No, I do not wish to participate in this research.  
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1. I confirm that I have read and understand the information sheet 
dated August 2003 (version 1) for the above study and have had the 
opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected. 
 
3. I give permission for the research interview to be recorded on audio 
tape. 
 
YES   NO   (please tick as appropriate) 
 
 
4. I agree to take part in the above study. 
 
      
      
   
 
 
___________________ __________________ ______________ 
Name of Patient Signature Date  
 
 
 
___________________ __________________ ______________ 
Researcher Signature Date   
 
 
 
 
1 for patient;  1 for researcher;  1 to be kept with hospital notes
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